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ABSTRACT 
QUAKER HARMON: Variations in Inflammatory and Cell Cycle Genes and Preterm Birth, Small for 
Gestational Age and Hypertensive Disorders of Pregnancy 
(Under the direction of Stephanie Engel) 
 
The maternal outcome of preeclampsia and the fetal outcomes of preterm birth and poor 
intrauterine growth often occur together, share placental pathology and are marked by changes 
in inflammatory biomarkers. Genetic polymorphisms in inflammatory genes have been 
investigated with respect to all of these outcomes with conflicting results. In previous studies 
case groups have been small or non-representative of US populations, and coverage of 
candidate genes has been sparse. We sought to expand coverage of inflammatory genes related 
to natural killer cells and T cells and in addition included candidate genes related to cell cycle 
function. In a sample of 1646 women from a bi-racial prospective pregnancy cohort, we 
examined the relationship between 503 tagSNPs in 40 genes and the outcomes of preterm birth, 
small for gestational age, gestational hypertension and preeclampsia. 
Six genes involved in natural killer cell function (IL12A, CSF2, IFNGR2 and KIR3DL2) and Th2 
immunity (IL13 and IL4) were associated with preterm birth among European Americans with 
some evidence of an association for African Americans as well (IL12A and CSF2). IL6 and KLRD1 
were associated with term small for gestational age births among African Americans with similar 
results for IL6 alone among European Americans. LTA, TNF and TBKBP1 were associated with 
preeclampsia among European Americans only. There were no associations with any cell cycle 
genes or with the outcome of gestational hypertension. 
 iv 
In summary, this study found novel associations with a number of genes related to natural 
killer cells, Th2 immunity and TNF signaling pathways and the outcomes of preterm birth, poor 
fetal growth and preeclampsia among both European and African Americans. 
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CHAPTER 1 BACKGROUND 
Introduction 
Pregnancy is a state of altered inflammatory function.1, 2 In the majority of pregnancies, the 
altered inflammatory function works to the benefit of both mother and fetus by mitigating the 
immune rejection of fetal tissue3, 4 while restricting the extent of invasion of the fetally derived 
placenta.5 As the pregnancy progresses, the balance of pro and anti-inflammatory cytokines may 
act as a determinant of the timing of delivery.4 Perturbations in inflammatory pathways from 
pre-conception through delivery have significant impacts on the success of the pregnancy and 
the health of both the mother and the fetus. Increased inflammation has been implicated in 
preterm birth,2, 6 poor fetal growth as measured at birth (Small for Gestational Age, SGA)4, 7 and 
Hypertensive Disorders of Pregnancy including Preeclampsia (PE) and Gestational Hypertension 
without proteinuria (GHTN).1, 8  
Previous studies have identified a number of inflammatory biomarkers that are altered in 
PE and SGA.1, 7-10 Studies of heredity have established a genetic component in PE,11 preterm 
birth12-14 and SGA.15 Genetic epidemiology studies to date have found some associations with 
preterm birth, SGA and PE and polymorphisms in inflammatory pathway genes (see Section 1.6). 
Although there have been some large studies for preterm birth, studies for PE in US populations 
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have been limited and only a handful of studies have measured associations with SGA, covering 
fewer than 10 inflammatory genes in total.  
Given the dramatic growth of the placenta during pregnancy and the pivotal role it plays in 
sustaining the fetus, factors that limit placental growth or function may be involved in SGA, PE 
and preterm birth. In addition to placental growth, remodeling of the uterine wall and 
vasculature is extensive and must occur for a successful pregnancy. Cell cycle processes are 
fundamental for cell proliferation, and genetic polymorphisms in cell cycle genes may result in 
reduced cell proliferation and poor placental development, leading to poor fetal growth and/or 
preeclampsia. Genetic polymorphisms in cell cycle genes have not been extensively studied for 
the outcomes of PE, SGA or preterm birth. A few studies have found associations with other 
reproductive outcomes such as missed abortion16 and gestational diabetes.17  Additionally, a 
number of cell cycle genes have been implicated in related outcomes such as cardiovascular 
disease18 and type 2 diabetes.19 Animal and human placental expression studies have also 
suggested that cell cycle genes are differentially expressed in placental tissue20, 21 and may differ 
in expression, quantity or function in women with PE or SGA. Therefore cell cycle genes 
contribute to a novel pathway that may be important in the outcomes of PE, SGA and preterm 
birth.  
The Pregnancy Infection and Nutrition Cohort offers a good opportunity to study 
polymorphisms in a panel of candidate genes in the inflammatory and cell cycle pathways in a 
biracial population with well-measured covariates. Knowledge about these genetic variants will 
improve our knowledge about these heterogeneous phenotypes, aide in the identification of 
susceptible populations and identify target genes for further study.  
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Descriptive epidemiology of Preterm, SGA/IUGR and Preeclampsia/Gestational Hypertension 
Preterm birth, poor fetal growth and gestational hypertension are maternal and infant 
outcomes that often co-occur. Hypertensive disorders of pregnancy (including both 
preeclampsia and gestational hypertension) are maternal conditions that result in preterm birth 
in up 60% of pregnancies complicated by preeclampsia and poor fetal growth in up 25%.22 
Preterm birth due to medical indications, which may include maternal disease due to gestational 
hypertension, only accounts for 30% of preterm births23 with the majority of preterm births 
having an etiology unrelated to gestational hypertension. While poor fetal growth is present in 
some pregnancies complicated by gestational hypertension, the association with preterm birth 
is more complicated. While there is evidence that infants born preterm may be smaller than 
their in utero peers at a given gestational age,24 a measure of fetal growth such as SGA (small for 
gestational age) that is adjusted for gestational age, should have a similar proportion of ‘small’ 
infants at each gestational age. 
Despite the similarities and co-occurrence of these outcomes, they share distinct risk 
factors and etiologies, which will be explored below. In studying closely associated outcomes 
such as these, similarities in genetic associations must be examined for confounding, and 
phenotypes should be adjusted when appropriate. By examining this group of outcomes in the 
same population, it is our hope that identification of both similar and distinct genetic 
associations will inform knowledge of important biologic pathways and identify opportunities 
for both primary and secondary prevention. 
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1.2.1 Preterm Birth 
Descriptive Epidemiology 
Preterm birth is defined as delivery before 37 completed weeks of gestation. In the United 
States, preterm birth occurs in approximately 12% of births. Although it is primarily defined by 
the timing of delivery, preterm birth is a heterogeneous outcome with multiple pathways 
leading to a birth before term. Preterm birth has been divided into subtypes based on the 
indication for delivery, the timing of delivery, or the presumed underlying pathology. Preterm 
birth is of importance due to the significant medical and societal impacts borne by the infants 
and their families throughout the life course.25 
Classification 
Based on indication for delivery, preterm birth can be characterized as preterm labor, 
preterm premature rupture of the fetal membranes or a medically indicated delivery for the 
health of the mother or infant. Although these subtypes are commonly used and may have 
different risk factors, the distinction between the indications for preterm delivery may not 
always be etiologically important.26-28 
Timing of delivery is also used to classify preterm births. Extremely preterm (delivery 
before 28 weeks), very preterm (delivery before 32 weeks) and late preterm (34 to 36 weeks) 
have all been used as gestational age classifications of preterm birth. The severity of preterm 
birth with regard to gestational age may be most important for predicting the mortality and 
morbidity of the infant. Infants born extremely preterm have the highest risk of both neonatal 
 5 
and infant mortality as well as the highest risk of later complications.25 There is some indication 
that early preterm birth may have distinct risk factors.26   
A classification of preterm based on the underlying pathology resulting in preterm birth 
would be most interesting from an etiologic perspective. While specific maternal medical 
conditions (preeclampsia, underlying chronic disease), fetal conditions (severely low amniotic 
fluid, fetal distress, and certain congenital defects), maternal trauma or serious illness may often 
be an apparent cause of preterm birth, many etiologies of preterm birth (subclinical placental 
abruption, placental pathology, subclinical uterine infection or inflammation) are neither 
apparent, nor susceptible to diagnosis prior to delivery. 
Time Trends 
Although the preterm birth rate had appeared to be steadily increasing from 8.9% in 198029 
to a high of 12.8% in 2006,30 recent data suggest that the rate may be plateauing or even 
decreasing with the preterm birth rate declining for two consecutive years to 12.3% in 2008.31, 32 
Changes since the 1980s in the preterm birth rate have been attributed to changes in maternal 
demographics, increasing use of reproductive technologies and medical interventions such as 
cesarean section in the late preterm period.33 The greatest increases in the preterm birth rate 
were seen among late preterm births with medical indications. The decline in the preterm birth 
rate observed in 2008 was evident among all maternal age groups below 40, in White, African 
American and Hispanic mothers, in almost all US states and in both cesarean and vaginal 
births.32 Although the preterm birth rate has generally been increasing, fetal outcomes have 
been improving over the same time period, with increased survival among the earliest preterm 
infants.25 
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Sequelae 
Infant 
Neonatal and infant death is the most serious consequences of preterm birth. In 2006 the 
U.S. the infant mortality rate for preterm was 35 per 1,000, compared with 2 per 1,000 among 
term infants. Among preterm infants, the risk of mortality is highest for those born earliest with 
very preterm infants (less than 32 weeks) having an infant mortality rate of 176 per 1,000, 
compared with 7 per 1,000 among late (34-36 week) preterm infants.34 Although preterm birth, 
and in particular very preterm birth, is relatively uncommon, the high death rate among preterm 
infants results in infant mortality among preterm infant accounting for 68% of total infant 
mortality in 2006. 
In addition to mortality, preterm infants are at increased risk for significant morbidity. 
Acute complications include respiratory distress, necrotizing enterocolitis, feeding intolerance, 
apnea, infection, cardiac abnormalities, anemia, and brain injury (intraventricular hemorrhage 
and periventricular leukomalacia). Chronic health concerns include chronic lung disease, gastro-
espohageal reflux, vulnerability to infection (particularly respiratory syncitial virus), hearing loss, 
eye disorders (retinopathy of prematurity), cerebral palsy, cognitive deficits, behavioral 
problems and epilepsy.25, 35 Follow-up studies have also shown an association between 
gestational age at birth and educational attainment and income later in life.35, 36  As with 
mortality, the risk and severity of acute and chronic morbidity is associated with the severity of 
preterm, with infants born before 28 weeks at highest risk.33 
Although very preterm infants face the highest risks of mortality and morbidity, there is an 
increasing awareness of the risk associated with late preterm birth. Infants born between 34 
and 36 weeks continue to have an elevated neonatal mortality rate compared with full term 
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infants, and these infants also had increased respiratory distress syndrome, sepsis, 
intraventricular hemorrhage and NICU admission.37 Although there are fewer long-term studies 
among late preterm infants specifically, there is some indication that there may be a risk of long 
term behavioral problems as well.38 
Maternal 
Maternal health consequences from preterm birth are fewer compared with infant 
sequelae, and they may be attributable to shared pathways between preterm delivery and later 
health outcomes, rather than early delivery itself. Women with a previous preterm birth are 
more likely to have subsequent preterm births.23, 39 Many of the medical sequelae for women 
with preterm delivery are related to the underlying pathology that necessitated the preterm 
birth such as complications from preeclampsia, gestational diabetes, coagulation disorders or 
underlying cardiac or respiratory conditions. As such, the preterm delivery is associated with 
subsequent maternal health complications, but the preterm delivery is not causative. 
There is some suggestion that women with a previous preterm delivery are at increased risk 
of later cardiovascular disease;40 however, this may be due to shared vascular and metabolic risk 
factors which predispose to both preterm delivery and later CVD risk. 
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Risk Factors 
Apart from pre-existing or emergent maternal medical conditions and previous preterm 
birth, few strong risk factors for preterm birth have been identified. Table 1.1 highlights the 
most commonly identified risk factors. Heritability will be discussed in Section 1.5. 
Table 1.1 Risk factors for preterm birth23, 25, 41, 42 
Behavioral and Psychosocial  Pregnancy Complications Maternal Medical Condition 
Smoking Infection Assisted Reproduction 
High psychological or social stress Vaginal bleeding Short inter-pregnancy interval 
Long work hours, hard physical labor. Placental abruption History of thyroid, renal,  
Cocaine, heroin use High or low amniotic fluid respiratory, cardiac, diabetes, 
Heavy alcohol use Placenta previa auto-immune conditions, 
Depression Abdominal surgery  hypertension. 
Poor nutrition Multiple gestation  Cervical cone biopsy or LEEP 
 Pre eclampsia Previous preterm 
Demographic and Anthropometric  Short cervical length  
African American race Environmental Exposures Uterine abnormalities 
Low socio-economic status Lead  
Low education Occupational exposure to PCB  
Extremes of age DDT  
Unmarried status Environmental tobacco smoke  
Low pre-pregnancy BMI Air pollution  
 
1.2.2 Hypertensive Disorders of Pregnancy 
Descriptive Epidemiology 
Pregnancy is a state of great physiologic change for the mother. Measures such as blood 
pressure vary throughout pregnancy with a usual pattern that includes a decrease in blood 
pressure during the second trimester.43, 44 Hypertensive disorders of pregnancy, as used here, 
encompass three conditions of increased blood pressure that emerge after the 20th week of 
gestation. The estimates of incidence of hypertensive disease in pregnancy range from a low of 
2%-7% for preeclampsia in healthy nulliparous women22 to a high of 12-22% for hypertensive 
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disorders overall.45 Although the exact incidence may be uncertain, hypertensive disorders of 
pregnancy are a leading cause of maternal mortality. In the United States, from 1991 to 1999 
hypertensive disorders of pregnancy was the identified cause of death in 15.7% of maternal 
deaths46 while from 1998 to 2005 hypertensive disorders of pregnancy were identified as cause 
of death in 12.3% of maternal deaths.47  
Classification 
Although there is some variation in the nomenclature used to describe the specific 
conditions,45 the following terminology will be used. Gestational hypertension (GHTN) is an 
increase in blood pressure after 20 weeks of gestation without proteinuria (protein in urine). 
Preeclampsia (PE) is an increase in blood pressure after 20 weeks gestation with evidence of 
proteinuria. Women with preeclampsia may also have edema, visual disturbances, headache 
and abdominal pain. Severe preeclampsia includes a blood pressure above 160 mmHg systolic or 
110 mmHg diastolic, proteinuria in excess of 5 grams per 24 hours (3+ dipstick), low urine 
output, pulmonary edema, low platelets and elevated liver enzymes.  Eclampsia is diagnosed 
when a woman with preeclampsia experiences a new-onset seizure. In a woman with pre-
existing hypertension or renal impairment, a diagnosis of superimposed preeclampsia can be 
made with worsening of hypertension or proteinuria or the new involvement of other systems 
(neurological, liver, hematologic).22,45 
Recent guidelines45 suggest that an elevation in blood pressure should be defined as a 
blood pressure above 140mmHg systolic or 90 mmHg diastolic at least twice after 20 weeks 
gestation in women who were previously normotensive. Proteinuria can be defined as more 
than 300mg of protein in a 24 hour collection of urine or a protein dipstick value of >=1+ 
(300mg/L) on two random urine samples taken more than 24 hours apart. Previous definitions 
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of preeclampsia used a “30-15” rule; an increase in systolic blood pressure of 30 mmHg or an 
increase in 15 mmHg in the diastolic blood pressure over baseline.45 
There is some suggestion that preeclampsia is a heterogeneous disorder with different 
pathophysiology for those cases arising early in pregnancy with impaired fetal growth compared 
to cases arising later in pregnancy with little fetal compromise.48 
Time Trends 
The changing and differing diagnostic criteria for hypertensive disorders of pregnancy, as 
well as poor data quality on birth certificates, has complicated the analysis of these disorders 
over time. Using data from the National Hospital Discharge Survey, Wallis found an increase in 
both gestational hypertension and preeclampsia over the period from 1987 to 2004. GHTN 
increased from 10.7 per 1,000 deliveries in 1987-1988 to 30.6 per 1,000 deliveries in 2003-2004. 
Over the same time period preeclampsia increased from 23.6 per 1,000 deliveries to 29.4 per 
1,000.49 An analysis of preeclampsia in Norway, which has had more stable diagnostic criteria 
and universal access to care, over the period of 1967-2003 suggested a gradual increase in the 
incidence of preeclampsia in first pregnancies from 3.1% in the first decade of the study to 5.5% 
in the final decade.50 Currently, rising rates of obesity, a risk factor for preeclampsia, have led to 
concerns that the incidence of preeclampsia may continue to increase.22, 43 
Sequelae 
Fetal 
Up to one quarter of infants in pregnancies complicated by a hypertensive disorders of 
pregnancy will have poor intrauterine growth, and up to two-thirds will be delivered preterm for 
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fetal or maternal indications.22  Preterm birth can be indicated due to intrauterine growth 
restriction, placental abruption, low amniotic fluid or non-reassuring fetal testing. Acute and 
chronic sequelae from preterm birth and poor fetal growth are covered in Sections 1.2.1 and 
1.2.3.  Still birth and infant death are rare fetal outcomes, which are elevated compared with 
non-hypertensive pregnancies.22, 50  
Maternal 
Many of the symptoms of hypertensive disorders of pregnancy resolve with the delivery of 
the infant. In severe cases, there can be longer lasting sequelae including neurologic deficits as a 
result of seizure or stroke, renal failure, liver failure or hemorrhage.45 Hypertensive disorders of 
pregnancy are one of the leading causes of maternal mortality. 
Women with a prior pregnancy complicated by hypertension are more likely to have 
recurrent gestational hypertension and preterm birth.22, 45  There is also evidence that women 
with gestational hypertension or preeclampsia are at increased risk for cardiovascular disease 
(CVD) and diabetes later in life,51, 52  with some evidence to suggest that early preeclampsia or 
recurrent preeclampsia are stronger risk factors for later CVD.  
Risk Factors 
The strongest known risk factor for preeclampsia is the presence of antiphospholipid 
antibodies and a previous pregnancy with preeclampsia.53  These are associated with a more 
than 5 fold increase in risk. However preeclampsia is most often associated with first 
pregnancies, and antiphospholipid antibodies are rare. Heritability will be discussed in Section 
1.5. Additional risk factors are outlined in Table 1.2. 
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Table 1.2 Risk factors for hypertensive disorders of pregnancy 22, 45, 53 
Maternal Medical Conditions Pregnancy Related Conditions 
Demographic and 
Anthropometric Factors 
Antiphospholipid syndrome Previous PE Increased BMI 
Chronic Hypertension First birth Extremes of age 
Diabetes Multiple Gestations  Family History of PE 
Pre-existing disease; renal, Long Inter pregnancy Interval African American race 
autoimmune, vascular, Infection  
connective tissue, rheumatic, New Father* Behavioral 
thrombophilias   Smoking (protective) 
*The risk associated with novel sperm exposure is quite controversial 
 
Smoking 
Of note, smoking has an accepted and seemingly robust, if weak, protective association 
with preeclampsia. Multiple studies and systematic reviews have shown an association between 
smoking and both gestational hypertension and preeclampsia in the range of OR 0.5-0.754-56 with 
some suggestion that heavy smokers, women who smoke until the end of pregnancy and lean 
women57 have more protection.  
1.2.3 Fetal Growth 
Fetal Growth as a Reproductive Outcome 
Fetal growth over the course of pregnancy is a result of genetically determine growth 
potential, maternal ability to meet the nutritional needs of the fetus through adequate nutrients 
and adequate delivery of the nutrients, fetal nutritional demands, which may be influenced by 
fetal pathology, and the length of gestation, which provides time for growth.  Maternal, fetal 
and environmental factors may act at any of these levels to influence how well a fetus grows 
over the course of pregnancy. Given the individual variation of growth potential, the strong 
association of birth weight with gestational age, difficulty in accurately defining gestational age 
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and the inability to obtain a true fetal weight until the time of delivery, assessment of fetal 
growth is quite difficult. 
Despite the difficulties in assessing the trajectory of fetal growth, the final product of fetal 
growth, birth weight, is a well-measured and well recorded outcome. Low birth weight (<2500 g) 
in particular, is associated with a number of important neonatal outcomes including neonatal 
mortality and morbidity. However, focusing simply on birth weight obscures important 
individual level and population associations. Historically, given the difficulty is assessing 
gestational age accurately, preterm birth was sometimes equated with low birth weight. 
However, not all preterm births are also low birth weight. Additionally small term infants may 
have undergone restricted growth in utero, and so-called “normal” birth weight infants may not 
have reached their full potential. At the population level, factors such as altitude that result in a 
lower mean birth weight may not be pathological.  
Within the population of “small” infants, only a fraction are small for reasons that will 
result in meaningful health consequences. Yet attempts to identify small infants who are also 
high risk for other outcomes have had only limited success. At a population level with large 
numbers, the residual distribution of birth weight can help identify populations at risk for higher 
infant mortality by identifying a surplus of small preterm infants.58 At the individual level, birth 
weight adjusted for gestational age through a small for gestational age (SGA) or z-score 
measurement overcomes some of the difficulty with looking solely at low birth weight by taking 
time in utero available for growth into account.  
However, an SGA measure based on live births only identifies the lowest fraction (often 5th 
or 10th percentile) of infants at a given gestational age. Preterm infants are often smaller than 
their in utero counterparts who go on to deliver at term.24, 59  The SGA measure fails to capture 
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this discrepancy and may fail to capture many preterm infants who have been growth restricted 
in utero.60  Use of ultrasound-based measures of fetal growth has been offered as a possible 
solution to the difficulties of a live birth standard.60  Ultrasound-based measures however are 
algorithms that also have inherent errors and can only be established and validated in a select 
population, inviting bias and non-generalizabilty .  
For purposes of this study, the outcome of interest is intrauterine or placental conditions 
that prevent the fetus from attaining maximal growth. While frequent longitudinal ultrasound 
measurements starting at a very early in pregnancy for cohort members along with a 
comparable population sample would be ideal, these data were not available for this secondary 
analysis. The SGA variable collected for the study cohort may under-represent growth restricted 
preterm infants, but the cut-point of 10% offers a reasonable balance between more stringent 
definitions, which would further bias the preterm infants, and a more permissive definition, 
which would identify more constitutionally small infants. 
Types 
Poor fetal growth has sometimes been characterized as proportional or symmetric and 
non-proportional or asymmetric. Symmetrically small infants have reduced weight, length and 
head circumference while asymmetrically small infants have reduced weight but “normal” 
length and head circumference. Theoretically, complications or maternal malnutrition arising at 
conception will result is symmetrically small infants while complications that arise later in 
pregnancy will impact final weight but spare bone and head growth, which have already neared 
completion. Studies that have been able to accurately determine gestational age and account 
for confounding variables however have failed to find etiologic differences between these two 
groups of small infants.61, 62 
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Time trend 
As measured by SGA, poor fetal growth will, by definition, remain stable over time. 
Therefore continuous measures such as the distribution of birth weights, residual distributions 
of small preterm infants, or mean birth weight over time will provide more information about 
temporal trends in birth weight. National statistics from the US suggest a fairly stable birth 
weight distribution between 1950 and 2000 with a very slight shift towards heavier births.33  A 
study in Norway examined birth weights from 1860 to 1984, a time period that included both 
industrialization and periods of industrial collapse, World Wars and modern times with a strong 
social support system, all of which all affect the livelihood, nutrition and general health of 
women. Over this period of time in Norway birth weights increased just under 200g over the 
course of 120 years.63  These data suggest that population-level birth weight has remained fairly 
stable over time. 
Sequelae 
Infant 
Low birth weight is consistently associated with increased neonatal mortality33 although it 
is difficult to ascribe causation given the number of causes of low birth weight (preterm birth in 
particular) and the possibility of an unknown common cause of low birth weight and neonatal 
mortality.64  The immediate neonatal sequelae of low birth weight are often intertwined with 
the sequelae of early gestational age, although the association between infant mortality and 
birth weight is evident at all gestational ages.58 
The long term effects of low birth weight on subsequent health and mortality can also be 
difficult to assess given the implausibility that birth weight per se is causally related to later 
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health outcomes.65  However, while birth weight may not be causally linked to subsequent 
outcomes, there are a number of observed associations between birth weight and later health 
outcomes. 
The Barker Hypothesis66-68 suggests that impaired growth and development in fetal life and 
infancy programs persistent changes in metabolic, physiologic and structural processes that 
influence the development of chronic disease later in life. In particular, heart disease and 
diabetes have been associated with lower weight at birth. While the association with all-cause 
mortality has been less clear cut, there is the suggestion of higher cardiovascular and all-cause 
mortality among low birth weight infants compared with their “normal” birth weight peers.69 
Maternal 
Delivery of a small fetus is often less physically difficult for women with lower incidence of 
perineal damage and need for c-section due to fetal size. As with preterm delivery, the 
immediate maternal sequelae depend on the cause of the low birth weight. There is some 
suggestion that women who deliver low birth weight infants may be at increased risk for later 
CVD. The association with later CVD seems to be driven by the preterm aspect of low birth 
weight and is likely due to common cause between CVD and poor fetal growth or preterm 
birth.40, 70  There is however suggestive evidence that a biologic process activated during 
pregnancy that results in a low birth weight infant may persist and result in later CVD.71 
Risk Factors 
In general, fetal growth, as measured at birth, is considered as a possible negative outcome 
at both ends of the birth weight distribution. Both small and large infants have increased risk of 
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negative sequelae. Although this study is focused on poor fetal growth as a marker of placental 
dysfunction, large infants also can have poor outcomes. 
Risk factors for poor or excessive fetal growth are complex. Birth weight is the culmination 
of fetal, maternal and environmental factors. Potential for infant height and weight is 
determined by fetal genetics. Attainment of that potential is influenced by maternal ability to 
supply the necessary nutrients and the intervention of many possibly environmental insults. 
A number of natural experiments in maternal malnutrition, such as severe famines during 
times of war, have shown that acute maternal malnutrition, below 1,500 calories a day, 
especially during the third trimester, is associated with birth weight decrements of 
approximately 300g. However, above this minimum level, maternal adaptation appears to 
protect the fetus from significant weight loss.63 
Table 1.3 lists a number of factors that are associated with birth weight across the range of 
birth weight with some conditions increasing the risk for large infants (diabetes) and others 
associated with small infants (smoking). Heritability and recurrence of low birth weight will be 
explored in Section 1.5.  
Table 1.3 Factors associated with fetal growth 33, 41, 61 
Maternal/Paternal Pregnancy Related Environmental (all limited evidence) 
Ethnicity/ Race  Parity  Lead  
Social Class  Plurality  DDT/DDE  
Maternal height and weight Smoking Environmental Tobacco Smoke  
Parental birth weight  Fetal sex Outdoor air pollution  
Previous LBW infant Gestational hypertension Disinfection by products  
 Gestational diabetes Nitrate in water  
 Gestational weight gain  
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1.3 Role of Inflammation in Adverse Pregnancy Outcomes 
Pregnancy is a state of altered inflammatory function.1  During an uncomplicated 
pregnancy, there are distinct changes in maternal immunity that result in an enhancement of 
defensive or innate immunity and a decrease in adaptive immunity through reduced natural kill 
cell and T cell inflammatory activity. Compared with post-partum levels, there are marked 
changes in cytokine concentrations, activity and response to stimulation.72, 73  In the majority of 
pregnancies, the altered inflammatory function benefits both mother and fetus by mitigating 
the immune rejection of fetal tissue3 while restricting the extent of invasion of the fetally-
derived placenta.5  As the pregnancy progresses, the balance of pro- and anti-inflammatory 
cytokines may act as a determinant of the timing of delivery.74  Dysregulation in inflammatory 
pathways from pre-conception through delivery may impact the success of the pregnancy and 
the health of both the mother and the fetus.  
1.3.1 Preterm Birth 
 
Although the biological pathways behind the initiation of labor, whether at term or 
preterm, are still poorly understood, inflammatory cytokines are integral to a number of 
processes that occur at the time of delivery. As reviewed by Bowen,74 pro-inflammatory 
cytokines tend to increase towards term, and labor itself is a pro-inflammatory state. 
Inflammatory cytokines (IL-1, TNFα, IL-6) in addition to anti-inflammatory cytokines (IL-4 and IL-
10) influence the production and metabolism of prostaglandins which enhance uterine 
contractility.75 TNFα, IL-1β, IL-6, CSF1, TGFβ and IL-8 influence the secretion of 
metalloproteinases that degrade fetal membranes at the time of birth. IL-8 has been implicated 
in cervical ripening.   
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Given the role of infection in preterm delivery, evidence of elevated inflammatory 
cytokines in preterm deliveries may be due to underlying acute or chronic infection. However 
pregnancies uncomplicated by infection show elevated levels of IL-8 and IL-1β, suggesting an 
independent role of inflammatory cytokines.75 
1.3.2 Hypertensive Disorders of Pregnancy and SGA 
Although distinct outcomes, Hypertensive Disorders of Pregnancy and SGA share certain 
common biologic process and will be considered together. Among the similarities, Ness9 and 
others3, 7, 10 note that many cases of SGA and PE share common placental pathology that 
includes shallow placentation. In normal pregnancy, fetal cytotrophoblasts invade the maternal 
tissue and orchestrate remodeling of the maternal vasculature.  Maternal spiral arteries that 
had previously been narrow and contractile become wider with erosion of the muscular lining so 
that resistance to placental blood flow is reduced and no longer subject to vasomotor 
contraction.3, 8  The process of changes in the maternal uterine wall (myometrium and decidua) 
is referred to as remodeling. Part of the pathology associated with both preeclampsia and poor 
fetal growth is shallow placentation, with both the myometrium and decidua showing reduced 
transformation. For PE there is sometimes evidence of absence of vascular remodeling in the 
myometrium and reduced remodeling in the decidua. For pregnancies that result in poor fetal 
growth, however, there is some, but still diminished, remodeling in both the myometrium and 
decidua.76  
Inflammatory cytokines play a role in successful placental invasion and development74 and 
may influence the invasive phenotype of trophoblasts. The interaction between fetal 
trophoblasts and maternal decidual cells may be mediated by maternal natural killer cells. These 
NK cells create a local “microenvironment” which, while permitting placental implantation and 
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remodeling, limits the extent of the invasion.5  Inflammatory cytokines may also play a role in 
placental development by influencing the hypoxia inducible factor (HIF), a transcription factor 
which is central in placental angiogenesis.9  
The later manifestations of poor placentation can be maternal, fetal or both, with SGA and 
PE occurring both concurrently and in isolation.77 Fetal effects of poor placentation include SGA. 
With inadequate transformation of spiral arteries, the resistance to placental blood flow 
remains high, and as a result there is inadequate delivery of both oxygen and other nutrients to 
the fetus. While some degree of maternal and fetal adaptation can occur (increased maternal 
cardiac function and increased erythropoiesis to improve oxygen carrying capacity and delivery, 
and fetal shunting of blood, decreased fetal movement and tone), in SGA these adaptations are 
insufficient to overcome the restricted oxygen and nutrients available to the fetus.78  
Maternal effects of poor placentation can include symptoms of gestational hypertension 
including increased blood pressure, decreased renal function and endothelial dysfunction. As 
result of shallow placentation, hypoxia and ischemic-reperfusion injuries occur with increased 
levels of inflammatory cytokines. These inflammatory cytokines may act directly to create the 
symptoms of preeclampsia or may act through other biological pathways including angiogenesis, 
the rennin-angiotensin system, endothelial activation, or clotting system disturbances.1, 8, 9  Ness 
also hypothesizes that the inflammatory cytokines may interact with preexisting risk factor for 
metabolic syndrome (adiposity, hyperglycemia, insulin resistance, hyperlipidemia, 
coagulopathy) to predispose some women with poor placentation to exhibit symptoms of PE.9 
Animal models of preeclampsia are limited by differences in placental structure. However 
LaMarca8 was able to reproduce some of the maternal symptoms of preeclampsia (increased 
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blood pressure, decrease blood flow and renal function) by infusing rats with pro-inflammatory 
cytokines. 
Inflammatory cytokines have been measured in the serum of women with gestational 
hypertension, preeclampsia and SGA. Increases in pro-inflammatory cytokines (TNFα, IL-6, IL-8) 
have been identified in women with PE8 and SGA (IL-6, TNFα, IL-1, IL-8) 1, 4, 7, 9  and in women 
who will go onto develop PE. 74, 79, 80  Decreased levels of anti-inflammatory cytokines (IL-10) has 
also been associated with PE 8 and SGA.4, 74   Although not all studies are consistent and vary 
with respect to timing of sample collection, sample tissue, outcome definition and comparison 
groups, there is sufficient evidence to implicate inflammatory cytokines in the outcomes of 
GHTN and SGA. 
1.3.3 Selection of Inflammatory Genes 
 The inflammatory pathway is complex and interconnected with a number of other 
biologic pathways. Review of existing genetic studies (Section 1.6) suggested some genes that 
are important to consider (TNFα, LTA (TNFβ), IL6, IL6R, IL1A, IL1B, IL10, IL2, IL4, IL13). Some of 
the genes found in previous studies (TNFR1, TNFR2, IL5, IL1RA) were not included in the current 
panel due to design issues, including identification of more biologically relevant genes, poor tag 
design scores, difficulty tagging the gene in a combined CEU and YRI population, too many SNPs 
required to tag the gene, or previous findings based solely on tags with poor replication.  
In order to expand on candidate genes, we considered the underlying immune system and 
links to cardiovascular outcomes. Although the three outcomes under consideration have 
different underlying pathology, the inflammatory genes involved may be similar. The 
inflammatory pathway in preeclampsia has received the most attention with numerous in vitro 
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and placental studies. Saito81, 82 provides a conceptual framework for preeclampsia that 
highlights the delicate balance between different arms of the immune system during pregnancy.  
The human immune system can be divided into the innate immune system and the 
adaptive immune system.83  The innate immune system is non-specific and acts quickly in 
response to multiple insults (injury, pathogens) by recruiting immune cells, activating cells to 
identify pathogens and remove dead cells, and activating the adaptive immune system. 
Inflammation is one of the first responses in the innate immune system and can be induced by 
infection or injury to prevent the spread of infection and promote healing. Cytokines released as 
a part of the innate immune system (IL1, IL6, IL8, IFNγ, TNFα) induce local reactions (swelling, 
redness, warmth) and recruit additional immune cells to the site. Innate immunity is non-
specific and does not produce long-term immune memory or protection.  
The adaptive immune system, while slower to respond compared with the innate immune 
system, results in the creation of antibodies and generates specific immune responses based on 
the type of pathogen present. The adaptive system is responsible for immunologic memory and 
longer-term immune protection. The adaptive immune system functions through T cells and B 
cells and can produce Type 1 (Th1) or Type 2 (Th2) cytokines.  
In general, Th1 cytokines induce cell-mediated immunity. Type 1 cytokines (IL2, TNF, IFNγ) 
drive the production of cytotoxic T cells and activated macrophages. Cytotoxic T cells lyse cells 
expressing specific antigens and also play a role in graft rejection when cells are recognized as 
‘non-self’. Activated macrophages engulf invading organisms, dead cells, immune complexes 
and antigens. Macrophages also release cytokines (TNF and IL1).  
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The Th2 response results in humoral immunity. Type 2 cytokines (IL4, IL5, IL6, IL10, IL13) 
recruit and stimulate B cells, which produce antibodies. These antibodies are responsible for 
marking pathogens for death and for immune memory. Type 2 cytokines also activate 
phagocytic cells (macrophages and neutrophils) to remove antigen, bacteria and complement, 
which can destroy organisms or make it easier to be spotted as foreign so that other cells will 
destroy it. 
The mechanism that drives the differentiation of naïve T cells to Th1 or Th2 is unknown and 
is thought to depend on the local cytokine milieu. IFNγ and IL12 drive Th1 cell production while 
IL10 and IL4 inhibit Th1. IL4, along with IL6 and IL1, drives Th2 production while IFNγ inhibits Th2 
cells. Therefore the two cells lines act to inhibit the other and, in as much as both Th1 and Th2 
are needed for complete immunity, the two cell lines compete for dominance depending on the 
unique situation. 
Saito suggests that while pregnancy is generally a pro-inflammatory state, the balance of 
inflammation during pregnancy is in favor of Th2 cells as opposed to Th1 cells. In pregnancy an 
over expression of the Th1 response may result in rejection of the semi-foreign fetus and 
trophoblast cells, which are necessary for placental development.  
Saito posits that an excessive Th1 response results in the rejection of the fetus 
(miscarriage) or poor placentation (preeclampsia), while an increased Th2 response allows for a 
successful pregnancy.82 Given the nature of biological systems however, inflammatory cytokines 
are not uniquely situated in a single pathway and have both autocrine and paracrine activity, 
making the true pathways complex.  
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In choosing genes to include on the panel, we considered both the role of the gene in 
inflammation as well as evidence that the gene might be associated with cardiovascular disease 
or conditions associated with metabolic syndrome (diabetes, obesity, and hypertension). In 
addition, changes in immune function over the course of uncomplicated pregnancy was 
considered.72, 73  Cytokines that normally change over the course of pregnancy may influence 
these outcomes if polymorphisms result in the alteration of expected ratios between different 
cytokines.   Table 1.4 outlines the genes chosen, the immune function, association with 
reproductive outcomes and association with other CVD of metabolic syndrome diseases.  
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Table 1.4 Candidate genes involved in inflammation  
Gene 
Role in Immune 
System 
Association with Reproductive Outcomes 
Association with 
CVD and Metabolic 
Syndrome 
IL1A Innate 
Preeclampsia,
84, 85
 PTB.
86
 Increased in 
response to hypoxia
22
 
 
IL1B Innate 
Recurrent Fetal Loss,
87
 PTB,
88, 89
 PE,
85
 
Increased in response to hypoxia
22
 
 
TNFα Innate/ Th1 
PE with IUGR.
90
  PTB
6, 91
 Increased in 
response to hypoxia.
22
 In rat models 
infusion mimics PE
8
 
SBP, Cholesterol 
ratios, CVD risk 
factors.
92
 Diabetes
93
 
IL6 Innate/Th2 
Recurrent pregnancy loss.
87
 PTB
6, 91, 94, 95
 
PE
1
 Increased in response to reduced 
placental blood flow
22
 
Type 1 and Type 2 
Diabetes
93
 MI
96
 
IL6R Innate/Th2 Associated with PTB
94, 97, 98
 
CRP levels.
99
 CRP 
levels and risk of 
CHD.
100
 Type 2 
diabetes
101
 
IL8 Innate 
Increased in response to reduced 
placental blood flow.
22
 Levels increased 
in PE
8
 Increased placental expression 
with hypoxia (Thomas Moran) 
 
IL8RB Innate Receptor for IL8  
CSF2 
Innate (5q31 
cluster) 
Shows variable expression over the 
course of pregnancy (Thomas Moran) 
 
LTA Innate/Th1 Recurrent pregnancy loss.
102
 PTB
6
 MI
103, 104
 
IL10 (Tr1) 
Blocks excessive 
inflammation 
Associated with PTB
105
 PE
106-108
 Levels 
decreased in PE
8
 
Graft v host 
disease
109
 
TGFB1, TGFB3 
(Th3) 
Block excessive 
inflammation 
May regulate T cell differentiation
110
 
PTB.
4, 111
 Involved in trophoblast 
differentiation
112
 
 
TNFRSF1B Innate/Th1 PTB
113, 114
 Hypertension
115
 
IL2 Th1 Increased expression in placenta
9
 Type 1 Diabetes
116
 
TBX21 (TBET) Th1 Key transcription factor in Th1
110
  
IFNγ Th1 Associated with PTB
111
  
IFNGR2 Th1 
Recommended by Thomas Moran (Mt. 
Sinai Immunologist) 
 
IL12A/IL12B Th1 
Influences release of IFNγ by NK cells
22
 
Plays a role in T cell differentiation
82
 
Type 1 Diabetes
117, 
118
 
IL18 Th1 Plays a role in T cell differentiation
82
 
Obesity, diabetes, 
CHD
119
 CVD and 
CVD mortality
120
 
CXCL10 Th1 Closely associated with IFNγ.  
IL4 Th2 Associated with PTB
4, 105
 SGA
4
 PE
121
 MI
122
 
IL13 Th2 Associated with PTB
4
  
GATA3 Th2 Key transcription factor in Th2 cells
110
 Asthma
123
 
IL15 Th1/ NK Associated with PTB
98
  
NFκB1 
Transcription 
factor implicated 
in many pathways 
NFκB signaling in involved in the 
inflammatory excess seen in obesity
124
 
Diabetes
125
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Abbreviations: PTB (preterm birth), PE (preeclampsia), IUGR (intrauterine growth restriction), 
SBP (systolic blood pressure), CVD (cardiovascular disease), MI (myocardial infarction), CRP (c-
reactive protein), CHD (coronary heart disease), SGA (small for gestational age), NK (Natural 
Killer Cells)  
 
In addition we had an interest in Natural Killer cells and their role in these outcomes given 
placental expression data.73  Natural Killer (NK) cells are a part of the innate immune system 
although they play an important role in adaptive immunity as well. They induce apoptosis in 
cells and can be activated by mitogens (chemical substance that triggers mitosis), INFγ and IL12 
in the absence of antigen or antibody.83  As a response to NK cells, inhibitory KIR cells bind to 
specific receptors on MHC class 1 molecules and provide protection against cell destruction. 
Uterine NK cells are the predominate leukocyte in the uterine mucosa and are most abundant in 
early pregnancy, less conspicuous after 20 weeks and nearly absent at term.126  The fetus and 
invading trophoblasts are in a sense semi-foreign tissue and are at risk of being destroyed by the 
maternal immune system. In order to evade detection and destruction, trophoblasts only 
express the MHC molecules (HLA-C, HLA-E and HLA-G) which have specific ligands for NK cell 
receptors such as KIRs. Inhibitory KIR binding to the HLA-G expressed by the trophoblast may 
protect these cells from maternal immune detection and destruction by NK cells.127 There is 
some evidence that the KIR haplotypes maybe implicated in recurrent miscarriage and PE.128, 129 
KIR haplotypes vary in the number and specific genes present. Individuals have between 7 
and 12 KIR genes expressed on a single haplotype. However the genes 2DL4, 3DP1, 3DL2 and 
3DL3 are present in virtually all haplotypes and have been called framework loci. For this study 
the framework KIRs KIR3DL3, KIR3DL2 and KIR2DL4 were chosen along with CD94 (KLRD1) which 
was shown to vary during pregnancy. 
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1.4 Role of Cell Cycle in Outcomes 
1.4.1 Description of the Cell Cycle 
The cell cycle refers to the processes that occur within a cell that leads to duplication of the 
genetic material and the division of the cell into two daughter cells. Cell cycle functions are vital 
for the growth of embryonic, fetal and placental tissue and continue to play a role throughout 
the life cycle in the maintenance and renewal of human tissues and organs. 
The cell cycle can be divided into two periods: interphase, during which genetic material is 
replicated, and mitosis, when the cell splits into two daughter cells each with a full complement 
of genetic material. 
Interphase is composed of G1, S and G2 phase. Briefly, G1 and G2 are periods of cell growth 
and maintenance during which time biochemical processes ready the cell for DNA synthesis (G1) 
or mitosis (G2). During S phase, DNA replication occurs and the cell temporarily has two sister 
chromatids. Since accurate DNA replication and successful cell division is critical to an 
organism’s survival, regulation of the cell cycle is tightly controlled. Transitions between the 
phases of the cell cycle are controlled by checkpoint proteins, which ensure that the cell is 
prepared to enter the next phase. When factors that might be damaging to the cell, such as UV 
radiation, reactive oxygen species, and inflammation, are present, and/or DNA damage is 
detected, arrest of cell cycle progression allows time for a variety of processes, including DNA 
repair and reduction of cellular stress. If damage is irreparable, arrest of cell cycle progression 
may result in the cell entering apoptosis (cell death) as opposed to replication. 
Two important checkpoints occur before S phase and before mitosis. Groups of cyclins and 
cyclin dependent kinases form activated units that regulate the orderly progression through the 
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cell cycle. Disruptions of these cell cycle regulatory proteins can result in cells that are arrested 
in G1 or G2 and cease replication and/or division. In addition, inhibitory proteins, including 
cyclin-dependent kinase inhibitors and protein 53 (p53), can block progression of the cell cycle 
and arrest the cell in a specific phase. 
M phase includes both mitosis and cytokinesis. Mitosis is the process by which the 
chromosomes are separated into two identical sets of chromosomes in two nuclei. Following 
mitosis, cytokinesis occurs, and the single cell with two nuclei is divided into two daughter cells 
that are each diploid. M phase accounts for approximately 10% of the cell cycle. Although M 
phase is vital for cell division, this project will focus on genes associated with interphase and the 
checkpoint proteins that regulate the entry into S and M phase. 
1.4.2 Relevance of cell cycle processes 
Epidemiologic studies have noted a strong correlation between placental weight and birth 
weight and SGA.130-132 Placentas from pregnancies complicated by PE also tend to be smaller, 
although small placentas are more likely in preterm PE and in PE complicated by SGA.131, 133  As 
the placenta is essentially an organ that grows de novo over the course of pregnancy, 
fundamental cell growth processes maybe influence placental growth. Poor cell cycle function 
due to genetic polymorphisms may result in reduced cell proliferation and poor placental 
development with the ultimate outcome of poor fetal growth and/or preeclampsia.  
Genetic polymorphisms in cell cycle genes have not been extensively studied for the 
outcomes of preterm birth, GHTN or SGA. A few studies have documented associations with 
missed abortion16 and gestational diabetes.17  However, a number of cell cycle genes have been 
implicated in cardiovascular disease18 and type 2 diabetes.19  Animal and human placental 
 29 
expression studies have also suggested that cell cycle genes are differentially expressed in 
placental tissue20, 21 and may differ in expression, quantity or function in women with PE or 
SGA.134-138  Therefore cell cycle genes comprise a novel pathway that may be important in the 
outcomes of preterm birth, GHTN, PE and SGA.  
1.4.3 Selection of Candidate Cell Cycle Genes 
Candidate genes were chosen to represent a number of important check points in the cell-
cycle. In addition, placental expression studies and associations with reproductive, metabolic or 
cardiovascular outcomes were used to focus on genes that may be relevant (Table 1.4.3). 
Table 1.5 Overview of role and supporting evidence for cell cycle genes 
Gene Alias Role Evidence 
CCNA2 Cyclin A2, CCN1, CCNA G1/S and G2/M transition 
Plays a role in trophoblast 
differentiation
112
 
NOV 
Neuroblastoma 
overexpressed gene 
Regulate cellular 
migration, invasion and 
differentiation 
Lower expression in placentas with 
early onset PE.
138
  Trophoblast 
levels altered with hypoxia, 
regulated by HIF-1α and TGFB3.
139
 
CCND1 Cyclin D1 G1/S transition 
Decreased placental expression in 
PE and IUGR.
136
 Differential 
placental expression throughout 
pregnancy.
20
 
CDKN2A/2B 
Cyclin dependent kinase 
inhibitor 2A/2B 
G1 control, interacts with 
p53 
Associated with Type 2 diabetes
140
 
Gestational diabetes
17
 MI, CHD
18
 
RASSF1 
Ras associated domain 
family member 1 
Tumor suppressor 
function, induce cell cycle 
arrest through cyclin D1 
 
CNNM2 Cyclin M2  
Downregulated in mouse placenta 
with hypoxia.
141, 142
 SBP.
143
 
MDM2 
p53 binding protein 
homolog 
G1 and apoptosis through 
interaction with p53 
Associated with spontaneous 
miscarriage
16
 and subfertility
144
 
CCNH Cyclin H G1/S and G2/M transition 
Associated with transplant 
rejection
145
 
GADD45A 
Growth arrest and DNA-
damage-inducible, alpha 
Respond to stress by 
activating inflammation 
and innate immunity 
Important upstream regulator in 
preeclampsia (correlated with sFlt-
1)
135
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1.5 Evidence of Genetic Component 
Preterm Birth 
One of the stronger risk factors for preterm birth is a previous preterm pregnancy.33  In 
addition to the high risk of recurrence, twin studies suggest a heritability of 34% for birth 
timing.146  The genetic risk of preterm birth is complicated by the contributions of three genetic 
lineages -- maternal, paternal and fetal -- as well as the role of shared environment within a 
single woman or within her family of birth. Recent population based studies in Norway,12 
Denmark13 and Sweden14 have attempted to assess the role of maternal genes in the outcome 
of preterm birth.  
The study in Sweden14 used three generations to generate pairwise odds ratios between 
siblings and within siblings to assess familial aggregation. Modeling also allowed the estimation 
of maternal and fetal genetic effects and environmental effects of the couple, sibling 
environment and non-shared environment. The Swedish study found an increased risk of 
preterm birth among sisters (OR 1.9, 95% CI 1.6, 2.2) but not among brothers or mixed sibling 
pairs. The increased risk among sisters could reflect maternal or fetal genetic effects or a shared 
sibling environment. The modeling of environmental as well as genetic effects suggested no role 
for shared sibling environment but a significant effect for maternal genes (25%), fetal genes 
(5%), couple environment (18%) and unshared environmental effects (52%). The effect of 
maternal genes was stronger in spontaneous preterm birth while the effect of fetal genes 
increased in medically indicated births. 
In Denmark,13 Boyd identified women with a singleton birth between 1978 and 2004 and 
assessed her family history and her partner’s family history with respect to preterm birth. 
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Cohorts for each type of family history (personal, family, partner and partner family history) 
were constructed to assess the risk of preterm birth for each type of family history. While a 
woman with a previous preterm birth had an increased risk of subsequent preterm birth (RR 5.9, 
95% CI 5.7, 6.1), having a partner with a previous preterm birth (with a different woman) did not 
increase her risk (OR 1.1, 95% CI 1.0, 1.2). Family history of preterm birth was also associated 
with preterm birth. Women with a history of preterm birth among their mothers, full sisters or 
maternal half-sisters were 55% more likely to deliver preterm. There was no increased risk due 
to a preterm birth in a woman’s paternal half-sisters, female partners of the woman’s male 
relatives and any relation in the biological father’s family.  In addition to documenting the high 
recurrence of preterm birth, this study suggests a strong heritable factor that is transmitted 
through female relatives. The paternal effect, which may also be considered an effect of fetal 
genes, was generally absent. The authors suggest that imprinting or mitochondrial genes may 
explain some of the distinctly female transmission seen. This study was unable to assess 
environmental risk factors. 
The Norwegian study12 examined 2 generations of singleton births without preeclampsia 
for recurrence of preterm birth in a first birth among mothers and fathers born preterm 
themselves. While women born preterm had an increased risk of preterm birth in their first 
pregnancy (RR 1.5, 95% CI 1.4, 1.7), men born preterm had only a small increase in preterm 
birth for their first child (RR 1.1, 95% CI 1.0, 1.2). In women the association was stronger if she 
had been born in the early (<34 weeks) preterm period. 
These three population based studies support a role for maternal genes in the risk of 
preterm birth while failing to find evidence of an association with fetal genotype. The role of 
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imprinted genes, mitochondrial genes and shared environmental factors has not been fully 
explored and may explain some of the patterns observed. 
SGA 
History of a previous SGA infant is a strong risk factor for SGA, and women who were born 
SGA themselves are more likely to have an SGA infant.15  Twin studies suggest a heritability of 
34%. A population-based study in Sweden18 compared the risk of SGA between full and half 
siblings looking at sisters, brothers, sister-brother pairs and successive pregnancies within 
couples. The methods used allowed for the examination of maternal, fetal, couple environment, 
sibling environment and non-shared environment. Among full siblings there was a stronger 
effect among sisters (OR 1.8, 95% CI 1.7, 1.9) than among brothers or sister-brother pairs (OR 
1.3, 95% CI 1.2-1.4). The association among brothers suggests a fetal genetic component, while 
the stronger association among sisters suggests an additional maternal genetic component. 
Among half-siblings there was only an association between sisters (OR 1.2, 95% 1.1, 1.4) 
although half-sisters were not classified by maternal or paternal sharing. An analysis of the 
discrete genetic and environmental components suggests that the fetal genetic effect explains 
37% of the variance while the maternal genes explain an additional 9% (a total of 27.5%) while 
the couple environment (18%) and non-shared environment (36%) are also important. 
Preeclampsia 
The genetic component of preeclampsia is complex due to the possible contributions of 
fetal, maternal and paternal genes.147 One twin study estimated the heritability of preeclampsia 
(54%) and gestational hypertension (24%), although the rarity of the outcome and the 
restriction to female twins has limited the number of twin studies with sufficient power.148 
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A large population based study in Norway11 using two generations of birth certificate data 
showed that both a maternal and a fetal mode of transmission is implicated in preeclampsia. 
Women who had been born in a pregnancy complicated by preeclampsia had an increased risk 
of preeclampsia in their own pregnancies (OR 2.2, 95% CI 2.0, 2.4). Men who had been born in a 
pregnancy complicated by preeclampsia also had an increased risk of fathering a pregnancy 
complicated by preeclampsia (OR 1.5, 95% CI 1.3, 1.7). While the women could be expressing 
genes in a maternal or fetal pathway, fathers can only contribute to the fetal pathway. In 
addition, siblings from normal pregnancies in families with a history of preeclampsia were also 
examined. The sisters in this situation could possess maternal genes but not fetal genes, and the 
brothers could also possess the maternal gene but this would not contribute to the 
preeclampsia risk in their partner. The findings supported the hypothesis of a dual genetic 
pathway, with the sisters having an increased (but attenuated) risk for PE (OR 2.0, 95% 1.7, 2.3) 
and the brothers having no increase in risk (OR 1.1, 95% CI 0.9, 1.4).  
A study in Sweden148 looked at mother-daughters pairs, full sisters, maternal half-sisters 
and paternal half-sisters. The inclusion of paternal half-sisters along with the assumption that 
children live with their mothers, allowed the authors to attempt to disentangle genetic and 
environmental contributions. The Swedish study found an increased risk among women who 
had a full sister with PE (OR 3.3, 95% CI 3.0, 3.6) or who had a mother with PE (OR 2.6, 95% CI 
1.6, 4.3). However the risk among maternal half-sisters was reduced (OR 1.4, 95% CI 0.9, 2.2) 
and absent in paternal half-sisters (OR 1.0, 95% CI 0.6, 1.6). A small sample of monozygotic twins 
showed a substantially increased (and imprecise) increased risk. Gestational hypertension 
showed a similar association, although the strength of the effect was stronger and maternal 
half-sisters had an increased risk (OR 2.7, 95% CI 1.2, 6.0). An analysis of the risk of gestational 
hypertension among pairs where the primary diagnosis was preeclampsia (and vice versa) 
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suggested that each outcome was a risk factor for the other. They estimated that the genetic 
component of preeclampsia is approximately 30%.  
Both studies note the possible role of shared environmental risk factors, in particular 
obesity and smoking. The Swedish study was able to model shared environment under a strong 
assumption regarding family dynamics and found that shared environmental factors were not 
significant. However the possibility for shared environment playing a role in the apparent 
heritability of gestational hypertension is still possible. 
These studies suggest that both preeclampsia and gestational hypertension have genetic 
causes. Although it is clear that there are both fetal and maternal components to the genetic 
risk, the maternal portion is substantial. 
Summary 
The studies of heritability in preterm birth, SGA and GHTN suggest that a genetic etiology is 
plausible. While preterm birth shows a predominately maternal genetic effect, both SGA and PE 
suggest the addition of a fetal genetic effect. Given the role of fetal genes in the development of 
the placenta, the presence of a fetal genetic effect in SGA and PE is not surprising. Reproductive 
outcomes must always consider the role of three distinct genetic contributions- maternal, fetal 
and paternal. While this study only has access to maternal DNA, the maternal genetic effect is 
substantial enough in all three outcomes to consider the maternal effect in isolation.  
1.6 Review of Genetic Epidemiologic Studies 
Compared with cancer or cardiovascular outcomes, genetic epidemiologic studies in 
reproductive outcomes are still limited. Although pregnancy can be considered a critical event in 
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genetic evolution, large-scale reproductive cohorts similar to the genetic cohorts for chronic 
disease do not exist. Most of the reproductive epidemiology studies looking at PE or preterm 
birth have been small, with fewer than a few hundred cases. The genes used in these studies 
have often been limited to a few SNPs for a few genes, with only a couple of studies using a 
larger, candidate gene approach. One of the difficulties that the existing studies share with 
almost all diseases is the definition of the outcome of interest. For preeclampsia, although 
guidelines exist for diagnosis, many studies use different classification or exclusion criteria, 
resulting in phenotypes that vary from study to study. Given the differences in allelic 
frequencies among groups of different genetic ancestry, existing studies from Europe or South 
America may not be generalizable to US populations. Given these difficulties, the current study 
will be able to add to what is currently known about genetic determinants of adverse pregnancy 
outcome. Given the size of the study population, the depth of the genetic panel, and the 
inclusion of US Whites and African Americans, this study is well positioned to advance the 
knowledge of these important outcomes. 
Preterm Birth 
A HuGE91 review of genetic variation in preterm birth reviewed 18 studies published before 
June, 2004 and concluded that inflammatory cytokines (TNFα in particular) showed the most 
consistent increase in the risk of PTB. In addition matrix metalloproteinase genes (involved in 
the degradation of fetal membranes) such as MMP1 and MMP9, Toll-like receptor 4 (TLR4 
involved in the response to certain bacteria), Beta-2-adrenergic receptor (ADRB2 links the 
sympathetic nervous system to the immune system), Vascular endothelial growth factor (VEGF; 
angiogenesis), Methylene tetrahydrofolate reductase (MTHFR; folate metabolism) and Factor 5 
(FV; coagulation pathway) genes may all be implicated in preterm birth. 
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A search of the Genetics Association Database (http://geneticassociationdb.nih.gov/cgi-
bin/index.cgi) as well as a review of PubMed revealed 20 genetic epidemiology studies that 
considered preterm birth as an outcome. The review was limited to studies that considered 
maternal DNA and had included at least one gene in the inflammatory pathway. The studies 
revealed quite a bit of heterogeneity with the outcome of interest with respect to the timing of 
preterm birth, the subtypes of preterm birth (preterm labor, PPROM, indicated delivery) 
included and the genetic ancestry of the populations studied. Most studies were small (largest 
had 300 cases and most had fewer than 200 cases) and the findings of early studies did not 
always replicate in subsequent studies. Table 1.6 has an overview of all the studies. 
Overall IL6, IL6R, TNFα (with or without LTA) and its receptors TNFR1 and TNFR2, IL1A, IL1B, 
IL1RN, IL5 and TGFβ1 showed the most consistent associations with preterm birth. Genetic 
associations often varied between White and African-American mothers, with each population 
showing different associations when stratified. 
A number of candidate gene approaches using a 1536 panel have been conducted in the 
US,98, 149  Chile,150, 151 and Norway.152 While these studies examined a wider range of genes in the 
inflammatory pathway, coverage of each gene was less intense with fewer tagSNPs per gene. 
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Table 1.6 Review of Genetic Epidemiology Studies of Preterm Birth  
Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Dizon-
Townson, 
DS
153
 
1997 Women possibly recruited in Utah Case-control 
203 
mothers,  
44 infants 
41 multips 
SPTB (PTL, 
PPROM) 
 < 37 wks 
TNFα None 
Simhan, 
HN
95
 
2003 
Women recruited at Magee-Women’s 
Hospital, Pittsburg, PA. Black and 
White women included. Subset of 
Prenatal Exposures and PE Prevention 
Study. 
Case-control 
51 cases  
(39 white,  
12 African 
American) 
156 
controls 
(110 
White, 46 
African 
American) 
PTL < 34 
wks (no 
PPROM) 
IL6 
Genotypic association 
among white mothers 
OR 0.14 (0.01-0.62) 
Hartel 
CH
154
 
2004 Retrospective study in Germany of 
VLBW infants and their mothers. Non-
white births excluded. 
Case-control 466 mothers 
of PTB VLBW 
infants 
281 
mothers of 
term 
infants 
PTB VLBW 
not 
defined 
IL6 
One genotypic (p=0.018) 
and one allelic (p=0.02) 
association. 
Strengthened among 
spontaneous PTB 
   CD14 None 
       NOD2 None 
       TLR2 None 
       TLR4 None 
Hao, K
155
 2004 
Women delivered at Boston Medical 
Center. Cases and controls matched 
for maternal age and ethnicity. 
Includes African American (453), 
Hispanic (194) and White (111) 
mothers. 
Case-control 300 cases 
458 
controls 
term 
>=2500g 
PTB <37 
wks  
31 genes 
(111 SNPs) 
 
     F5 
Haplotype association 
p=0.025 
      IL1R2 
Haplotype association in 
Blacks (p=0.0002) 
       NOS2A 
Haplotype association in 
Whites (p<0.001) 
       OPRM1 
Haplotype association in 
Hispanics (p=0.0004) 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Annells, 
MF
105
 
2004 Women with a previous preterm birth 
from North Adelaide, Australia. All of 
European descent. 
Case-control 202 cases 185 term, 
no history 
of PTB 
SPTB (PTL, 
PPROM)  
<35 wks  
TNFα 
(3 SNPs) 
Haplotype association 
with early PTB OR 2.4 
(1.1-5.5) 
IL1A None 
    
IL1B 
(2 SNPs) 
None 
       IL4 
Genotypic association 
with early PTB OR 3.4 
(1.2-9.6) 
       
IL10 
(3 SNPs) 
Haplotype association 
with early PTB OR 2.1 
(1.0-4.1) with a 
strengthening seen for 
PPROM 
       
TGFβ1 
(2 SNPs) 
None 
       
MBL2 
(5 SNPs) 
Allelic association with 
early PTB 2.3 (1.1-5.0) 
       IL6 None 
       IL1RN None 
       IL1R1 None 
       
TNFRSF6 
(2 SNPs) 
None 
Engel, SA
6
 2004 
Women recruited from hospitals in 
Wake and Orange County, NC. 
Restricted to African American and 
White. 
Nested case-
control 
67 African 
American, 
69 White 
238 African 
American, 
336 White 
SPTB (PTL, 
PPROM) < 
37wks 
IL1A 
(2 SNPs) 
Association in white 
mothers OR 1.8 (0.9-3.7)  
IL1B 
(3 SNPs) 
Association in white 
mothers for 2 
haplotypes OR 1.7 (0.9-
3.2) and OR 2.1 (0.9-5.2) 
       IL2 
None 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
       IL6 
Association  in both 
Whites and African 
Americans  
       TNFα 
Association in white 
mothers OR 2.9 (0.9-4.0) 
       
LTA 
(2 SNPs) 
One SNP showed an 
increased risk of PTB in 
white mothers OR 2.6 
(1.3-5.5) 
       TNFα/LTA 
Association in white 
mothers for two 
haplotypes OR 1.5 (0.8-
2.6) and OR 1.6 (0.9-2.9) 
Engel, SA
4
 2005 
Women recruited from hospitals in 
Wake and Orange County, NC. 
Restricted to African American and 
White. 
Nested case-
control 
67 African 
American, 
69 White 
238 African 
American, 
336 White 
SPTB (PTL, 
PPROM) 
 < 37wks 
IL4 
(3 SNPs) 
Haplotype association in 
African American 
mothers OR 2.9 (1.2-7.4) 
IL5 
Possible association in 
white mothers 
combined in haplotype 
with IL13 OR 0.5 (0.3-
1.0) 
       
IL13 
(3 SNPs) 
Haplotype association in 
African American 
mothers OR 2.7 (1.0-7.2) 
       
IL10 
(3 SNPs) 
None 
       
TGFβ1 
(2 SNPs) 
Haplotype association in 
white mothers OR 3.0 
(0.9-9.9) 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Speer, 
EM
111
 
2006 
Women recruited at Magee-Women’s 
Hospital in Pittsburg, PA from 
consecutive eligible deliveries. Term 
controls matched by maternal age, 
race, infant sex. African American 
20%. 
Case-control 
80 mother-
infant pairs 
80 mother 
infant 
spont term  
SPTB (PTL 
or PPROM)  
< 35 wks  
TNFα None 
IFNγ 
Conditional on fetal IFNγ 
genotype, maternal T 
allele negatively 
associated with PTB OR 
0.5 (0.3-0.98) 
       
IL6 & IL10  
(1 & 3 
SNPs) 
None 
       TGFβ1 
Genotypic association 
with gestational age of 
preterm deliveries 
p=0.025   
Menon, 
R
114
 
2006 
White women recruited from 2 
academic hospitals in Nashville, TN 
and Pittsburg, PA 
Case-control 101 Cases 
321 
Controls 
PTL< 36 
(0/7) 
TNFα 
(6 SNPs) 
None 
TNFR1 
(6 SNPs) 
Allelic and genotypic 
association with PTB 
       
TNFR11 
(7 SNPs) 
Genotypic association 
with PTB   
       
IL6, IL6R 
(5&3 
SNPs) 
None 
       
TNFα/IL6/I
L6R 
Multilocus association 
OR 3.5 (2.52-4.87) 
         
         
Velez, 
DR
156
 
2007 
Women recruited from 2 academic 
hospitals in Nashville, TN & Pittsburg, 
PA. 
Race 
stratified 
case-control  
White 149, 
African 
American 76 
White 347, 
African 
American 
321  
PTL 
<36(0/7) 
wks  
IL6 
(5 SNPs) 
None 
IL6R 
(3 SNPs) 
One SNP; African 
American mothers both 
genotypic and allelic 
(p=0.05, p=0.04) 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Stonek, 
F
157
 
158
 
2008 Consecutive Caucasian women 
present to antenatal clinic before 12 
wks GA in Vienna, Austria   
Case cohort 
(analyzed as 
case 
control) 
259 (Fetal 
Death 13, PE 
14, PTB 87, 
SGA 146) 
1367 with 
no 
outcome 
 PTB (<37 
wks). Also 
PE, SGA 
and Fetal 
Death 
IL10 None 
2008 IL6 None 
Moura, 
E
159
 
2008 
Two independent case-control 
samples (Mulatto, White and Mulatto) 
from two hospitals in Brazil. Women 
matched on ethnicity within each 
hospital. 
2 case-
control 
studies 
Cases 122 
and 82 
Controls 
101 and 
105 
(multips) 
SPTB < 37 
wks  
TNFα None 
IL10 
(3 SNPs) 
None 
       IL6 None 
       IFNγ None 
       
TNFα/IL6/ 
IFNγ 
Genotype combination 
associated with PTB 2.26 
(1.32-3.91) p=0.002 
Hollegaard 
MV
88
 
2008 
Women selected from the 
Copenhagen First Trimester Study 
based on availability of blood spots 
for DNA extraction. 
Case-control 62 cases 55 term 
SPTB <37 
wks 
TNFα 
(5 SNPs) 
Genotypic association 
OR 3.1 (1.0-10.3) with 2 
haplotypes also showing 
an association (p=0.04 
and p=0.05) 
       
IL1B 
(2 SNPs) 
Genotypic association 
with PTB 6.4 (1.3-60.5) 
       
IL6 
(3 SNPs) 
None 
Fortunato, 
SJ
94
 
2008 
Women recruited at a single hospital 
in Nashville, TN. Only included women 
of self-reported African American or 
White race (non-Hispanic). For white 
women adds to case group in Menon 
2006 
Case-control 
stratified by 
race 
242 cases  
(166 White, 
76 African 
American) 
385 
controls 
(194 
White, 191 
African 
American) 
PTL <36 
wks  
TNFα 
(5 SNPs) 
None 
TNFR1 
(5 SNPs) 
Genotypic and allelic 
association in white 
mothers (p=0.001, 
p=0.002) for one SNP 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
      
TNFR2 
(7 SNPs) 
Genotypic and allelic 
association in white 
mothers (p=0.04, 
p=0.02) for 1 SNP. Allelic 
association for 2 SNPs in 
black mothers. 
       
IL6 (7 
SNPs) 
None 
       
IL6R (3 
SNPs) 
Allelic association with 2 
SNPs in black mothers. 
       
IL6/IL6R/T
NFα 
Multilocus association in 
white mothers OR 2.3 
(1.6-3.4) 
Velez, 
DR
149
 
2008 
Women recruited at Centennial 
Medical Center in Nashville, TN. This 
paper is only White women with a 
single reported racial ancestry 
through 2 generations. Maternal and 
fetal DNA collected. Only maternal 
reported here. 
Case-control 172 White 198 White 
PTL 
<36(0/7) 
wks  
130 genes (1536 panel) 
CRHBP Allelic and genotypic  
FV Allelic and genotypic  
      IL5 Allelic and genotypic  
       PTGER3 Allelic and genotypic  
       tPA Allelic and genotypic  
Velez, 
DR
98
 
2009 
Women recruited at Centennial 
Medical Center in Nashville, TN. This 
paper is only African American with 
only a single reported racial ancestry 
through 2 generations. Maternal and 
fetal DNA collected. Only maternal 
reported here. 
Case-control 
76 African 
American 
191 African 
American 
PTL 
< 36( 0/7) 
wks  
130 genes (1536 panel) 
 
IL15 Genotypic association 
IL1RAP Allelic and genotypic  
      IL2A Allelic and genotypic  
      IL6R 
Allelic, genotypic and 
haplotype  
       TNFRSF1B 
Allelic, genotypic and 
haplotype 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Gebhardt 
S
160
 
2009 
Consecutive low-risk obstetrical 
primip in Western Cape, South Africa. 
Restricted to Coloured and Black 
women 
Prospective 
cohort of 
450 low risk 
women 
Preterm 33, 
PE 35, IUGR 
2 
421 
controls 
Preterm 
Labor  
<37 wks  
IL4 None 
IL1B None 
IL1RN 
Genotypic 2.28 (1.17-
4.44) 
       
IL10 (3 
SNPs) 
None 
       
TNFα (3 
SNPs) 
Genotypic and allelic 
2.09 (1.01-4.31) 
       
LGALS13  
(10 SNPs) 
Allelic  2.27 (1.20-4.29) 
Sata, F
86
 2009 
Consecutive women recruited 
postpartum from a university hospital 
in Sapporo, Japan 
Case-control 73 cases 341 term 
PTB <37 
wks 
IL1A  
(2 SNPs) 
Genotypic and 
haplotype associations 
with PTB overall with 
larger estimates for PTL. 
Permutation p =0.01 for 
haplotype associations 
with all PTB combined 
       
IL1B 
(2 SNPs) 
Suggestion of a 
haplotype association 
       IL2 None 
       IL6 None 
Kalinka, 
J
161
 
2009 
Abstract only. Polish Caucasian 
women 
Case-control 62 cases 63 controls 
SPTB (PTL, 
PPROM)  
<36 wks 
ILIRN 
Increased risk of PTB OR 
2.75 (1.02-4.13) 
IL1B None 
       IL6 
Genotypic association 
when coincident with 
IL1RN genotype OR 3.0 
(1.0-8.9) 
       TNFα None 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Romero, 
R
151
 
2010 
Women recruited from a single site in 
Puento Alto, Chile. All women of 
Hispanic origin 
Case-control 223 cases 
599 
controls 
PTL 
< 37 wks 
190 genes 
(775 SNPs) 
 
IL6R Allelic and haplotype  
       COL4A3 Allelic and haplotype  
       LTF Allelic and haplotype  
       FGF1 Allelic and haplotype  
       GNB3 Allelic association 
       IGF1 Allelic association 
       TIMP2 Allelic association 
Romero, 
R
150
 
2010 Women recruited from a single 
hospital in Santiago Chile, all mothers 
Hispanic 
Case-
Control 
225 mothers 
599 
mothers PPROM 
<37 weeks 
190 genes (775 SNPs) 
     TIMP2 Allelic association 
       ANG Allelic association 
       TLR1 Allelic association 
       NOS3 Allelic association 
       COL4A3 
Allelic and haplotype 
association. 
       PTGER1 Allelic association 
Gomez, 
LM
162
 
2010 Women recruited from prenatal 
clinics in Philadelphia. 85% African 
American 
Case-control 
(post-hoc 
merger of 
RCT) 
68 cases 
675 
controls 
SPTB <37 
wks 
1536 Plate but full results not 
reported 
     PRKCA 
6 risk alleles among 
women with BV 
       FLT1 
among BV+ OR 1.9 (1.1-
3.3) 
       IL6 
among BV+ OR 3.5 (1.6-
7.8) 
Liang, 
M
163
 
2010 Han Chinese from Anqing Hospital 
Hybrid 
(Triad and 
Control 
parents) 
250 case 
families 
247 control 
families 
SPTB 
delivery 
<37 wks 
TNFα 
Heterozygote RR 0.46 
(0.2-1.04) 
   Interaction 
RR 0.20 (0.07-0.58) 
mother and fetus het 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Ryckman, 
KK
164
 
2010 
MoBA and Centennital (TN, USA) 
Study 
See Velez 2009 for details on 
Centennial Study 
Case-control MoBA 207  MoBA 217  
PPTB<36 
(6/7) 
MoBA  
1430 SNPs in MoBA Maternal. 
"Suggestive" Inflammatory Results 
       COL1A2 Allelic and genotypic  
       IL18 Genotypic association 
       IL1B Allelic and genotypic  
       
IL1R1        
(2 SNPs) 
Allelic and genotypic  
       
IL1R2        
(3 SNPs) 
Allelic and genotypic 
Replicated 
       
IL1RAP 
(3 SNPs) 
Allelic and genotypic. 
One replicated 
       
IL1RN 
(3 SNPs) 
Allelic and genotypic  
       
IL2RA  
(5 SNPs) 
Allelic and genotypic. 
One replicated 
       
IL2RB  
(3 SNPs) 
Allelic and genotypic  
       
IL4R  
(2 SNPs) 
Allelic and genotypic. 
Replicated 
       
IL6R  
(2 SNPs) 
Allelic and genotypic. 
Replicated 
       IL8RA Allelic and genotypic  
       TNFRSF1A 
Association in pooled 
results 
Myking, 
S
152
 
2011 MoBA (Ryckman Data) Hybrid 
(triad, 
control 
dyads) 
196 triads 
211 control 
dyads 
PTB <36 
(6/7) Term 
39 (0/7) - 
40 (6/7) 
Maternal genotype results not 
available 
     IL10RA 
Significant when 
maternal and fetal 
alleles combined 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
       IL1A 
Significant when 
maternal and fetal 
alleles combined 
       IL10RB 
Significant when 
maternal and fetal 
alleles combined 
Jones, 
NM
165
 
2011 
Women recruited from community 
clinics in Michigan 
Sub-cohort 
stratified by 
self 
reported 
race 
131 Non-
Hispanic 
white, 49 
African 
American 
356 non-
Hispanic 
white, 239 
African 
American 
PTB <37 
wks with 
subtype 
analysis 
IL1-RN 
(CEU) PTB OR 1.9 (1.2-
2.9) sPTB OR 2.0 (1.2-
3.3) additive interaction 
with fetal genotype 
   MMP-9 
(CEU) sPTB OR 1.7 (1.0-
2.8) 
       TNFR2  
(YRI) sPTB OR 2.3 (1.1-
4.6) mulitplicative 
interaction with fetal 
genotype 
       IL-1β No association 
       TNFα No association 
       TNFRSF6   No association 
       
MBL (2 
SNPs) 
No association 
       CD14 No association 
       TLR4 No association 
Nuk, M
166
 2012 
Women recruited from a single 
Hospital in Graz, Austria 
Correlation 106 cases 200 
PTB <37 
wks 
TNFα No correlation 
       IL10 No correlation 
Abbreviations: SPTB spontaneous preterm birth; PTL preterm labor; PPROM preterm premature rupture of membranes; wks weeks; 
OR odds ratio; VLBW very low birth weight; g grams; GA gestational age; SGA small for gestational age; IUGR intrauterine growth 
restriction. 
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Hypertensive Disorders of Pregnancy 
A review by Mutze in 2008 of genes and the preeclampsia syndrome notes that up to 70% 
of the candidate gene research has focused on eight genes in the rennin-angiotensin system 
(angiotensinogen AGT, angiotensin converting enzyme ACE, and angiotensin receptors), 
inherited thrombophilias (factor V, prothrombin, methylene tetrahydrofolate reductase), NOS3 
genes, and TNFα.167  Among the immunogenetics research, which includes natural killer cells 
(KIRs) and cytokines on the inflammatory pathway, she notes the conflicting evidence in support 
of 10 cytokines (TNFα, IL1A, IL1B, IL1RA, IL6, IL10, IFNγ, TGFβ, CD14 receptor and CTLA-4) with 
most SNPs showing more evidence against an association or only a single study showing an 
association. She notes that outcome classification is heterogeneous; the studies have focused 
on white European women, and the likely interaction between maternal and fetal genotypes 
and the small sample size of most studies are limitations that must be addressed. Among the 
more promising associations, she highlights the placental genes ACVR2 and STOX1 and genes 
involved in angiogenesis (PIGF, VEGF, Flt-1, ENG). 
A review of the Genetics Association Database and PubMed revealed 20 genetic 
epidemiology studies of preeclampsia using maternal DNA. Studies that included at least one 
inflammatory gene were selected and studies focusing on coagulation pathway or angiogenesis 
were not reviewed. As noted by Mutze, there was a good deal of outcome heterogeneity with 
variation in the diagnostic criteria for preeclampsia, the inclusion of severe PE, and restrictions 
based on parity. While some of the studies were based in the US, many were European, with 
additional studies from Brazil, Chile, Iran, South Africa and Australia. Apart from a study utilizing 
the HUNT cohort in Norway, most studies were small with fewer than 200 cases. Overall there 
has been little consistency in results, with some genes showing an association in some 
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populations but not others. TNFα, IL1A, IL1B, IL10 showed associations in at least two studies, 
although there were also negative results for each gene. The diversity of genetic ancestry and 
the differences in association among women in the US studies suggests the possibility of 
heterogeneity by race. Table 1.7 provides an overview of the studies. 
A case group at the Hospital of the University of Pennsylvania168, 169 ran a 50,000 SNP panel 
designed for cardiovascular, metabolic and inflammatory syndromes. While they have reported 
on angiogenic and solute carrier genes, results from the inflammatory genes have not yet been 
published.
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Table 1.7 Review of Genetic Epidemiology Studies of Preeclampsia 
Study Year Population 
Study 
Design 
Cases Controls 
Outcome 
Criteria* 
Genes Association 
Dizon-
Townson, 
DS
170
 
1998 
Mothers admitted for delivery 
(94% Caucasian) from a common 
referral population. Possibly 
Utah. 
Case-
control 
131 severe PE, 
75 HELLP 
41 multips 
Severe PE 
[BP (8 or 9) 
and Pr (7, 8) 
with PC (1)]  
TNFα 
(2 SNPs) 
None 
Livingston, 
JC
171
 
2001 
Mothers and infants recruited at 
delivery in Memphis, TN and 
Lexington KY. 57% African 
America. 
Prospective 
cross-
sectional 
112 severe PE 
106 matched 
for GA 
Severe PE 
[BP (7 or 6) 
and Pr] 
HELLP 
TNFα 
(2 SNPs) 
None 
Lachmeijer, 
AMA
172
 
2002 
Affected sisters and their parents 
from discharge records, 
obstetrical charts and 
advertisements in The 
Netherlands  
Family 
based 
150 sib-pairs 
104 healthy 
blood donors 
(male and 
female) 
PIH [BP (4)] 
PE [BP (4) Pr 
(1 or 3)] 
Severe PE 
[BP (5) Pr (6)] 
IL1B 
(2 SNPs) 
None 
    IL1RN None 
Lachmeijer, 
AMA
173
 
2001 
Affected sisters and their parents 
from discharge records, 
obstetrical charts and 
advertisements in The 
Netherlands 
Family 
based 
150 sib pairs 
divided into 
'strict' 'index' 
'sister' PE 
HELLP 
98 men and 
women from 
Vrije 
University 
(same as 
above missing 
6 men) 
PIH [BP (4)] 
PE [BP (4) Pr 
(1 or 3)] 
Severe PE 
[BP (5) Pr (6)] 
TNFα and 
LTA 
(5 
markers) 
Haplotype 
association in 
'strict index' 
group OR 1.9 
(1.1, 3.3) 
Witt, CS
174
 2002 
Not stated. Authors associated 
with Royal Perth Hospital, 
Western Australia 
Comparison 
of 
frequency 
45 primips 48 primips 
PE [BP (3) Pr 
(1) 
KIR2DL4 None 
de Groot, 
CJM
108
 
2004 
Cases selected from database 
and patient charts at 2 hospitals 
in The Netherlands. Controls 
were matched for maternal age 
and delivery date. 
Case-
control 
163 primips 163 primips 
PE [BP (11) 
or (2) Pr (11) 
IL10 
(4 SNPs) 
Genotypic 
OR 0.29 
(0.10-0.83) 
for 1 SNP 
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Study Year Population 
Study 
Design 
Cases Controls 
Outcome 
Criteria* 
Genes Association 
Haggerty, 
CL
85
 
2005 
Sub-sample of the PEPP study at 
Magee-Women’s Hospital in 
Pittsburg, PA.  
Case-
control 
stratified by 
race 
150 primips 661 primips 
PE [BP (12) 
and (10) Pr 
(1) or (9) and 
(10)] 
TNFα 
Genotypic 
association 
among white 
women 
      IL1A 
Genotypic 
association 
among black 
and white 
women 
       IL1B 
Haplotype 
with IL1A 
association in 
all women 
       IL10 
Suggestion of 
association in 
White 
women 
OR=1.7 
Goddard, 
KA
84
 2006 
Mothers and Infants from a 
hospital based population in 
Puerto Alto, Chile 
Case-
control 
394 mothers 
602 Full term 
"hyper 
healthy" 
PE [BP(1) 
Pr(1 or 2)] 
190 genes, 775 SNPs  
 Additive model maternal  
       IL1A 
1.60 (1.19, 
2.07) 
       IL12RB1 
2.85 (1.29, 
6.26) 
      Additive global haplotype based 
       IL4R p=0.0006 
       IL1A p=0.0193 
       IL1B p=0.0272 
      Maternal Fetal Interaction Model 
       IL4R p=0.0036 
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Study Year Population 
Study 
Design 
Cases Controls 
Outcome 
Criteria* 
Genes Association 
Kamali-
Sarvestani, 
EK
175
 
2006 
Women who had delivered at a 
single hospital in Iran. Controls 
matched on age and race. 
Case-
control 
134 primips  
164 multips 
(all  'normal')  
PE [BP(2) 
Pr(1 or 3)] 
Severe PE 
[BP(9) Pr(4 
or 2)] 
IFNγ None 
 
IL10 
(3 SNPs) 
SNP (-1082 
G) differed 
significantly 
between 
cases and 
controls 
p=0.045. 
Daher, S
107
 2006 
Cases and controls ascertained 
consecutively at study hospital in 
Sao Paulo, Brazil. 
Case-
control 
White primips 
56 
White multips 
92 PE [BP(2) 
Pr(1 )]  
TNFα None 
Non White 
primips 95 
Non White 
multips 97 
TGFβ1 None 
       IL10 
Lower 
frequency in 
White 
women with 
PE p=0.02 
       IL6 None 
       IFNγ None 
Saarela, T
176
 2006 
Retrospective case ascertainment 
at a single hospital in Finland.  
Case-
control 
133 primips 115 multips 
PE [BP (1) Pr 
(1)] 
IL6 None. 
HL None 
       CAPN-10 None 
Mirahmadian, 
M
106
 
2008 
Consecutive patient with PE at 2 
hospitals in Tehran, Iran 
Case-
control 
160 cases 100 healthy 
pregnancies 
during same 
time period 
PE [PC (2)] 
TNFα 
(2 SNPs) 
Allelic and 
genotypic 
different 
p=0.0001 
      
IL10 
(3 SNPs) 
Genotypic 
and alleliic 
differences. 
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Study Year Population 
Study 
Design 
Cases Controls 
Outcome 
Criteria* 
Genes Association 
Fraser, R
121
 2008 
Cases and Controls selected from 
the GOPEC cohort. All white 
Europeans. 
Case-
control 
117 cases 
146 controls 
with 
uncomplicated 
term 
deliveries 
PE [BP (2) Pr 
(1)] 
IL4 
Genotypic 
association 
OR 4.5 (1.3-
15.4) 
       TLR2 None 
       MMP9 None 
Molvarec, A
90
  2008 
Caucasian women from a single 
hospital in Budapest, Hungary 
Case-
control 
140 PE, 69 
HELLP 
144 healthy 
pregnancies 
PE [BP (1) Pr 
(1)] HELLP. 
Also IUGR. 
TNFα 
Increased 
allelic 
frequency in 
women with 
both PE and 
severe IUGR. 
Stonek. F
157
 2008 
Consecutive Caucasian women at 
antenatal clinic before 12 wks GA 
in Vienna, Austria   
Case cohort 
(analyzed 
as case 
control) 
259 with at 
least one 
outcome (Fetal 
Death 13, PE 
14, PTB 87, 
SGA 146) 
1367 with no 
outcome PE [PC (1)]. 
Also PTB, 
SGA and 
Fetal death 
IL10 None 
 2008
158
  IL6 None 
de Lima, 
TH
177
 
2009 
Mulatto women recruited from a 
single maternity hospital in NE 
Brazil 
Case-
control 
92 with PE, 73 
with Eclampsia 
101 multips 
PE and 
Severe PE 
[PC (2)] 
TNFα None 
       IL6 None 
       IFNγ 
Higher allelic 
frequency in 
severe PE 
p=0.02 
       
IL10 
(3 SNPs) 
None 
       
TGFβ1 
(2 SNPs) 
None 
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Study Year Population 
Study 
Design 
Cases Controls 
Outcome 
Criteria* 
Genes Association 
Tan, CY
178
 2009 
Malay women recruited from 
maternity hospitals in Singapore 
or Malaysia 
Case-
control 
83 cases 240 controls 
PE [BP (1) Pr 
(1)] 
KIR2DL4 
(23 SNPs) 
None 
HLA-G 
Interaction 
of fetal  HLA-
G*0160 and 
maternal 
KIR2DL4  
Johnson, 
MP
179
 
2009 
Australian Family Cohort and 
Norwegian Case Control (from 
HUNT cohort and biobank) 
Family 
based and 
case-
control 
74 Aust/NZ 
families with 
140 affected 
women, 
Norway 1,139 
Aust/NZ 90 
unaffected, 
Norway 2,269 
controls 
PE [PC (3) in 
Aust/NZ and 
PC (2) in 
Norway] 
10 genes (56 SNPs) within 
a previously identified 5q 
critical region 
   
IL4 
(3 SNPs) 
None 
       
CSF2 
(2 SNPs) 
None 
       
IL13 
(7 SNPs) 
None 
       
IL3 
(1 SNPs) 
None 
       
IL5 
(2 SNPs) 
None 
Gebhardt, 
S
160
 
2009 
Consecutive low-risk obstetrical 
primips in Western Cape, South 
Africa. Restricted to Coloured and 
Black women 
Prospective 
cohort of 
450 low risk 
women 
Preterm 33, PE 
35, IUGR 2 
421 controls 
PE [BP (13) 
Pr (1) or (2)] 
IL4 None 
IL1B None 
       IL1RN 
Genotypic 
OR 2.6 (1.4-5)  
       
IL10 
(3 SNPs) 
None 
       
TNFα 
(3 SNPs) 
None 
       
LGALS13 
(10 SNPs) 
None 
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Study Year Population 
Study 
Design 
Cases Controls 
Outcome 
Criteria* 
Genes Association 
Fenstad, 
MH
180
 
2010 
Familes from Austrailia and 
NewZealand, mothers from 
Norway 
Family 
linkage 
design, and 
case-
control 
74 Aus/NZ 
familes with 
140 affected 
women and 
851 women in 
Norway 
Aus/NZ 146 
unaffected, 
1440 controls 
in Norway 
PE [PC (3) in 
Aus/NZ and 
PC (2) in 
Norway)  
TNFSF13B 
(7 SNPs 
Aus/NZ, 3 
SNPs 
Norway 
3 rare SNPs 
associated in 
Aus/NZ 
familes but 
not in 
Norway 
Hill, LD
181
 2011 
Mothers and infants from 
Santiago Chile, Philidelphia, PA 
and Detroit, MI 
Case 
control 
Chilean: 528 
dyads, African 
American 
(unpaired): 424 
mothers, 375 
infants 
Chilean: 575 
dyads, African 
American 
(unpaired): 
412 mothers, 
462 infants. 
All term  
PE [PC (1, 2)] 
ERAP2 (2 
SNPs) 
Association 
for fetal SNP 
in African 
American 
infants only 
Abbreviations: HELLP hemolysis, elevated liver enzymes, low platelets; PE preeclampsia; PTB preterm birth; SGA small for gestational age; NE northeast; IUGR 
intrauterine growth restriction; primip primiparous; multip multiparous. 
 
LEGEND 
BP: Blood pressure criteria 
1. >=140 mmHg SBP or >=90 mmHg DBP 
2. >=140/90 mmHg SBP 
3. >140/90 mmHg 
4. >=90 mmHg DBP with increment of at least 20mmHg 
5. >=110 mmHg DBP 
6. >110 mmHg DBP 
7. >160 mmHg SBP 
8. >=160 mmHg SBP or >=110 mmHg DBP 
9. >=160/110 mmHg 
10. Increase of >15 mmHg diastolic or >30 mmHg systolic 
11. Increase of >=15 mmHg diastolic or >=30 mmHg systolic 
12. >140 mmHg SBP or >90 mmHg DBP 
13. >=90 mmHg DBP 
 
Pr: Proteinuria criteria 
1. >=300mg/24h 
2. 2+ dip 
3. 1+ dip 
4. 2g/24h 
5. >=2+ dip 
6. >=1g/24h 
7. >500mg/24h 
8. 3+ or 4+ 
9. 0.3 protein/creatinine ratio 
10. Hyperuricemia >1SD for GA 
11. >=2+ voided or >=1+ catheter sample 
PC: Published Criteria 
1. ACOG 
2. 2000 National Working Group on Hypertension in Pregnancy 
3. Australasian Society for the Study of Hypertension in Pregnancy 
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SGA 
Very few genetic epidemiology studies have been conducted looking at SGA. While fetal 
growth potential is considered to be genetically influenced, SGA as an outcome has yet to be 
comprehensively studied from a genetic perspective. Only 6 studies (from four case groups) 
were found that looked at SGA as an outcome. In all but the Edwards study,182  case groups were 
small (<200), and SGA was considered along with other outcomes (PE, PTB, Fetal Death). The 
Molvarec90 study was primarily interested in the intersection of IUGR and PE, and all SGA cases 
also had concurrent PE. The Edwards182 study was the largest of the group with 530 case 
mothers and 190 genes examined. The population was drawn from Puente Alto, Chile and may 
not be generalizable to White and African American populations in the US.  Table 1.8 provides 
overview of the studies. 
IL1B and IL10 were the only genes to replicate in White US mothers and Chilean mothers. 
TNFα, IL2, IL4, IL13, IL6R, CSF1, CSF2, IL4R and IL12B each showed an association in at least one 
population.  
A European consortium, NESTEGG183 with 800 children born SGA along with parents, 
siblings and control, will be conducting candidate gene analysis. The children have been 
followed up to 11 years, and the focus of the study is on genetic factors influencing both fetal 
and childhood growth in SGA and idiopathic short stature children. A single result for the 
association between polymorphisms in growth hormone receptor and response to growth 
hormone treatment has been published. Further candidate gene results are hopefully 
forthcoming.
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Table 1.8 Review of Genetic Epidemiology Studies of Small for Gestational Age  
Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Engel, SA
6
 2004 
Women recruited 
from hospitals in 
Wake and Orange 
County, NC. 
Restricted to 
African American 
and White. 
Nested 
case-
control 
87 African 
American, 
93 White 
240 African 
American,  
323 White  
SGA (below 10th 
percentile for GA for 
race, sex and parity) 
IL1A 
(2 SNPs) 
No association 
IL1B 
(3 SNPs) 
Haplotype association in white 
mothers OR 0.6 (0.3-1.0) 
      IL2 
Allelic association in white 
mothers OR 1.6 (1.0-2.6) 
       IL6 No association 
       TNFα No association 
       
LTA 
(2 SNPs) 
No association 
Engel, SA
4
 2004 
Women recruited 
from hospitals in 
Wake and Orange 
County, NC. 
Restricted to 
African American 
and White. 
Nested 
case-
control 
87 African 
American, 
93 White  
240 African 
American, 
323 White  
SGA (below 10th 
percentile for GA for 
race, sex and parity) 
IL4 
(3 SNPs) 
Haplotype association in white 
mothers OR 0.2 (0.2-1.2). 
Possible allelic association for 
both Whites and African 
Americans. 
   IL5 No association 
       
IL13 
(3 SNPs) 
Possible allelic association in 
African American mothers 
       
IL10 
(3 SNPs) 
Haplotype association in white 
mothers OR 0.5 (0.3-0.8) 
       
TGFβ1 
(2 SNPs) 
None 
Molvarec, 
A
90
  
2008 
Caucasian women 
from a single 
hospital in 
Budapest, Hungary 
Case 
control 
140 PE,  
69 HELLP 
94 cases of 
SGA 
144 healthy 
pregnancies 
IUGR (<10th or 3rd 
percentile for GA and 
gender using 
Hungarian 
percentiles) 
TNFα 
 Increased allelic frequency in 
women with both PE and 
severe IUGR 
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Study Year Population 
Study 
Design 
Cases Controls Outcome Genes Association 
Stonek, 
F
157
 
2008 
Consecutive 
Caucasian women 
present to 
antenatal clinic 
before 12 wks GA 
in Vienna, Austria   
Case 
cohort 
(analyzed 
as case 
control) 
259 with at 
least one 
outcome 
(Fetal Death 
13, PE 14, PTB 
87, SGA 146) 
1367 with 
no outcome 
SGA (<10th 
percentile) also PE, 
PTB and Fetal Death 
IL10 
No association with all 
outcomes grouped or singly 
 2008
158
 IL6 
No association with all 
outcomes grouped or singly 
Edwards, 
DR
182
 
2011 
Chilean women 
from Puente Alto 
Case 
control 
530 mothers 
and 436 
infants 
599 
mothers 
and 628 
term 
infants 
SGA (<10th percintile 
for Chile) 
190 genes (775 SNPs) 
     IL6R OR 1.57 (1.18-2.1) 
       CSF1 OR 1.22 (1.00-1.48) 
       CSF2 OR 0.79 (0.65-0.97) 
       IL10 OR 1.25 (1.04-1.50) 
       IL1B OR 0.73 (0.57-0.93) 
       IL4R OR 0.80 (0.67-0.95) 
       IL12B OR 2.28 (1.01-5.14) 
Abbreviations: SGA Small for gestational age, OR Odds ratio, GA gestational age, PE preeclampsia, HELLP hemolysis, elevated liver 
enzymes, low platelets, IUGR intrauterine growth restriction. 
  
 
CHAPTER 2 METHODS 
2.1 Specific Aims 
Preterm birth, hypertensive disorders of pregnancy and SGA are important maternal and 
fetal outcomes with acute and chronic sequelae for both mother and infant. In addition to 
increased fetal morbidity and mortality, there is some indication that women who experience 
these reproductive outcomes are also at risk for future cardiovascular disease. Inflammatory 
biomarkers and genetic variation in inflammatory genes have been found to be associated with 
all of these reproductive outcomes as well as with later cardiovascular outcomes. Cell cycle 
genes have been shown to play a role in placentation and fetal growth and have also been 
linked with diabetes and cardiovascular disease.  These two pathways offer insight into the 
biological process of both reproductive outcomes and later chronic disease. 
The Pregnancy Infection and Nutrition Cohort offers an opportunity to study 
polymorphisms in a panel of candidate genes in the inflammatory and cell cycle pathways in a 
biracial population with well-measured covariates. Knowledge about these genetic variants will 
improve our knowledge about these heterogeneous phenotypes, aide in the identification of 
susceptible populations and identify target genes for further study. 
Specific Aim #1: Evaluate the association between variation in genes associated with 
inflammation and the outcomes of preterm birth, preeclampsia, isolated gestational 
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hypertension and SGA. We will used a gene based test to evaluate SNPs, grouped by gene, in 31 
genes chosen to represent the innate and adaptive (Th1 and Th2) immune system, and their 
association with preterm birth, small for gestational age, gestational hypertension and 
preeclampsia. 
Hypothesis #1 Pro-inflammatory genes will be associated with preterm birth. A pro-
inflammatory state may arise through variation in pro-inflammatory genes or anti-inflammatory 
genes. 
Hypothesis #2 Genes that are associated with poor placentation will be associated with GHTN 
and SGA. This includes genes associated with trophoblast invasion (IL10), maternal semi-
allograft rejection (KIRs) and inflammatory cytokines that are stimulated by hypoxia (IL1A, IL1B, 
TNFα, IL8, TNFRSF1B, IL6). 
Hypothesis #3 Genes that have shown previous association with co-morbid diseases in the 
metabolic syndrome (hypertension, CVD, diabetes) are associated with GHTN (IL6R, IL6, TNFα, 
TNFRSF1B, IL18, NFkB1).  
Hypothesis #4 Genes that promote a shift towards Th1 by mutations in Th1 genes (IL2, IFNγ, 
TNFα, LTA, Il12A, IL12B, IL18, CSF2, TBX21, CXCL10, IL15)  or Th2 genes (IL6, Il6R, GATA3, IL4, 
IL13) will be associated with hypertensive disorders of pregnancy more so than SGA or preterm 
birth. 
   
Specific Aim#2: Evaluate the association between genetic variation in cell-cycle regulation 
genes and the outcomes of GHTN, SGA and preterm birth. We will use a gene based test to 
evaluate SNPs, grouped by gene, in 10 cell cycle genes and their association with gestational 
hypertension, small for gestational age and preterm birth.  
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Hypothesis #1 Cell cycle genes will show a stronger associated with placental and fetal growth 
outcomes (GHTN and SGA) as opposed to preterm birth.  
Few studies have evaluated the association between cell cycle variants and preterm birth, 
hypertensive disorders of pregnancy or small for gestational age. Furthermore, this study is one 
of the most comprehensive efforts to date of variants in the inflammatory pathway and the 
outcome of  SGA. This study will add to the growing set of studies of inflammation and the 
outcomes of GHTN and PTB by including novel inflammatory genes and studying two well-
defined racial groups. 
2.2 Study Population 
2.2.1 Pregnancy Infection and Nutrition Study 
The Pregnancy, Infection and Nutrition (PIN) Study recruited women from August 1995 
through June 2005. Three distinct cohorts make up the study population for this analysis. 
Recruitment for PIN 1 and 2 cohorts occurred between August 1995 and June 2000 in Wake and 
Orange Counties, North Carolina. Recruitment at prenatal clinics at Wake County Human 
Services Department and the Wake Medical Center occurred between February 1996 and June 
1998. Recruitment from prenatal clinics at University of North Carolina (UNC) Hospitals occurred 
between August 1995 and June 2000.184, 185  Recruitment for PIN 3 occurred between January 
2001 and June 2005 at the prenatal clinics at UNC Hospitals. Potential subjects were identified 
through a chart review of all prenatal patients and recruited between 24 and 29 weeks for PIN1 
and 2 (N=3163). PIN 3 women were recruited at their second prenatal visit if they were 20 
weeks gestation or less (N=2006). Exclusion criteria at enrollment were similar between cohorts: 
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less than age 16, non-English speaking, not planning to continue care or deliver at the 
recruitment hospital, carrying multiple gestations, or lacking a telephone.  
Data collection protocols varied slightly between the early and later cohorts. For PIN 1 and 
2, data collection occurred at the recruitment visit (weeks 24-29), during a telephone interview 
within 2 weeks of recruitment, and through abstraction of the medical record following delivery. 
PIN 3 started recruitment earlier in pregnancy and include data collection at the recruitment 
visit (<=20 weeks), two self-administered questionnaires (<=20 weeks and 24-29 weeks), two 
telephone interviews (17-22 weeks and 27-30 weeks), and abstraction of the medical record 
following delivery. All participants gave informed consent at the time of recruitment, and the 
institutional review boards of the University of North Carolina School of Medicine and Wake 
Medical Center (for PIN 1) approved the study. 
Figure 2.1 graphically displays the sample selection used in this project. Overall 
demographic and relevant covariate information was very similar in the entire cohort (N=5169) 
those eligible for genotyping (N=3065) and those genotyped (N=1646) (Table 2.1) 
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Figure 2.1 Flow Chart of sample selection 
 
Eligibility criteria included maternal self-reported race of White or African American, consent for 
DNA analysis, suitable DNA sample available and non-missing preterm status. Some women 
contributed more than 1 birth to the original cohort. Only one birth per woman is represented 
in the final genotyping sample.  
  
PIN 1/2 N=3163 
PTB Case or 
Control N=1201 
Eligible N=848 
Genotyped 
N=703 
Other N=1946 
Eligible N=1433 
Genotyped 
N=450 
PIN 3 N=2006 
Eligible N=784 
Genotyped 
N=493 
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Table 2.1 Comparison of the entire PIN cohort, eligible for genotyping and genotyped 
 All N=5169 N(%) 
Eligible N=3065 
N(%) 
Genotyped N=1646 
N(%) 
Age yrs Mean (SD) 26.8 (6.2) 26.2 (6.3) 26.1 (6.3) 
White 3035 (58.7) 1918 (62.6) 1031 (62.6) 
African American 1746 (33.8) 1147 (37.4) 615 (37.4) 
Other 387 (7.5) 0 0 
Missing race 1 0 0 
Poverty mean (median, IQR) 305 (223, 109-476) 284 (198, 96-473) 273 (179, 95-464) 
Missing poverty 741 375 199 
Married 2959 (57.4) 1646 (53.7) 868 (52.8) 
Single 1843 (35.8) 1199 (39.1) 658 (40.0) 
Other 352 (6.8) 218 (7.1) 119 (7.2) 
Missing marital 15 2 1 
BMI Mean (median, IQR) 26.0 (24,21-29) 25.8 (24, 21-29) 26.5 (24, 21-30) 
Missing BMI 364 188 82 
Height inches Mean (SD) 64.8 (2.7) 65.0 (2.7) 64.9 (2.7) 
Missing height 304 147 61 
Smoker 935 (20.8) 657 (23.6) 383 (25.6) 
Missing smoking 670 0 152 
First birth 2347 (45.6) 1400 (45.8) 769 (46.8) 
Multiparous 2803 (54.4) 1659 (54.2) 873 (53.1) 
Missing parity 19 5 4 
Male Infant 2560 (50.6) 1530 (50.1) 818 (49.7) 
Missing gender 106 14 1 
GDM 312 (6.6) 190 (6.7) 127 (8.0) 
Missing GDM 442 235 58 
Preterm 686 (13.5) 377 (12.3) 347 
Missing PTB 80 0 0 
Preterm Labor (% PTB) 214 (33.9) 120 (35.2) 111 (35.5) 
PPROM (% PTB) 127 (20.1) 66 (19.4) 63 (20.1) 
Medically Indicated (% PTB) 290 (46.0) 155 (45.5) 139 (44.4) 
Missing preterm subtype 137 38 36 
Chronic Hypertension 263 (5.6) 139 (4.9) 113 (7.1) 
Isolated GHTN 777 (15.0) 479 (15.6) 454 
PE 393 (8.3) 239 (8.4) 217 
Missing chronic hypertension 442 235 59 
Missing PE 440 233 57 
SGA 371 (8.2) 239 (8.3) 216 
Missing SGA 658 167 105 
Abbreviations: SD standard deviation, IQR interquartile range, BMI Body Mass index (kg/m2), 
GDM Gestational Diabetes Mellitus, PTB Preterm Birth, GHTN Gestational Hypertension, PE 
Preeclampsia, SGA Small for gestational age.  
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2.2.2 Selection of Cases and Controls 
Cases and controls were selected from eligible women from the entire PIN cohort. Initial 
eligibility criteria included consent for DNA analysis, availability of a suitable biospecimen, non-
missing preterm outcome and self reported maternal race of White or Black. Overall 3539 
(68.5%) of the women in all three PIN cohorts provided consent for genetic analysis. These 
eligibility criteria resulted in 3065 (59.3%) women who were eligible for selection into our study. 
Case distributions among the entire cohort and the eligible cohort were very similar (Table 2.2).  
Table 2.2 Case distribution in the entire PIN cohort and the Eligible PIN sample 
 
All N=5169 
N(%) 
Eligible N=3065 
N(%) 
Genotyped N=1646 
N (% of eligible genotyped) 
Preterm 686 (13.5) 377 (12.3) 347 (92.0) 
SGA 371 (8.2) 239 (8.2) 216 (90.4) 
PE 393 (8.3) 238 (8.4) 217 (91.2) 
Isolated GHTN 777 (15.0) 479 (15.6) 454 (94.8) 
No case status 3335 (64.5) 1973 (64.4) 629 (31.9) 
Percents do not sum to 100% due to multiple case definitions for some women 
Abbreviations: SGA small for gestational age, PE preeclampsia, GHTN gestational hypertension 
Case selection 
Women with a preterm delivery, an infant with SGA or identified as having preeclampsia or 
gestational hypertension were identified as cases as described below (Section 2.3.1). Attempts 
were made to genotype all cases, however poor or insufficient biospecimens resulted in a lack of 
suitable DNA for some women. Between 90% and 95% of all eligible cases were genotyped 
(Table 2.2).  
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Non-case Selection 
Only 32% of eligible non-cases (N=629) were genotyped (Table 2.2). During selection of 
non-cases priority was given to non-cases with existing extracted DNA.  Extracted DNA was 
available for women who were a part of a PIN subcohort or who had been included in previous 
genetic studies. 
Sources of DNA (Figure 2.2) 
The PIN subcohort was randomly chosen at the time of enrollment into PIN1/2 using an 
automated system that selected the subcohort in a one-to-one ratio to preterm cases delivering 
at 35-36 weeks and a two-to-one ratio for preterm cases delivering prior to 35 weeks. The 
randomization resulted in a subcohort of 1201 women including 921 women selected as 
controls (122 of whom became preterm cases) and 280 additional preterm cases.  While most 
specimens were collected and stored for all women in PIN, specimens from women who were in 
the subcohort were assayed with priority. Women in the subcohort also had additional 
biospecimens collected at the time of delivery and were re-interviewed within 2 months of 
delivery. 
The subcohort had been used in previous genetic studies4, 6 investigating the outcomes of 
spontaneous preterm birth and SGA. For these studies, non-cases were randomly selected from 
the subcohort for DNA extraction and genotyping.  
One additional study extracted DNA using the PIN biospecimens. Monique Chireau 
extracted DNA from 476 women from PIN 3 who had available biospecimens and had consented 
to participate in genetic analysis. Selection into this study also required the successful collection 
of a placenta at the time of delivery. Selection into Dr. Chireau’s sample was based on timing of 
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entry into PIN and likely represents a random selection of women enrolled in PIN 3 at the time. 
Further description of the births included in Dr. Chireau’s study is provided in Section 2.5.1  
In addition to existing extracted DNA, additional cases of PE and GHTN were identified in 
PIN 1/2 women outside the subcohort. Additional non-cases were also drawn from this 
population. Additional PIN 3 cases (all outcomes) were identified and extracted at the Broad 
Institute as a part of an ongoing genetic study being conducted by Dr. Stuebe.  
Figure 2.2 Sources of DNA for the current study   
 
Abbreviations: SGA Small for Gestational Age, GHTN Gestational Hypertension, PE preeclampsia  
Engel N=947 
847 Case-Cohort 
100 SGA Other 
Stuebe N=1363 
930 PIN 1/2 
433 PIN 3 
Chireau  
476 PIN 3 
Cases and 
Controls 
Stuebe Broad 
Remaining PIN 3 
Cases only 
Other PIN 1/2 
N=381 
 PIN 1/2 PIN 3 Total 
 Case-Cohort Other   
Total 703 450 493 1646 
Preterm 255 (36.3%) 0 92 (18.7%) 347 (21.1%) 
SGA 69 (9.8%) 94 (20.9%) 53 (10.8%) 216 (13.1%) 
Isolated GHTN 97 (13.8%) 215 (47.8%) 142 (28.8%) 454 (27.6%) 
PE 83 (11.8%) 79 (17.6%) 55 (11.2%) 217 (13.2%) 
No case status 324 (46.1%) 87 (19.3%) 218 (44.2%) 629 (38.2%) 
 
Engel 
847 Case-Cohort 
Engel 
100 SGA Other 
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2.3 Variable Measurement 
2.3.1 Outcomes 
2.3.1.1 Preterm Birth 
Gestational age at delivery was calculated based on the first ultrasound performed prior to 
22 weeks’ gestation. For women without an early ultrasound, self-reported Last Menstrual 
Period (LMP) was used to determine gestational age at delivery. Preterm birth was defined as a 
live birth before 37 complete weeks of gestation. Subtypes of preterm birth were classified as 
spontaneous preterm labor (PTL), preterm premature rupture of membranes (rupture of 
membranes preceded onset of uterine contractions by at least 4 hours, PPROM) or medical 
indication based on chart review by a collaborating obstetrician.  
Medically indicated preterm births are sometimes a result of worsening hypertension or 
poor fetal growth. In order to isolate the preterm births due to other causes, Spontaneous 
Preterm Birth (including PTL and PPROM) was considered as an additional outcome. 
2.3.1.2 Hypertensive Disorders of Pregnancy 
PIN collected information on three gestational hypertension variables; chronic 
hypertension, gestational hypertension (GHTN) and preeclampsia (PE). While chronic 
hypertension was collected similarly for all women, the GHTN and PE variables were collected in 
a variety of ways depending on the cohort and the data sources available. 
Chronic Hypertension: Chronic hypertension was evaluated based on diagnoses in the 
discharge summary or labor and delivery charts. In addition, for some women, individual values 
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in the prenatal chart (before 20 weeks) were examined for evidence of hypertension. Women 
were assigned a binary outcome of chronic hypertension present or absent.  
Gestational Hypertension (GHTN): For PIN 1 and PIN 3, two different GHTN variables were 
created. One variable (PIN Discharge) was based on diagnoses in the labor and delivery chart or 
discharge record. Another variable (PIN Prenatal ACOG) was abstracted using ACOG criteria45 
and clinical variables (blood pressure, proteinuria) from the prenatal record. For PIN 2 women, 
data abstractors inspected the prenatal and labor and delivery record and used the following 
criteria (PIN Prenatal non-ACOG): After 20 weeks gestation, SBP increase >=30 mmHg or DBP 
increase >= 15mmHg or BP>=140/90 mmHg on two occasions >=6 hrs apart to indicate the 
presence or absence of GHTN. The criteria used for PIN 2 reflect clinical practice before the 2002 
ACOG guidelines. 
Preeclampsia (PE): For PIN 1 and PIN 3, two different PE variables were created. One 
variable (PIN Discharge) was based on diagnoses in the labor and delivery chart or discharge 
record. Another variable (PIN Prenatal ACOG) was abstracted using ACOG criteria45 and clinical 
variables (blood pressure, proteinuria) from the prenatal record. For PIN 2 women, data 
abstractors inspected the prenatal and labor and delivery record and used the following criteria 
(PIN Prenatal non-ACOG): After 20 weeks gestation SBP increase >=30 mmHg or DBP increased 
>= 15mmHg or BP>=140/90 mmHg on two occasions >=6 hrs apart PLUS the presence of 
proteinuria (>=0.3g/24 hrs or >=30 mg/dl [1+dipstick] on two occasions >6hrs apart) OR Edema 
(1+ 2+ 3+) to indicate the presence or absence of PE. The criteria used for PIN 2 reflect clinical 
practice before the 2002 ACOG guidelines. 
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ACOG Criteria for Preeclampsia:45 
Criteria for Diagnosis of Preeclampsia 
• Blood pressure of 140 mm Hg systolic or higher or 90 mm Hg diastolic or higher that occurs after 20 
weeks of gestation in a woman with previously normal blood pressure 
• Proteinuria, defined as urinary excretion of 0.3 g protein or higher in a 24-hour urine specimen 
 
Validation Study 
For GHTN and PE the presence of two variables creates a challenge in case definition. The 
PIN Discharge variables are not based on standardized criteria and reflect physician diagnostic 
practices. These diagnostic practices may include noting a diagnosis when there is a poor 
maternal or fetal outcome and failing to make a diagnosis when a healthy term infant is 
delivered. On the other hand, the variables based solely on prenatal records were assessed 
using 2 different sets of standardized criteria. Additionally the prenatal record abstraction does 
not capture events following the last prenatal visit and disease onset at the time of delivery will 
have been missed. While term deliveries may have prenatal visits at weekly or biweekly intervals 
preceding delivery, preterm births may occur during pregnancy intervals when routine prenatal 
visits are less frequent.  
Given the presence of up to two variables for case definition, a validation study was 
conducted using the UNC Perinatal Database to determine the utility of using both PIN variables 
to identify cases. The UNC Perinatal Database is a clinical database containing pregnancy 
information for all deliveries at UNC after April 1996. Clinical nurse researchers enter 
standardized data into the database from a woman’s complete medical record. While in theory 
this should capture both prenatal and delivery time periods, in practice, the database contains 
mostly clinical information from the time of delivery. 1626 women from PIN who were eligible 
for the genetic study who had discordant diagnoses based on the PIN variables (discordant for 
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GHTN or discordant for PE) OR who were missing one or both of the PIN variables, were 
compared to the UNC database. 1223 women were matched in the database. 
Results of Validation Study (Table 2.3) 
 
Chronic hypertension was present in the UNC database and showed strong agreement with 
the PIN variable with a kappa of 0.92 (0.89, 0.95). Although the case group for the validation 
study was comprised of women who were discordant on other variables related to 
hypertension, the good agreement of the chronic hypertension variable is reassuring. 
The PIN Discharge variables had strong agreement with the UNC database. This reflects the 
reliance of both variables on the labor and delivery and discharge records. 
The PIN variable based on non-ACOG criteria and abstracted from the complete medical 
record also had strong agreement with the UNC database.  
The PIN Prenatal variable based on ACOG criteria does not have good agreement with the 
UNC database. While the PIN variable captures 10 times more cases of isolated GHTN compared 
to the UNC database, <1% of the PIN GHTN variables are validated by the UNC Database. For PE 
the agreement is also quite poor (Kappa=0.20) and many of the cases missed by the PIN variable 
are cases of late onset disease that arose at the time of delivery. 
Table 2.3: Agreement between PIN variables and the UNC Perinatal Database for 1223 women 
with discordant PIN values 
 PE Isolated GHTN 
PIN Variable 
PIN 
Cases 
UNC 
Cases 
Kappa (95% CI) 
PIN 
Cases 
UNC 
Cases 
Kappa (95% CI) 
Discharge 161 148 0.93 (0.89, 0.96) 39 41 0.89 (0.82, 0.97) 
non-ACOG 41 42 0.91 (0.84, 0.98) 28 20 0.82 (0.71, 0.94) 
ACOG 114 148 0.20 (0.11, 0.28) 466 41 -0.12 (-0.16, -0.08) 
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Conclusions based on the validation study 
The initial PIN protocol released data solely based on the PIN ACOG assessment due to 
increased confidence in the standardized criteria used for ascertainment. The strong correlation 
of the Discharge and non-ACOG variables with the UNC Database however gives support for 
their use as well. Discussions with UNC OB/GYN Dr. Thorpe revealed that clinical practice at the 
time was in flux with changes in criteria for both PE and GHTN. In fact until 2002, gestational 
hypertension had been called pregnancy-induced hypertension 45 which further complicates the 
MD diagnosis of GHTN. Given the fact that the PIN ACOG variables were not able to assess 
disease onset at the time of delivery and that the Discharge and non-ACOG variables correlated 
with one other clinical source of information, all three variables were used to determine case 
and control status in this study. 
Case status Definition for GHTN and PE  
 Women who were found to have PE by any of the PIN variables are considered PE cases.  
 Women who were found to have GHTN by any of the GHTN variables and did not 
progress to PE are identified as cases of isolated GHTN. 
 Women with chronic hypertension will be initially considered as cases if they also have 
PE or isolated GHTN. They will be removed from the case definition as part of a 
sensitivity analysis. 
Table 2.4 Case definitions for Preeclampsia (PE) and Isolated Gestational Hypertension (GHTN) 
 PIN Discharge PIN nonACOG PIN ACOG 
Chronic 
Hypertension 
Preeclampsia 
PE=Yes, 
GHTN= Yes or No 
Or PE= Yes, 
GHTN= Yes or No 
Or PE=Yes, 
GHTN= Yes or No 
Yes or No 
Isolated GHTN 
PE=No and 
GHTN=Yes 
Or PE=No and 
GHTN=Yes 
Or PE=No and 
GHTN=Yes 
Yes or No 
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Additional validation 
In order to clarify the validity of the PIN diagnoses, 125 records for women who were both 
genotyped and had discordant PIN diagnoses were validated against UNC antenatal and delivery 
records. 
Blood pressure and proteinuria data were abstracted from the medical record and 
preeclampsia and gestational hypertension were assessed using ACOG criteria. For women that 
PIN identified as having PE by any measure, the validation suggested a sensitivity of 77%, 
specificity of 62% and a positive predictive value of 63%. The low PPV was due to women that 
PIN identified with PE for whom there was only evidence of isolated gestational hypertension in 
the chart (24/70, 34%). 
For isolated gestational hypertension the sensitivity was 63%, specificity 75% and positive 
predictive value 73%. The low positive predictive value was due primarily to women who PIN 
identified as having gestational hypertension but in fact had preeclampsia (13/55 24%). 
Given the underlying data set included only women with discordant diagnoses of either 
gestational hypertension or preeclampsia, the PPV is the most informative value. For both 
diagnoses the PPV is fairly low, with PIN PE diagnoses including a large proportion of women 
with gestational hypertension, and PIN gestational hypertension diagnoses including a smaller 
proportion of women with preeclampsia. 
Given the changing diagnostic criteria over the course of the study, those women who were 
diagnosed by PIN prior to publication and acceptance of the ACOG rules might not meet current 
PE diagnostic criteria and their inclusion as PE cases will increase the heterogeneity of the case 
group and perhaps limit our ability to find associations. 
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Within the analysis, refinement of the PE case definition is possible based on the results of 
the chart abstraction to assess the sensitivity of the estimates to stricter case definitions. The 
single SNP analysis will be conducted using a refined case group that includes; 1. Concordant PIN 
diagnoses of preeclampsia or 2. Validated PE diagnosis based on the UNC chart review. Although 
this will be a small group, the direction of the association can be assessed to determine how the 
change in case definition will alter inference about the SNPs. 
2.3.1.3 Small for gestational age 
Birth weight was recorded at time of delivery for all infants. SGA was defined as below the 
10th percentile for weight for gestational age stratified by race, sex and parity. The percentiles 
used were developed by Zhang186 based on 1989 United States births.  
Women with PE are more likely to have infants born SGA.132  This association may be 
stronger among women with early onset PE and preterm birth.133  In addition, infants born 
preterm for any reason are more likely to have impaired fetal growth compared to infants who 
go on to a term delivery. For these reasons term SGA was also considered as a discreet outcome 
in order to capture pathways independent of prematurity and sever preeclampsia. 
2.3.2 Main Exposures 
2.3.2.1 Sample Collection and DNA Extraction 
Whole blood was collected from PIN participants, centrifuged and the buffy coat fraction 
was stored in CPT tubes and placed in -80˚C storage. DNA was extracted using various protocols 
for each study. For PIN1/2 women used in Dr. Engel’s study, DNA was extracted using the 
 74 
Applied Biosystems (ABI) automated DNA extractor.6  DNA extraction for PIN3 women at Wake 
Forest University (Winston-Salem, NC) and PIN3 cases at the Broad Institute (Cambridge, MA) 
was performed using Qiagen AutoPure chemistry. In addition to previously extracted DNA, some 
cases and controls had DNA extracted specifically for this study at the Biospecimen Processing 
Laboratory at UNC (Chapel Hill, NC). DNA was extracted from the buffy coat sample using similar 
Qiagen (Gentra) Puregene chemistry. 
2.3.2.2 Tag Selection 
For each gene, the Illumina database was queried for all polymorphism design scores within 
our genes of interest, allowing for 20kb upstream and 10kb downstream margins. Genes in close 
proximity were analyzed together. A scoring algorithm for each SNP was created, taking into 
account Illumina design score, Illumina error codes, DNA coding changes, and presence in a 
possible 5’ promoter site. This composite SNP database consisting of over 30,000 
polymorphisms was analyzed using TagZilla for multiple populations (populations consisting of 
more than one racial group), to select an optimal tagSNP within each bin.187  Given power 
considerations, we selected an R2 = 80% and limited tags to minor allele frequencies ≥ 10%. Due 
to the inclusion of two genetic ancestry groups, some tagSNPs chosen were unique to a specific 
genetic ancestry group.  
In addition to tagSNPs, some SNPs that had previously shown an association in the 
literature were forced onto the panel.  
SNPs selected for both inflammatory and cell cycle genes are in the Appendix (Tables S1 
and S2). Minor allele frequencies were obtained from the Illumina database and supplemented 
with data from NCBI (http://www.ncbi.nlm.nih.gov/projects/SNP/) when Illumina data was 
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missing. MAF are noted for CEU (Northern and Western European Ancestry) and YRI (Yoruba n 
Ibadan, Nigeria). Some SNPs are non-polymorphic in a given genetic ancestry group (MAF=0.0). 
2.3.2.3 GoldenGate Process 
The DNA sample is first activated for binding to paramagnetic particles. Three 
oligonucleotides are designed for each SNP locus. Two oligos are specific to each allele of the 
SNP site and a third that hybridizes several bases downstream is the locus-specific oligo. All 
three contain regions of genomic complementarity and universal PCR primer sites. During the 
primer hybridization process, the assay oligonucleotides hybridize to the genomic DNA sample 
bound to the paramagnetic particles. Following hybridization, several wash steps are performed 
to reduce noise by removing excess oligos. Extension of the appropriate allele-specific oligos and 
ligation of the extended product to the locus-specific oligo joins information about the genotype 
present at the SNP site to the address sequence of the locus. These provide the template for 
PCR using universal PCR primers P1-P3. Universal primers P1 and P2 are Cy3 and Cy5-labeled. 
The single-stranded, labeled DNAs are hybridized to their complement bead type through the 
locus-specific oligo. Hybridization of the GoldenGate assay products onto the array matrix or 
beadchip allows for the separation of the assay products in solution, onto a solid surface for 
individual SNP genotype readout. The intensities of the beads’ fluorescence are detected by the 
Illumina BeadArray Reader and are in turn analyzed using Illumina’s software for automated 
genotype calling. Genotyping results will be reported as allele sizes of the polymorphic markers 
of called alleles as well as values normalized to a CEPH individual.  
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2.3.2.4 Quality Control 
Genotyping 
Genotyping was performed by the University of North Carolina Mammalian Genotyping 
Core using the Illumina GoldenGate assay. Assay intensity and genotype cluster images for all 
SNPs were reviewed individually. Of the 1536 makers on the panel, 1430 were successfully 
genotyped with 106 markers (6.9%) excluded due to low signal intensity or inability to 
distinguish between genotype clusters. Seven QC samples were included on each plate. Three 
blind duplicates and 4 ‘open’ CEPH controls (a family trio and one family member repeated). 
Blind duplicates were chosen at random from all genotyped samples (approximately 3% of all 
samples) with sufficient quantity of DNA. Blinded duplicates were examined for inconsistency 
between genotypes and SNPs were excluded if they have >2 genotype call errors between 
duplicates. The open controls were examined for mendelian inheritance errors or 
inconsistencies across plates, which may be evidence of genotyping errors or batch effects. 
Hardy Weinberg 
HWE was examined using Plink among non-cases stratified by race to detect possible 
genotyping errors (p<0.01). SNPs which show evidence HW disequilibrium were reviewed with 
the UNC Lab to determine possible reasons for discrepancies (difficulty distinguishing clusters, 
close proximity to another SNP) and they were dropped if the genotyping results remain 
inconsistent. 
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Participants 
1649 PIN samples were plated. In the initial run 99.1% of the samples had a call rate >=95%. 
Following the initial genotyping an additional plate was run to capture samples (N=19) that 
initially failed genotyping. The additional plate had 73.7% with a call rate >=95%. Ultimately 
1646 unique individuals were successfully genotyped. Given the very low failure rate for 
individuals, those individuals failing genotyping were individually inspected with regards to case 
status to exclude any major systematic issues. Markers for gender were also genotyped and 
were inspected. Given that all cases and controls gave birth, non-female gender among subjects 
would be a sign of sample contamination. Subjects were also examined for 100% concordance 
of genotype to identify unintended duplicates. 
2.3.3 Genetic Ancestry 
Previous studies188 suggest that there may be important differences between allelic 
frequencies in genes related to inflammatory cytokines between self-reported African-
Americans and Caucasians in the United States.  As race has also been associated with all three 
outcomes, the potential for confounding by population stratification is possible. 
Self-reported race was collected for all PIN mothers, and maternal race for this study was 
restricted to self-reported race as “White” or “Black or African American”. Women who 
reported mixed race including African-American or White were not selected for genotyping. 
In addition to self-reported race, a panel of 157 ancestry informative markers (AIMs) were 
chosen based on AIMs that have performed well on the same platform and in a similar (North 
Carolina) population.189  The selected AIMs maximize the difference in allele frequency between 
the assumed ancestral populations, Yorban individuals from Ibadan in Nigeria and the HapMap 
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CEPH population representing Northern and Western Europe populations. For the Carolina 
Breast Cancer Study (CBCS), AIMs were selected based on δ and Fisher’s Information Criteria 
across three possible admixture proportions; 10% European/90%African, 
50%European/50%African and 90%European/10%African. Previous assessment of admixture 
among contemporary women in North Carolina suggests proportion of European Ancestry is 
approximately 15-20% for African Americans and 90% for Whites.189, 190  
2.3.4 Additional covariates 
2.3.4.1 Smoking 
Women reported the duration and amount smoked during the telephone interview 
between 24 and 30 weeks gestation. The variable captures the average number of cigarettes 
smoked during the first 6 months of pregnancy. Previous analysis in the early cohorts in PIN 
showed a high correlation between smoking in this interval and in later intervals in pregnancy. 
Urinary cotinine (a metabolite of nicotine) was analyzed for a subset of the women in PIN 1 and 
2 between 24 and 29 weeks and shortly after delivery. A previous analysis185 suggested that 
postpartum cotinine levels were somewhat more strongly associated with preterm birth 
compared to self-report, however cotinine levels at 24-29 weeks showed a similar pattern of 
association. Given that only a small fraction on the entire cohort had measured cotinine levels, 
self-reported smoking was used.  
2.3.4.2 Height and  Body Mass Index  
Women were measured for height at their recruitment visit and they provided a self-
reported pre-pregnancy weight. Maternal weight throughout the pregnancy was abstracted 
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from the medical record and the date of the last reported weight was noted to determine 
gestational weight gain. Self reported pre-pregnancy weight was corrected if it was not 
consistent with the first measured weight. Body Mass Index (BMI) was categorized based on the 
2009 IOM Guidelines191 (<18.5 kg/m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2 and >=30.0kg/m2).  
2.3.4.4 Parity 
Number of previous pregnancies was self reported by women at the recruitment visit. 
Parity was calculated was calculated as number of live born infants plus number of still born.  
2.3.4.5 Age 
Maternal age at conception was self-reported and collected at the recruitment visit. 
2.3.4.6 Poverty 
Percent poverty was constructed based on self report of total family income adjusted for 
the total number of adults and children relying on the income. The adjusted income was 
compared to regional values for poverty. For PIN 1/ 2 the benchmark was 1996 poverty levels 
while for PIN 3 the benchmark is 2001.  
2.4 Analysis Plan 
Analysis proceeded in stages with the analysis and study design dictated by the goals of 
each stage. The following section will discuss the specifics of each stage in detail. 
In general Stage 1 was focused on gene level associations with the outcomes and was a 
case control design using SNPs which are grouped at the level of the gene. The analysis was 
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stratified by genetic ancestry and adjusted for continuous genetic ancestry. As a discovery 
phase, a false discovery rate of 20% was used to identify gene sets which proceed to Stage 2.  
Stage 2 focused on identifying the specific SNPs within the genes that are driving the 
relationship seen in Stage 1. Inverse probability weighting was used to include the entire 
genotyped cohort to estimate risk ratios for each SNP. Robust variance estimators were used to 
construct confidence intervals. SNPs within gene sets were ranked based on strength and 
precision of the association. Investigation of LD was used to further understand the relative 
importance of each SNP. Stage 2 was also stratified by genetic ancestry and adjusted for 
ancestry. Additional covariates were explored based on DAGs for the specific outcomes. 
Stage 3 was exploratory and involved a Stage 2 analysis of all SNPs in both pathways 
regardless of the results of Stage 1. 
2.4.1 Stage 1  
Traditional analysis of candidate gene panels usually includes a SNP-based analysis with the 
possible addition of a haplotype analysis.  For outcomes with strong associations with a single 
polymorphism, this approach has resulted in some meaningful discoveries. However for 
complex disorders, current SNP by SNP approaches are often finding modest effects with single 
SNPs, and these associations are often hard to replicate.  
For complex disorders, analysis at the level of the gene may be more relevant. Particularly 
when analyzing tag SNPs, multiple SNPs on a given gene may be in LD with causal SNPs. 
Although each individual SNP may have a weak association, epistatic interactions may result in 
individual SNPs showing little effect while their interactions may have a larger effect.192, 193   A 
gene based analysis approach also has the potential to reduce the multiple testing issues 
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associated with large numbers of SNPs, especially in the context of genome wide association 
studies (GWAS). 
Advantages of gene based analyses include improved reproducibility, power and 
interpretability. Since different studies often genotype different SNPs, reproducibility may be 
hampered if different tag SNPs or different genetic panels are assayed by different study groups. 
Gene based results allow for the assessment of genes across study centers and may help more 
quickly focus fine mapping of relevant genes. Power is improved due to the reduction in the 
number of tests and a lowering of a panel-wise significance level. Gene based associations are 
also likely to be stronger than the individual SNP associations. Finally, interpretations at the 
gene level can be made based on known biomarkers and gene products as opposed to 
speculation about the functional implication of an unknown causal SNP which is being captured 
by a tagSNP.194 
Michael Wu194 has developed an attractive method (SKAT- SNP-set Kernel Association Test) 
for performing a gene based analysis which offers a powerful and flexible framework that allows 
for complex SNP interactions and non-linear effects. In addition, the method allows for inclusion 
of covariates and does not penalized SNPs with opposing effects (risk or protective) within a 
single gene. Although SKAT allows for any biologically informed method for grouping SNPs into 
sets; gene, pathway, conserved regions, haplotype blocks or windows, gene based sets with a 
suitable upstream and downstream regulatory region will be used for this analysis. 
SKAT initially assumes an additive model and uses a logistic kernel-machine regression 
model. This model form assesses the influence of all the SNPs in a given SNP set through a 
semidefinite kernel function. The kernel can be specified to accommodate different model 
forms from linear kernels, which represent the logistic model, to highly non-linear kernels.  
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Kernel functions convert information for each pair of subjects to a value that represents their 
similarity. As all possible pairs are integrated into the function, the resulting matrix must be 
positive semidefinite (a positive semidefinite matrix has only non-negative eigenvalues and 
possesses properties which facilitate the calculation of optimal solutions).195 
Kernel choice is important as it drives the modeling of the association between the SNPs in 
the SNP-set and disease status. A number of kernels exist and many more are being 
developed.196  SKAT incorporates 6 predefined kernels (linear, linear weighted, IBS, IBS weights, 
quadratic and a product kernel which allows for interactions). Through simulation, Wu suggests 
use of a linear kernel (comparable to a usual logistic model) or the identical by state (IBS) kernel. 
The IBS kernel compares the number of alleles shared IBS at the SNPs within the SNP-set. The 
IBS kernel can be augmented by weights based on MAF or on prior information regarding 
expected associations between specific tags and the trait of interest.193  The logistic model can 
also be weighted by the MAF which allows for rare variants to be up-weighted relative to 
common variants. 
Hypothesis testing is conducted using a variance component score test of the null 
hypothesis that the general function for the SNP set equals 0.197  The degrees of freedom are 
adjusted for the correlation of the SNPs within the SNP set with higher correlation between 
SNPs resulting in fewer degrees of freedom.  
Compared to other existing multi-SNP tests, SKAT has several advantages.194  Compared to 
tests which rely on the most significant p-value for an individual SNP within a given SNP-set, this 
method allows for interaction between SNPs within a SNP-set. When a given SNP is not in LD 
with a causal SNP, this method borrows power across a number of SNPs that may each be 
correlated to the causal SNP. Omnibus tests for multiple SNPS allow for simultaneous analysis of 
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all SNPs within a given SNP-set, but are crippled by a large number of degrees of freedom and 
cannot account for opposing directions of effect. Omnibus methods also do not allow for the 
incorporation of covariates. 
In Stage 1 a gene based analysis was used to identify genes of interest. Stage 1 was 
conducted as a stratified analysis. For each racial group, defined by genetic ancestry, the 
appropriate SNP set was assembled for each gene. As tag SNPs were chosen using a 20kb 
upstream and 10kb downstream region, the gene set included all tag SNPs within this region. 
Tag SNPs which are only polymorphic in a single genetic ancestry group were excluded from the 
analysis in the other group. Genes that are tightly clustered with overlapping upstream and 
downstream regions were considered as a single gene set. Rare SNPs were included as long as 
the SNP is truly rare in the population in general (as confirmed by HapMap) and there was at 
least one individual with the variant allele in the case or non-case group. Given that missing 
genotypes in a single SNP removed an individual from analysis in the entire geneset, individuals 
included for analysis varied by outcome and geneset. While imputation could be used to fill in 
those alleles that failed to genotype, using a complete case analysis captures greater than 90% 
of individuals for each outcome/ genetic ancestry combination. Given the logistical difficulties of 
imputing the missing alleles and the high coverage of a complete case approach, imputation was 
not attempted. Tables 2.7 through 2.9 provide information on each geneset in terms of the 
number of individuals and SNPs included in analysis. 
For Stage 1 cases included all genotyped cases with non-missing genotypes for the specific 
outcome. As this is a case-control design, controls were genotyped women who are free from 
any outcome of interest (Table 2.10). 
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Table 2.5 Number of SNPs in each gene set for inflammatory genes 
GENE SNPs SNPs dropped (outcome)* 
TNFRSF1B 9  
IL6R 31 
rs12060250 (all)  
rs12096944 (all)  
IL10 17  
IL1A 2 Replication SNPs 
IL1B 2 Replication SNPs 
IL8RB 6  
IL12A 26  
IL8 17 
rs16849893 rs4694634 rs7693566 (SGA, PE, tSGA, nPE) 
rs16849896 rs16849907 (GHTN, PE, tSGA, nGHTN, nPE) 
CXCL10 9  
NFKB1 28  
IL2 9 
rs10034410 (PE, nPE) 
rs10027390 out of HWE (YRI) 
IL15 22 
rs17007476 (PE, sPTB nPE) 
rs17007480 rs17007503 (PTB, SGA, PE, sPTB tSGA nPE) 
CSF2 18 rs743677 (PE, tSGA, nPE) 
IL13;IL4 26 
rs2243240 rs2243246 rs2243261 (PE, sPTB, nPE)  
rs4621555 (PE, sPTB, tSGA, nPE), rs2243253 (SGA, tSGA, nPE) 
IL12B 19  
LTA;TNF 14  
IL6 26 rs2069842 (SGA, PE, sPTB, tSGA, nPE) 
GATA3 34 
rs12262237 (PTB, SGA, GHTN, sPTB, tSGA, nGHTN)  
rs263425 (SGA, GHTN, tSGA, nGHTN) 
IL18 12 rs11214098 non-polymorphic (all) 
KLDR1 8  
IFNG 12 rs17104856 (PTB, SGA, GHTN, sPTB, tSGA, nGHTN, nPE) 
TGFB3 2 rs4252345 non-polymorphic (all) 
TBX21 7  
TGFB1 1  
KIR3DL3 14  
KIR2DL4 2  
KIR3DL2 6  
IFNGR2 14  
*All SNPs dropped from European Americans except for IL2 rs10027390 which was out of HWE 
in African Americans and was dropped for all analyses in this genetic ancestry group 
 
Table 2.6 Number of SNPs in each gene set for cell cycle genes 
GENE SNPs SNPs dropped* (outcome) 
GADD45A 20 rs1511686 (PTB, SGA, PE, sPTB, tSGA) 
RASSF1 7  
CCNA2 9 rs3217760 (PTB, GHTN, PE, sPTB, sGHTN, sPE) 
CCNH 1  
NOV 14  
CDKN2A;CDKN2B 24  
CNNM2 16 rs7902220 (PTB, SGA, PE, sPTB, tSGA, nPE) 
CCND1 18 rs7106515 non-polymorphic (all) 
MDM2 1  
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Table 2.7 Number of individuals with complete genotype information for each gene set and outcome stratified by genetic ancestry group 
 PRETERM SPONTANEOUS 
PRETERM 
SGA Term SGA GHTN GHTN w/o CHTN PE GHTN w/o CHTN 
 EA AA EA AA EA AA EA AA EA AA EA AA EA AA EA AA 
Total 603 338 512 269 526 296 505 268 688 371 650 347 524 301 498 274 
Inflammation Genes               
TNFRSF1B 598 333 507 266 521 290 500 263 682 365 644 342 520 298 494 271 
IL6R 592 329 504 261 521 285 500 258 680 356 642 335 518 293 492 266 
IL10 600 335 509 266 523 295 502 267 686 368 648 345 522 300 496 273 
IL1A 603 338 512 269 526 296 505 268 688 371 650 347 524 301 498 274 
IL1B 603 338 512 269 526 296 505 268 688 371 650 347 524 301 498 274 
IL8RB 603 338 512 269 526 296 505 268 688 371 650 347 524 301 498 274 
IL12A 594 317 504 253 520 277 499 250 683 342 645 319 520 282 494 256 
IL8 599 311 509 247 522 271 502 247 680 343 642 325 519 281 493 256 
CXCL10 602 336 511 267 525 295 504 267 687 370 649 346 523 300 497 273 
NFKB1 598 321 507 255 522 280 501 253 683 355 645 333 520 287 495 262 
IL2 601 337 510 268 524 295 503 267 685 370 647 347 521 301 495 274 
IL15 580 325 492 261 507 284 486 259 658 362 622 339 505 293 480 268 
CSF2 590 330 503 262 516 287 495 260 676 364 639 341 515 294 489 267 
IL13;IL4 583 335 502 267 512 293 491 266 670 368 633 344 517 299 491 272 
IL12B 594 335 504 266 520 294 499 266 679 369 642 345 518 298 493 271 
LTA;TNF 580 332 495 264 505 290 484 263 662 362 625 338 504 296 478 270 
IL6 599 337 509 268 522 292 501 264 684 366 646 343 520 299 494 272 
GATA3 586 332 497 263 513 288 492 261 663 361 626 337 509 293 484 266 
IL18 603 337 512 268 526 295 505 267 688 369 650 345 524 299 498 273 
KLDR1 601 335 511 266 525 294 504 266 686 368 648 344 523 299 497 272 
IFNG 585 331 498 264 514 292 496 264 673 365 638 342 515 297 489 270 
TGFB3 603 338 512 269 526 296 505 268 688 371 650 347 524 301 498 274 
TBX21 602 338 511 269 526 296 505 268 687 371 649 347 524 301 498 274 
TGFB1 602 338 511 269 525 296 504 268 687 371 649 347 523 301 497 274 
KIR3DL3 584 327 496 259 510 286 489 258 668 359 632 337 506 291 480 265 
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 PRETERM SPONTANEOUS 
PRETERM 
SGA Term SGA GHTN GHTN w/o CHTN PE GHTN w/o CHTN 
 EA AA EA AA EA AA EA AA EA AA EA AA EA AA EA AA 
KIR2DL4 600 335 509 268 522 293 501 267 683 370 646 346 520 298 494 272 
KIR3DL2 600 332 509 266 523 292 502 265 682 367 644 344 521 297 495 271 
IFNGR2 597 336 508 268 523 294 503 267 683 369 645 345 521 301 495 274 
Cell Cycle Genes                
GADD45A 587 311 498 247 509 270 488 246 668 336 632 316 508 278 483 252 
RASSF1 602 338 511 269 525 296 504 268 687 370 649 346 523 301 497 274 
CCNA2 598 338 508 269 521 296 500 268 682 371 644 347 520 301 494 274 
CCNH 603 338 512 269 525 296 504 268 688 371 650 347 524 301 498 274 
NOV 595 336 504 268 518 295 497 268 678 369 640 345 516 301 490 274 
CDKN2A; 
CDKN2B 
594 329 503 263 516 286 495 261 678 362 640 339 518 292 493 266 
CNNM2 599 337 508 268 523 294 502 267 684 368 646 344 521 301 495 274 
CCND1 600 335 509 267 523 292 502 265 684 368 646 345 521 298 495 272 
MDM2 603 338 512 269 526 296 505 268 688 371 650 347 524 301 498 274 
 
Abbreviations: SGA Small for Gestational Age, GHTN Gestational Hypertension, CHTN Chronic Hypertension, PE Preeclampsia, EA European 
American, AA African American
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Multiple Comparisons 
While use of SKAT in Stage 1 will limit the number of hypotheses being tested, there is still 
a concern with multiple comparisons. The Bonferroni correction has traditionally been used to 
correct for multiple comparisons. This correction provides a straightforward way to ensure 
global error rate by correcting the per test alpha by dividing alpha by the total number of 
statistical tests being performed. While Bonferroni correction works well for a relatively small 
number of independent tests, it does not take into account that linkage disequilibrium between 
SNPs, complex biologic interactions between genes and similarities between genetic models 
that will result in correlation between tests. Ignoring this correlation makes Bonferroni too 
conservative and may result in an unacceptable Type II error rate198, 199 especially in the context 
of small effects in relatively small studies. 
The False Discovery Rate (FDR) is less conservative than the Bonferroni Correction and may 
be more appropriate when discovery is the goal. When implemented, FDR results in alpha (α 
Type I errors) to be the expected proportion of errors among all of the rejected hypotheses. For 
example an FDR alpha of 0.05 will result in 5% of identified SNPs being false positive discoveries. 
The FDR method ranks all the p-values and considers each in a decreasing fashion by searching 
for the first for which the p-value is ≤ the rank of the SNP/total number of SNPs tested *alpha. 
All SNPs with that p value and smaller are then considered significant. In this way the degree of 
correction is more stringent for smaller p-values.199 
Use of FDR is appropriate in this situation as Stage 1 is being used to identify genes which 
are associated with the outcomes and underwent further investigation in Stage 2. Given the 
discovery nature of Stage 1, a generous FDR of 20% was used. This can be interpreted as 20% of 
the genes which enter Stage 2 are false positive. Genes with a single SNP, or with SNPs that 
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were chosen purely for replication, were considered only in Stage 2.  As a result there were be 
24 genes ranked for FDR in the inflammatory pathway (IL1A and IL1B are replication SNPs, 
TGFB1 and TGFB3 have single SNPs) while 7 genes were ranked in the cell cycle pathway (CCNH 
and MDM2 have single SNPs) for a total of 31 genesets in Stage 1. 
2.4.2 Stage 2 
While SKAT offers an attractive method for assessment of significance at the gene-level it 
does not quantify the strength or direction of the association and does not identify the SNPs 
within the gene that may be associated with the outcome. Although covariate adjustment is 
possible in SKAT, model reduction methods are not practical given lack of fit statistics and the 
absence of a single measure of effect for the SNP-set. Given the low power of this study 
however, SKAT remains a very desirable approach. 
While information at the level of the gene is relevant from a biologic perspective and allows 
for guidance of future studies, identification of the specific genetic changes within the gene is 
also desirable. Associations between specific SNPs and the outcomes of interest were examined 
in Stage 2 based on strength of association, precision of the estimate and association with other 
SNPs in the set (LD). 
Stage 2 focused on identifying the SNPs which are likely associated with the observed gene 
effect and further explored possible confounding. As the data for Stage 2 is the same as the data 
used in Stage 1, the two stages are not independent and interpretations of the results from 
Stage 2 were cautious. Although measures of effect and p-values were calculated, this stage was 
used to generally assess direction of effect and the relative rank of the SNPs within the genes for 
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a given outcome. Also, specific regions of interest within each gene were identified. These 
regions can be targeted in future fine mapping studies. 
2.4.2.1 Study Design 
Stage 2 assessed the association between each SNP and the outcomes of interest. Given 
the frequency of preterm birth, SGA and gestational hypertension in this population (Table 2.1) 
estimation of an odds ratio could not be considered a valid estimate of a risk ratio. While a 
common non-case group was valid for the estimation of an odds ratio in Stage 1, the genotyped 
population is not a suitable “cohort” for the estimation of a relative risk. The genotyped 
population includes an excess of “cases” relative to the underlying PIN cohort. Given that the 
biology, and therefore the SNPs, underlying these outcomes are related, a straightforward 
estimation of a relative risk using the entire genotyped population will misrepresent the 
distribution of the exposure in the base PIN population.  
An approach that allowed estimation of a risk ratio, while accounting for the over 
representation of cases in the genotyped population, is Inverse Probability Weighting (IPW) 
using a log linear model. IPW allows the entire genotyped population to be used as a cohort 
while representing the case (and covariate) distribution of the entire eligible population. While 
generalizing to the original PIN Cohort would be ideal, selection criteria for eligibility precluded a 
reasonable estimation of the variance of the point estimates using the base PIN Cohort as the 
reference population. 
The analysis of Stage 2 proceeded as a two-stage selection design. Considering the entire 
eligible population (N=3065), the probability of being selected for genotyping was calculated. 
Probability of selection was modeled using the following variables: general birth outcome 
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(liveborn v. all other outcomes), PIN cohort (two indicator variables), any case status (yes/no), 
selection into original PIN subcohort (yes/no), presence of a second birth in the cohort (yes/no), 
maternal age (indicator variables for <25 yrs, >=35yrs), parity (multiparous or nulliparous), any 
smoking in months 1-6 (yes/no), maternal education (<=12 yrs or 13+ years), pre-pregnancy BMI 
(indicator variables for underweight <18.5, overweight 25-29.9, obese >=30), percent of poverty 
level (continuous and standardized), marital status (married or non-married), site of PIN 
recruitment (UNC or Wake), self reported race (White or African American). Given missing in 
some of the covariates, values were imputed using means for specific PIN cohort/Site/Self-
reported Race groups.  
Selection probabilities were calculated for each individual in the eligible cohort. The inverse 
of the selection probability was used as a weight for each individual in the genotyped population 
who was included in analysis. Cases were identified for each outcome, and controls were all 
those without the specific case definition as outlined in Table 2.10. 
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Table 2.8 Breakdown of Cases and Controls by outcome and genetic ancestry 
 Stage 1 Stage 2 
 Cases Non-Cases Cases Controls 
Preterm EA 194 409 194 813 
Preterm AA 134 204 134 457 
Spont. Preterm EA 103 409 103 813 
Spont. Preterm AA 65 204 65 457 
SGA EA 117 409 117 890 
SGA AA 92 204 92 499 
Term SGA* EA 96 409 96 717 
Term SGA* AA 64 204 64 393 
GHTN EA 279 409 279 728 
GHTN AA 167 204 167 424 
GHTN (sens)† EA 245 405 245 699 
GHTN (sens)† AA 145 202 145 397 
Preeclampsia EA 115 409 115 892 
Preeclampsia AA 97 204 97 494 
Preeclampsia (sens)† EA 93 405 93 851 
Preeclampsia (sens)† AA 72 202 72 470 
*Controls include only term births 
†Cases and controls have women with pre-existing hypertension excluded 
Abbreviations: Spont. Spontaneous, EA European American, AA African American, sens 
Sensitivity 
 
While usual log linear models using IPW will produce valid point estimates, calculation of 
the variance of the estimates is more problematic. In SAS the usual variance estimator (here 
reported as “naïve”) will underestimate the variance and result in confidence intervals that are 
overly precise. Other options for calculation of variance for a model that includes selection 
weights, three levels of exposure (additive genetic model) and a continuous covariate (percent 
African American ancestry) include use of a robust variance estimator and use of bootstrapping. 
While a naïve SE may be overly small, a robust estimator is usually overly conservative. The true 
SE is likely between the two estimates.200  
To explore the impact of different models on both point estimates and variance, point 
estimates and SE were generated using three different methods.  For each analysis, models 
were stratified by genetic ancestry and continuous percent African American ancestry was 
included as a covariate. Genotype was modeled as additive with the variant allele harmonized 
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between the ancestry groups. Odds ratios were generated using PLINK for each SNP and each 
outcome using the same case-control group that was used in Stage 1. SAS was used to generate 
RR and SE for each SNP and each outcome using a log linear risk model. Two models were 
generated. While both used IPW, one used the “naïve” variance while the other used a robust 
variance estimator.  
A fourth model was generated using boot strapping. All 3065 women eligible for 
genotyping were sampled with replacement for 1,000 iterations. Each iteration was used to 
calculate an individual selection probability that represented the probability of being selected 
into the genotyping sample in the specific iteration. Each of the 1,000 iterations was used to 
generate a point estimate using a log linear model. The 1,000 point estimates were then used to 
generate a point estimate (mean) and a distribution (2.5th and 97.5th percentile of the 1,000 
estimates). 
Comparing these 4 models suggested that in general the RR estimates were slightly closer 
to the null compared to the OR for PTB and GHTN. The SE for the naïve models were smaller 
than the SE from the robust models although the magnitude of difference was generally small. 
Boot strapping results did not differ from the standard analysis using naïve or robust SE 
equations. Point estimates and precision were comparable while analysis time was greatly 
increased. 
As the true SE is likely between the naïve estimate and the robust estimate and the 
difference between these two was not great, the robust SE was chosen for analysis. Although 
this may be a slightly conservative estimate leading to slightly less precision, the Stage 2 analysis 
is designed to rank SNPs within genes. The decrease in precision will not alter ranking while 
 93 
avoiding overly optimistic interpretations. Models will be adjusted for genetic ancestry and 
additional covariates as outlined in Section 2.4.2.  
An additive genetic model was assumed in Stage 2 although cell counts for the homozygote 
variant were monitored and dominant models were used when small cell counts (<5) result in 
unstable estimates. 
Reporting of SNPs from Stage 2 was based on the observed strength of association as well 
as the precision of the estimate. Unstable estimates were not reported. Estimates were 
examined across related outcomes and between ancestry groups to identify single SNPs and 
genomic regions which appeared relevant.  
Linkage disequilibrium between SNPs within each gene in this population was calculated 
and visualized using Haploview.201 In addition, long range LD was used to assess the association 
between typed SNPs and untyped SNPs in adjacent genes. The tagging process included both 
upstream and downstream regions and other genes were captured by the chosen tagSNPs. 
Visualizing long range LD also helped identify different LD patterns between ancestry groups. 
SNAP202 allows for the visualization of long range LD between typed and untyped SNPs using 
various reference populations. The 1000 Genomes Project CEU and YRI reference groups were 
used when possible. 
Sensitivity analysis in Stage 2 included exploration of covariates in the top ranking SNPs. 
Nested models adjusted for all possible covariates as well as each covariate singly203 were 
compared with models adjusted only for continuous ancestry. Adjustments that change the 
estimate >10% were considered for inclusion in the models. 
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2.4.3 Stage 3 
Given the novelty of this multistage SKAT approach in a population with suspected 
heterogeneity, a sensitivity analysis was conducted in Stage 3. All SNPs were assessed using the 
Stage 2 analysis. Of interest were SNPs with a p-value below a Bonferroni correction (using the 
number of SNPs for each pathway) that were missed by the Stage 1 analysis.  
2.4.4 Covariate analysis 
Overview of procedures common to both pathways and all outcomes 
A number of covariates were considered in this analysis. While covariates related to race were 
considered for all outcomes, other covariates were considered specifically for each outcome and 
pathway. Complex biological processes such as the ones under consideration are hard to 
capture completely in a DAG leading to possible misspecification. Simulations of misspecified 
DAGs suggest that a full model based on a conservative DAG (inclusion of variables when there 
is doubt) followed by a change-in-estimate using the fully adjusted model as the reference, 
provides the best outcome with respect to bias and precision.203  In this study, model 
constraints, missing data on covariates, and power must also be taken into consideration.  
2.4.4.1 Cell cycle 
Very little information regarding possible confounders exists for cell cycle genes. Smoking 
may be associated with cell cycle function through the downstream gene p53, which is involved 
in the regulation of apoptosis. Among the genes under consideration, smoking may act directly 
through MDM2. Additionally CDKN2a is an upstream regulator of p53 while GADD45a has its 
expression regulated by p53. This association is tentative however. Given the amount of missing 
 95 
in smoking (Table 2.4.2.2a), and the possibility that the association is an interaction, smoking 
was not considered as a covariate in initial assessments.  If MDM2, CDKN2A or GADD45A had 
been found to be significant genes in Stage 1 of the analysis, a sensitivity analysis of the 
individual SNPs would have been conducted using smoking as a covariate to identify if the 
ranking of the SNPs would have changed by the addition of smoking to the model. 
2.4.4.2 Inflammation 
 
All outcomes 
A general DAG of the form that follows (Figure 2.4.2.2) can be drawn for each of the 
outcomes. The covariates may vary for each of the outcomes; however, barring the presence of 
an unmeasured confounder, these pathways are blocked by the gene product which is a 
collider.204  Unmeasured covariates could include other genetic polymorphisms that are 
correlated with the measured SNPs and the covariate of interest. At the level of the Stage 1 
gene analysis, “U” would need to be associated with the entire gene and not just single SNPs 
which may decrease the likelihood that “U” will introduce considerable bias. Unmeasured 
confounding cannot, by definition, be controlled. If “U” does exist, adjusting for the “covariates” 
in Figure 2.4.2.2 would block the back door path through “U”.  
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Figure 2.3- General DAG for inflammation pathway 
 
However given the high degree of missing data in a number of covariates in this data set 
(Table 2.11), the potential improvement in bias by adjusting would be offset by a significant 
decrease in power and precision.  
Table 2.9 Missing in possible covariates stratified by self-reported race 
Variable 
African American (N=615) 
Missing (N) 
White (N=1031) 
Missing (N) 
Total (N=1646) 
Missing (N) 
Smoking 80 72 152 
Age 0 0 0 
BMI 48 34 82 
SES 115 84 199 
Parity 1 2 3 
Height 37 24 61 
Abbreviations: BMI body mass index kg/m
2
; SES socioeconomic status represented by percent poverty 
 
Adjustment for covariates will result in a reduction of both the case and control groups due 
to missing in the covariates. The possible covariate sets vary by the outcome of interest, 
however case groups would decrease by 12% to 41% and non-case group would decrease by 9% 
to 28% if all possible covariates were included in the model. Decreases are higher in African 
SNP ↓↑ Gene Product Outcome 
Covariates 
U 
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Americans and highest for the SGA outcome, which also suffers from missing in the outcome 
(N=85) (Table 2.12). 
Table 2.10 Impact of adjustment for all possible covariates for each case group and the non-
case group 
  Complete Data Available (N) 
Outcome Adjustment set* 
African American 
N=615 
White 
N=1031 
Total 
N=1646 
Preterm None 145 202 347 
 All  111 165 276 
SGA None 96 120 216 
 All 57 98 155 
Isolated GHTN None 171 283 454 
 All 135 248 383 
Preeclampsia None 100 117 217 
 All 81 100 181 
Non Case None 210 419 629 
 Adjusted for PTB 159 378 537 
 Adjusted for SGA 150 367 517 
 Adjusted for GHTN 164 380 544 
*Adjustment sets: None (no covariates included). All (adjusted for all covariates as follows): 
Preterm birth (PTB): Smoking, age, body mass index, percent poverty (Total non-missing N=1341) 
SGA (small for gestational age): Smoking, body mass index, percent poverty, parity, gestational diabetes, 
height (Total non-missing N=1301) 83 missing SGA 
GHTN (gestational hypertension): Smoking, age, body mass index, parity, previous diabetes (Total non-
missing N=1380) 
 
Due to missing data, a conservative approach to adjustment by including all possible 
covariates would have result in an unacceptable loss of power. Absent “U”, all covariates in 
Figure 2.3 are on blocked paths and do not require adjustment. For these reasons, only 
covariates which do not fit into the covariate box in Figure 2.3 in each subsequent DAG will be 
considered for inclusion in models. For the remaining DAGs “U” will be left off the DAG although 
the discussion will assume that the “U” association described here is a possibility. 
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To explore the possibility of confounding, I will conduct a sensitivity analysis on high 
ranking SNPs in the Stage 2 analysis comparing the change in estimate between unadjusted 
models (adjusted for ancestry), fully adjusted and single adjusted models.203 
Preterm Birth 
 
Covariates for consideration 
Risk factors for preterm birth which are also associated with SNPs in inflammatory genes 
are likely acting through gene products of cytokines (Figure 2.4). For instance, the effect of 
psychosocial stress may influence pregnancy outcomes through changes in inflammatory 
biomarkers.205  BMI and active infection will also increase the circulating levels of inflammatory 
biomarkers. 
Of the covariates listed here, smoking, BMI and age are well measured in our cohort 
although both suffer from missing data. A number of psychosocial and infection related 
variables were collected in portions of the PIN cohort. Socioeconomic status (SES) can be 
captured using a variety of variables in PIN including percent poverty. 
Infection and stress are less well characterized in the PIN cohort. The presence of bacterial 
vaginosis was assessed for only a fraction of the cohort.6, 206  Self-reported sexually transmitted 
infections, as well as yeast infections, were collected for PIN1 and 2 but not for PIN 3. Measures 
of depression (CES-D) and social support (MOS Social Support Scale) were assessed for all three 
PIN cohorts, but these measures were not among the psychosocial measures which have 
previously been associated with preterm birth.207  Measures of perceived stress, state trait 
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anxiety and life events were collected for some of the PIN cohorts, however the timing varied 
enough to make construction of a valid variable across cohorts difficult. 
Possible covariates on the causal pathway 
An alternate DAG (Figure 2.5) for preterm is possible with the covariates separated into 
those that are likely associated with the gene product (age, stress, and smoking) and those that 
may be caused by the gene product (BMI, infection). The first group is associated with the gene 
product in the sense that stress or smoking may increase inflammatory cytokines. However 
inflammatory cytokines themselves will not cause psychosocial stress nor smoking during 
pregnancy. For this set of covariates, the gene product is a collider unless there is a “U”. For the 
second group of covariates however the relationship is not as clear. BMI, as a measure of 
adipose tissue, may result in higher circulating cytokines as the adipose tissue provides 
substrate for cytokine production (red arrow). Alternately genetic polymorphisms may influence 
inflammatory cytokines and result in an increased BMI (green arrow). In the first case BMI would 
be considered a possible confounder only in the presence of “U”. In the second case BMI would 
be on the causal pathway between the SNP and the outcome of interest and should not be 
considered as a confounder.  
The direction of the “arrow” for these covariates will depend largely on the gene product 
under consideration. In sensitivity analyses where these covariates are kept in the model, closer 
examination of the biology involved will help inform the decision about inclusion or exclusion of 
the covariate.  
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Figure 2.4 DAG for Preterm Birth 
 
Figure 2.5 Alternate DAG for Preterm Birth 
 
  
SNP 
Infection 
BMI 
↓↑ Gene Product 
SNP 
Preterm Birth 
↓↑ Gene Product 
Smoking 
Infection 
BMI 
Stress 
Age 
Preterm Birth 
Self-identified Race 
GHTN 
Genetic ancestry 
SES 
GHTN 
 101 
Gestational Hypertension 
 
Figure 2.6 DAG for Gestational Hypertension 
 
Covariates for consideration 
Although PE and GHTN were considered as discrete outcomes, the risk factors for both are 
similar and can be represented by a single DAG (Figure 2.6). Hypertensive disorders of 
pregnancy share many similar covariates with preterm birth. Smoking, BMI age, chronic 
hypertension and both pre-existing and gestational diabetes are well measured. Although some 
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sources suggest that infection during pregnancy may be associated with preeclampsia, the 
stronger associations are with urinary tract infections and periodontal diseases and not the STDs 
measured in PIN.208 
Confounding by previous reproductive outcomes 
Unlike preterm birth, preeclampsia has a strong association with parity. First births are 
more likely to be complicated by preeclampsia. Difficult first pregnancies may influence family 
planning choices and limit subsequent pregnancies resulting in fewer high-risk mothers with 
higher parity. Parity is well documented in PIN. Data was also collected on self-report of a 
previous pregnancy complicated by preeclampsia for multiparous women. As can be seen on the 
DAG, adjusting for parity is a better choice given the likelihood that unmeasured variables 
influence the outcomes in serial pregnancies. Parity is not missing for any observations in the 
data set (Table 2.11). 
The special case of chronic hypertension 
Preexisting hypertension makes the diagnosis of GHTN and PE difficult. Older diagnostic 
criteria included an increase in blood pressure of 15mmHg DBP or 30mmHg SBP after 20 weeks 
of pregnancy. Current guidelines restrict the diagnosis of GHTN or PE to women with a normal 
blood pressure before 20 weeks and recognize the diagnosis of superimposed PE or GHTN for 
women with preexisting hypertension who have a worsening of hypertension or develop new 
onset proteinuria (or worsening proteinuria) during pregnancy.209  However in PIN 1 and 2 some 
women were not enrolled until after 20 weeks and an elevated BP after 20 weeks may be either 
chronic hypertension or GHTN. Additionally there is a tendency for BP to drop slightly in the first 
trimester of pregnancy.210  Women who do not obtain routine medical care outside of 
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pregnancy may present for prenatal care with a ‘normal’ blood pressure even in the presence of 
undetected chronic hypertension. Given these factors, chronic hypertension was approached as 
outcome misclassification by conducting a sensitivity analysis with exclusion of women with self-
reported chronic hypertension.  
SGA 
 
Figure 2.7 DAG for SGA 
 
Covariates for consideration 
SGA shares many similar possible covariates with preterm birth with the addition of 
maternal anthropometric parameters such as height that influence growth potential. Parity is 
also associated with SGA. Unlike gestational hypertension however, there is not as much of a 
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concern that subsequent pregnancies will be limited. Infants born to multiparous women tend 
to be slightly heavier compared to nulliparous births.61 
2.4.5 Population Stratification 
Population stratification has been defined as differences in allele frequencies between 
cases and controls due to systematic differences in ancestry rather than associations of genes 
with disease. In genetic epidemiology studies, population stratification may result in biased 
results when the outcome of interest also varies based on genetic ancestry. Population 
stratification can result in both false positive and false negative results and the strength of the 
bias will depend on the magnitude of allelic variation among ancestry groups and differences in 
disease among those same groups.211  In non-genetic epidemiologic studies race is often 
considered as a confounder for similar reasons. Self-reported race is considered a marker for a 
wide variety of social, cultural, dietary, economic, stress, and educational experiences. In 
genetic epidemiologic studies however, race is also seen as a marker of genetic ancestry which 
will have practical consequences for LD structure, haplotypes, and allelic frequencies. In this 
setting self-reported race is often an inadequate surrogate for genetic ancestry. Not only are 
individuals poor reporters of their genetic ancestry212 at a level necessary for genetic studies, 
self-reported race may not adequately capture the genetic heterogeneity among self-reported 
racial groups.213, 214 
While population stratification can be quite complex when dealing with large metropolitan 
populations with a wide variety of genetic ancestry, the concern still remains in largely biracial 
populations as present in this study. In the United States, among those who self-report as 
African American, the percent of European genetic ancestry is quite variable. As measured in 
metropolitan centers across the US, estimated European ancestral proportion ranged from 
 105 
11.6% in Charleston, SC to 22.5% in New Orleans, LA215 with geographically isolated areas 
showing even more extreme values.216 
A number of methods have been proposed for addressing population stratification in 
genetic epidemiology studies. Genomic control was an early method which used random 
markers to estimate an inflation factor which was used to adjust all test statistics. Genomic 
control only protects against false positives and tends to overcorrect when non-random markers 
are used.211 
More recent work has focused on choosing informative markers called ancestry informative 
markers (AIMs), which are independent markers throughout the genome that have large allele 
differences between the ancestral populations of interest. Although allele differences between 
ancestral populations (δ) is important in selecting AIMs, factors such as the allele frequency in 
the ancestral population irrespective of δ (p) and the respective genetic contribution of each 
ancestral population to the admixed population (m) also influence the precision of ancestral 
estimates.217  Pfaff’s Fisher Information Criterion217 captures δ, p, and m into a single 
information estimate which allows for marker selection to optimize precision based on the 
actual, or hypothesized, ancestral populations and admixture proportions. 
Estimating genetic ancestry using AIMs can be accomplished using a number of different 
methods. Consensus on the optimal method of calculating genetic ancestry has not yet 
emerged. Commonly used methods include maximum likelihood estimation (MLE) methods, 
structured association and principal component analysis.218  Under situations with informative 
markers and large and accurate ancestral group information, both MLE and structured 
association methods perform well.219  MLE methods have been shown to be superior when 
marker information is low and there is little information on the allelic frequency in the ancestral 
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population. MLE methods are generally faster and less computationally intensive, however, 
when the assumption of independence among markers is violated, the confidence intervals may 
be too narrow.219  Structured association methods use Bayesian and MCMC methods to assign 
individuals to clusters or sub-populations. Structured association methods are dependent on the 
number of ancestral populations specified. This specification is at the discretion of the 
investigator and can be difficult to both determine and interpret in cosmopolitan populations.211 
Principal Component Analysis (PCA) is also used to correct for population stratification. PCA 
methods infer continuous axes of genetic variation by using eigenvectors of the covariance 
matrix of SNPs between samples.220  Unlike structured association methods, which are 
dependent on the correct choice of the number of clusters, PCA techniques are invariant to the 
number of axes chosen. Although many PCA techniques employ all the SNPs genotyped in GWAS 
panels, work has shown that well-chosen AIMs panels of 50-200 SNPs are equally good at 
controlling bias and optimizing power.221 
Software exists for both MLE (FRAPPE), Structured Association (STRUCTURE) and PCA 
(Eigenstrat) methods. Given the informativeness of the AIMs used, the relatively small size of 
the study population, the presence of only two ancestral populations, ease of use and familiarity 
of the software and previous work using similar populations in North Carolina189 which has 
found high correlation between MLE and Structure methods, Structure will be used initially for 
calculation of ancestry.  
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Additional issues with ancestry 
While adjustment for genetic ancestry will address confounding by population 
stratification, there is also the possibility of heterogeneity between the two genetic ancestry 
groups included in this study. Previous genetic epidemiologic studies looking at preterm birth4, 6, 
97, 98, 113, 114, 149, 155, 156 found that genetic associations varied by genetic ancestry. Pathway analysis 
in one cohort composed of US Whites and African Americans with the outcome of spontaneous 
preterm birth suggested that different pathways were operating in the two racial groups.97  Tag 
selection for this study resulted in some SNPs that are polymorphic in a single ancestry group 
(Table S1 and S2 in Appendix). While these private SNPs may be important for a specific ancestry 
group, they will provide no additional information for the other group.  
Although an analysis with all women combined would have more power due to an 
increased case and control group, differences in the size of the racial groups, the likelihood that 
different genes and SNPs are acting in different genetic ancestry groups, and the presence of 
private SNPs, increases the likelihood that associations would be missed in a combined analysis 
of both genetic ancestry groups. For this reason all analyses were performed within strata of 
genetic ancestry and additionally adjusted for continuous percent ancestry. 
2.4.6 Power  
Power will depend on the study design used -- case-cohort v. case-control -- due to the 
differences in the number of “controls”. As the proposed method for this study (SKAT) does not 
conform to a typical power calculation, certain simplifying assumptions are used.  
Given the lack of a power model for SKAT, an unmatched case-control design was 
simulated within Quanto (http://hydra.usc.edu/gxe/ ) to calculate power. For all calculations a 
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log-additive, gene only, unmatched case-control model was assumed. Two-sided Type 1 error of 
0.05 was used for both study designs. Initial calculations also included a Bonferroni correction 
using the assumed number of genes in each pathway. For inflammatory genes the Bonferroni 
corrected p value= 0.002 and for cell cycle genes p=0.006. Baseline risk was calculated in the 
cohort.  
The case:control ratio was estimated using a hypothetical case-cohort study design. For the 
hypothetical study a ‘cohort’ was constructed by using the N=523 women in the existing PIN1/2 
subcohort and adding the non-cases and an appropriate number of cases from each of the two 
(PIN1/2 non-subcohort, PIN 3) remaining sampling groups. The appropriate number of cases was 
chosen to reflect the distribution of cases in the established subcohort (PIN1/2= 87 non-cases 
and 53 cases, PIN3= 218 non-cases and 134 cases). The total reconstructed cohort was 
composed of 1015 women. Table 2.12 outlines the criteria used for each outcome for the power 
calculations. 
Table 2.11 Criteria used in power calculations 
Outcome Risk Cases 
Case:Control Ratio 
Case-Cohort N=1015 
Preterm birth 12% 347 3 
SGA 10% 216 5 
Isolated PIH 15% 454 2 
PE 8% 217 5 
 
Table 2.12 Range of odds ratios with 80% power for each outcome with the specified type 1 
error  
 PTB SGA GHTN PE 
 Type 1 error Type 1 error Type 1 error Type 1 error 
MAF 0.002 0.005 0.05 0.002 0.005 0.05 0.002 0.005 0.05 0.002 0.005 0.05 
10% 1.7 1.7 1.5 1.9 1.8 1.6 1.7 1.6 1.5 1.9 1.8 1.6 
20% 1.5 1.5 1.4 1.7 1.6 1.5 1.5 1.5 1.4 1.7 1.6 1.5 
30% 1.5 1.4 1.3 1.6 1.5 1.4 1.5 1.4 1.3 1.6 1.5 1.4 
40% 1.5 1.4 1.3 1.6 1.5 1.4 1.4 1.4 1.3 1.6 1.5 1.4 
Abbreviations: PTB preterm birth, SGA small for gestational age, GHTN gestational hypertension, PE 
preeclampsia, MAF minor allele frequency. 
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For the more common outcomes of PTB and GHTN power is adequate at or below OR 1.7 
within the full range of MAF. For the less common outcomes however power is adequate only 
below an OR of 1.9 (Table 2.13).  
The applicability of this approach to power calculations is limited given the study design.  
The SKAT model will be based on genes and not on single SNPs. While this should increase 
the overall power to detect a relevant gene, the association between MAF for a single SNP and 
the resulting power is not as clear.  
The Quanto program used for the power calculation relies on an unmatched case-control 
design. Due to the presence of cases in both the case group and the control group in a case-
cohort design, the Quanto method likely under estimates power for the case-cohort design.  
The outcomes above are not mutually exclusive and non-independent. “Pure” case groups 
would be quite small with much lower power.  
The above calculations include women of both races. Racially stratified analyses will have 
much lower power. 
The assumption of the Quanto power calculation is that there is a single causative SNP. The 
power calculated reflects the ability to detect the single causative SNP among a large number of 
null SNPs. 
An alternative approach to power calculation assumes that there exists more than one 
causative SNP and seeks to assess power to find one of many causative SNPs.222  Under this 
framework, Table 2.14 outlines the number of causative SNPs which must be assumed to be 
present to have 80% to find one of them given the range of power to find a single SNP if only 1 
 110 
SNP is causative. For instance if the power to find a single causative SNP is 2%, the presence of 
80 causative SNPs would result in 80% power to find one of them. 
Table 2.13 Power to detect multiple risk alleles 
Power for a single allele 
assuming only 1 risk 
allele 
Number of risk alleles 
needed to have 80% 
power to find 1 SNP 
 0.01 >100 
0.02 80 
0.03 53 
0.04 40 
0.05 32 
0.06 27 
0.08 20 
0.10 16 
0.12 13 
0.15 10 
0.20 8 
0.25 6 
0.30 5 
 
In this study an assumption of 15-20 underlying risk alleles seems reasonable. This would 
place the target single SNP power in the range of 8% to 10%. Although the previous power 
calculation suggested adequate single SNP power below OR 1.7-1.9, SNP effects are likely to be 
much more modest. 
Given that sample size, baseline risk and MAF are fixed in this study, the only variable 
which can be modified to influence power is the Type 1 error. Type 1 error can be considered as 
a function of the number of tests conducted, with more tests resulting in a lower type 1 error 
due to multiple comparisons. 
Quanto was again used to estimate power for an OR of 1.4 at a range of MAF given four 
different type 1 errors. Specifications within Quanto were the same as presented in Table 2.12. 
Given the similarity between power calculations for SGA and PE, only SGA is presented. The 
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candidate type 1 errors were chosen based on convenient Bonferroni corrections. The 
Bonferroni correction for the number of genes in the inflammatory pathway is 0.002. At the 
other extreme the Bonferroni correction for the total number of SNPs is 0.0001. Midway 
between these values, assuming 200 SNPs for analysis would result in a Bonferroni correction of 
0.0002 and assuming 100 SNPs would result in a Bonferroni correction of 0.0005. 
Table 2.14 Power with OR 1.4 to find one allele with a range of MAF and Type 1 error 
 PTB SGA GHTN 
 Type 1 error Type 1 error Type 1 error 
MAF 0.0001 0.0002 0.0005 0.002 0.0001 0.0002 0.0005 0.002 0.0001 0.0002 0.0005 0.002 
10% 0.08 0.10 0.15 0.26 0.03 0.05 0.07 0.15 0.10 0.13 0.19 0.31 
20% 0.25 0.30 0.39 0.54 0.11 0.15 0.21 0.34 0.32 0.38 0.48 0.63 
30% 0.38 0.45 0.55 0.69 0.19 0.27 0.32 0.46 0.49 0.56 0.65 0.78 
40% 0.46 0.53 0.62 0.76 0.23 0.29 0.37 0.53 0.57 0.64 0.72 0.84 
Abbreviations: PTB preterm birth, SGA small for gestational age, GHTN gestational hypertension, PE 
preeclampsia, MAF minor allele frequency. 
 
Table 2.15 suggests that for the more common outcomes of PTB and GHTN, the study has 
80% power to detect a single SNP with OR 1.4 assuming that there are at least 20 causative SNPs 
on the panel. With a MAF >10% the number of causative SNPs falls to 6. For SGA an assumption 
of 53 causative SNPs would be needed at the most stringent type 1 error and lowest MAF. 
However at less stringent type 1 error levels the assumptions about the number of causative 
SNPs becomes more reasonable (fewer than 30 and often fewer than 10). 
As a way of informing the number of SNPs which could reasonably proceed to Stage 2, a 
goal of a single SNP power of 8%-10% suggests that a type 1 error of 0.0002 to 0.0005 would be 
a reasonable choice. This type 1 error corresponds to the analysis of 100-200 SNPs in Stage 2. 
The number of genes that would result in this number of SNPs will depend on the gene. 
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2.4.7 Strengths and Limitations 
 
This study offers an innovative approach to studying genetic associations with these important 
reproductive outcomes in a number of ways.  
At its inception, this study was the largest candidate gene analysis for the outcome of SGA. Since 
the study was designed, however, another 1536 panel was completed with an SGA outcome.182 
Nevertheless, the Edwards study was in a Chilean population that may not be generalizable to African 
Americans. Additionally, while the Edwards study examined more genes related to inflammation, the 
number of SNPs per gene was limited. This study expanded coverage of the genes investigated, was 
conducted within a population of African Americans and considered novel genes within both 
inflammation and cell cycle pathways.   
For the outcomes of gestational hypertension and preeclampsia, this study assessed the largest 
number of genes related to inflammation in a North American population. Although some of the 
inflammatory genes have been examined in other populations, this study includes African Americans 
and expanded the breadth of genes examined with the addition of cell cycle genes and novel 
inflammatory genes identified through placental expression studies. 
For preterm birth, a study of similar breadth in a US bi-racial population has already been 
conducted. While many of the genes will overlap, this panel expanded the tagSNP coverage of most 
genes and added additional candidate genes in the inflammatory pathway, considered novel genes in 
the cell-cycle pathway and doubled the number of African American women in the preterm case group. 
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For all outcomes, the choice of candidate genes reflects careful consideration of the complexity of 
the inflammatory pathway. Candidate genes were chosen to reflect important components of the innate 
and adaptive (both Th1 and Th2) pathways. In addition genes related to natural killer cells were included 
based on emerging in vitro studies of placental expression. 
For all outcomes, cell cycle genes represent a novel pathway and this will be the first study of these 
genes in relation to reproductive outcomes. 
The methods of analysis (see Section 2.4.4) represent an emerging approach to analysis of genetic 
data with a focus on the gene as opposed to individual SNPs. A gene based approach is both more 
powerful and has more relevance for directing future in vitro and clinical studies which focus on gene 
products as opposed to SNPs which may simply be associated. 
Despite the many strengths, there are a number of limitations. 
1. The study has low power for a single SNP analysis, especially given the need to stratify by genetic 
ancestry. While single SNP analysis may have low power, study design and analysis strategies are 
designed to enhance power. The use of SKAT enhanced power by decreasing the number of tests 
(reducing multiple comparison corrections) and leveraging small SNP effects across a gene. Despite low 
power, this study still surpasses most existing studies with respect to the number of cases and controls. 
2. Reproductive outcomes are a combination of maternal, paternal and fetal genetic effects. 
Maternal genes influence the intrauterine environment, comprise half of the fetal genome and have the 
possibility of interacting with the fetal genes. Paternal genes comprise the remaining half of the fetal 
genome. Fetal genes not only determine the fetal potential for growth but are also expressed in 
trophoblasts and influence placental development. Although heritability studies suggest that maternal 
genes are primarily responsible for preterm birth,12-14  SGA appears to have a stronger fetal genetic 
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association15 while hypertensive disorders of pregnancy have both maternal and fetal genetic effects.11, 
148  In particular the role of cell cycle genes in placental development may be most influenced by fetal 
genes as opposed to maternal genes. 
The PIN study did not collect paternal or fetal DNA. Null findings for genes of interest in this study 
should be followed up in datasets with mother-infant, or trio, data given the possibility that fetal genes, 
or a maternal-fetal interaction are important. 
3. Preeclampsia and gestational hypertension are difficult outcomes to assess. While PIN attempted 
to collect clinical data throughout pregnancy, clinician reporting bias, changing study and clinical criteria, 
and differential outcome assessment based on other maternal and fetal outcomes, makes 
misclassification possible. Attempts to validate the GHTN and PE variables against an existing database 
provided reasonable support for the use of the existing variables. Further chart abstraction of a subset 
of women provided a subset of “validated” cases for sensitivity analysis. 
  
 
CHAPTER 3 QUALITY CONTROL RESULTS 
3.1 Quality Control Summary  
Individual Samples 
Genotyping was conducted on an Illumina custom GoldenGate platform with 1824 samples typed 
for 1536 SNPs. Samples included in the genotyping included women for this study, samples for 
additional projects, and quality control samples 
Of these 1824 samples, only 1795 were related to the present study, including quality control 
samples. During initial genotyping 8 samples were excluded for genotyping call rates <=95% resulting in 
1787 PIN samples entering the QC phase.  
From these 1787 samples the following were removed during the QC process: 
83 CEPH trio samples included for duplicate and mendelian inheritance QC 
64 blind PIN duplicates included for QC 
5 mislabeled samples 
10 still births 
24 births with congenital anomalies 
3 individuals with >5% missing in genotype data
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In total of 189 samples were dropped from the original genotyping and 1598 PIN women available 
for analysis. Figure X reflects the sample process and Section 3.3 explores each exclusion criteria. 
SNPs 
The GoldenGate platform contained 1536 SNPs. One hundred and six (106) failed initial genotyping 
(Table X in Appendix). In addition one SNP (rs11119449) was missing genotype information for all 
individual and was excluded. This resulted in 1429 SNPs that entered the QC process. Section 3.2 
explores the SNP quality control in more detail 
3.2 Quality Control for SNPs 
3.2.1 Blinds 
Inclusion of duplicate blinded samples allows for the identification of genotyping errors by 
identifying SNPs, plates, or run batches, with discordant alleles. For purposes of this analysis, both PIN 
duplicates and CEPH duplicates were included. PIN duplicates were chosen randomly when sufficient 
sample was available and will allow for the identification of problems during the process of DNA 
isolation, purification and plating. CEPH replicates were more plentiful and represented fewer 
individuals overall. This allowed for plating to detect both intra and inter-plate quality control. 
Blind PIN and CEPH replicates were included on the 20 genotyping plates. Sixty-four (64) PIN 
samples were included in duplicate on the 20 genotyping plates. In addition 2 PIN samples were 
inadvertently plated in duplicate (Table S4). In addition, 67 sets of CEPH controls (representing 15 
different individuals and 71 unique samples) were included on the 20 genotyping plates. Nineteen (19) 
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of these CEPH duplicate sets were present on the same plate and 48 were on different plates. In total 
199 unique samples were a part of the blind assessment. 
The assessment of blinds was conducted for the 1429 SNPs that passed initial genotyping quality 
control. Among these 1429 SNPs, there were 622 missing genotypes from 257 unique SNPs. This 
represents 622/(1429*199) = 0.22% missing. The majority (N=200) of SNPs were missing in 2 or fewer 
samples (77.8%). All duplicate sets were inspected for concordance. When genotypes were non-missing, 
only two instances of non-concordant genotypes were identified. SNPs rs1538537 (possible allele A/T- 
gene CA9) and rs2243250 (possible allele C/T- gene IL4) each had one instance of mismatch. Otherwise 
all duplicate pairs had identical genotypes.  (For the purposes of analysis, each set (Blind/ Non-blind PIN 
sample) was inspected to identify the sample with the least missing. In 15 sets, the blind sample had the 
least missing and was retained for analysis. In 6 sets, the sample retained for analysis had missing allele 
data which could be filled in from the duplicate. For the inadvertent duplicates, the most complete 
sample was retained for analysis. (Table S5) 
Overall the missing was low in the blinds and the assessment of concordance did not reveal any 
serious genotyping problems. No SNPs were dropped from analysis based on this quality control step. 
3.2.2 Trios 
In addition to providing information for duplicates, CEPH trios were included to allow for quality 
control assessment by confirming mendelian inheritance. Five families from the Coriell Institute 
CEPH/Utah pedigrees were included in the genotyping (Table S6). For the trios analysis trios with all 
three members on the same plate (N=20) were chosen for analysis. For a single trio the members were 
on two plates (N=1) (Table S7). Overall 21 trio sets were analyzed representing covering all 20 
genotyping plates and representing 15 unique individuals and 63 samples. 
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PLINK version 1.07223 was used to assess mendelian inheritance in 1429 SNPs which had passed 
initial quality control screening (plink –file trios –compound-genotypes –mendel). Overall genotyping 
was 0.999367 with no mendelian errors detected. Based on this assessment no SNPs were dropped from 
the analysis based on this quality control step. 
3.2.3 Hardy Weinberg Equilibrium 
Deviations from Hardy Weinberg Equilibrium (HWE) can indicate poor genotyping quality. 
Assessment of HWE was assessed in all 1429 SNPs that passed initial genotyping quality control using 
non-cases stratified by genetic ancestry.  Genetic ancestry was determined using STRUCTURE (see 
Section 3.5). For purposes of HWE, individuals with >=40% African ancestry were considered as one 
genetic ancestry group (African American). This cut point kept all individuals with genetic ancestry 
proportions between 40% and 60% African American ancestry within their self-described racial group.  
HWE was assessed using SAS 9.2.224  Exact p-values for HWE were calculated using 10,000 
permutations. Given the large number of SNPs assessed, a p-value of 0.05/1429= 3.5*10-5 (Bonferroni 
correction) was used to identify SNPs with possible HW disequilibrium. 
The distribution of p-values for HWE in the entire panel of 1429 SNPs was as expected with only a 
small excess of p-values <0.001 (Table 3.1). 
 
Table 3.1. Distribution of p-values for 1429 SNPs 
European Ancestry (1390 polymorphic SNPs) African Ancestry (1424 polymorphic SNPs) 
HWE exact p-value N SNPs (%) HWE exact p-value N SNPs (%) 
< 0.001 4 (0.3%) <0.001 6 (0.4%) 
<0.01 17 (1.2%) <0.01 16 (1.1%) 
<0.05 59 (4.2%) <0.05 67 (4.7%) 
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For the 503 SNPs specific to this study, a single SNP (IL2: rs10027390) had a p-value <10-5. This SNP 
will be excluded from analysis for the YRI ancestry group. All SNPs with p-values <0.01 are in Table 3.2. 
Although not meeting the p-value criteria, the low HWE p-value may be noted if these SNPs prove 
significant in further analysis. Of note only one of these low p-value SNPs (KIR3DL2   rs3745900) is in 
common between the ancestry groups. This suggests that assay wide genotyping quality per say may not 
be an issue for these SNPs. Instead the departures from HWE in these SNPs may represent population 
specific concerns (non-random mating, selection or migration, mutation, residual population 
stratification or small population size).  
Table 3.2 SNPs with exact p-value for HWE <0.01 among non-cases stratified by genetic ancestry  
European American Ancestry African American Ancestry 
Gene/ SNP P exact Gene/ SNP P exact 
CDKN2A;CDKN2B   rs1063192 0.0006 IL2   rs10027390 <.000001 
CDKN2A;CDKN2B   rs3217989 0.0027 IL12A   rs12492730 0.0027 
NFKB1   rs12648696 0.0028 IFNGR2   rs9978223 0.0033 
KIR3DL3   rs4441391 0.003 IL4   rs2243283 0.004 
KIR3DL3   rs11883241 0.0036 KIR3DL2   rs3745900 0.0045 
IL12A   rs13064168 0.004 KIR2DL4   rs17771961 0.0077 
LTA;TNF   rs915654 0.007 KIR3DL3   rs270775 0.0099 
NFKB1   rs11733293 0.0083 IL6   rs6949149 0.0111 
KIR3DL3   rs1325155 0.0087 CSF2   rs246844 0.0155 
CDKN2A   rs3088440 0.0112   
IL12B   rs2546890 0.0132   
NFKB1   rs3817685 0.0134   
3.2.4 Additional SNP considerations 
Despite and effort in the planning stage, a handful of SNPs which were genotyped were non-
polymorphic in our sample. There was 1 non-polymorphic SNPs dropped from the sample. 
In addition, among those with <=40% YRI ancestry there were an additional 3 non-polymorphic 
SNPs. These will be dropped from analysis in models stratified by genetic ancestry. (Tables S8 and S9) 
Figure 3.1 outlines the QC process with regard to SNPs. 
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3.3 Quality Control for Individuals 
3.3.1 Cryptic Associations 
Given the limited geographical area used for subject recruitment in PIN (Orange, Durham and Wake 
Counties, NC) the possibility exists for individuals to be related to each other. Given the small number of 
SNPs and the residual LD in the SNPs, there was no easy method to test for cryptic relatedness. PLINK223 
offers tools to assess for Identical by descent (IBD) among unrelated individuals. However their method 
need a minimum of 1,000 independent SNPs and is only recommended for genome wide size assays. 
Given the relatively small number of SNPs in this sample, PLINK tended to overestimate relatedness. As 
an example, the CEPH trios with known relatedness were assessed using PLINK’s pairwise IBD 
estimation. PLINK provides an estimate of pi hat (proportion IBD) for each pair in the sample. Identical 
samples (or monozygotic twins would have an expected pi hat=1, parents and offspring, siblings and 
dizygotic twins would have pi hat=0.5, uncle-nephew relations would have pi hat=0.25, and first cousins 
would be expected to have pi hat=0.125. In the CEPH trios we can identify with certainty parent-child 
relations (expected pi hat 0.5) and unrelated individuals (married couples and individuals from different 
pedigrees (expected pi hat=0). Plink however estimated pi hate for parent-offspring from 0.53-0.62 and 
unrelated individuals had estimated pi hat from 0-0.30. Although PLINK overestimated relatedness it did 
correctly call pi hat=1 for all individuals paired with themselves.  
Given this shortcoming with PLINK cryptic relatedness was not formally assessed in this sample. The 
pairs with the highest PLINK estimates of relatedness (pi hat >=0.5, 13 sister pairs including 23 
individuals) were examined in MERLIN (a pedigree based program) and confirmed as unrelated (kinship 
coefficient=0 for all markers). PLINK did identify two sets of mis-labeled duplicates (samples with 
different IDs but identical genotypes). 
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In the first set (PINID 10042 and 21027) the samples appear to be from the same individual (age 
and interpregnancy intervals match, delivered at both UNC and Wake which may explain the lack of a 
duplicate flag in the PIN database) and two distinct pregnancies. The first pregnancy was kept 
(PINID=10042). 
In the second set (PINID 12682 and 25217) the samples appear to come from different women 
(different ages, and recruitment site) who were recruited within 3 days of each other. This may 
represent a labeling problem. Both samples were excluded from analysis. 
Although a formal test of cryptic relatedness was not possible, this step identified two unexpected 
duplicates. Three women were dropped from the analysis based on this step, Table S10 lists the 
participant IDs of all women excluded. 
3.3.2 Missing Genotype Information 
Genotyping failure (<95% of genotypes called) resulted in the loss of 8 PIN participants. These 
participants were not included in the QC process. In addition, 3 PIN participants were found to have 
>=5% missing genotype data after the completion of the QC process. These women were dropped from 
further analysis. Table S10 lists the participant IDs that were dropped due to poor or incomplete 
genotyping. 
3.3.3 Exclusions based on pregnancy outcome 
Women with two pregnancy outcomes were excluded from analysis. Pregnancies ending in still 
birth (N=24) were excluded for a number of reasons. Birth weight in still born infants is unreliable due to 
tissue necrosis in the interval between intrauterine death and birth. The interval between time of death 
and date of birth can vary and result in inaccurate assessment of time at risk. The pathology which 
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results in still birth may result in unique causes of preterm birth and hypertension disorders of 
pregnancy. Pregnancies with congenital anomalies identified at birth were also excluded from analysis. 
The primary reason for exclusion is that early delivery (preterm birth) may be induced for reasons 
related to the congenital anomaly and thus represent a different causal process. In addition birth weight 
may be related to the congenital anomaly and again represent a different causal process. While some 
birth defects (cleft lip or palate, hypospadias etc) may be relevant to include in this analysis, the type of 
congenital anomaly noted at birth is included in the data set. 
Table S10 provides the IDs of women excluded for still birth or congenital anomaly. 
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3.4 Flow charts of Individual and SNP exclusions 
 
Figure 3.1 Flow Chart of Exclusions of Individuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1795 Samples (Plate 1-20) 
8 excluded for genotyping <95% 
1787 
Quality Control Samples 
83 CEPH Trios 
64 Duplicates 
 
1640 
-8 
-147 
5 Mislabeled Samples 
 
-5 
1635 
Pregnancy Outcome Exclusions 
10 Still births 
24 Congenital Anomalies 
 
-34 
1601 
3 >=5% missing in genotyped 
SNPs 
 
-3 
1598 Women for Analysis 
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Figure 3.2 Flow Chart of SNP Exclusions 
 
  
1536 SNPs genotyped 
1429 SNPs pass initial genotyping >=95% 
1429 SNPs pass QC assessment for 
blinds and mendelian inheritance 
503 SNPs in current study 
502 Polymorphic SNPs 
CEU Ancestry 
499 SNPs for analysis 
YRI Ancestry 
501 SNPs for analysis 
1 SNP out of HWE 3 Non-polymorphic SNPs 
1 Non-polymorphic SNP 
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3.5 Assessment of genetic ancestry 
Structure225 was used to determine genetic ancestry in the individuals for analysis. One hundred 
and forty-nine (149) AIMs were successfully genotyped.  Initial Hardy-Weinberg analysis in the original 
PIN cohort suggested possible genotyping problems with two AIMS (rs11150219 p=0.0042 in self-
reported African Americans and rs11652805 p=0.0083 in self-reported Whites) so these SNPs were 
dropped from analysis in their respective race.  As a result 148 AIMS were used for the assessment of 
genetic ancestry. 
Structure was used with the following parameters: 
Ancestry Model: Admixture 
Allele Frequency Model: Independent 
Number of populations: 2 
Burn-In: 10,000 
Iterations: 100,000 
 
Alterations in the model assumptions (ancestry model and allele frequency model did not change 
the results).  Red is c_mrace=1 (White) and Green is c_mrace=2 (African American). The triangle plot 
suggests a greater spread in ancestry among individuals who self report as African American (Figure 3.3) 
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Figure 3.3 Triangle Plot of Genetic Ancestry 
 
The bar plot (Figure 3.4) suggests that while most individuals are clearly associated with a single 
genetic ancestry, a number of individuals show an even mixture of the two ancestry groups and some 
individuals have a conflict between self-reported race and genetic ancestry. 
Figure 3.4 Bar plot of %ancestry for all individuals by self-reported race  
 
 
Following assessment of genetic ancestry two groups emerged as problematic. Individuals who 
have an even mixture of ancestry do not fall neatly into either group. Among the PIN sample, 13 
individuals had evenly mixed genetic ancestry (Table S12). All but one of these individuals self-identified 
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as African American. A cut point of 0.40% African American was chosen as the cut point for genetic 
ancestry. This places all individuals in this middle area with their self-identified race.  
In addition, assessment of genetic ancestry identified individuals with a clear discrepancy between 
self-reported race and genetic ancestry (N=12) (Table S13). For purposes of analysis when the concern is 
population stratification, these individuals will be included in the group corresponding to their genetic 
ancestry. For analyses where self-reported race (as a measure of the lived experience of race in the 
United States) is a concern as a confounder, these individuals will be dropped from the analysis.
  
 
CHAPTER 4 RESULTS 
Summary Paper 1 
Polymorphisms in Natural Kill Cell Related Genes are Associated with Preterm Birth 
Harmon QE, Engel SM, Olshan A, Moran T, Stuebe AM, Luo J, Wu MC, Avery C 
Background: Inflammation is implicated in preterm birth; however genetic studies of inflammatory 
genes have yielded inconsistent results.  We expanded coverage of genes related to T-cell and natural 
killer cell mediated immunity while addressing population stratification in a biracial pregnancy cohort. 
Methods: We utilized maternal genetic samples from the Pregnancy Infection and Nutrition Cohort 
which enrolled women in North Carolina between 1995 and 2005. Preterm cases and term controls 
(N=1646) were genotyped for 432 tagSNPs in 30 candidate genes. Gene-level and single SNP 
associations were modeled in strata of genetic ancestry defined by ancestry informative markers. 
Results: Six genes were associated with preterm birth among European Americans; IL12A, CSF2, IFNGR2, 
KIR3DL2, IL4 and IL13. Among the four genes related to Natural Killer cell function, two (IL12A and CSF2) 
showed consistent protective associations for both European and African Americans. IFNGR2 and 
KIR3DL2 showed single SNP associations for European Americans only with a strengthening of 
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the association for spontaneous preterm birth for IFNGR2 (rs2268241 RR=0.57 95% CI 0.3-0.9). IL4 and 
IL13 are associated with TH2 immunity and SNPs tagging a locus control region have an increased risk of 
spontaneous preterm birth for European Americans (rs3091307 RR=1.9 95% CI 1.4-2.5).  
Conclusions: Although gene level associations were found in European Americans only, single SNP 
associations among African Americans were often similar in direction although estimated with less 
precision. In particular, genes related to Natural Killer cells and SNPs tagging a control region for IL13 
and IL4 are associated with the risk of preterm birth. 
Summary Paper 2 
Polymorphisms in Inflammatory Genes are Associated with Term SGA and Preeclampsia 
Harmon QE, Engel SM, Wu MC, Moran T, Luo J, Stuebe AM, Avery CL, Olshan A 
Background: Poor fetal growth and hypertensive disorders of pregnancy frequently co-occur and are 
related to measured levels of inflammatory biomarkers. Genetic epidemiologic studies of poor fetal 
growth in particular have been limited in scope and inclusion of African Americans in the United States. 
We sought to expand coverage of inflammatory genes, explore novel cell cycle genes in a bi-racial 
pregnancy cohort from North Carolina, USA. 
Methods: Women who enrolled in the Pregnancy, Infection and Nutrition cohort between 1995 and 
2005 were eligible for genotyping. Cases of gestational hypertension, preeclampsia and poor fetal 
growth were identified based on abstraction of antenatal and hospital records. A total of 1646 women 
were genotyped for 503 tagSNPs in 40 genes and a panel of ancestry informative markers. Gene-set 
analyses were stratified by race and were followed by a single SNP analysis within significant (FDR<0.2) 
candidate genes. 
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Results: Gene level associations were found for African Americans and term SGA for IL6 and KLRD1 while 
LTA/TNF and TBX21 were associated with preeclampsia among European Americans only. Single SNP 
analyses for IL6 showed consistent increased risk of term small for gestational age for both African and 
European Americans with risk ratios ranging from 1.8 to 2.5. For KLRD1 however the single SNP 
associations were apparent only for African Americans with rs3759270 having an RR=0.4 (95%CI 0.3-
0.8). For preeclampsia single SNP associations were seen only among European Americans and implicate 
LTA, TNF and a gene upstream from TBX21, TBKBP1. The strongest association was for an upstream 
regulator of TNF with RR=1.8 (95% CI 1.1-2.7). 
Conclusion: Novel associations with TBX21 & TBKBP1 were found for preeclampsia among European 
Americans, while among African Americans, variation within KLRD1 was associated with term SGA. 
Although previous studies have suggested null associations, increased tagging and stratification by 
genetic ancestry suggests important associations between IL6 and term SGA for African Americans and a 
TNF regulator and preeclampsia among European Americans. 
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Paper #1: Polymorphisms in Natural Kill Cell Related Genes are Associated with Preterm Birth 
Harmon QE, Engel SM, Olshan A, Moran T, Stuebe AM, Luo J, Wu MC, Avery C 
Introduction 
Preterm birth affects approximately 12% of US births.31 Significant medical and societal impacts are 
borne by the infants and their families due do the increased risk of mortality as well as both acute and 
chronic medical and neurocognitive disease.25 While the earliest preterm births result in the most severe 
outcomes, late preterm births are also associated with increased risk of mortality and respiratory 
difficulties.37  
Having a previous preterm birth is one of the strongest risk factors for a subsequent preterm birth 
and may reflect innate susceptibility factors, including maternal genes.12, 13 Although a number of 
candidate pathways have been identified,226 inflammatory pathways have been a particular focus. 
Pregnancy is a state of altered inflammatory and immune function. Changes in both gene expression 
and measured levels of inflammatory cytokines have been documented during the course of 
uncomplicated pregnancies.72-74, 227  In particular, T-cells and Natural Killer cells (NK) decrease in both 
number and function over the course of pregnancy, while defensive immunity is enhanced.72 Candidate 
inflammation genes have been examined in a number of diverse populations,6, 88, 94, 98, 105, 114, 149-151, 156, 160, 
164 although many of the studies have had small case groups and few address issues of population 
stratification despite very racially diverse study populations. Studies with larger case groups98, 149-152, 164 
focused on exploring more genes with limited single nucleotide polymorphisms (SNP) coverage per 
gene. In addition, studies conducted among US populations have identified differences in the genes and 
biologic pathways associated with preterm birth in Whites and African Americans, 94, 97, 98, 149, 156 
reinforcing the need to consider ancestry in the context of this outcome. 
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Using the Pregnancy, Infection and Nutrition Cohort (PIN), we attempted to: replicate previous 
associations; broaden the inflammation gene coverage to include lesser studied genes in the critical T-
cell and NK cell pathways; and deepen the per-gene SNP coverage, while carefully addressing issues of 
population stratification in this well-characterized biracial cohort.  We additionally improve upon 
previous studies by incorporating novel statistical methodology to identify gene-based associations, and 
using inverse probability of selection modeling to account for any differences between the genotyped 
and parent cohort. In this paper, we describe our findings for polymorphisms in 30 candidate genes and 
the risk for preterm birth. 
Methods 
Study population 
We utilized a nested case-control subset of the Pregnancy Infection and Nutrition Study (PIN), a 
prospective pregnancy cohort designed to assess antenatal risk factors for preterm birth, fully described 
by Savitz.185 Women were recruited between August 1995 and June 2005 through Wake County Human 
Services Department, Wake Medical Center and University of North Carolina (UNC) prenatal clinics. 
Exclusion criteria at enrollment included age less than 16 years, non-English speaking, not planning to 
deliver at the recruitment hospital, carrying multiple gestations, or lacking a telephone.  
Outcome information was abstracted from the medical record following delivery. Maternal blood 
for genetic analysis was obtained during the first study visit. Covariates were collected through self-
administered questionnaires or telephone interviews. All participants gave informed consent, and the 
institutional review boards of the UNC School of Medicine and Wake Medical Center approved the 
study. 
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Cases and controls for this study were selected among eligible women from the entire PIN cohort 
(N=5169). Initial eligibility criteria included consent for DNA analysis (N=3539), collection of a suitable 
biological specimen (N=3289), self-reported maternal race of White or African American (N=3075) and 
known birth date, resulting in 3065 (59.3%) women who were eligible for selection into our study. Of the 
eligible women, all preterm cases with sufficient DNA were genotyped (N=347, 92%). Term births 
(N=1299) selected for genotyping included births with other reproductive outcomes of interest 
(gestational hypertension, small for gestational age) as well as women with uncomplicated pregnancies. 
In total 1646 women were genotyped. 
Outcome Assessment 
Gestational age at delivery was calculated based on the first ultrasound performed prior to 22 weeks 
gestation. For women without an early ultrasound, self-reported last menstrual period was used. 
Preterm birth was defined as a live birth before 37 complete weeks of gestation. Subtype of preterm 
birth was assessed by physician review.185 While this study does not have sufficient power to consider 
each subtype of preterm birth, spontaneous preterm birth, which includes both preterm labor and 
preterm prelabor rupture of membranes, was considered as an additional outcome. 
Gene Selection 
Thirty candidate genes were selected from the innate and adaptive immune system with a focus on 
representing Th1 and Th2 cytokines and their regulators, inflammatory mediators (including TNF 
signaling), selected chemokines and NK cells. In particular, we aimed to represent inflammatory genes 
for which marked changes in protein concentrations across trimesters have been demonstrated, 
because dysregulation in these genes could result in initiation of parturition before term.72, 73  
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SNP analysis 
Whole blood was collected, centrifuged and the buffy coat fraction was stored in CPT tubes and 
placed in -80˚C storage. DNA was extracted using various protocols including the Applied Biosystems 
automated DNA extractor and Qiagen (Gentra) Puregene chemistry. 
A custom 1536 Illumina GoldenGate plate was designed which included the 30 genes (432 SNPs) 
from this study as well as genes from angiogenesis, apoptosis and cell cycle pathways. TagSNPs were 
chosen using TagZilla for multiple populations allowing for 20kb upstream and 10kb downstream 
margins and restricting to tags with minor allele frequencies of at least 10% and linkage disequilibrium 
(LD) with r2<80%. Genotyping was conducted at the University of North Carolina Genomics Core (Chapel 
Hill, NC) and genotypes were called by the Illumina BeadArray Reader and software for automated 
genotype calling.  
Genotyping was performed on 1646 PIN samples. Individuals were dropped when fewer than 95% 
of SNPs were successfully called (N=11). We further excluded unintentional duplicate samples (N=3), 
congenital anomalies (N=24) and stillbirths (N=11), resulting in 1598 women included in the analysis.  
Poor genotyping quality (<95% call rate) resulted in the loss of 39 SNPs. Quality control included 
duplicate PIN samples and standardized samples from Corriel CEPH trios on each plate.  Of the 393 SNPs 
that entered quality control, there was one instance of a single base pair genotyping discrepancy found 
in 199 blind samples and no instances of Mendelian errors among 21 trios examined. HWE was assessed 
using SAS 9.2 (Cary, NC) among non-cases stratified by genetic ancestry. One SNP (IL2: rs10027390) 
significantly violated HWE (p<10-5) in African American non-cases and was dropped from analysis for this 
ancestry group. 
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Tagging for two genetic ancestry populations resulted in redundant (LD>0.8) tagSNPs in the 
European American population. Haploview (Cambridge, MA)201 was used to calculate LD (using r2) and 
generate LD heatmaps.  
Confounding by population stratification 
Previous studies suggest that there may be important differences between allelic frequencies in 
genes related to inflammatory cytokines between self-reported African-Americans and Whites in the 
United States.188  As race has also been associated with preterm birth,25 there is potential for 
confounding by population stratification. 
A panel of 157 ancestry informative markers was chosen to estimate genetic ancestry using SNPs 
identified in a similar North Carolina bi-racial population.189 STRUCTURE (Chicago, IL)228 was used to 
quantify genetic ancestry assuming two underlying populations.  Genetic ancestry was then used to 
stratify the analyses by race (European American and African American), and continuous percent African 
American ancestry was included in all models. 
Additional covariates 
Covariates were selected based on previous studies and an examination of a directed acyclic graph 
(DAG). Possible covariates included self-reported maternal smoking during the first 6 months of 
pregnancy (yes/no), maternal age (<25 yrs, 25-34 yrs, >=35 yrs), pre-pregnancy body mass index (<18.5 
kg/m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2 and >=30.0 kg/m2), and socio-economic status, as represented 
by total family income adjusted for the number of individuals in the household relative to contemporary 
local poverty levels. In addition, a number of additional demographic, pregnancy health and study 
characteristics were included for the calculation of selection probabilities. All values were self-reported 
with the exception of measured height.  
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Statistical Analysis 
We used a 2-stage analysis approach to examine the influence of inflammatory genes on both 
preterm and spontaneous preterm birth. Stage 1 was a gene-level analysis using the SNP-set Kernel 
Association Test (SKAT)194 with a linear kernel (analogous to logistic regression with an additive genetic 
effect). Gene level analysis is particularly useful in genetically diverse populations where different SNPs 
are in LD with the causal SNPs. SKAT also allows for complex SNP interactions, permits covariate 
adjustment, and does not penalized SNPs with opposing associations (increased or decreased risk) 
within a single gene. SNPs were grouped by gene into SNP-sets and genes in close proximity (within 25 
kbp) were analyzed together. Individuals with at least one missing genotype were dropped from the 
relevant SNP-set but were included in other SNP-sets where they had complete data. On average, 98% 
of individuals were included in each SNP-set with a range of 92-100% (Table S14).  Hypothesis testing in 
SKAT was conducted using a variance component score test of the null hypothesis that the general 
function for the SNP-set equals 0.197 Analyses were performed within strata defined by genetic ancestry 
and additionally adjusted for percent African American ancestry. A false discovery rate (FDR) of 20% was 
used to identify genes which progressed to Stage 2. The FDR was calculated as a Q value229 using R 
(p.adjust, FDR). Cases included all preterm births with a subset analysis of spontaneous preterm birth. 
Controls included term births without gestational hypertension or small for gestational age 
complications (Table 4.1, “Disease Free”). 
The goal of Stage 2 was to identify the SNPs in each gene responsible for the significant SNP-set 
association p-values estimated in Stage 1. Given the prevalence of preterm birth in this population 
(13.5%), risk ratios were estimated using the entire genotyped cohort and a log-linear risk model. 
Inverse probability weighting was used so that the estimates reflect the eligible population. Cases were 
all preterm births with a subset analysis of spontaneous preterm births. Controls were all genotyped 
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term births (Table 4.1 Term Births). Briefly, the probability of being selected into the genotyped sample 
(N=1646) was calculated for all eligible women (N=3065) using a logistic model including all covariates in 
Table 1 as well as additional demographic and study related characteristics. The inverse of these 
selection probabilities was used to weight the analysis. Robust variance estimators were used. Given the 
dependence between Stage 1 and Stage 2, top ranking SNPs from Stage 2 were reported based on the 
consistency of the observed association in both preterm birth and spontaneous preterm birth, as well 
consistency across genetic ancestry groups. 
Results 
The final analysis set included N=1598 individuals. Women were predominantly White (62.6%), 
non-smoking (74.4%), well-educated (52% with at least high school education) with a mean BMI of 26.5 
kg/m2 and a mean age at the start of pregnancy of 26.1 years (Table 4.1).  In the underlying cohort, 
preterm birth occurred in 13.5% of births, and 62.1% of these were spontaneous. The eligible and 
genotyped population did not differ appreciably from the entire cohort (Table S15). 
Stage 1: Gene Set Analysis 
Proximity of genes resulted in 24 gene-sets with IL13 and IL4, and LTA and TNF, respectively, 
considered jointly in the SKAT analysis. Genes with a single SNP (TGFB1, TGFB3) or with SNPs genotyped 
solely for replication purposes (IL1A and IL1B each with 2 SNPs) were not included in the Stage 1, gene-
level analysis.  
For preterm birth, four gene-sets (IFNGR2, IL12A, KIR3DL2, CSF2) associated with Natural Killer Cells 
and one gene associated with Th2 immunity (IL13/IL4) met the FDR criteria of 20% (Table 4.2) among 
European Americans. IFNGR2 and IL13/IL4 also met the FDR criteria for spontaneous preterm birth. No 
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gene-sets were significantly associated with preterm birth or spontaneous preterm birth among African 
American participants. 
Stage 2: Single SNP Analysis 
The five gene-sets identified in Stage 1 (90 SNPs) and 7 SNPs not included in Stage 1, were 
examined in Stage 2 in both European and African Americans. Table 3 presents the RR and 95% CI for 
the strongest single SNP results. All of the single SNP results can be found in Table S16. In the 
assessment of covariates, nested models adjusted only for percent genetic ancestry were compared 
with fully and singly adjusted models for a subset of the SNPs with the strongest associations. 
Adjustment for all, or any, of the covariates failed to change the point estimates (>10%) (Results not 
shown). 
IL12A 
Two SNPs (rs6441282 and rs692890) showed consistent associations (RR 0.7-0.8) for both ancestry 
groups and both outcomes, with the variant allele conferring reduced risk of both preterm and 
spontaneous preterm birth. The variant alleles were the minor alleles for European American women 
(allele frequency: 0.47 and 0.33) but were more common in African American women (allele frequency: 
0.66 and 0.63). These two SNPs were in strong LD among African American women but not among 
European American women (Figure 4.1). 
In European American women, another SNP in moderate LD with rs692890 (rs609907) (Figure 4.1) 
also conferred a reduced risk (RR=0.6-0.7) for total and spontaneous preterm birth. A number of SNPs 
had consistent results for both outcomes among European American women only: rs503582, rs7653097 
and rs755004 (RR 1.3- 1.5), rs13064168 (RR 0.6) and rs17826053 (RR 0.8). SNP rs4680536 showed an 
increased risk with spontaneous preterm only (RR=1.3, 95% CI 1.0-1.7).  
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CSF2 and IL3 
Two LD blocks in European American women (Figure 4.2) show an association between CSF2 and 
preterm birth. A group of three SNPs (rs25881, rs25882, rs27438 r2>0.8 ), including one intron variant 
and one missense variant, conferred increased risk (RR=1.3-1.4) for preterm birth only.  
As second LD block (rs721121, rs4705916, rs743564, rs6898270, r2>0.85 in European American 
women) was associated with generally reduced risk of preterm for both European and African American 
women. For African American women there was a strengthening of the risk reduction for spontaneous 
preterm birth for rs721121 and rs4705916 (RR=0.57, 95% CI 0.4, 0.9).  
Upstream tags for CSF2 also captured SNPs which are more closely associated with IL3. One intronic 
variant in IL3 (rs31481) was associated with an increased risk for preterm birth among both ancestry 
groups (RR 1.3-1.4). Among white women only, a downstream SNP (rs11575022) was associated with an 
increased risk for both preterm and spontaneous preterm birth (RR 1.6 and 1.4 respectively). 
IL13 and IL4  
IL13 and IL4 are very close on Chromosome 5 and were considered together for Stage 1. In both 
genes, associations were generally found for European American women only, and these associations 
were strongest for spontaneous preterm birth. For IL13, a cluster of 3 SNPs in strong LD (r2>0.8) (Figure 
4.3) (rs7737470, rs3091307, rs1881457) had RR from 1.8-1.9 for spontaneous preterm birth. A second 
cluster in LD (r2>0.7) (rs2243204, rs2243210, rs2243218, rs2243219) had RR from 1.3-1.5. The results for 
IL4 were more varied with both protective and risk alleles. One cluster of SNPs in strong LD (r2>0.8) 
(rs2243267, rs2243270, rs11242123) showed both risk (RR 1.6-1.8) and protective variants (rs2243250) 
(RR 0.6). A single SNP (rs11242122) downstream of IL4 showed a particularly strong protective 
association for spontaneous preterm birth with an RR=0.5 (95% CI 0.4-0.7).  
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KIR3DL2 
Results for SNPs in KIR3DL2 were found only for European American women. Two downstream 
SNPs (rs11672983, rs3816051) showed consistent increased risk for both preterm and spontaneous 
preterm births (RR 1.3-1.4). A single SNP rs4806457 which is an intron variant showed a risk association 
with preterm birth only (RR=1.7, 95% CI 1.1-2.7). 
IFNGR2 
Among European American women, two LD clusters in IFNGR2 were seen (Figure 4.4). Rs9978223, 
rs2268241 and rs9808753 (r2>0.9) all showed a reduced risk, with a strengthening of the association for 
spontaneous preterm (RR 0.6-0.7). An additional cluster of two SNPs (rs9808685, rs2834210 r2=0.97) 
showed a consistent risk association with both preterm and spontaneous preterm births (RR 1.3).  
Discussion 
We undertook an investigation of T-cell and NK-cell related gene variants in a biracial pregnancy 
cohort. In addition to novel findings in KIR genes, we found important associations for genes associated 
with NK cells and Th2 immunity. 
In our study a number of the genes which showed a gene level association are related to Natural 
Killer (NK) cells and their function (IL12A, IFNGR2, CSF2 and KIR3DL2). NK cells and the cytokines 
associated with them (IL12, IL15, IL6, IFNγ, TNFα and CSF2) have been documented to change 
dramatically over the course of pregnancy72, 73 and may be closely involved in immune tolerance to the 
developing placenta and adequate placental implantation early in pregnancy. Related to NK Cells, killer 
cell immunoglobulin-like receptor (KIR) genes may be particularly important in allowing trophoblast cells 
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to evade destruction by NK cells during placental development. Indeed, KIR genes have been implicated 
in both recurrent miscarriage and preeclampsia.128 
While this is the first study to examine the association between KIRs and preterm birth, previous 
studies have genotyped IL12A, IFNGR2, CSF2 , IL13 and IL4 with fewer than 8 SNPs per gene and often 5 
or fewer SNPs, which vastly underestimates the underlying genetic variation. The positive findings in this 
study relative to the previous null findings may be due to more extensive coverage of the gene, and 
additionally the enhanced power of our Stage 1 gene level analysis.  
IL12A and CSF2 showed single SNP associations in both ancestry groups suggesting common 
pathways. IL12A is an important stimulator of NK cells and results in production of both TNF-α and IFN-
γ.22 As an upstream regulator of NK cells, IL12 can stimulate the release of TNF-α which increases in 
amniotic fluid with the onset of labor. TNF-α is associated with membrane degradation, cervical ripening 
and uterine contractions.74 Upstream changes in the regulation of Natural Killer cells could have 
significant impact on TNF-α levels in women with an otherwise normally functioning TNF gene. 
CSF2 is also released from NK cells and levels are suppressed in the 2nd and 3rd trimester in 
uncomplicated pregnancies.72  Of interest, two of the CSF2 SNPs (rs4705916 and rs721121) with 
consistent associations with spontaneous preterm birth in both European and African Americans, flank a 
possible regulatory region on chromosome 5 that regulates both CSF2 and IL3.230 
The two remaining NK associated genes (KIR3DL2 and IFNGR2) were associated with preterm birth 
only among European Americans. IFNGR2 is the receptor for IFN-γ which is an important NK cell 
cytokine. IFNGR2 expression changes over the course of normal pregnancy227 and dysregulation of 
IFNGR2 through polymorphisms may influence the timing of parturition through its role in multiple 
immune related cell lines. Although KIR3DL2 may be implicated directly in placental implantation,128 two 
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SNPs which were used to tag KIR3DL2 are closer to a gene related to IgA response (FCAR). FCAR has 
shown altered expression over the course of pregnancy227 although the significance of this change is 
unknown. More extensive examination of FCAR is warranted to distinguish which gene these tags are 
capturing. 
In addition to the genes related to NK cells, Th2 cytokines IL13 and IL4 had strong gene level and 
single SNP associations. These genes, and IL5, are quite close together on chromosome 5 and share 
regulatory elements located between RAD50 and IL13.231 The strongest associations for IL13 appear for 
three SNPs which are in strong LD (r2=0.9) with each other and share strong LD with a number of 
untyped SNPs within both RAD50 and an intergenic locus control region. As this regulatory region has 
the potential to influence expression of IL13, IL4 and IL5, further investigation of this region would be 
worthwhile.  
Both gene and SNP level results differed for groups stratified by genetic ancestry. It is possible that 
fewer African American participants, weaker patterns of LD, and population substructure which reduces 
effective sample size, could explain the lack of an association with any of the candidate genes we 
explored. However, despite our inability to detect a significant gene level association for African 
Americans, the similar single SNP results for CSF2 and IL12A suggest that similar genes are important for 
both groups. 
Apart from power issues, evidence suggests that different genes and biological pathways may be 
associated with preterm birth in US Whites and African Americans.97, 113 Reproductive outcomes such as 
preterm birth have strong selective pressures.232 While the negative selective pressure of increased 
neonatal mortality is clear, positive selective pressure may also act on genes related to preterm birth. 
Decreased cephalopelvic disproportion232 and hostile intrauterine environments in the presence of 
uterine or placental infection233 may make preterm delivery a lifesaving event for both infant and 
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mother.  In the face of different infectious and environmental exposures over generations and across 
populations, divergent genes and biological pathways may have emerged in geographically and 
genetically distinct ancestral groups.234 Given the possibility that the biologic and genetic underpinnings 
of preterm birth vary by ancestral origins, stratification by ancestry is essential. And additionally, it may 
not be reasonable to assume that results from geographically distinct populations are generalizable, 
especially if the social and environmental exposures among these populations can differentially activate 
the relevant pathways. It would follow, then, that gene by environment studies which account for 
differences in both genetic structure and socio-environmental exposures and are needed to clarify 
disparate associations across studies. 
This study has several limitations that should be considered in future studies examining genetic 
associations with preterm and spontaneous preterm birth. Fetal genes may also play a role in preterm 
birth. This study did not have access to fetal DNA and was unable to explore main effects or interactions 
with fetal DNA. While inclusion of fetal DNA is important to understand all possible pathways to preterm 
birth, the findings of this study support population based studies which suggest that maternal genetics 
may play an independent role in the risk of preterm birth. Additionally, tagSNPs themselves are not 
expected to be the causal SNP and further fine mapping of genomic regions identified by this study is 
necessary to identify the causal SNPs. 
In summary, this study broadened coverage of polymorphisms in genes related to inflammation 
and explored novel genes related to NK cells. Using a larger population of African American women 
compared with previous candidate gene studies also allowed us to identify common risk alleles for both 
genetic ancestry groups. Genes associated with NK cells (IL12A, IFNGR2 and KIR3DL2) were novel 
findings, and results suggest that further examination of the regulatory regions associated with 
cytokines on 5q31 (IL4, IL13, IL3, CSF2) may be fruitful. 
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Table 4.1: Demographic Characteristics of PIN Mothers 
 Preterm Case Disease Free Term Birth
a
 
Genetic Ancestry
b 
European 
American 
African 
American 
European 
American 
African 
American 
European 
American 
African 
American 
N=194 N=134 N=409 N=204 N=813 N=457 
Maternal Age        
<25 yrs 94 (48.5) 50 (37.3) 215 (52.6) 68 (33.3) 401 (49.3) 159 (34.8) 
25-34 yrs 77 (39.7) 73 (54.5) 133 (32.5) 132 (64.7) 294 (36.2) 281 (61.5) 
35+ yrs 23 (11.9) 11 (8.2) 61 (14.9) 4 (2.0) 118 (14.5) 17 (3.7) 
Smoking
c
  
      
No 115 (66.5) 95 (80.5) 302 (77.4) 148 (84.6) 541 (71.0) 325 (81.9) 
Yes 58 (33.5) 23 (19.5) 88 (22.6) 27 (15.4) 221 (29.0) 72 (18.1) 
Missing 21 (10.8) 16 (11.9) 19 (4.6) 29 (14.2) 51 (6.3) 60 (13.1) 
BMI (kg/m
2
)
d 
      
<18.5 14 (7.5) 8 (6.5) 23 (5.7) 16 (8.3) 41 (5.2) 30 (7.1) 
18.5-24.9 95 (50.8) 43 (34.7) 250 (62.2) 79 (40.9) 431 (54.9) 158 (37.3) 
25-29.9 44 (23.5) 28 (22.6) 71 (17.7) 39 (20.2) 146 (18.6) 85 (20.1) 
30+ 34 (18.2) 45 (36.3) 58 (14.4) 59 (30.6) 167 (21.3) 151 (35.6) 
Missing 7 (3.6) 10 (7.5) 7 (1.7) 11 (5.4) 28 (3.4) 33 (7.2) 
Poverty Index   
     
Mean (SD) 331 (254) 132 (94) 367 (238) 144 (123) 343 (234) 148 (126) 
Missing 23 (11.9) 17 (12.7) 24 (5.9) 37 (18.1) 57 (7.0) 94 (20.6) 
Marital Status  
     
Married 134 (69.1) 39 (29.3) 313 (76.5) 32 (15.7) 587 (72.2) 83 (18.2) 
Unmarried 60 (30.9) 94 (70.7) 96 (23.5) 172 (84.3) 226 (27.8) 374 (81.8) 
Missing 0 1 (0.7) 0 0 0 0 
Education  
     
13+ yrs 105 (54.1) 56 (41.8) 275 (67.2) 68 (33.3) 498 (61.3) 172 (37.6) 
<=12 yrs 89 (45.9) 78 (58.2) 134 (32.8) 136 (66.7) 315 (38.8) 285 (62.4) 
Parity 
      
Nulliparous 88 (45.4) 49 (36.8) 189 (46.4) 88 (43.1) 398 (49.1) 219 (47.9) 
Multiparous 106 (54.6) 84 (63.2) 218 (53.6) 116 (56.9) 413 (50.9) 238 (52.1) 
 Missing 0 1 (0.7) 2 (0.5) 0 2 (0.2) 0 
Spontaneous Preterm 
     
Yes 103 (53.1) 65 (48.5) 
    
a  Term births include disease free term births plus term births with other outcomes of interest: small for gestational age, 
gestational hypertension and preeclampsia. 
b  Genetic ancestry determined using 148 AIMs and STRUCTURE.  
c  Self-reported smoking during months 1-6 of pregnancy. 
d Pre-pregnancy BMI calculated from self-reported pre-pregnancy weight and measured height. 
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Table 4.2: Qa values from SKAT analysis for each geneset stratified by genetic ancestry 
 European Americanb African Americanb 
Gene Preterm Spontaneous Preterm Spontaneous 
IFNGR2   0.06* 0.18 0.93 1.00 
IL13 & IL4 0.10   0.01* 1.00 1.00 
KIR3DL2 0.10 0.43 0.89 1.00 
IL12A 0.10 0.44 0.89 0.64 
CSF2 0.14 0.67 0.89 0.82 
IL18 0.40 0.44 0.93 1.00 
GATA3 0.40 0.48 0.89 1.00 
IL10 0.40 0.48 0.89 0.82 
IL12B 0.54 0.81 0.93 1.00 
IL6 0.54 0.79 0.93 0.92 
KIR2DL4 0.54 0.43 0.89 1.00 
IL15 0.66 0.67 0.93 0.89 
LTA & TNF 0.70 0.70 0.48 1.00 
IFNG 0.75 1.00 0.89 0.64 
TBX21 0.75 1.00 0.89 0.92 
NFKB1 0.75 1.00 0.93 1.00 
TNFRSF1B 0.75 0.67 0.89 0.64 
IL8 0.75 0.67 0.93 0.82 
KIR3DL3 0.75 0.67 0.89 0.64 
KLDR1 0.85 1.00 0.89 1.00 
IL6R 0.88 0.67 0.93 1.00 
IL2 0.89 0.81 0.89 0.82 
IL8RB 1.00 0.81 0.93 1.00 
CXCL10 1.00 0.81 0.89 1.00 
a Genetic ancestry determined from 148 AIMS and STRUCTURE 
b Q values represent the proportion of false positives (number of false rejections/total number of 
rejections) 
*Bonferroni p-value for p=0.05 and 24 genesets= 0.002. The p-value for IL13&IL4 met this criterion for 
spontaneous preterm among White mothers. The p-value for IFNGR2 met this criterion for preterm 
among White mothers. 
Bold meets FDR <0.2 
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Table 4.3: Single SNP Relative Risk and 95% Confidence Intervals for Preterm and Spontaneous 
Preterm Birth among Mothers Stratified by Genetic Ancestry  
 European American a African Americana 
Gene/SNP
b 
Preterm Spont. Preterm Preterm Spont. Preterm 
IL12A 
    
rs503582 1.3 (1.1, 1.7) 1.3 (1.0, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs7653097 1.5 (1.0, 2.1) 1.4 (0.9, 2.3) 1.0 (0.7, 1.4) 0.9 (0.6, 1.5) 
rs13064168 0.6 (0.4, 0.8) 0.7 (0.4, 1.0) 1.1 (0.7, 1.7) 1.3 (0.7, 2.4) 
rs609907* 0.6 (0.5, 0.8) 0.7 (0.5, 1.0) 1.1 (0.8, 1.6) 1.2 (0.7, 2.0) 
rs2647929 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.1 (0.8, 1.6) 1.6 (1.0, 2.4) 
rs9811792 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.1 (0.8, 1.4) 1.5 (1.0, 2.2) 
rs7372767 1.1 (0.9, 1.4) 1.1 (0.9, 1.5) 1.3 (0.9, 1.7) 1.7 (1.1, 2.6) 
rs6441282 0.8 (0.6, 1.0) 0.8 (0.6, 1.0) 0.8 (0.6, 1.0) 0.7 (0.5, 1.0) 
rs692890 0.7 (0.6, 0.9) 0.7 (0.5, 0.9) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 
rs755004 1.3 (1.0, 1.7) 1.5 (1.1, 2.1) 0.6 (0.3, 1.2) 0.6 (0.2, 1.7) 
rs17826053 0.7 (0.5, 1.0) 0.7 (0.5, 1.1) 1.0 (0.7, 1.4) 0.7 (0.4, 1.2) 
rs4680536 1.1 (0.9, 1.4) 1.3 (1.0, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 
IFNGR2 
    
rs6517167 1.3 (1.0, 1.7) 1.1 (0.7, 1.6) 1.1 (0.8, 1.4) 0.9 (0.6, 1.3) 
rs9978223 0.7 (0.5, 0.9) 0.6 (0.4, 1.0) 1.1 (0.8, 1.4) 1.1 (0.7, 1.5) 
rs2268241 0.6 (0.5, 0.9) 0.6 (0.3, 0.9) 1.2 (0.9, 1.6) 1.3 (0.9, 1.8) 
rs9808685 1.3 (1.1, 1.7) 1.3 (1.0, 1.8) 1.0 (0.8, 1.3) 0.9 (0.6, 1.3) 
rs2834210 1.3 (1.0, 1.6) 1.3 (0.9, 1.7) 1.0 (0.8, 1.4) 0.9 (0.6, 1.3) 
rs9808753 0.7 (0.5, 1.0) 0.6 (0.4, 1.0) 1.2 (0.9, 1.6) 1.1 (0.7, 1.8) 
rs2834213 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.2 (0.7, 2.1) 1.8 (0.9, 3.5) 
KIR3DL2 
    
rs4806457 1.7 (1.1, 2.7) 1.5 (0.7, 3.1) 1.0 (0.5, 1.8) 0.7 (0.3, 1.7) 
rs11672983 1.3 (1.0, 1.5) 1.3 (1.0, 1.7) 0.8 (0.6, 1.0) 0.9 (0.6, 1.4) 
rs3816051 1.4 (1.2, 1.7) 1.4 (1.1, 1.9) 0.9 (0.6, 1.1) 0.9 (0.6, 1.3) 
IL3 
    
rs31481 1.4 (1.1, 1.8) 1.0 (0.7, 1.5) 1.3 (0.9, 1.8) 1.2 (0.7, 2.0) 
rs11575022 1.6 (1.1, 2.3) 1.5 (0.9, 2.6) 1.1 (0.7, 1.5) 1.0 (0.6, 1.7) 
CSF2 
    
rs721121 0.8 (0.7, 1.0) 0.9 (0.7, 1.2) 0.7 (0.5, 1.0) 0.6 (0.4, 0.9) 
rs4705916 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 0.6 (0.4, 0.9) 
rs743564 0.8 (0.6, 1.0) 0.9 (0.6, 1.2) 0.7 (0.5, 1.0) 0.8 (0.5, 1.2) 
rs25881 1.4 (1.0, 1.8) 1.2 (0.8, 1.7) 1.0 (0.8, 1.4) 0.9 (0.6, 1.4) 
rs25882 1.3 (1.0, 1.7) 1.1 (0.7, 1.6) 1.1 (0.8, 1.5) 1.0 (0.7, 1.6) 
rs27438 1.3 (1.0, 1.7) 1.1 (0.8, 1.6) 0.9 (0.7, 1.1) 0.8 (0.6, 1.2) 
rs6898270 0.8 (0.6, 1.0) 0.9 (0.6, 1.2) 0.8 (0.6, 1.2) 0.8 (0.5, 1.3) 
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Table 4.3 continued 
 European American a African Americana 
 
Preterm Spont. Preterm Preterm Spont. Preterm 
IL13 
    
rs7737470* 1.4 (1.1, 1.8) 1.9 (1.4, 2.5)* 1.1 (0.8, 1.4) 1.0 (0.6, 1.5) 
rs3091307* 1.4 (1.1, 1.8) 1.9 (1.4, 2.6)* 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 
rs1881457* 1.5 (1.1, 1.9) 1.8 (1.3, 2.5)* 1.0 (0.7, 1.3) 1.1 (0.7, 1.8) 
rs1295686 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 1.1 (0.9, 1.5) 1.2 (0.8, 1.7) 
rs20541 1.2 (0.9, 1.6) 1.5 (1.1, 2.1) 0.9 (0.6, 1.2) 0.8 (0.5, 1.3) 
rs848 1.2 (0.9, 1.6) 1.5 (1.0, 2.0) 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 
rs1295683 1.3 (0.9, 1.7) 1.5 (1.0, 2.2) 0.8 (0.5, 1.3) 0.7 (0.4, 1.4) 
rs2243204 1.2 (0.9, 1.8) 1.5 (0.9, 2.3) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs2243210 1.0 (0.7, 1.6) 1.3 (0.8, 2.2) 0.8 (0.6, 1.1) 0.8 (0.5, 1.3) 
rs2243218 1.2 (0.8, 1.7) 1.5 (1.0, 2.3) 1.0 (0.7, 1.3) 1.0 (0.7, 1.5) 
rs2243219 1.2 (0.9, 1.8) 1.5 (1.0, 2.3) 1.0 (0.8, 1.3) 0.9 (0.7, 1.3) 
IL4 
    
rs2243250 0.7 (0.5, 0.9) 0.6 (0.4, 0.9) 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 
rs2243263 1.2 (0.9, 1.7) 1.6 (1.1, 2.3) 1.1 (0.8, 1.5) 1.2 (0.8, 1.9) 
rs2243267 1.5 (1.1, 2.0) 1.8 (1.2, 2.6) 1.1 (0.8, 1.5) 1.2 (0.8, 1.9) 
rs2243270 1.4 (1.1, 1.9) 1.7 (1.1, 2.5) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs11242122* 0.7 (0.6, 0.9) 0.5 (0.4, 0.7)* 1.0 (0.8, 1.3) 0.8 (0.5, 1.2) 
rs11242123 1.4 (1.0, 1.9) 1.7 (1.2, 2.6) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
a Based on genetic ancestry 
b SNPs arranged by base pair position within each gene 
*SNPs and estimates have p-value <0.0005 (Bonferroni correction for 100 SNPs in Stage 2) 
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Figure 4.1: Linkage Disequilibrium in IL12A within European and African Americans 
European Americans    African Americans 
 
Values represent r2 for pairs of SNPs with darker boxes having stronger correlation. Grey bar represent 
approximate location of IL12A. * highlights blocks of LD for SNPs discussed in results. 
 
Figure 4.2: Linkage Disequilibrium in CSF2 in European Americans      
  
Values represent r2 for pairs of SNPs with darker boxes having stronger correlation. Grey bar represent 
approximate location of CSF2. * and # highlight blocks of LD for SNPs discussed in results. 
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Figure 4.3: Linkage Disequilibrium within IL13 and IL4 within European Americans 
IL13       IL4 
 
Values represent r2 for pairs of SNPs with darker boxes having stronger correlation. Grey bar represent 
approximate location of IL13 and IL4. * and # highlight blocks of LD for SNPs discussed in results. 
 
Figure 4.4: Linkage Disequilibrium within IFNGR2 for European Americans
 
Values represent r2 for pairs of SNPs with darker boxes having stronger correlation. Grey bar represent 
approximate location of IFNGR2. * and # indicate blocks of LD for SNPs discussed in results. 
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Paper #2: Polymorphisms in Inflammatory Genes are Associated with Term SGA and Preeclampsia 
Harmon QE, Engel SM, Wu MC, Moran T, Luo J, Stuebe AM, Avery CL, Olshan A 
Introduction 
Hypertensive disorders of pregnancy and poor fetal growth often co-occur22 and may share 
underlying pathology.9  Hypertensive disorders of pregnancy, including gestational hypertension (GHTN) 
and preeclampsia (PE), occur in up to 20% of pregnancies45 and are a leading cause of maternal 
mortality.47  Pregnancies complicated by hypertension are at increased risk of stillbirth, poor fetal 
growth and preterm birth.22, 50  The prevalence and health consequences of poor fetal growth depend 
largely on the metric of assessment60 and the specific etiology.64  However, low birth weight is 
consistently associated with increased infant mortality.33  Each outcome has also been associated with 
later risk of cardiovascular disease in the mother.40, 51, 52, 70 
Hypertension in pregnancy and poor fetal growth often share common placental pathology 
including shallow or inadequate placentation.3, 7, 9, 10  In addition, women with either outcome exhibit 
altered inflammatory biomarkers both preceeding74, 79, 80 and at the time of diagnosis.1, 4, 7, 9, 74  Adequate 
placentation is to a large degree dependent on tightly regulated local inflammatory processes9, 74-- in 
particular natural kill (NK)5 and T cell82 activity. Placental growth and uterine wall remodeling may 
additionally be influenced by cell cycle genes that regulate cell growth and division in rapidly growing 
tissue such as the placenta.20, 21 Human and animal placental expression studies suggest that cell cycle 
genes may differ in expression or function in women with hypertension in pregnancy or small for 
gestational age (SGA).134-138 
Although a fetal genetic component has been identified for both hypertension in pregnancy11, 148 
and fetal growth,15  these disorders also have a maternal genetic component. However, sparse gene 
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coverage, small case groups and lack of control for population stratification have limited previous 
studies of genetic associations in small for gestational age infants and preeclampsia. To address these 
limitations, we examined the associations between both inflammatory and cell cycle gene and 
preeclampsia and SGA with increased gene coverage and measured genetic ancestry. Here we report on 
the association between 40 genes and the outcomes of SGA, gestational hypertension and preeclampsia 
in a well characterized biracial pregnancy cohort in North Carolina.  
Methods 
Study participants were drawn from the Pregnancy, Infection and Nutrition (PIN) cohort,184, 185 
which was established to assess antenatal risk factors for a variety of reproductive outcomes. Briefly, 
women were enrolled between August 1995 and June 2005 from prenatal clinics at Wake County 
Human Services Department, Wake Medical Center and the University of North Carolina (UNC) 
Hospital.184, 185  Women were ineligible if they were less than 16 years old, did not speak English, lacked 
a telephone, were carrying more than one fetus or did not plan to continue care at the recruitment 
hospital.  
Outcome and covariate data were collected through self-administered questionnaires, telephone 
interviews during pregnancy and abstraction of maternal and infant medical records. Maternal blood for 
genetic analysis was collected during the first study visit. All participants gave consent and the study was 
approved by the institutional review boards of UNC School of Medicine and Wake Medical center. 
Of those enrolled, 3539 women (68.5%) allowed their DNA to be used for genetic analysis. Eligibility 
for genotyping in the current study also included collection of a suitable bio-specimen (N=3289), self-
reported race as White or African American (N=3075) and recorded date of delivery (N=3065). These 
eligibility criteria resulted in 3065 (59.3%) women who were eligible for selection. From the eligible 
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population, 1646 pregnancies were selected for genotyping. Attempts were made to genotype all 
eligible cases. Missing or inadequate samples resulted in (N, % of eligible); 216 (90.4%) SGA, 398 (95.2%) 
GHTN and 170 (91.9%) PE cases. Control births (N=918) were selected from the remaining eligible 
women. 
Outcome assessment 
SGA status was defined as birth weight below the 10th percentile for gestational age, stratified by 
infant race and sex and maternal parity based on percentiles from 1989 US births.186  As a proxy 
measure for impaired fetal growth, SGA may not appropriately classify preterm infants59, 60 and may 
misidentify constitutionally small infants as SGA. In as much as common causes may exist for preterm 
birth and poor intrauterine growth,24  term SGA was considered as an additional phenotype. 
Gestational hypertension and preeclampsia were assessed using clinical records. Prior to 2002, 
hypertension during pregnancy was defined using a relative increase of 30mmHg in Systolic Blood 
Pressure (BP) or a 15mmHg increase in the Diastolic Blood Pressure from a woman’s baseline blood. 
Following American College of Obstetrics and Gynecology (ACOG) recommendations in 2002 the 
definition of hypertension was changed to an absolute cut point of Systolic BP >=140 mmHg or Diastolic 
BP >=90 mmHg.45  Diagnoses in this study reflect the clinical criteria in use at the time of the pregnancy. 
While the newer ACOG criteria reduces the number of women who receive a diagnosis of preeclampsia, 
however the positive predictive value for adverse maternal and infant outcomes is similar for the two 
sets of criteria.235  Preexisting hypertension, onset of hypertension after 20 weeks and evidence of 
proteinuria were abstracted from antenatal charts and discharge diagnoses. Gestational hypertension 
was defined as new onset hypertension following 20 weeks in the absence of proteinuria. Preeclampsia 
was defined as new onset hypertension (using the criteria appropriate at the time of pregnancy) and 
evidence of proteinuria. Women with preexisting hypertension, or hypertension before 20 weeks, were 
 153 
excluded from both the case and control groups for all analyses of gestational hypertension and 
preeclampsia. 
Additional Covariates 
Covariates of interest were selected based on previous studies and explored as potential 
confounders using directed acyclic graphs.236  All values were self-reported, with the exception of 
measured height. Covariates included maternal age (<25 yrs, 25-34 yrs, >=35 yrs), body mass index191 
(<18.5 kg/m2, 18.5-24.9 kg/m2, 25.0-29.9 kg/m2 and >=30.0 kg/m2), any maternal smoking during the 
first 6 months of pregnancy (yes/no), parity (nulliparous, multiparous) and a continuous measure of 
socio-economic status based on contemporary levels of poverty indexed to household income and 
household size. In addition, study related variables, and additional demographic and pregnancy health 
characteristics were included for the calculation of selection probabilities. 
Single Nucleotide Polymorphisms: Selection and Assessment 
Thirty inflammatory and 10 cell cycle genes (546 SNPs) were selected as candidate genes. Tag SNPs 
were selected using TagZilla187 for two population with a 20kb upstream and 10kb downstream margin 
restricting to minor allele frequencies >=10% and linkage disequilibrium (LD) <0.8 (r2) . A custom 1536 
Illumina GoldenGate plate was designed which also included SNPs from genes associated with 
angiogenic and apoptosis pathways.  
Buffy coat fractions were isolated from fresh whole blood and stored at -80○C in CPT tubes. DNA 
was extracted using Applied Biosystems automated DNA extractor6 and Qiagen chemistry. 
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Genotyping was conducted at the University of North Carolina Genomics Core (Chapel Hill, NC) and 
alleles were read using the Illumina BeadArray Reader and were analyzed using Illumina’s software for 
automated genotype calling. 
Poor genotyping quality (<95% of individuals called) resulted in the loss of 43 SNPs. Further quality 
control was conducted on the remaining 503 SNPs using blinded PIN samples and standardized controls 
from Corriel Utah family trios. There was one instance of a single base pair genotyping discrepancy 
found in 199 blind samples (IL4: rs2243250), and there were no instances of mendelian errors among 21 
trios examined. Hardy Weinberg Equilibrium was assessed using SAS 9.2224 among non-cases stratified 
by genetic ancestry. One SNP (IL2: rs10027390) significantly violated HWE (p<10-5) in African American 
non-cases and was dropped from analysis for this ancestry group. 
In tagging two populations, redundant SNPs (Linkage Disequilibrium with r2>0.8) were included for 
European Americans, and use of a Yoruban reference population also resulted in some redundant SNPs 
for our African American population. Linkage Disequilibrium (LD) in the study population was calculated 
and heatmaps were created using Haploview.201  In addition to pairwise LD in this population, long range 
LD with untyped SNPs was explored using SNAP202 with the 1000 Genomes Project Pilot 1. 
Genetic ancestry  
Differences in the allelic frequency in genes associated with inflammation have been reported 
among Whites and African Americans in the United States.188  The incidence of preeclampsia45 and birth 
weight33 also vary by self-reported race presenting the possibility of confounding by genetic ancestry. 
Genetic ancestry was therefore assessed using ancestry informative markers (N=157) that have 
previously been used in a similar population in North Carolina.189  STRUCTURE228 was used to calculate a 
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continuous genetic ancestry variable. All analyses were stratified by genetic ancestry (European and 
African American) and also included continuous percent African ancestry. 
Statistical analysis 
We employed a two-stage approach to identify associations between inflammatory and cell cycle 
genes and the outcomes of SGA, GHTN and PE. Stage 1 utilized the SNP-set Kernel Association Test194 
(SKAT) with a linear kernel (analogous to logistic regression with an additive genetic model). SKAT was 
chosen as it permits SNP interactions within a gene, allows adjustment for covariates and accounts for 
SNPs with opposing effects (protective or risk) within a gene. SNP-sets were constructed based on 
candidate genes and genes within 25kBP were analyzed together. Genes with single SNPs (CCNH, TGFB3, 
TGFB1, MDM2) or SNPs chosen solely for replication (IL1A, IL1B) were not included in the Stage 1 
analysis. Individuals with missing genotype information on any SNPs in a set were dropped from the 
analysis. On average 99% of individuals were included in each SNP-set with a minimum of 91% 
(Supplemental Table 1). Analyses were conducted for each outcome with uncomplicated term births as 
the control group. For GHTN and PE, women with chronic hypertension were removed from the control 
group. The null hypothesis that the general function for the SNP-set equals zero is tested using a 
variance component score test in SKAT.197  A false discovery rate (FDR)199 of 20% was used to identify 
SNP-sets which advanced to Stage 2 analysis. P-values from SKAT were transformed to Q229 values using 
R(p.adjust, FDR)237 accounting for the number of SNP-sets analyzed (N=31).  
The Stage 2 analysis was used to quantify the individual SNP associations within the SNP-sets 
identified as significant in Stage 1. GHTN was not rare in this population (15% in the underlying PIN 
cohort); therefore, we estimated risk ratios for all outcomes using a log-linear risk model. Given a high 
proportion of small cell (<5) counts of homozygous recessives in some of the case groups, dominant 
genetic models were used unless the smallest cell was >5. Inverse probability of selection weighting was 
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used so that the estimates are generalizable to the eligible population. Briefly, a logistic model was used 
to calculate the probability that an eligible woman (N=3065) was selected for genotyping (N=1646) 
based on all covariates in Table 1 and other study-related, demographic and pregnancy-related 
variables. The inverse of this probability was then used to weight the model. Robust variances were 
used, although they are likely overestimate the true variance.200  Stage 2 is not independent of Stage 1, 
therefore top ranking SNPs from Stage 2 were reported based on the consistency of the observed 
association in associated outcomes (SGA and Term SGA) as well as between groups based genetic 
ancestry groups. Analyses were stratified based on genetic ancestry and additionally adjusted for a 
continuous ancestry variable. In a limited subset of high priority models (N=15) we also examined the 
influence of maternal age, smoking, BMI, parity and socio economic status on point estimates and 
precision. 
Results 
The final analysis dataset included 1598 women. Tables 4.4 and 4.5 presents the demographic 
characteristics of the case and control groups for SGA and hypertensive disorders of pregnancy 
respectively. Women who consented and were successfully genotyped were similar to the underlying 
PIN cohort and were predominately White (62.6%), well educated (51.9% with more than high school 
education), non-smokers (74.4%) with a mean age of 26.1 years and a mean BMI of 26.5 kg/m2 (Table 
S17). Although demographics differed between European and African Americans, the differences were 
not as pronounced between cases and controls within strata of genetic ancestry.  Adjustment for any or 
all of the covariates in Table 4.4 failed to change the single SNP point estimates more than 10% (results 
not shown). Therefore we only present estimates adjusted for genetic ancestry. 
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Stage 1: Gene-set analysis 
SNPs were combined into 31 SNP-sets. Due to proximity on the genome LTA and TNF, IL13 and IL4, 
and CDKN2A and CDKN2B were considered as single SNP-sets. Four SNP-sets met the FDR criteria of 20% 
in Stage 1: IL6 and KLRD1 were associated with term SGA among African Americans and TBX21 and 
LTA/TNF were associated with PE among European Americans. No SNP-sets met the FDR criteria for SGA 
or GHTN (Table 4.6). 
Stage 2: Single SNP analysis 
The 55 SNPs associated with the SNP-sets identified in Stage 1 and the 8 SNPs not included in Stage 
1 were assessed in Stage 2 in both ancestral groups (Table 4.7 and Table 4.8). Single SNP results for all 
genes and outcomes can be found in Tables S18 and S19. 
SGA 
IL6 and KLRD1 were associated with Term SGA only among African Americans. Single SNP 
associations within IL6 however were generally consistent in both ancestry groups, although slightly 
weaker for European Americans (Table 4.7). The strongest single SNP associations for Term SGA (RR 1.9-
2.4) for both ancestry groups were seen for a group of 3 intronic IL6 SNPs (rs1548216, rs2069843, 
rs2069849). This group of SNPs is in full LD (r2=1) among European Americans and partial LD in African 
Americans (r2=0.72-0.85) (Figure 4.5).  Another group of SNPs upstream from IL6 was also associated 
with an increased risk of Term SGA (RR 1.8-2.5) for both African and European Americans (rs6963444, 
rs7784987, rs3087221).  
For KLRD1 however, single SNP associations were dissimilar across the two ancestry groups. The 
tagSNPs chosen represent a single block of high LD among European Americans, except for two SNPs 
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which were quite rare in European Americans (rs10772256, rs7301562) (Figure 4.6). Seen as a block, 
there was an overall null association with both SGA and Term SGA for European Americans. In contrast, 
among African Americans, a number of SNPs were relatively strongly associated with Term SGA. In 
particular, rs10772256 (missense) and rs7301562 (r2=1), were associated with a decreased risk of Term 
SGA (RR= 0.5, 95% CI 0.3-0.9). Additionally rs3759270 was also associated with a fairly substantial 
decreased risk of Term SGA (RR=0.4, 95%CI 0.3-0.8). Finally two SNPs in perfect LD (rs3809214, 
rs2302489) were associated with an increased risk of Term SGA (RR=1.6) among African Americans. 
Preeclampsia 
LTA/TNF and TBX21 were associated with preeclampsia, but only for European American women. 
Moreover, the single SNP results were generally null for African Americans (Table 4.8). LTA and TNF are 
quite close on chromosome 6 (6p21.3) and tagging for LTA also captured intronic regions of NFKBIL1. 
Single SNP results for tags within NFKBIL1 were generally null. In LTA two SNPs in high LD (r2=0.99) 
(Figure 4.7), rs909253 and rs1041981 (missense) were associated with an increased risk of preeclampsia 
(RR=1.5 and 1.4). Another missense SNP in LTA rs2229094 was associated with a decreased risk of 
preeclampsia (RR=0.6, 95% CI 0.4-1.0). In TNF, rs1800629 an upstream SNP that is thought to upregulate 
TNF expression,85 was found to increase the risk of preeclampsia (RR=1.8, 95% CI 1.1-2.7). 
TagSNPs for TBX21 captured two upstream SNPs which were closer to another gene TBKBP1 
(rs2013383, rs1808192). These two SNPs are in moderate LD with each other (r2=0.68) (Figure 4.8) and 
have long range LD extending through TBKBP1 with very little pairwise or long range LD with typed or 
untyped SNPs in TBX21. The two TBKBP1 SNPs were associated with a decreased risk of preeclampsia 
RR=0.6. For tagSNPs within TBX21 itself, the associations were null. 
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Preeclampsia exists on a spectrum and clinical diagnostic criteria changed over the course of 
participant recruitment. In addition, diagnostic criteria were abstracted from both antenatal records and 
discharge records, which sometimes conflicted and were not always both available. Given these 
challenges a validation of the preeclampsia diagnosis was performed in a subset. Among women who 
had discordant PE diagnoses (antenatal record differed from discharge diagnosis) we were able to 
review the complete antenatal and delivery record of a subsample (N=125). A sensitivity analysis of the 
single SNP estimates for SNPs in LTA/TNF and TBX21 was conducted using a more refined PE diagnosis 
on the basis of this validation work. Women were considered a validated PE case if they had both an 
antenatal record and discharge diagnosis of PE, or if they were included in the chart review and were 
found to have PE using ACOG criteria. Among the 76 validated cases, the single SNP results for LTA and 
TNF were generally consistent in strength and direction. For TBKBP1 the estimates were attenuated and, 
although in the same direction, the overall effect was null. However SNPs in TBX21, which were null 
using the entire PE case group, were strengthened and, although imprecise, suggest a possible risk 
association. 
Discussion 
We examined 40 genes related to inflammation and cell-cycle pathways and their association with 
SGA, GHTN and PE in a biracial North Carolina population. There were no significant associations for any 
of the cell cycle genes. Among African American women, IL6 and KLRD1 were associated with term SGA. 
Single SNP associations within IL6 suggest that a similar, though weaker, association may exist for 
European Americans. For the outcome of preeclampsia, associations within LTA and TNF were seen for 
European American women. Two SNPs within a novel gene, TBKP1, were associated with a decreased 
risk of preeclampsia among European American women only. 
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We report gene level associations among African Americans only within the term SGA phenotype, 
suggesting that these associations are mediated by pathways unrelated to prematurity. It is unclear why 
distinctive association patterns emerged for African Americans and whites; however it may reflect 
distinct phenotypes, or possibly interactions with social or environmental exposures that are 
differentially distributed across these two populations. IL6 has been examined previously in relation to 
SGA with null associations, although many fewer SNPs were used to tag the gene6, 158, 182 and apart from 
the Engel study6 the populations were white. IL6 expression decreases over the course of uncomplicated 
pregnancy72 and IL6 early in pregnancy may influence the ability of the placenta to become adequately 
implanted.238   
KLRD1 (CD94) codes for a portion of receptor on both NK and T cells that recognizes HLA-E 
molecules expressed by trophoblasts during pregnancy239. Tight regulation of maternal immunity at the 
time of implantation mitigates against rejection of fetal trophoblasts. Dysregulation of KLRD1 therefore 
could result in poor placental implantation due to low levels of maternal rejection. In this study 
polymorphisms in KLRD1 were only associated with term SGA among African Americans. Although 
genetic diversity of HLA-E is much lower than the diversity seen in other MHC genes, there have been 
haplotype differences documented between individuals of European and African descent.240  Underlying 
differences in HLA-E haplotypes may explain the different results seen in ancestry groups. 
Genes coding for TNF-α (TNF) and TNF-β (LTA) were associated with an increased risk of 
preeclampsia among European American women. TNF-α has been implicated in the pathogenesis of 
preeclampsia22 both as a modulator of placental implantation and as a response to the hypoxia created 
by poor placental perfusion.8  Infusions of TNF induce hypertension in pregnant rats.241  Despite the 
credibility of the biology implicating TNF with preeclampsia, results of genetic epidemiologic studies 
have been less encouraging. A meta-analysis of the -308A missense mutation (rs1808192) by Bombell87 
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found a null pooled RR. The Bombell study however combined estimates from populations of very 
different genetic ancestry. Work in US populations suggest that allele frequencies for TNF and its related 
receptors vary by self-reported race, and regulation of TNF-α levels during pregnancy appears to be 
different between White and African American women.113  In our stratified analysis, an association at 
the gene-level was only apparent for European Americans.  Despite the null association in the meta-
analysis, the complexity of TNF regulation and apparent heterogeneity based on genetic ancestry 
support further investigation into this gene.   
A gene level association was found for TBX21 which is an important regulator of TH1 immunity.242 
However the single SNP analysis revealed that the association was most likely with a close upstream 
gene TBKBP1 (aka SINTBAD). TBKBP1 was identified in 2004 and its function is still being elucidated. It 
appears to be related to signaling in the TNF-α/NFκB pathways and the activation of interferon.243, 244 
Given the role of TNF-α in preeclampsia, further investigation of this novel gene is warranted. 
Diagnosis of preeclampsia is difficult both clinically and from a research perspective. Preeclampsia 
exists on a spectrum and lacks a gold standard biomarker. Our study also spans a period of time when 
the diagnostic criteria were in flux. Some subset of women diagnosed with PE prior to 2002 may now be 
considered to only have had gestational hypertension if they met the relative increase in blood pressure 
criteria but did not exceed the current threshold of a blood pressure of 140/90. Although our PE case 
definition is heterogeneous, our ability to exclude women with preexisting hypertension was a strength. 
Our validation study supported our initial findings for LTA/TNF with conflicting results for 
TBX21/TBKBP1. Admittedly, heterogeneity still exists within our case definition, however, and future 
studies will need to improve case ascertainment.   
This study was limited by the lack of fetal DNA, which is an important genetic factor in both of these 
reproductive outcomes. While examination of fetal DNA may have identified additional important 
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pathways or highlighted interactions with maternal DNA, the results of this study support population 
based studies that identify an independent role of maternal genes in these outcomes. Although we 
incorporated genetic variation in up and downstream regions, our pre-specified boundaries may be too 
narrow to capture long range regulatory elements.245  Finally, previous research has demonstrated that 
a candidate gene approach has been only modestly successful in identifying genetic associations that 
replicate across populations. Nonetheless, the results presented herein are consistent with current 
understanding of the biology underpinning preeclampsia and SGA although verification in an 
independent population is needed. 
In summary, this study expanded coverage of known candidate inflammatory genes and examined 
novel cell cycle and natural kill cell genes while carefully addressing population stratification. The results 
of this study reveal important differences in the genetic underpinnings of term SGA and preeclampsia in 
European and African Americans while also finding that there may be pathways in common. Novel 
associations between KLRD1 and term SGA and TBKBP1 and preeclampsia need further exploration with 
more dense tagging of polymorphisms within TBKBP1 and consideration of HLA-E haplotypes for KLRD1. 
Associations for IL6 and TNF/LTA in the face of previous null results, highlight the difficulty in studying 
these important outcomes that have both phenotypic complexity and multiple environmental and social 
risk factors that are likely interacting with biologic pathways. 
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Table 4.4 Paper #2 Demographic characteristics of small for gestational age (SGA) cases and controls 
 SGA Cases Disease Free Non-SGA Controls
a 
Genetic Ancestry
b 
European 
American 
African 
American 
European 
American 
African 
American 
European 
American 
African 
American 
N=117 N=92 N=409 N=204 N=890 N=499 
Maternal Age       
<25 55 (47.0) 27 (29.4) 215 (52.6) 68 (33.3) 440 (49.4) 182 (36.5) 
25-34 46 (39.3) 59 (64.1) 133 (32.5) 132 (64.7) 325 (36.5) 295 (59.1) 
35+ 16 (13.7) 6 (6.5) 61 (14.9) 4 (2.0) 125 (14.0) 22 (4.4) 
Smoking
c 
      
No 68 (63.6) 58 (72.5) 302 (77.4) 148 (84.6) 588 (71.0) 362 (83.2) 
Yes 39 (36.5) 22 (27.5) 88 (22.6) 27 (15.4) 240 (29.0) 73 (16.8) 
Missing 10 (8.5) 12 (13.0) 19 (4.6) 29 (14.2) 62 (7.0) 64 (12.8) 
BMI (kg/m
2
)
d 
      
<18.5 11 (9.9) 11 (13.1) 23 (5.7) 16 (8.3) 44 (5.1) 27 (5.8) 
18.5-24.9 72 (64.9) 35 (41.7) 250 (62.2) 79 (40.9) 454 (52.7) 166 (35.8) 
25-29.9 16 (14.4) 13 (15.5) 71 (17.7) 39 (20.2) 174 (20.2) 100 (21.6) 
30+ 12 (10.8) 25 (29.8) 58 (14.4) 59 (30.6) 189 (22.0) 171 (36.9) 
Missing 6 (5.1) 8 (8.7) 7 (1.7) 11 (5.4) 29 (3.3) 35 (7.0) 
Marital Status       
Married 77 (65.8) 13 (14.1) 313 (76.5) 32 (15.7) 644 (72.4) 109 (21.9) 
Unmarried 40 (34.2) 79 (85.9) 96 (23.5) 172 (84.3) 246 (27.6) 389 (78.1) 
Education (years)       
13+  61 (52.1) 27 (29.4) 275 (67.2) 68 (33.3) 542 (60.9) 201 (40.3) 
<=12  56 (47.9) 65 (70.7) 134 (32.8) 136 (66.7) 348 (39.1) 298 (59.7) 
Parity       
Nulliparous 49 (41.9) 48 (52.2) 189 (46.4) 88 (43.1) 437 (49.2) 220 (44.2) 
Muliparous 68 (58.1) 44 (47.8) 218 (53.6) 116 (56.9) 451 (50.8) 278 (55.8) 
Missing 0 0 2 (0.5) 0 2 (0.2) 1 (0.2) 
Poverty Index       
Mean (SD) 310 (237) 119 (85) 367 (238) 144 (123) 345 (237) 148 (124) 
Missing 10 (8.6) 26 (28.3) 24 (5.9) 37 (18.1) 70 (7.9) 85 (17.0) 
Term SGA 96 (82.1) 64 (69.6) 0 0 0 0 
Gestational HTN 19 (17.0) 14 (16.9) 0 0 226 (27.2) 131 (28.5) 
Preeclampsia 11 (9.8) 10 (12.1) 0 0 82 (9.9) 62 (13.5) 
Preterm Birth 21 (18.0) 28 (30.4) 0 0 173 (19.4) 106 (21.2) 
a. Non-SGA controls include non-SGA births with other outcomes of interest: preterm birth (PTB), gestational hypertension 
(GHTN) and preeclampsia (PE). 
b. Genetic ancestry determined using 148 AIMs and STRUCTURE.  
c. Self-reported smoking during months 1-6 of pregnancy. 
d. Pre-pregnancy BMI calculated from self-reported pre-pregnancy weight and measured height. 
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Table 4.5 Paper #2 Demographic characteristics of gestational hypertension (GHTN) and preeclampsia (PE) cases and controls 
 GHTN Case PE Case Non Casea GHTN Controlb PE Controlb 
Genetic 
Ancestryc 
European 
American  
African 
American 
European 
American 
African 
American 
European 
American 
African 
American 
European 
American 
African 
American 
European 
American 
African 
American 
N=245 N=145 N=93 N=72 N=394 N=190 N=699 N=397 N=851 N=470 
Age (years)           
<25 107 (43.7) 54 (37.2) 52 (55.9) 22 (30.6) 211 (53.6) 64 (33.7) 355 (50.8) 131 (33.0) 410 (48.2) 163 (34.7) 
25-34 101 (41.2) 85 (58.6) 36 (38.7) 48 (66.7) 123 (31.2) 122 (64.2) 254 (36.3) 254 (64.0) 319 (37.5) 291 (61.9) 
35+ 37 (15.1) 6 (4.1) 5 (5.4) 2 (2.8) 60 (15.2) 4 (2.1) 90 (12.9) 12 (3.0) 122 (14.3) 16 (3.4) 
Smokingd           
No 150 (65.8) 101 (80.2) 57 (71.3) 56 (86.2) 293 (77.5) 135 (83.3) 468 (72.0) 283 (81.6) 561 (70.3) 328 (80.4) 
Yes 78 (34.2) 25 (19.8) 23 (28.8) 9 (13.9) 85 (22.5) 27 (16.7) 182 (28.0) 64 (18.4) 237 (29.7) 80 (19.6) 
Missing 17 (6.9) 19 (13.1) 13 (14.0) 7 (9.7) 16 (4.1) 28 (14.7) 49 (7.0) 50 (12.6) 53 (6.2) 62 (13.2) 
BMI (kg/m2)e          
<18.5 7 (3.0) 6 (4.6) 4 (4.4) 1 (1.5) 22 (5.7) 16 (8.9) 48 (7.0) 32 (8.6) 51 (6.2) 37 (8.5) 
18.5-24.9 106 (46.1) 46 (34.9) 41 (45.6) 23 (33.8) 242 (62.2) 74 (41.1) 406 (59.5) 149 (40.1) 471 (57.3) 172 (39.5) 
25-29.9 47 (20.4) 29 (22.0) 21 (23.3) 15 (22.1) 69 (17.7) 36 (20.0) 132 (19.4) 74 (19.9) 158 (19.2) 88 (20.2) 
30+ 70 (30.4) 51 (38.6) 24 (26.7) 29 (42.7) 56 (14.4) 54 (30.0) 96 (14.1) 117 (31.5) 142 (17.3) 139 (31.9) 
Missing 15 (6.1) 13 (9.0) 3 (3.2) 4 (5.6) 5 (1.3) 10 (5.3) 17 (2.4) 25 (6.3) 29 (3.4) 34 (7.2) 
Marital Status          
Married 171 (69.8) 41 (28.3) 58 (62.4) 13 (18.3) 304 (77.2) 30 (15.8) 504 (72.1) 66 (16.7) 617 (72.5) 94 (20.0) 
Unmarried 74 (30.2) 104 (71.7) 35 (37.6) 58 (81.7) 90 (22.8) 160 (84.2) 195 (27.9) 330 (83.3) 234 (27.5) 376 (80.0) 
Education (years)          
13+  141 (57.6) 62 (42.8) 47 (50.5) 31 (43.1) 267 (67.8) 65 (34.2) 420 (60.1) 140 (35.3) 514 (60.4) 171 (36.4) 
<=12  104 (42.5) 83 (57.2) 46 (49.5) 41 (56.9) 127 (32.2) 125 (65.8) 279 (39.9) 257 (64.7) 337 (39.6) 299 (63.6) 
Parity           
Nulliparous 136 (55.5) 70 (48.3) 59 (63.4) 43 (60.6) 181 (46.2) 81 (42.6) 328 (47.1) 181 (45.7) 405 (47.7) 208 (44.3) 
Muliparous 109 (44.5) 75 (51.7) 34 (36.6) 28 (39.4) 211 (53.8) 109 (57.4) 369 (52.9) 215 (54.3) 444 (52.3) 262 (55.7) 
SGA 19 (7.8) 14 (9.7) 11 (11.8) 10 (13.9) 0 0 93 (13.3) 69 (17.4) 101 (11.9) 73 (15.5) 
PTB 19 (7.8) 17 (11.7) 29 (31.2) 19 (26.4) 0 0 160 (22.9) 97 (24.4) 150 (17.6) 95 (20.2) 
a. Non case controls are uncomplicated term births without preexisting hypertension used in Stage 2 for both outcomes. b. GHTN and PE controls include pregnancies with SGA 
and Preterm Birth, but exclude those with pre-existing hypertension. GHTN controls further exclude women with PE. c. Genetic ancestry determined using 148 AIMs and 
STRUCTURE. d. Self-reported smoking during months 1-6 of pregnancy. e. Pre-pregnancy BMI calculated from self-reported pre-pregnancy weight and measured height.
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Table 4.6 Paper #2 Qa values from SKAT analysis for each SNP-set stratified by genetic ancestry 
 European 
Americanb 
African Americanb European 
American 
African 
American 
Pathway/Gene SGA Term SGA SGA Term SGA GHTN PE GHTN PE 
TH1         
TBX21* 1.00 1.00 0.87 0.83 0.84 0.05 0.83 0.99 
IFNGR2 0.84 1.00 1.00 1.00 0.80 0.39 0.84 0.81 
IL12A 0.84 0.91 0.87 0.83 0.80 0.39 0.83 0.99 
IL18 0.84 1.00 0.87 0.83 0.80 0.81 0.83 0.81 
CSF2 0.84 1.00 0.87 0.83 0.80 0.91 0.84 1.00 
IL12B 0.84 1.00 0.87 0.83 0.35 0.91 0.83 1.00 
IL2 0.84 1.00 0.87 0.83 0.35 0.91 0.83 0.81 
IFNG 1.00 1.00 0.88 1.00 0.80 1.00 0.84 0.81 
Inflammatory Mediators        
LTA&TNF* 0.84 0.91 1.00 1.00 0.58 0.05 0.83 0.81 
IL6* 0.84 1.00 0.87 0.17 0.58 0.91 0.83 0.99 
NFKB1 0.84 0.91 0.89 0.83 0.80 0.81 0.84 1.00 
TNFRSF1B 0.84 0.91 0.87 0.83 0.98 0.91 0.83 0.81 
IL6R 0.84 0.91 0.87 0.83 0.58 0.91 0.83 0.81 
Natural Killer Cell        
KLRD1* 0.84 0.91 0.87 0.17 0.83 0.91 1.00 1.00 
IL15 0.84 1.00 0.87 0.83 0.80 0.53 0.83 0.81 
KIR3DL2 0.84 1.00 0.87 0.84 0.92 0.81 0.83 0.81 
KIR2DL4 0.84 1.00 0.87 0.87 0.53 0.91 0.83 0.81 
KIR3DL3 0.84 1.00 0.94 1.00 0.62 0.91 0.83 0.81 
TH2         
IL13&IL4 0.84 1.00 0.87 0.87 0.58 0.81 0.83 0.81 
GATA3 0.84 1.00 0.87 0.83 0.84 1.00 0.83 0.81 
Anti-Inflammatory        
IL10 0.84 1.00 0.87 0.83 0.35 0.91 0.83 0.81 
Chemokine         
IL8 0.84 0.91 0.87 0.83 0.62 0.91 0.83 0.81 
IL8RB 0.84 0.91 0.87 0.83 1.00 0.91 0.83 0.81 
CXCL10 0.84 1.00 0.87 0.83 0.80 0.91 0.84 0.81 
Cell Cycle         
RASSF1 0.84 1.00 0.79 0.83 0.35 0.23 0.83 0.81 
NOV 0.84 1.00 0.87 0.83 0.80 0.81 0.83 0.81 
CNNM2 0.84 1.00 0.87 0.83 0.80 0.81 0.83 0.81 
GADD45A 0.84 1.00 0.87 0.83 0.80 0.91 0.83 0.88 
CDKN2A&CDKN2B 0.84 1.00 0.87 0.83 0.80 0.91 0.84 0.81 
CCND1 0.84 1.00 0.87 0.83 1.00 0.91 0.83 0.81 
CCNA2 1.00 1.00 0.87 0.83 1.00 1.00 0.83 1.00 
a. Q values represent the proportion of false positives (number of false rejections/total number 
of rejections) 
b. Genetic ancestry determined from 148 AIMS and STRUCTURE 
*Meets FDR <0.20 for at least one outcome 
Abbreviations: SGA small for gestational age, GHTN gestational hypertension, PE preeclampsia 
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Table 4.7 Paper #2  Single SNP associations, risk ratio and 95% confidence interval for 
maternal SNPs for SGA and Term SGA in infants stratified by maternal genetic ancestry 
 African Americana European Americana 
Gene/SNP SGA Term SGA SGA Term SGA 
IL6b     
rs4719711 1.0 (0.7, 1.6) 0.9 (0.5, 1.5) 0.7 (0.4, 0.9) 0.7 (0.4, 1.0) 
rs6963444 1.8 (1.2, 2.8) 2.5 (1.5, 4.2) 1.9 (1.0, 3.7) 2.1 (1.0, 4.2) 
rs1546762 1.1 (0.7, 1.7) 0.8 (0.5, 1.5) 0.6 (0.4, 0.9) 0.6 (0.4, 1.0) 
rs7784987 1.5 (1.0, 2.4) 2.1 (1.2, 3.6) 2.0 (1.0, 3.8) 2.1 (1.1, 4.4) 
rs3087221 1.4 (0.9, 2.3) 1.8 (1.1, 3.1) 2.3 (1.0, 5.4) 2.0 (0.8, 5.4) 
rs1800795 1.1 (0.6, 2.2) 0.7 (0.3, 1.8) 0.9 (0.6, 1.3) 1.0 (0.7, 1.6) 
rs1548216 1.6 (1.0, 2.5) 2.1 (1.2, 3.5) 2.3 (1.2, 4.2) 2.4 (1.2, 4.7) 
rs2069843c 1.5 (1.0, 2.3) 2.0 (1.3, 3.1) 2.1 (1.2, 3.8) 2.4 (1.2, 4.6) 
rs2069849 1.4 (0.9, 2.3) 1.9 (1.1, 3.2) 2.2 (1.2, 4.1) 2.4 (1.2, 4.6) 
KLRD1 
    
rs3759270 0.6 (0.4, 1.0) 0.4 (0.3, 0.8) 1.3 (0.9, 2.0) 1.3 (0.8, 2.0) 
rs3809214c 1.3 (0.9, 1.8) 1.6 (1.1, 2.4) 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 
rs2302489c 1.3 (0.9, 1.8) 1.6 (1.1, 2.4) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 
rs7301562 0.6 (0.4, 1.0) 0.5 (0.3, 0.9) 1.1 (0.2, 7.9) 1.6 (0.2, 11.8) 
rs10772256 0.6 (0.4, 1.0) 0.5 (0.3, 0.9) 1.1 (0.2, 7.9) 1.6 (0.2, 11.8) 
rs2270238 0.8 (0.4, 1.8) 0.8 (0.3, 2.1) 1.5 (1.0, 2.2) 1.5 (1.0, 2.4) 
rs11611333c 1.1 (0.8, 1.5) 1.0 (0.7, 1.5) 1.3 (1.0, 1.6) 1.2 (0.9, 1.7) 
rs12829155c 1.3 (0.9, 1.9) 1.5 (0.9, 2.4) 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 
a Genetic ancestry determined from 148 AIMS and STRUCTURE 
b Selected results for IL6 presented. Results from all SNPs available in Supplemental Table 2 
c Additive model presented 
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Table 4.8 Paper #2 Single SNP associations, risk ratio and 95% confidence interval for maternal 
SNPs and Preeclampsia stratified by genetic ancestry 
Gene/SNP European Americana African Americana 
NFKBIL1   
rs2857605 1.1 (0.7, 1.6) 1.0 (0.5, 1.9) 
rs2239707 1.0 (0.6, 1.5) 1.4 (0.8, 2.4) 
rs2230365 1.0 (0.6, 1.5) 1.5 (0.8, 3.0) 
rs3130062 1.2 (0.7, 2.1) 1.7 (0.5, 5.4) 
rs4947324 0.6 (0.3, 1.1) 0.9 (0.5, 1.7) 
rs2857709 1.0 (0.6, 1.6) 0.8 (0.3, 1.9) 
LTA   
rs915654 1.0 (0.6, 1.5) 1.7 (0.9, 3.1) 
rs909253b 1.5 (1.1, 2.0) 1.0 (0.7, 1.4) 
rs2229094 0.6 (0.4, 1.0) 1.3 (0.8, 2.1) 
rs1041981b 1.4 (1.0, 2.0) 1.0 (0.7, 1.5) 
Intergenic   
rs1799964 0.7 (0.4, 1.1) 1.0 (0.6, 1.8) 
rs1800630 0.8 (0.5, 1.2) 1.4 (0.8, 2.4) 
TNF   
rs1800629 1.8 (1.1, 2.7) 0.6 (0.3, 1.2) 
rs7769073 0.8 (0.4, 1.8) 0.9 (0.4, 1.7) 
TBKBP1   
rs2013383 0.6 (0.4, 0.9) 1.1 (0.7, 1.8) 
rs1808192 0.6 (0.4, 0.9) 1.0 (0.6, 1.6) 
TBX21   
rs4461115 1.2 (0.8, 1.9) 0.8 (0.3, 2.0) 
rs16946264 1.1 (0.6, 1.8) 1.0 (0.6, 1.6) 
rs11079788 0.8 (0.5, 1.3) 1.2 (0.7, 1.9) 
rs16946878 1.3 (0.7, 2.4) 1.0 (0.5, 1.9) 
rs16947078 0.8 (0.5, 1.3) 0.8 (0.5, 1.3) 
a Genetic ancestry determined from 148 AIMS and STRUCTURE 
b Additive model presented 
  
 168 
Figure 4.5 Linkage disequilibrium (r2) in IL6 stratified by genetic ancestry 
European American           African American 
 
r2 is the amount of correlation between two SNPs with empty black cells representing 100% 
correlation and lighter cells representing less correlation. 
*SNPs are mentioned in results section. 
Approximate SNP location (vertical bars) and IL6 location (grey bar) noted along genome. 
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Figure 4.6 Linkage disequilibrium (r2) in KLRD1 stratified by genetic ancestry 
European American     African American 
 
r2 is the amount of correlation between two SNPs with empty black cells representing 100% 
correlation and lighter cells representing less correlation. 
*SNPs are mentioned in results section. 
Approximate SNP location (vertical bars) and KLRD1 location (grey bar) noted along genome. 
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Figure 4.7 Linkage disequilibrium (r2) among European Americans in LTA, TNF and TBX21 
LTA and TNF      TBX21 
 
r2 is the amount of correlation between two SNPs with empty black cells representing 100% 
correlation and lighter cells representing less correlation. 
*SNPs are mentioned in results section. 
Approximate SNP location (vertical bars) and gene location (grey bar) noted along genome. 
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Additional results 
Results for cell cycle SNPs and the outcome of preterm birth and spontaneous preterm 
birth were null and were not reported in Paper #1. The full results for these SNPs can be found 
in Table S20.
  
 
CHAPTER 5 DISCUSSION 
Summary of results 
 
This was an ambitious project that considered 40 genes and three distinct yet related 
reproductive outcomes. At the core, the specific aims were to evaluate the associations 
between inflammatory and cell cycle genes and the outcomes of Preterm Birth, Poor Fetal 
Growth, Gestational Hypertension and Preeclampsia. 
Cell cycle genes were identified as candidates given the rapid placental and fetal growth 
that occurs during pregnancy and the observed association between these genes and the 
related outcomes of cardiovascular disease and metabolic syndrome. No gene level associations 
were seen for any of the cell cycle genes and any of the outcomes. Single SNP results were 
intriguing for CDKN2A/2B with a few SNPs showing strong associations with preterm and 
preeclampsia for European American women. A number of SNPs in CNNM2 showed strong 
associations with all outcomes for both European and African Americans. Although follow-up on 
CDKN2A/2B and CNNM2 may be warranted in larger populations, cell cycle genes as a whole 
show little promise as causative genes.
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There were more interesting results in the inflammatory genes. For preterm and spontaneous 
preterm, genes involved in natural killer cell function (IL12A, CSF2, KIR3DL2 and IFNGR2) and the Th2 
cytokines IL13 and IL4 showed associations with preterm birth. Although gene level associations were 
seen for European American women only, single SNP associations revealed similar, if less precise, 
associations for African Americans for IL12A and CSF2. The genes identified with preterm birth highlight 
the important role of NK cells during pregnancy and warrant further investigation. In addition, tagSNPs 
for IL13, IL4 and CSF2 were closely associated with long range regulatory regions on chromosome 5. 
These regulatory regions have the potential to influence additional cytokines (IL3 and IL5) and should be 
further investigated with fine mapping. 
For SGA, gene level associations were seen only for term SGA among African Americans for IL6 and 
KLRD1. Single SNP results suggest a similar but weaker association for IL6 and Term SGA among 
European Americans as well. IL6 may be involved in early placentation and is known to decrease in 
concentration over the course of normal pregnancy. Its role in poor fetal growth appears to be 
independent of a pathway through prematurity and may involve poor placental development. KLRD1 
has not been explored before with SGA and showed essentially null results for European Americans. 
KLRD1 is involved in the mitigation of maternal rejection of fetal trophoblasts during early gestation and 
may influence fetal growth through inadequate placental invasion or function. 
Results for hypertensive disorders of pregnancy were isolated to the most refined phenotype of 
preeclampsia without evidence of chronic hypertension. The inflammatory cytokines LTA and TNF were 
associated with preeclampsia for European American women only. These cytokines play multiple roles in 
early placentation and in maternal response to hypoxia. In addition tagSNPs meant to capture variation 
in TBX21 instead identified an association with TBKBP1, a gene involved in TNF signaling and interferon 
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production. TNF, LTA and TBKBP1 warrant further investigation with careful attention to both genetic 
ancestry and phenotype definition.  
We found associations in genes (TNF, IL13, IL6) that had previous null findings for these same 
outcomes. While this may point to spurious findings, it may also be a result of the methods used in this 
analysis. By focusing on the gene-level in a stratified analysis, we were able to assess related SNPs across 
the length of the gene with both risk and protective associations contributing to the overall association 
of the gene. In the single SNP analysis, the use of log-linear risk models protected us from 
overestimating the association for the more common outcomes (Preterm birth and Gestational 
Hypertension both exceeded 10% in the underlying cohort). Use of inverse probability weighting 
allowed the use of the entire genotyped cohort, while use of the more conservative robust variance 
estimator mitigates over interpretation of the results. In comparison to other studies, we also used 
more tagSNPs for many of the genes capturing more of the genetic variation present in each gene.  
Heterogeneity by genetic ancestry 
One of the more intriguing results was the heterogeneity of results between ancestry groups. Our 
lower power among African Americans could explain some of the observed differences. In fact, the 
similarity of single SNP associations for IL12A and CSF2 support the hypothesis that low power was a 
factor in not identifying an association between these genes and preterm birth in African Americans. 
However the same argument cannot be made for gene-level associations with term SGA among African 
Americans, particularly for KLRD1. We had more power to detect an association among European 
Americans and yet the single SNP results were null. Although differences in the genetic structure of 
KLRD1 and its biologic interaction with HLA-E may explain the differences between African and 
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European Americans for this gene, growing evidence suggests that there are true differences in the 
genetic and biological pathways leading to these reproductive outcomes. 
Previous work by Menon and Velez has suggested that not only do the pathways responsible for 
preterm birth differ between US Whites and African Americans, but that the actual function and 
response of critical cytokines (TNF and its receptors) may vary by self-reported race.97 This biological 
diversity based on race leads to two important questions; 1. Is it credible that genetically based causal 
pathways vary by race? 2. What are the implications for future genetic and general epidemiologic 
studies of these outcomes?  
It is generally accepted that allele frequencies vary by genetic ancestry due to differences in the 
underlying genetic structure based on human migration patterns, genetic recombination and population 
admixture. These differences are generally thought to impact studies through population stratification 
(confounding) and the possibility that linkage between tagSNPs and causal SNP may differ in populations 
with different genetic ancestry. The results of this and other studies of reproductive outcomes however, 
suggest that not only is the genetic structure different, but that the biologic pathways that result in 
these reproductive outcomes may vary by genetic ancestry.   
Are reproductive outcomes so different from other outcomes that evolutionary pressure has 
resulted in different causative genes based on genetic ancestry? Reproductive outcomes differ from 
diseases with later onset in two important ways. There is strong selective pressure on genetic variants 
that favor conception and fetal survival regardless of potential negative side effects of these variants 
that emerge past reproductive age.  Additionally, selection acts on both the fetus and the mother, 
although their interests may not always be congruent. From an evolutionary perspective, an individual’s 
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goal is to reproduce and to have their biological progeny reproduce. The optimal result, for both mother 
and fetus, is a live born infant with a mother that survives delivery. In an evolutionary context a small, 
but live born, infant is a good outcome whereas a large infant that results in an obstructed labor and 
maternal death is a very bad outcome. Maternal and fetal death is a genetic dead end. A small infant 
with a living mother allows for future pregnancies and, despite increased perinatal mortality and 
morbidity, the infant’s genes have the potential to continue. The reproductive outcomes investigated 
here all result in smaller infants, and as such may have been the result of selective pressures acting on 
fetal growth to enhance infant and maternal survival. 
Maternal and fetal interests (from an evolutionary perspective) may not always be congruent 
during pregnancy, and this results in a maternal-fetal conflict.233  The mother balances her expenditures 
for the current pregnancy with her need to have sufficient reserve for potential future pregnancies. The 
fetus however is concerned primarily with being born alive. Under this hypothesis of maternal-fetal 
conflict, both mother and fetus must have a biological “escape hatch” that allows the pregnancy to 
respond to varying exposures during gestation that may make continuation of the pregnancy less 
desirable for the fetus or the mother. How the mother and fetus respond to environmental exposures 
will vary based on the timing of the exposure during gestation, the severity of the exposure and the type 
of exposure. Early miscarriage, poor fetal growth and preterm birth are all examples of an “escape 
hatch” outcome where there is early pregnancy termination or a reduced investment in the pregnancy. 
If both maternal and fetal pathways exist to influence the success and timing of delivery, why 
would these vary by genetic ancestry? These pathways evolved in response to specific environmental 
and pathogenic conditions that vary by geographic region. Malaria provides an example of a 
geographically isolated selective pressure that influences selection of specific polymorphisms. Maternal 
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malaria can have devastating results for both the fetus and the mother.234, 246  A study in Tanzania 
showed that during the rainy season when malaria was most prevalent, infants were more likely to be 
born with a specific FLT1 haplotype. In a non-malaria pregnancy the FLT1 haplotype is associated with 
fetal growth and maternal polymorphisms in FLT1 are associated with preeclampsia. Taken to the scale 
of the entire human population over the length of human evolution, specific geographic exposures 
(infection, nutritional, climactic) may have influenced the specific genetic variants that allow mothers 
and fetuses to negotiate the maternal-fetal conflict. While malaria exposure in specific regions of African 
may have promoted pathways which function through angiogenesis, exposures in other regions may 
have promoted immunologic or coagulation pathways.   
The hypothesis that different biological pathways are acting during pregnancy can also be explored 
by examining differences in gene expression during pregnancy and in response to infection. Menon113 
examined cytokine levels and the response of TNF and its receptors in the amniotic fluid of African 
American and White women at the time of delivery. In addition to finding an excess of minor allele 
frequency differences, Menon also found that regulation of TNF-α levels varied by self-reported race and 
that cytokine response to signs of intrauterine infection also varied by race. Although the selective 
pressure that acted to influence the allelic frequency of variants in these genes cannot be discerned, 
there do seem to be important differences in the regulation and response of this important cytokine 
during pregnancy based on self-reported race. 
While this study does not provide conclusive evidence that that the pathways underlying these 
reproductive outcomes vary by race, it does provide support to this hypothesis. If there are differences 
in the genetic underpinnings and biological pathways of reproductive outcomes based on genetic 
ancestry, what are the implications for the study of these outcomes? The conclusion should not be that 
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since these outcomes are genetically influenced that there is no way of modifying the outcome. The 
conclusion also should not be that observed disparities are based in biology and therefore should be 
accepted as inevitable. Although the exposures which gave rise to the underlying pathways may no 
longer be relevant-- malaria is no longer a threat to African Americans in the United States-- the 
underlying biologic pathways are still responsive to contemporary exposures. The underlying pathways 
evolved in response to environmental and pathogenic exposures and it is through identification and 
control of these exposures that we will be able to reduce the prevalence of these outcomes. 
If the underlying pathways are in fact different, this has important implications for how we study 
these outcomes. Instead of treating race as a confounder, studies should be stratified and exposure-
outcome relationships should be examined within the specific population of interest. Genetic 
associations with preterm birth from a Chilean population may not be relevant to a Polish population. 
Given the importance of interactions with exposures, there must also be increased attention to gene by 
environment interactions with studies that have adequate power and exposure assessment to consider 
interactions. 
This study did not have the power to explore interactions between women with specific genetic 
susceptibility and measured exposures. However, interactions which would be relevant in this 
evolutionary context would include exposures which could be interpreted by the body as a threat to 
mother or child. These exposures would include infections (especially ones such as influenza which 
historically have a high mortality rate), malnutrition or an abrupt decline in nutrition or extreme 
psychosocial stress. Additionally, exposures which vary by self-reported race could have potential 
interactions including poor air quality, chronic stress from poverty and racism, poor nutritional quality, 
and toxic exposures related to urban environments or poor housing.   
 179 
In non-genetic studies the possibility of differing biology would also translate into studies stratified 
by self-reported race so that exposures that are only relevant in a subset of susceptible individuals can 
be identified. While stratified studies will require increased enrollment of the populations of interest, 
and will therefore require additional funding, we will miss the opportunity to identify important 
exposures if all mothers are assumed to be equally susceptible to every exposure. Preterm birth and 
preeclampsia are important outcomes, and while we have improved our ability to treat women and 
infants, we have failed to identify successful interventions to reduce the initial incidence of these 
outcomes. A study of the scale of the National Children’s Study would provide a wonderful opportunity 
to study these outcomes in adequately sized populations. The threated long term viability of the 
National Children’s Study is a great loss. More studies in US populations need to be designed with the 
scale to address these issues. 
Future approaches 
To date there have been a number of candidate gene studies for these outcomes, although 
replication and consistent findings have been elusive. Despite evidence of a genetic component for all of 
these outcomes, candidate gene studies on their own do not appear to be providing the answers. 
Further attention to stratification by ancestry, larger case groups, and the exploration of gene by 
environment interactions may provide more insight in future candidate gene studies. However more 
advanced methodological approaches are also worth pursuing. 
Given the complexity of the underlying pathways, GWAS may reveal associations beyond the usual 
suspects of candidate genes. Findings in this study of associations in intergenic regions, which may 
correspond to regulatory regions, argue for GWAS studies that focus on the entire genome and not 
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panels restricted to exonic regions. GWAS studies however will require even larger case groups to have 
adequate power. Additionally, due to underlying differences in both genetic architecture and biologic 
pathways, GWAS panels should be designed to specifically capture the diversity of the genome in US 
African Americans. GWAS studies should specifically enroll sufficient African American cases to assess 
associations in this population. 
Epigenetic associations may also be important consideration in these outcomes. The activation of 
specific pathways that allow for maternal and fetal adaptation throughout the course of gestation may 
function through epigenetic changes. Differential methylation of the fetal genome at the time of 
implantation and over the course of early embryonic life may be a critical window when environmental 
exposures act to enhance or silence specific biologic functions. Epigenetic studies of these outcomes are 
more difficult due to the need for larger case groups, access to both maternal and fetal genetic material 
and the question of tissue specific methylation. 
Mitochondria are also a potential source of genetic variation that maybe implicated in these 
outcomes. Mitochondria are only present in the maternal ovum and are inherited exclusively through 
the maternal line. A population based study13 showed an increased risk of preterm birth among 
maternal but not paternal half-sisters, suggesting that mitochondrial genes may be involved. Given the 
diversity of mitochondria within cells and the differences in mitochondrial genetics between target 
tissues, studies of mitochondrial genetics and reproductive outcomes may be limited by difficulty 
ascertaining and obtaining the target tissue (placenta, placental bed, fetal blood, amniotic fluid). 
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Public Health Implications 
While research into preterm birth and preeclampsia in particular has been active for decades, our 
understanding of the underlying biological pathways remains limited. Although we have improved our 
ability to delay some preterm deliveries and care for infants born preterm, small or after a pregnancy 
complicated by preeclampsia, we have relatively few clinical interventions to accurately predict risk or 
prevent these outcomes. One of the hurdles to identification of effective interventions, or preventive 
strategies, is the heterogeneous phenotype captured by our relatively crude clinical definitions of these 
outcomes. Heterogeneous phenotypes may represent multiple causal pathways which cannot be 
discerned when considered as a group. We are further limited in our ability to identify modifiable risk 
factors when susceptibility to specific exposures varies among specific target populations. 
Genetic studies such as this help clarify phenotype and provide additional information to identify 
susceptible populations. Despite smaller case groups, gene level associations were found for the more 
distinct phenotypes of Term SGA and Preeclampsia suggesting that these outcomes are distinct from the 
more general SGA or Gestational Hypertension. On the other hand, spontaneous preterm birth did not 
improve the detection of associations, suggesting that either this outcome remains heterogeneous or 
that phenotypic distinction based on precipitating cause may be less etiologically important in preterm 
birth outcomes. 
The identified genes provide novel targets for further mapping, in vitro and in vivo investigation. 
Mapping of the regulatory regions identified for IL13 and IL4 as well as CSF2 and IL3 may provide insight 
into ways in which these cytokines become dysregulated during pregnancy. In vitro work with placental 
tissue and maternal serum could elucidate the role of these cytokines over the course of pregnancy, 
during placental implantation and in response to infectious exposures. Measurement of these cytokines 
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throughout pregnancy is needed to understand the changing concentrations, both absolute and relative 
to other cytokines, over the duration of both complicated and uncomplicated pregnancies. Further 
understanding of these genes will possibly identify measurable gene products which can predict risk or 
identify susceptible subpopulations. 
The differences in gene-level associations by genetic ancestry provides additional insight into the 
identification of susceptible populations. Racial disparity in preterm birth undoubtedly reflects different 
exposure distributions in US populations as defined by race. However differences in the underlying 
biological pathways suggest that the search for relevant exposures should be explored within studies 
stratified by race.  
In summary this work provides insight into both phenotype and susceptibility. This knowledge will 
inform future studies and enhance our ability to find the modifiable risk factors which will allow us to 
decrease the prevalence of these important outcomes. 
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APPENDIX: SUPPLEMENTAL TABLES 
Table S1: Placental Pathology in PIN 3 
 Entire Cohort N=2006 Eligible N=784 Genotyped N =493 
Pathology All Non-case All Non-case All Non-Case 
Fetal Vascular  1269 779 607 365 440 218 
Absent 593 (46.7) 379 (48.7) 286 (47.1) 181 (49.6) 208 (47.3) 112 (51.4) 
Mild 352 (27.7) 216 (27.7) 168 (27.7) 103 (28.2) 113 (25.7) 55 (25.2) 
Mild/Mod 255 (20.1) 155 (19.9) 121 (19.9) 71 (19.5) 92 (20.9) 44 (20.2) 
Mod/Severe 65 (5.1) 27 (3.5) 29 (4.8) 9 (2.5) 25 (5.7) 7 (3.2) 
Severe 4 (0.3) 2 (0.3) 3 (0.5) 1 (0.3) 2 (0.5) 0 
Maternal Vascular  1269 779 607 365 440 218 
Absent 212 (16.7) 128 (16.4) 100 (16.5) 57 (15.6) 76 (17.3) 35 (16.1) 
Mild 683 (53.8) 450 (57.8) 330 (54.4) 219 (60.0) 221 (50.2) 119 (54.6) 
Mild/Mod 307 (24.2) 176 (22.6) 140 (23.1) 75 (20.5) 113 (25.7) 55 (25.2) 
Mod/Severe 66 (5.2) 25 (3.2) 37 (6.1) 14 (3.8) 30 (6.8) 9 (4.1) 
Severe 1 (0.1) 0 0 0 0 0 
Fetal Acute Inflamm  1269 779 607 365 440 218 
0 1124 (88.6) 683 (87.7) 540 (89.0) 321 (87.9) 388 (88.2) 188 (86.2) 
1 53 (4.2) 41 (5.3) 20 (3.3) 16 (4.4) 15 (3.4) 11 (5.0) 
2 54 (4.3) 33 (4.2) 27 (4.4) 17 (4.7) 20 (4.5) 11 (5.0) 
3 35 (2.8) 21 (2.7) 18 (3.0) 10 (2.7) 15 (3.4) 7 (3.2) 
4 3 (0.2) 1 (0.1) 2 (0.3%) 1 (0.3) 2 (0.5) 1 (0.5) 
Mat Acute Inflamm  1269 779 607 365 440 218 
0 965 (76.0) 576 (73.9) 451 (74.3) 264 (72.3) 320 (72.7) 153 (70.2) 
1 223 (17.6) 152 (19.5) 120 (19.8) 79 (21.6) 89 (20.2) 48 (22.0) 
2 59 (4.6) 39 (5.0) 23 (3.8) 15 (4.1) 19 (4.3) 11 (5.0) 
3 19 (1.5) 12 (1.5) 13 (2.1) 7 (1.9) 12 (2.7) 6 (2.8) 
4 3 (0.2) 0 0 0 0 0 
Chronic Inflamm  1272 781 609 367 440 218 
No 1037 (81.5) 636 (81.4) 504 (82.8) 307 (83.7) 366 (83.2) 186 (85.3) 
Yes 235 (18.5) 145 (18.6) 105 (17.2) 60 (16.3) 74 (16.8) 32 (14.7) 
*Cases were also drawn from additional sources and were not required to have a placenta. 
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Table S2 RS number and minor allele frequency for SNPs in Inflammatory Genes 
RS # Gene Name MAF* CEU MAF* YRI Location  RS # Gene Name MAF* CEU MAF* YRI Location 
rs2069626 CSF2 0.02 0.13 intron  rs12412241 GATA3 0.33 0.26 flanking 3UTR 
rs25879 CSF2 0.21 0.31 flanking 5UTR  rs1244186 GATA3 0.25 0.22 3UTR 
rs25881 CSF2 0.16 0.25 intron  rs1269486 GATA3 0.28 0.19 flanking 5UTR 
rs25882 CSF2 0.19 0.41 coding  rs1399180 GATA3 0.18 0.40 intron 
rs25887 CSF2 0.39 0.46 flanking 3UTR  rs1778058 GATA3 0.42 0.38 flanking 3UTR 
rs27438 CSF2 0.21 0.38 flanking 3UTR  rs1877739 GATA3 0.23 0.18 flanking 3UTR 
rs31474 CSF2 0.20 0.43 flanking 5UTR  rs2275806 GATA3 0.37 0.12 5UTR 
rs4705916 CSF2 0.38 0.19 flanking 5UTR  rs2280015 GATA3 0.21 0.17 intron 
rs6898270 CSF2 0.43 0.16 flanking 3UTR  rs263419 GATA3 0.17 0.41 flanking 3UTR 
rs721121 CSF2 0.47 0.26 flanking 5UTR  rs263423 GATA3 0.23 0.45 flanking 3UTR 
rs743564 CSF2 0.43 0.25 intron  rs263425 GATA3 0.00 0.25 flanking 3UTR 
rs743677 CSF2 0.00 0.32 intron  rs369421 GATA3 0.18 0.14 intron 
rs10031051 CXCL10 0.02 0.10 3UTR  rs376397 GATA3 0.32 0.26 intron 
rs10518143 CXCL10 0.20 0.10 flanking 5UTR  rs3781093 GATA3 0.10 0.18 intron 
rs12504339 CXCL10 0.25 0.47 flanking 5UTR  rs3781094 GATA3 0.33 0.19 intron 
rs12651276 CXCL10 0.17 0.03 flanking 5UTR  rs379568 GATA3 0.09 0.38 flanking 3UTR 
rs3733236 CXCL10 0.13 0.26 3UTR  rs388957 GATA3 0.02 0.29 intron 
rs4508917 CXCL10 0.23 0.21 flanking 5UTR  rs406103 GATA3 0.23 0.28 intron 
rs7670156 CXCL10 0.12 0.47 flanking 5UTR  rs406571 GATA3 0.28 0.43 flanking 3UTR 
rs867562 CXCL10 0.16 0.03 flanking 5UTR  rs422628 GATA3 0.21 0.22 intron 
rs4302486 CXCL10 0.50 0.39 flanking 3UTR  rs434645 GATA3 0.12 0.18 flanking 3UTR 
rs1058240 GATA3 0.17 0.37 3UTR  rs444929 GATA3 0.20 0.21 intron 
rs10752126 GATA3 0.39 0.32 intron  rs477461 GATA3 0.15 0.33 flanking 3UTR 
rs10795588 GATA3 0.48 0.17 flanking 3UTR  rs528778 GATA3 0.19 0.19 intron 
rs10905284 GATA3 0.42 0.09 intron  rs532854 GATA3 0.28 0.38 flanking 3UTR 
rs11255509 GATA3 0.00 0.06 3UTR  rs556960 GATA3 0.26 0.13 intron 
rs11567934 GATA3 0.00 0.18 intron  rs569421 GATA3 0.19 0.48 intron 
rs12262237 GATA3 0.00 0.11 flanking 3UTR  rs570613 GATA3 0.35 0.43 intron 
rs578268 GATA3 0.47 0.47 flanking 3UTR  rs10494879 IL10 0.46 0.28 flanking 5UTR 
  
1
8
5
 
RS # Gene Name MAF* CEU MAF* YRI Location  RS # Gene Name MAF* CEU MAF* YRI Location 
rs7100967 GATA3 0.00 0.13 flanking 3UTR  rs11119449 IL10 0.35 0.42 flanking 3UTR 
rs10878760 IFNG 0.15 0.00 intron  rs11119451 IL10 0.34 0.25 flanking 3UTR 
rs11177074 IFNG 0.03 0.18 flanking 3UTR  rs13376708 IL10 0.12 0.33 flanking 3UTR 
rs12306852 IFNG 0.20 0.48 flanking 5UTR  rs17015767 IL10 0.21 0.09 flanking 5UTR 
rs17104856 IFNG 0.00 0.04 intron  rs1800871 IL10 0.17 0.46 flanking 5UTR 
rs1861494 IFNG 0.32 0.21 intron  rs1800872 IL10 0.20 0.48 flanking 5UTR 
rs2041864 IFNG 0.39 0.32 flanking 3UTR  rs1800890 IL10 0.38 0.20 flanking 5UTR 
rs2069727 IFNG 0.42 0.13 flanking 3UTR  rs1878672 IL10 0.48 0.27 intron 
rs2193047 IFNG 0.38 0.48 3UTR  rs3024490 IL10 0.22 0.48 intron 
rs2216163 IFNG 0.32 0.08 intron  rs3024491 IL10 0.39 0.27 intron 
rs3181032 IFNG 0.00 0.18 flanking 5UTR  rs3024493 IL10 0.17 0.02 intron 
rs3181035 IFNG 0.04 0.28 flanking 3UTR  rs3024496 IL10 0.48 0.37 3UTR 
rs6581794 IFNG 0.32 0.14 flanking 3UTR  rs4390174 IL10 0.32 0.29 flanking 3UTR 
rs7302488 IFNG 0.32 0.13 flanking 5UTR  rs6658896 IL10 0.02 0.18 flanking 3UTR 
rs11702844 IFNGR2 0.12 0.00 flanking 5UTR  rs6673928 IL10 0.27 0.12 flanking 3UTR 
rs16990664 IFNGR2 0.06 0.33 flanking 5UTR  rs6686931 IL10 0.18 0.39 flanking 5UTR 
rs2012075 IFNGR2 0.08 0.09 intron  rs6692511 IL10 0.34 0.26 flanking 3UTR 
rs2268241 IFNGR2 0.19 0.42 intron  rs6699203 IL10 0.33 0.25 flanking 3UTR 
rs2284556 IFNGR2 0.48 0.19 intron  rs7539748 IL10 0.26 0.00 flanking 3UTR 
rs2834210 IFNGR2 0.48 0.28 intron  rs7548373 IL10 0.07 0.25 flanking 3UTR 
rs2834212 IFNGR2 0.13 0.00 intron  rs1014486 IL12A 0.30 0.26 flanking 5UTR 
rs2834213 IFNGR2 0.25 0.02 intron  rs12492730 IL12A 0.00 0.15 flanking 3UTR 
rs6517167 IFNGR2 0.16 0.28 flanking 5UTR  rs13064168 IL12A 0.09 0.08 flanking 5UTR 
rs8131980 IFNGR2 0.25 0.12 flanking 3UTR  rs16830946 IL12A 0.00 0.14 flanking 5UTR 
rs9808685 IFNGR2 0.46 0.48 intron  rs16830949 IL12A 0.00 0.16 flanking 5UTR 
rs9808753 IFNGR2 0.10 0.20 coding  rs17826053 IL12A 0.18 0.20 flanking 3UTR 
rs9976971 IFNGR2 0.41 0.05 flanking 5UTR  rs2243115 IL12A 0.08 0.07 flanking 5UTR 
rs9978223 IFNGR2 0.19 0.49 flanking 5UTR  rs2243123 IL12A 0.24 0.13 intron 
rs9980428 IFNGR2 0.17 0.24 flanking 5UTR  rs2243131 IL12A 0.19 0.17 intron 
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RS # Gene Name MAF* CEU MAF* YRI Location  RS # Gene Name MAF* CEU MAF* YRI Location 
rs2243151 IL12A 0.33 0.36 flanking 3UTR  rs2546890 IL12B 0.47 0.29 flanking 5UTR 
rs2243154 IL12A 0.13 0.00 flanking 3UTR  rs2546893 IL12B 0.48 0.24 intron 
rs2647929 IL12A 0.49 0.20 flanking 5UTR  rs2569253 IL12B 0.48 0.20 intron 
rs2886666 IL12A 0.17 0.00 flanking 5UTR  rs2853694 IL12B 0.46 0.27 intron 
rs4608735 IL12A 0.07 0.12 flanking 3UTR  rs3212220 IL12B 0.23 0.43 intron 
rs4680536 IL12A 0.42 0.28 flanking 3UTR  rs3212227 IL12B 0.23 0.30 3UTR 
rs479952 IL12A 0.47 0.40 flanking 5UTR  rs4921466 IL12B 0.06 0.11 flanking 3UTR 
rs485497 IL12A 0.46 0.15 flanking 3UTR  rs6868898 IL12B 0.34 0.16 flanking 5UTR 
rs503582 IL12A 0.48 0.46 flanking 5UTR  rs7709212 IL12B 0.37 0.24 flanking 5UTR 
rs532953 IL12A 0.18 0.12 flanking 5UTR  rs7730126 IL12B 0.23 0.18 flanking 3UTR 
rs583911 IL12A 0.48 0.10 intron  rs919766 IL12B 0.08 0.33 intron 
rs598638 IL12A 0.22 0.00 flanking 3UTR  rs3091307 IL13 0.22 0.25 flanking 5UTR 
rs609907 IL12A 0.27 0.13 flanking 5UTR  rs4621555 IL13 0.00 0.15 flanking 3UTR 
rs6441282 IL12A 0.43 0.38 flanking 5UTR  rs7737470 IL13 0.22 0.26 intron 
rs692890 IL12A 0.35 0.38 flanking 5UTR  rs1295683 IL13; IL4 0.10 0.08 flanking 3UTR 
rs7372767 IL12A 0.49 0.21 flanking 5UTR  rs1295686 IL13; IL4 0.23 0.28 intron 
rs755004 IL12A 0.15 0.01 flanking 5UTR  rs1881457 IL13;IL4 0.16 0.30 flanking 5UTR 
rs7653097 IL12A 0.05 0.12 flanking 5UTR  rs20541 IL13;IL4 0.23 0.17 coding 
rs9811792 IL12A 0.48 0.30 flanking 5UTR  rs2069744 IL13;IL4 0.00 0.31 intron 
rs9852519 IL12A 0.36 0.21 flanking 3UTR  rs2243204 IL13;IL4 0.12 0.28 flanking 3UTR 
rs10052709 IL12B 0.11 0.20 flanking 5UTR  rs2243210 IL13;IL4 0.10 0.16 flanking 3UTR 
rs10072923 IL12B 0.23 0.34 flanking 3UTR  rs2243218 IL13;IL4 0.08 0.33 flanking 3UTR 
rs11574790 IL12B 0.08 0.28 intron  rs2243219 IL13;IL4 0.09 0.32 flanking 3UTR 
rs1368439 IL12B 0.22 0.03 3UTR  rs848 IL13;IL4 0.24 0.41 3UTR 
rs1433048 IL12B 0.18 0.00 intron  rs10519610 IL15 0.21 0.33 intron 
rs1549922 IL12B 0.46 0.37 flanking 3UTR  rs10833 IL15 0.40 0.09 3UTR 
rs2099327 IL12B 0.23 0.07 flanking 3UTR  rs12498901 IL15 0.20 0.10 intron 
rs2195940 IL12B 0.08 0.21 intron  rs12508866 IL15 0.27 0.03 intron 
rs12508955 IL15 0.28 0.17 intron  rs5744223 IL18 0.00 0.18 flanking 5UTR 
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RS # Gene Name MAF* CEU MAF* YRI Location  RS # Gene Name MAF* CEU MAF* YRI Location 
rs13117878 IL15 0.43 0.49 intron  rs5744238 IL18 0.00 0.13 intron 
rs1519551 IL15 0.48 0.47 intron  rs5744280 IL18 0.41 0.35 intron 
rs1519552 IL15 0.29 0.36 intron  rs578784 IL18 0.00 0.27 flanking 3UTR 
rs1589241 IL15 0.30 0.13 intron  rs17561 IL1A 0.31 0.13 coding 
rs17007476 IL15 0.00 0.18 intron  rs1800587 IL1A 0.31 0.44 5UTR 
rs17007480 IL15 0.00 0.10 intron  rs1143627 IL1B 0.37 0.36 flanking 5UTR 
rs17007503 IL15 0.00 0.14 intron  rs1143634 IL1B 0.29 0.11 coding 
rs17007508 IL15 0.00 0.20 intron  rs16944 IL1B 0.35 0.43 flanking 5UTR 
rs17007610 IL15 0.42 0.42 intron  rs10027390 IL2 0.31 0.20 flanking 3UTR 
rs17364630 IL15 0.20 0.12 intron  rs10034410 IL2 0.00 0.11 flanking 3UTR 
rs17461269 IL15 0.29 0.01 intron  rs11932411 IL2 0.00 0.42 flanking 3UTR 
rs1907949 IL15 0.09 0.14 intron  rs17454584 IL2 0.18 0.08 flanking 3UTR 
rs2087849 IL15 0.28 0.29 intron  rs2069762 IL2 0.29 0.07 flanking 5UTR 
rs2857261 IL15 0.42 0.48 intron  rs2069776 IL2 0.31 0.13 flanking 3UTR 
rs3775597 IL15 0.15 0.17 intron  rs2069778 IL2 0.19 0.00 intron 
rs6837991 IL15 0.30 0.18 intron  rs35914000 IL2 0.34 0.01 flanking 3UTR 
rs6850492 IL15 0.49 0.25 intron  rs4833248 IL2 0.11 0.00 flanking 5UTR 
rs7671458 IL15 0.21 0.23 intron  rs40401 IL3 0.21 0.30 coding 
rs7698675 IL15 0.28 0.23 intron  rs11575022 IL3/CSF2 0.10 0.20 flanking 3UTR 
rs11214098 IL18 0.00 0.14 flanking 3UTR  rs168681 IL3; CSF2 0.36 0.23 flanking 3UTR 
rs11214105 IL18 0.21 0.19 flanking 5UTR  rs2069801 IL3; CSF2 0.00 0.12 flanking 3UTR 
rs1946518 IL18 0.35 0.34 flanking 5UTR  rs246841 IL3; CSF2 0.10 0.01 flanking 3UTR 
rs2043055 IL18 0.44 0.50 intron  rs246844 IL3; CSF2 0.17 0.24 flanking 3UTR 
rs360714 IL18 0.02 0.10 intron  rs3091335 IL3; CSF2 0.00 0.42 flanking 5UTR 
rs4937075 IL18 0.25 0.27 flanking 3UTR  rs31400 IL3; CSF2 0.37 0.46 flanking 5UTR 
rs543810 IL18 0.11 0.25 flanking 3UTR  rs31481 IL3; CSF2 0.18 0.20 intron 
rs5744222 IL18 0.22 0.00 flanking 5UTR  rs2069842 IL6 0.00 0.04 intron 
rs11242122 IL4 0.26 0.33 flanking 3UTR  rs2069843 IL6 0.02 0.18 intron 
rs11242123 IL4 0.16 0.49 flanking 3UTR  rs2069845 IL6 0.46 0.30 intron 
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RS # Gene Name MAF* CEU MAF* YRI Location  RS # Gene Name MAF* CEU MAF* YRI Location 
rs2243240 IL4 0.01 0.13 flanking 5UTR  rs2069849 IL6 0.06 0.20 coding 
rs2243246 IL4 0.00 0.28 flanking 5UTR  rs3087221 IL6 0.01 0.21 flanking 5UTR 
rs2243248 IL4 0.09 0.12 flanking 5UTR  rs4719711 IL6 0.43 0.16 flanking 5UTR 
rs2243250 IL4 0.10 0.29 flanking 5UTR  rs6949149 IL6 0.05 0.13 flanking 5UTR 
rs2243253 IL4 0.00 0.19 intron  rs6954681 IL6 0.12 0.40 flanking 5UTR 
rs2243261 IL4 0.00 0.28 intron  rs6954897 IL6 0.31 0.19 flanking 5UTR 
rs2243263 IL4 0.11 0.14 intron  rs6963444 IL6 0.02 0.22 flanking 5UTR 
rs2243267 IL4 0.17 0.38 intron  rs6969927 IL6 0.20 0.18 flanking 5UTR 
rs2243270 IL4 0.17 0.23 intron  rs7776857 IL6 0.43 0.00 flanking 5UTR 
rs2243283 IL4 0.00 0.15 intron  rs7784987 IL6 0.02 0.15 flanking 5UTR 
rs2243292 IL4 0.00 0.12 flanking 3UTR  rs7805828 IL6 0.38 0.36 flanking 5UTR 
rs9282745 IL4 0.00 0.11 intron  rs11265607 IL6R 0.28 0.29 flanking 5UTR 
rs10156056 IL6 0.07 0.29 flanking 5UTR  rs11265608 IL6R 0.12 0.09 flanking 5UTR 
rs10242595 IL6 0.24 0.49 flanking 3UTR  rs11265610 IL6R 0.00 0.36 intron 
rs12700386 IL6 0.23 0.10 flanking 5UTR  rs11265618 IL6R 0.16 0.38 intron 
rs1474347 IL6 0.48 0.08 intron  rs11265621 IL6R 0.41 0.29 flanking 3UTR 
rs1546762 IL6 0.43 0.11 flanking 5UTR  rs12060250 IL6R 0.00 0.08 intron 
rs1548216 IL6 0.00 0.22 intron  rs12083537 IL6R 0.14 0.23 intron 
rs1800795 IL6 0.47 0.00 flanking 5UTR  rs12090237 IL6R 0.01 0.10 intron 
rs1800797 IL6 0.48 0.00 flanking 5UTR  rs12096944 IL6R 0.00 0.14 intron 
rs1880241 IL6 0.43 0.43 flanking 5UTR  rs1386821 IL6R 0.17 0.09 intron 
rs2056576 IL6 0.30 0.36 flanking 5UTR  rs1552481 IL6R 0.00 0.25 flanking 5UTR 
rs2069824 IL6 0.03 0.12 flanking 5UTR  rs17654071 IL6R 0.45 0.22 flanking 5UTR 
rs2069827 IL6 0.11 0.02 flanking 5UTR  rs2054855 IL6R 0.09 0.31 flanking 5UTR 
rs2069835 IL6 0.00 0.04 intron  rs2229238 IL6R 0.26 0.21 3UTR 
rs2069840 IL6 0.38 0.17 intron  rs1951240 IL8 0.40 0.48 flanking 3UTR 
rs4072391 IL6R 0.25 0.34 3UTR  rs1951242 IL8 0.40 0.16 flanking 3UTR 
rs4329505 IL6R 0.16 0.47 intron  rs4694634 IL8 0.00 0.35 flanking 5UTR 
rs4341355 IL6R 0.29 0.44 intron  rs4694635 IL8 0.00 0.19 flanking 5UTR 
  
1
8
9
 
RS # Gene Name MAF* CEU MAF* YRI Location  RS # Gene Name MAF* CEU MAF* YRI Location 
rs4537545 IL6R 0.34 0.31 intron  rs7654490 IL8 0.00 0.25 flanking 5UTR 
rs4553185 IL6R 0.49 0.49 intron  rs7658422 IL8 0.00 0.28 flanking 3UTR 
rs4601580 IL6R 0.49 0.39 intron  rs7693566 IL8 0.00 0.32 flanking 5UTR 
rs4845374 IL6R 0.16 0.31 intron  rs11676348 IL8RB 0.46 0.37 flanking 3UTR 
rs4845615 IL6R 0.00 0.16 flanking 5UTR  rs11677534 IL8RB 0.48 0.19 flanking 3UTR 
rs4845617 IL6R 0.39 0.37 5UTR  rs4674258 IL8RB 0.48 0.45 flanking 5UTR 
rs4845618 IL6R 0.49 0.43 intron  rs4674259 IL8RB 0.48 0.12 5UTR 
rs4845623 IL6R 0.35 0.43 intron  rs4674261 IL8RB 0.42 0.37 flanking 3UTR 
rs4845626 IL6R 0.16 0.45 intron  rs6761387 IL8RB 0.05 0.25 intron 
rs6427627 IL6R 0.40 0.38 flanking 5UTR  rs9797797 KIR2DL3 0.32 0.22 intron 
rs6427641 IL6R 0.40 0.27 intron  rs17771961 KIR2DL4 0.18 0.05 flanking 5UTR 
rs6684439 IL6R 0.05 0.01 intron  rs35950908 KIR2DL4 0.20 0.06 flanking 3UTR 
rs7518199 IL6R 0.35 0.10 intron  rs649216 KIR2DL4 0.48 0.21 flanking 5UTR 
rs7526293 IL6R 0.24 0.42 flanking 3UTR  rs10407958 KIR3DL2 0.18 0.20 intron 
rs7549250 IL6R 0.49 0.46 intron  rs11672983 KIR3DL2 0.41 0.14 flanking 5UTR 
rs10805066 IL8 0.33 0.40 flanking 5UTR  rs1654644 KIR3DL2 0.37 0.33 intron 
rs11729759 IL8 0.00 0.24 flanking 3UTR  rs17771967 KIR3DL2 0.41 0.35 flanking 3UTR 
rs11730667 IL8 0.39 0.20 flanking 5UTR  rs3745900 KIR3DL2 0.19 0.16 intron 
rs12506479 IL8 0.23 0.19 flanking 5UTR  rs3816051 KIR3DL2 0.46 0.30 5UTR 
rs13142454 IL8 0.00 0.16 flanking 3UTR  rs4806457 KIR3DL2 0.28 0.29 intron 
rs16849893 IL8 0.00 0.20 flanking 5UTR  rs4806585 KIR3DL2 0.16 0.12 intron 
rs16849896 IL8 0.00 0.22 flanking 5UTR  rs11671355 KIR3DL3 0.26 0.00 intron 
rs16849907 IL8 0.00 0.12 flanking 5UTR  rs11880171 KIR3DL3 0.31 0.34 intron 
rs16849928 IL8 0.40 0.42 flanking 5UTR  rs11882659 KIR3DL3 0.36 0.49 intron 
rs16849958 IL8 0.41 0.12 flanking 3UTR  rs2256974 TNF 0.15 0.41 intron 
rs11883241 KIR3DL3 0.27 0.40 flanking 3UTR  rs7769073 TNF 0.02 0.11 intron 
rs12151161 KIR3DL3 0.15 0.34 flanking 5UTR  rs1041981 LTA 0.30 0.48 coding 
rs12982080 KIR3DL3 0.36 0.28 flanking 3UTR  rs1799964 LTA;TNF 0.25 0.20 flanking 3UTR 
rs12982559 KIR3DL3 0.26 0.15 flanking 3UTR  rs1800629 LTA;TNF 0.17 0.08 flanking 5UTR 
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RS # Gene Name MAF* CEU MAF* YRI Location  RS # Gene Name MAF* CEU MAF* YRI Location 
rs1325155 KIR3DL3 0.42 0.31 flanking 5UTR  rs1800630 LTA;TNF 0.21 0.02 flanking 3UTR 
rs1325156 KIR3DL3 0.19 0.41 flanking 5UTR  rs2229094 LTA;TNF 0.26 0.29 coding 
rs1325158 KIR3DL3 0.30 0.36 flanking 3UTR  rs2230365 LTA;TNF 0.13 0.03 coding 
rs16985907 KIR3DL3 0.04 0.15 coding  rs2239707 LTA;TNF 0.37 0.11 intron 
rs2296370 KIR3DL3 0.31 0.33 flanking 3UTR  rs2516479 LTA;TNF 0.39 0.28 flanking 3UTR 
rs2296371 KIR3DL3 0.32 0.41 flanking 3UTR  rs2857605 LTA;TNF 0.28 0.08 intron 
rs270775 KIR3DL3 0.43 0.26 intron  rs2857709 LTA;TNF 0.00 0.05 flanking 3UTR 
rs4441391 KIR3DL3 0.23 0.16 flanking 5UTR  rs3130062 LTA;TNF 0.12 0.00 coding 
rs6509899 KIR3DL3 0.05 0.20 flanking 3UTR  rs4947324 LTA;TNF 0.09 0.11 flanking 3UTR 
rs7249048 KIR3DL3 0.00 0.25 UTR  rs909253 LTA;TNF 0.29 0.45 intron 
rs7249176 KIR3DL3 0.15 0.42 intron  rs915654 LTA;TNF 0.35 0.40 flanking 5UTR 
rs3809214 KLRD1/CD94 0.35 0.38 5UTR  rs10489113 NFKB1 0.23 0.48 flanking 3UTR 
rs7301562 KLRD1/CD94 0.00 0.26 Intron  rs11733293 NFKB1 0.35 0.34 flanking 3UTR 
rs10772256 KLRD1/CD94 0.00 0.25 Nonsynon  rs12648696 NFKB1 0.31 0.37 flanking 3UTR 
rs11611333 KLRD1/CD94 0.39 0.39 Intron  rs1598861 NFKB1 0.30 0.01 intron 
rs12829155 KLRD1/CD94 0.42 0.21 3UTR  rs1599961 NFKB1 0.46 0.41 intron 
rs2270238 KLRD1/CD94 0.28 0.00 Intron  rs17032705 NFKB1 0.38 0.33 intron 
rs2302489 KLRD1/CD94 0.38 0.37 5UTR  rs17032740 NFKB1 0.00 0.11 intron 
rs3759270 KLRD1/CD94 0.35 0.30 5UTR  rs17032779 NFKB1 0.02 0.16 intron 
rs7980604 KLRD1/CD94 0.00 0.25 Intron  rs10514934 TBX21 0.13 0.00 intron 
rs17032815 NFKB1 0.00 0.13 intron  rs11079788 TBX21 0.23 0.24 intron 
rs17033015 NFKB1 0.30 0.10 flanking 3UTR  rs16946264 TBX21 0.07 0.14 intron 
rs1801 NFKB1 0.40 0.25 intron  rs16946878 TBX21 0.03 0.11 intron 
rs230493 NFKB1 0.36 0.13 intron  rs16947078 TBX21 0.21 0.20 flanking 3UTR 
rs230515 NFKB1 0.38 0.06 intron  rs1808192 TBX21 0.35 0.13 flanking 3UTR 
rs230529 NFKB1 0.47 0.44 intron  rs2013383 TBX21 0.44 0.17 flanking 3UTR 
rs230530 NFKB1 0.36 0.11 intron  rs4461115 TBX21 0.29 0.02 flanking 3UTR 
rs230533 NFKB1 0.37 0.16 intron  rs4794067 TBX21 0.27 0.14 flanking 5UTR 
rs230547 NFKB1 0.06 0.14 intron  rs9910408 TBX21 0.45 0.28 flanking 5UTR 
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rs3755867 NFKB1 0.39 0.33 intron  rs1800471 TGFB1 0.11 0.10 Nonsynon 
rs3774933 NFKB1 0.46 0.30 intron  rs11466414 TGFB3 0.06 0.01 5UTR 
rs3817685 NFKB1 0.33 0.33 intron  rs4252345 TGFB3 0.00 0.02 Synonymous 
rs4648058 NFKB1 0.39 0.30 intron  rs1061622 TNFRSF1B 0.24 0.16 Nonsynon 
rs4648090 NFKB1 0.12 0.17 intron  rs1061624 TNFRSF1B 0.48 0.33 3UTR 
rs4648110 NFKB1 0.29 0.22 intron  rs1061628 TNFRSF1B 0.38 0.48 3UTR 
rs4648127 NFKB1 0.10 0.00 intron  rs1201157 TNFRSF1B 0.43 0.36 Intron 
rs4648135 NFKB1 0.08 0.18 intron  rs235214 TNFRSF1B 0.16 0.20 flanking 3UTR 
rs4648141 NFKB1 0.20 0.44 intron  rs3766730 TNFRSF1B 0.16 0.00 Intron 
rs7674640 NFKB1 0.43 0.29 flanking 3UTR  rs496888 TNFRSF1B 0.34 0.32 Intron 
rs909332 NFKB1 0.07 0.10 intron  rs5746051 TNFRSF1B 0.17 0.03 Intron 
rs9790601 NFKB1 0.37 0.21 intron  rs5746053 TNFRSF1B 0.18 0.15 Intron 
rs980455 NFKB1 0.46 0.47 flanking 5UTR  rs816050 TNFRSF1B 0.20 0.24 Intron 
* MAF Source CEU/YRI: Data from Illumina or NCBI when Illumina data was missing. Populations include: PGA University of Washington; Perlgen; 
HapMap; SNP500 Cancer 
Abbreviations: MAF minor allele frequency, CEU Northern and Western European ancestry; YRI Yoruban ancestry; UTR untranslated region. 
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Table S3 RS number and minor allele frequency for SNPs in Cell Cycle Genes 
RS # Gene Name MAF CEU MAF YRI Location  RS # Gene Name MAF CEU MAF YRI Location 
rs1507994 CCNA2 0.44 0.35 intron  rs2266690 CCNH 0.20 0.05 coding 
rs1803183 CCNA2 0.02 0.25 coding  rs10757261 CDKN2A 0.38 0.28 flanking 3UTR 
rs2071486 CCNA2 0.33 0.35 intron  rs10757262 CDKN2A 0.12 0.14 intron 
rs3217760 CCNA2 0.00 0.13 coding  rs2027938 CDKN2A 0.26 0.25 flanking 3UTR 
rs3217770 CCNA2 0.00 0.13 intron  rs2518722 CDKN2A 0.22 0.47 flanking 3UTR 
rs3217771 CCNA2 0.31 0.06 intron  rs2811708 CDKN2A 0.25 0.23 intron 
rs3217773 CCNA2 0.42 0.17 intron  rs2811720 CDKN2A 0.15 0.40 flanking 3UTR 
rs6815050 CCNA2 0.33 0.24 intron  rs3088440 CDKN2A 0.05 0.23 3UTR 
rs6825926 CCNA2 0.06 0.48 flanking 5UTR  rs3731239 CDKN2A 0.38 0.00 intron 
rs11827026 CCND1 0.05 0.34 flanking 5UTR  rs3731257 CDKN2A 0.27 0.08 flanking 3UTR 
rs1192925 CCND1 0.38 0.30 flanking 5UTR  rs4074785 CDKN2A 0.10 0.18 intron 
rs12281701 CCND1 0.00 0.28 flanking 5UTR  rs717326 CDKN2A 0.11 0.14 flanking 3UTR 
rs1352075 CCND1 0.48 0.22 intron  rs2811711 CDKN2A;CDKN2B 0.14 0.19 intron 
rs1982774 CCND1 0.39 0.16 flanking 5UTR  rs3217989 CDKN2A;CDKN2B 0.00 0.33 3UTR 
rs2450254 CCND1 0.40 0.36 flanking 5UTR  rs3217992 CDKN2A;CDKN2B 0.46 0.20 3UTR 
rs3212860 CCND1 0.00 0.18 flanking 5UTR  rs3217999 CDKN2A;CDKN2B 0.00 0.15 flanking 3UTR 
rs3212891 CCND1 0.41 0.49 intron  rs3218002 CDKN2A;CDKN2B 0.09 0.23 flanking 3UTR 
rs3212922 CCND1 0.02 0.34 intron  rs3218009 CDKN2A;CDKN2B 0.10 0.00 flanking 3UTR 
rs3862792 CCND1 0.07 0.26 coding  rs3218020 CDKN2A;CDKN2B 0.36 0.12 flanking 5UTR 
rs3918298 CCND1 0.03 0.30 intron  rs3218022 CDKN2A;CDKN2B 0.00 0.12 flanking 5UTR 
rs592483 CCND1 0.38 0.19 flanking 5UTR  rs3731191 CDKN2A;CDKN2B 0.00 0.30 intron 
rs603965 CCND1 0.48 0.16 coding  rs3731194 CDKN2A;CDKN2B 0.00 0.11 intron 
rs611003 CCND1 0.46 0.30 flanking 5UTR  rs3731204 CDKN2A;CDKN2B 0.15 0.11 intron 
rs649392 CCND1 0.38 0.35 intron  rs3731206 CDKN2A;CDKN2B 0.00 0.19 intron 
rs655089 CCND1 0.44 0.40 flanking 5UTR  rs1063192 CDKN2B 0.35 0.14 3UTR 
rs667515 CCND1 0.35 0.35 flanking 5UTR  rs11191457 CNNM2 0.22 0.08 flanking 3UTR 
rs7106515 CCND1 0.00 0.14 flanking 5UTR  rs11191512 CNNM2 0.21 0.16 intron 
rs7121246 CCND1 0.00 0.40 flanking 5UTR  rs11191527 CNNM2 0.10 0.03 intron 
rs7177 CCND1 0.43 0.15 3UTR  rs11191537 CNNM2 0.13 0.15 intron 
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RS # Gene Name MAF CEU MAF YRI Location  RS # Gene Name MAF CEU MAF YRI Location 
rs11191549 CNNM2 0.33 0.24 flanking 3UTR  rs646652 GADD45A 0.24 0.31 flanking 5UTR 
rs12264034 CNNM2 0.00 0.48 intron  rs674425 GADD45A 0.18 0.23 flanking 3UTR 
rs17787717 CNNM2 0.12 0.00 intron  rs675327 GADD45A 0.24 0.13 flanking 3UTR 
rs2296569 CNNM2 0.18 0.00 intron  rs685724 GADD45A 0.31 0.38 flanking 3UTR 
rs2297787 CNNM2 0.08 0.33 intron  rs7414246 GADD45A 0.37 0.30 flanking 3UTR 
rs4917991 CNNM2 0.22 0.23 intron  rs7546055 GADD45A 0.17 0.47 flanking 3UTR 
rs4917995 CNNM2 0.18 0.09 flanking 3UTR  rs769412 MDM2 0.06 0.13 coding 
rs6584535 CNNM2 0.22 0.00 intron  rs10505358 NOV 0.03 0.16 flanking 3UTR 
rs7087944 CNNM2 0.00 0.13 intron  rs11538929 NOV 0.12 0.02 coding 
rs7897654 CNNM2 0.28 0.20 flanking 3UTR  rs11775043 NOV 0.12 0.18 3UTR 
rs7902220 CNNM2 0.00 0.10 intron  rs13261466 NOV 0.31 0.01 flanking 5UTR 
rs7914558 CNNM2 0.42 0.28 intron  rs1381337 NOV 0.00 0.12 intron 
rs10889710 GADD45A 0.47 0.08 flanking 5UTR  rs1461693 NOV 0.15 0.38 flanking 3UTR 
rs11583718 GADD45A 0.37 0.39 flanking 3UTR  rs16892531 NOV 0.02 0.19 3UTR 
rs12405855 GADD45A 0.13 0.00 flanking 5UTR  rs16892578 NOV 0.02 0.26 flanking 3UTR 
rs12408005 GADD45A 0.50 0.07 flanking 3UTR  rs16892586 NOV 0.03 0.21 flanking 3UTR 
rs1511686 GADD45A 0.00 0.14 flanking 5UTR  rs1870779 NOV 0.04 0.35 flanking 3UTR 
rs2055904 GADD45A 0.01 0.15 flanking 5UTR  rs2071526 NOV 0.17 0.45 flanking 5UTR 
rs2815266 GADD45A 0.05 0.19 flanking 5UTR  rs7001184 NOV 0.01 0.17 flanking 3UTR 
rs344916 GADD45A 0.18 0.33 flanking 5UTR  rs7014927 NOV 0.17 0.32 intron 
rs344934 GADD45A 0.23 0.41 flanking 5UTR  rs7834596 NOV 0.13 0.33 intron 
rs3783468 GADD45A 0.42 0.13 intron  rs1989839 RASSF1 0.17 0.33 intron 
rs4655749 GADD45A 0.01 0.13 flanking 5UTR  rs2073498 RASSF1 0.16 0.00 UTR 
rs532446 GADD45A 0.30 0.38 intron  rs2073499 RASSF1 0.20 0.31 intron 
rs598602 GADD45A 0.25 0.15 flanking 3UTR  rs2236947 RASSF1 0.48 0.27 intron 
rs604043 GADD45A 0.24 0.19 flanking 5UTR  rs35455589 RASSF1 0.00 0.25 coding 
rs607375 GADD45A 0.28 0.48 flanking 3UTR  rs6446203 RASSF1 0.01 0.39 intron 
rs624790 GADD45A 0.12 0.38 flanking 5UTR  rs709210 RASSF1 0.33 0.03 coding 
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Table S4 List of PIN blinds and corresponding PIN ID 
Blind PIN ID  Blind PIN ID 
BLIND_1  10018  BLIND_41 21546 
BLIND_2  10370  BLIND_40 21384 
BLIND_3  21406  BLIND_42 21588 
BLIND_4  10025  BLIND_43 10004 
BLIND_5  10439  BLIND_44 10053 
BLIND_6  20750  BLIND_45 10082 
BLIND_7  10378  BLIND_46 10319 
BLIND_8  14359  BLIND_47 10329 
BLIND_9  14742  BLIND_48 10448 
BLIND_10 14839  BLIND_49 12445 
BLIND_11 15095  BLIND_50 12888 
BLIND_12 21009  BLIND_51 14183 
BLIND_13 10925  BLIND_52 14234 
BLIND_14 11655  BLIND_53 20589 
BLIND_15 21730  BLIND_54 21323 
BLIND_16 14386  BLIND_55 10092 
BLIND_17 20568  BLIND_56 21370 
BLIND_18 21416  BLIND_57 24269 
BLIND_19 21872  BLIND_58 11268 
BLIND_20 21910  BLIND_59 11380 
BLIND_21 22051  BLIND_60 11416 
BLIND_22 22150  dup_22641 22641 
BLIND_23 22213  dup_11294 11294 
BLIND_24 22379  dup_21365 21365 
BLIND_25 10745  dup_23840 23840 
BLIND_26 24552  dup_12220 12220 
BLIND_27 24803  dup_14971 14971 
BLIND_28 11621  dup_14356 14356 
BLIND_29 21344  Inadvertent  Duplicates 
BLIND_30 21602  31616_R 31616 
BLIND_34 10694  13584A 13584B 
BLIND_35 10658  
BLIND_36 10677  
BLIND_37 11004  
BLIND_38 20590  
BLIND_39 21341  
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Table S5 Summary of disposition of blinds and corresponding original sample 
Set ID Blind Action Note 
2 10370 BLIND_2 Take Blind  
3 21406 BLIND_3 Take Blind  
11 15095 BLIND_11 Take Blind  
14 11655 BLIND_14 Take Blind  
21 22051 BLIND_21 Take Blind  
35 10658 BLIND_35 Take Blind  
38 20590 BLIND_38 Take Blind  
44 10053 BLIND_44 Take Blind  
53 20589 BLIND_53 Take Blind  
59 21344 BLIND_29 Take Blind  
60 21602 BLIND_30 Take Blind  
62 11294 Dup_11294 Take Blind  
63 21365 Dup_21365 Take Blind  
64 23840 Dup_23840 Take Blind  
12 21009 BLIND_12 Take Blind Fill in rs10407958, rs3794400 from original 
40 21384 BLIND_40 Keep original Fill in rs35950908 from Blind 
61 22641 Dup_22641 Keep original Fill in rs17623313, rs4529792 from dup_ 
65 12220 Dup_12220 Keep original Fill in rs4879923 from dup_ 
66 14971 Dup_14971 Keep original Fill in rs17085265, rs2025804, rs6691346 from dup_ 
67 14356 Dup_14356 Keep original Fill in rs17086497, rs1870379, rs2297141, 
rs2359192, rs3025035 from dup_ 
90 31616 31616_R Keep 31616 31616_R had more missing  
91 13584A 13584B Keep 13584B 13584A had more missing 
 
Table S6 Identification of trio members from five Utah families* 
Family ID Child ID (gender) Paternal ID Maternal ID 
1347 10859 (F) 11881 11882 
1362- A# 10860 (M) 11992 11993 
1408 10831 (F) 12155 12156 
1362- B# 10861 (F) 11994 11995 
1341 06991 (F) 06993 06985 
*Pedigree information can be found at the Coriell website:  
http://ccr.coriell.org/sections/collections/nigms/CEPHFamilies.aspx?PgId=49&coll=GM 
# Familes 1362-A and 1362-B are two different branches of a single pedigree. The individuals 
used are unrelated beyond the expected parent/child relation. 
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Table S7 Trio IDs and plate assignment 
Child Parent1/ Father Parent2/ Mother Plate 
NA_10859_01E04 NA_11881_01C03 NA_11882_01E07 1 
NA_10860_02D01 NA_11992_02B12 NA_11993_19H12 2,19 
NA_10831_03B04 NA_12155_03G12 NA_12156_03D01 3 
NA_10861_04F09 NA_11994_04B01 NA_11995_04F02 4 
NA_06991_05F05 NA_06993_05D10 NA_06985_05B09 5 
NA_10861_06F08 NA_11994_06A01 NA_11995_06H06 6 
NA_10831_07C10 NA_12155_07D07 NA_12156_07F01 7 
NA_10859_08G09 NA_11881_08G06 NA_11882_08D12 8 
NA_10860_09D08 NA_11992_09E05 NA_11993_09A07 9 
NA_06991_10D06 NA_06993_10F11 NA_06985_10F10 10 
NA_10831_11B01 NA_12155_11D10 NA_12156_11B07 11 
NA_10860_12A10 NA_11992_12G05 NA_11993_12A02 12 
NA_10859_13H02 NA_11881_13B12 NA_11882_13D07 13 
NA_10861_14H05 NA_11994_14F02 NA_11995_14B08 14 
NA_06991_15D11 NA_06993_15D04 NA_06985_15A01 15 
NA_10831_16F02 NA_12155_16E05 NA_12156_16H07 16 
NA_10861_17H06 NA_11994_17C11 NA_11995_17B08 17 
NA_06991_18E06 NA_06993_18F10 NA_06985_18G01 18 
NA_10859_19H02 NA_11881_19G05 NA_11882_19E08 19 
NA_10859_20D06 NA_11881_20F10 NA_11882_20F11 20 
NA_10831_20H03 NA_12155_20H11 NA_12156_20H12 20 
Note: All CEPH samples in this study have the following naming protocol: NA_CoriellID_Plate 
number, well number. 
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Table S8 SNPs (N=106) deleted for poor genotyping 
rs7548373 rs9910408 rs12982080 
rs1800872 rs10889568 rs17771967 
rs235214 rs10434 rs4769604 
rs6660481 rs4795051 rs674425 
rs7177 rs1052576 rs1625895 
rs40401 rs2256974 rs4309 
rs10833 rs3789679 rs3212922 
rs3807373 rs4478599 rs4675801 
rs857440 rs2072324 rs2516479 
rs4601580 rs9282745 rs1484994 
rs16871960 rs2779251 rs734936 
rs3900115 rs7575147 rs11653716 
rs556960 rs2069827 rs16944 
rs2284556 rs833057 rs4794067 
rs2078486 rs2243123 rs12700386 
rs638889 rs2216163 rs4359744 
rs3934834 rs13173738 rs11077350 
rs6697014 rs578268 rs2154381 
rs2239680 rs3769823 rs998584 
rs9436299 rs3729508 rs11880171 
rs480568 rs7980604 rs3731714 
rs11223503 rs9436740 rs9790601 
rs11752276 rs8135345 rs3790433 
rs1800682 rs11882659 rs4350528 
rs31474 rs11255509 rs9551462 
rs4795050 rs11603042 rs7136446 
rs6718026 rs4318 rs4489979 
rs7414246 rs4459610 rs2296799 
rs13376708 rs10514934 rs7249176 
rs12405556 rs2243131 rs6556352 
rs7208775 rs1598861 rs4902083 
rs944725 rs9554311 rs1589241 
rs7149935 rs7097467 rs479952 
rs7915610 rs11912889 rs11900753 
rs649216 rs25879  
rs4806585 rs870300  
Bold are inflammatory genes  
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Table S9 SNPs excluded for being non-polymorphic 
 
Non-polymorphic in All 
KIR3DL3   rs9797797 
Non-polymorphic in Europeans 
CCND1   rs7106515 
IL18   rs11214098 
TGFB3   rs4252345 
 
 
Table S10 PIN participant IDs excluded from analysis (N=48) 
<95% genotyping call (N=8) Congenital Anomaly (N=24) 
13109 10048 
13290 10085 
13790 10634 
20446 10892 
21034 11052 
24845 11158 
31820 11301 
32438 11409 
>=5% missing after QC 11554 
31905 11845 
10760 11907 
33354 11954 
Unknown Duplicate 12137 
21027 12341 
Mislabeled Samples 13390 
12682 13773 
25217 13983 
Still births (N=10) 14912 
11201 14983 
11262 15164 
12441 23974 
12645 24096 
12647 24098 
12655 24785 
12856  
13174  
15336  
24235  
 
  
 199 
Table S11 List of AIMS Genotyped (N=156) 
rs11223503* rs12900552 rs2246695 rs6414248 
rs13173738* rs12926237 rs228768 rs645510 
rs4350528* rs12945601 rs2416791 rs6491743 
rs4489979* rs12997060 rs2426515 rs6494466 
rs6556352* rs1303629 rs2451563 rs6535244 
rs857440* rs13080353 rs2488465 rs6666101 
rs7575147* rs13169284 rs2593595 rs6765491 
rs11150219† rs13178470 rs2596793 rs6820509 
rs11652805† rs13261248 rs2660769 rs6937164 
rs10028057 rs13318432 rs2687427 rs7021690 
rs10041728 rs1335826 rs2777804 rs7086 
rs10056388 rs1372115 rs316598 rs710052 
rs1011643 rs1372894 rs328744 rs7107482 
rs10124991 rs1380014 rs33957 rs7111814 
rs10195705 rs1412521 rs344454 rs7134682 
rs10202705 rs1415723 rs3755446 rs7161 
rs10254729 rs1426654 rs3759171 rs7187359 
rs10255169 rs1462309 rs3791896 rs7189172 
rs1043809 rs1470608 rs385194 rs735480 
rs10806263 rs1477921 rs3861709 rs7424137 
rs10842753 rs1490728 rs4143633 rs7512316 
rs10908312 rs1508061 rs4149436 rs7689609 
rs10952147 rs155409 rs4506877 rs7788641 
rs10962612 rs16891982 rs4529792 rs7810554 
rs11000419 rs17049450 rs4602918 rs798443 
rs1117382 rs17261772 rs4619931 rs8113143 
rs1125217 rs17269594 rs4659762 rs833282 
rs11264110 rs1733731 rs4789070 rs870272 
rs11607932 rs17520733 rs4792105 rs897351 
rs11901793 rs1862819 rs4793237 rs9297712 
rs12094678 rs1870571 rs4811651 rs9306906 
rs12129648 rs1885167 rs4823460 rs9416026 
rs1256197 rs1911999 rs4859147 rs9416972 
rs1257010 rs1917028 rs4885162 rs9525462 
rs12594483 rs1982235 rs4896780 rs9530646 
rs12612040 rs1991818 rs4923940 rs9543532 
rs12640848 rs2075902 rs503677 rs9806307 
rs12676654 rs2184033 rs567357 rs9849733 
rs12900262 rs222674 rs6023376 rs9923864 
* Failed to genotype 
 †Out of HWE in one genetic ancestry group 
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Table S12 Individuals with ambiguous genetic ancestry 
PIN ID Self Reported Race %YRI 
10803 African American 0.5 
11184 African American 0.592 
12613 African American 0.587 
21370 African American 0.583 
24187 African American 0.476 
24535 African American 0.492 
24578 African American 0.495 
24827 African American 0.553 
30936 African American 0.477 
32257 African American 0.404 
21984 African American 0.604 
23496 African American 0.61 
32875 White 0.394 
 
 
Table S13 Individuals with discordant self-reported race and genetic ancestry 
PIN ID Self Reported Race %YRI 
12909 White 0.758 
20750 White 0.869 
31439 White 0.909 
34545 White 0.99 
12644 White 0.994 
23299 African American 0.002 
11513 African American 0.003 
34522 African American 0.003 
33822 African American 0.006 
10863 African American 0.008 
12818 African American 0.156 
15215 African American 0.253 
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Table S14 Paper #1 Number of individuals included in each SNP-set for SKAT analysis 
 
PRETERM SPONTANEOUS PRETERM 
 
European 
American 
African American 
European 
American 
African American 
Total N 603 338 512 269 
GENE N N N N 
CSF2 590 330 503 262 
CXCL10 602 336 511 267 
GATA3 586 332 497 263 
IFNG 585 331 498 264 
IFNGR2 597 336 508 268 
IL10 600 335 509 266 
IL12A 594 317 504 253 
IL12B 594 335 504 266 
IL13&IL4 583 335 502 267 
IL15 580 325 492 261 
IL18 603 337 512 268 
IL2 601 337 510 268 
IL6 599 337 509 268 
IL6R 592 329 504 261 
IL8 599 311 509 247 
IL8RB 603 338 512 269 
KIR2DL4 600 335 509 268 
KIR3DL2 600 332 509 266 
KIR3DL3 584 327 496 259 
KLDR1 601 335 511 266 
LTA&TNF 580 332 495 264 
NFKB1 598 321 507 255 
TBX21 602 338 511 269 
TNFRSF1B 598 333 507 266 
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Table S15 Paper #1 Demographics for entire PIN cohort, eligible cohort and genotyped cohort 
 
All N=5169 Eligible N=3065 Genotyped N=1646 
Self-Reported Race: White 3035 (58.7) 1918 (62.6) 1031 (62.6) 
African American 1746 (33.8) 1147 (37.4) 615 (37.4) 
Other 387 (7.5) 0 0 
Missing race 1 0 0 
Age years: Mean (SD) 26.8 (6.2) 26.2 (6.3) 26.1 (6.3) 
Smokera 935 (20.8) 657 (23.6) 383 (25.6) 
Missing smoking 670 0 152 
BMI: Mean (median, IQR)b 26.0 (24,  21-29) 25.8 (24, 21-29) 26.5 (24, 21-30) 
Missing BMI 364 188 82 
Poverty: Mean (median, 
IQR) 
305 (223, 109-476) 284.0 (198, 96-473) 273.0 (179, 95-464) 
Missing poverty 741 375 199 
Married 2959 (57.4) 1646 (53.7) 868 (52.8) 
Single 1843 (35.8) 1199 (39.1) 658 (40.0) 
Other 352 (6.8) 218 (7.1) 119 (7.2) 
Missing marital 15 2 1 
Education: 13+ years 3013 (58.5) 1663 (54.3) 854 (51.9) 
Missing Education 19 4 0 
First birth 2347 (45.6) 1400 (45.8) 769 (46.8) 
Multiparous 2803 (54.4) 1659 (54.2) 873 (53.1) 
Missing parity 19 5 4 
Preterm 686 (13.5) 377 (12.3) 347 
Missing PTB 80 0 0 
Preterm Labor (% PTB) 214 (33.9) 120 (35.2) 111 (35.5) 
PPROM (% PTB) 127 (20.1) 66 (19.4) 63 (20.1) 
Medically Indicated (% PTB) 290 (46.0) 155 (45.5) 139 (44.4) 
Missing preterm subtype 137 38 36 
a Self-reported smoking during months 1-6 of pregnancy. 
b Pre-pregnancy BMI calculated from self-reported pre-pregnancy weight and measured height. 
Abbreviations: SD standard deviation, IQR interquartile range, BMI Body Mass index (kg/m2), 
PTB Preterm Birth, PPROM preterm prelabor rupture of membranes 
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Table S16 Paper #1 Risk Ratio and 95% Confidence Interval for all SNPs stratified by genetic 
ancestry 
  European Americana African Americana 
Gene/SNPb 
Variant 
Allelec 
Preterm Spont. Preterm Preterm Spont. Preterm 
IL12A      
rs503582 T 1.3 (1.1, 1.7) 1.3 (1.0, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs532953 C 0.8 (0.6, 1.2) 0.9 (0.6, 1.4) 1.2 (0.8, 1.8) 1.2 (0.7, 2.1) 
rs7653097 C 1.5 (1.0, 2.1) 1.4 (0.9, 2.3) 1.0 (0.7, 1.4) 0.9 (0.6, 1.5) 
rs1014486 G 1.0 (0.8, 1.2) 0.9 (0.7, 1.3) 1.0 (0.8, 1.3) 0.9 (0.6, 1.4) 
rs13064168 A 0.6 (0.4, 0.8) 0.7 (0.4, 1.0) 1.1 (0.7, 1.7) 1.3 (0.7, 2.4) 
rs609907 C 0.6 (0.5, 0.8) 0.7 (0.5, 1.0) 1.1 (0.8, 1.6) 1.2 (0.7, 2.0) 
rs2647929 A 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.1 (0.8, 1.6) 1.6 (1.0, 2.4) 
rs2886666 T 1.2 (0.9, 1.6) 1.1 (0.8, 1.6) 0.7 (0.3, 1.4) 0.6 (0.2, 1.7) 
rs9811792 C 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.1 (0.8, 1.4) 1.5 (1.0, 2.2) 
rs16830946 G   1.1 (0.7, 1.6) 0.8 (0.4, 1.5) 
rs7372767 G 1.1 (0.9, 1.4) 1.1 (0.9, 1.5) 1.3 (0.9, 1.7) 1.7 (1.1, 2.6) 
rs6441282 T 0.8 (0.6, 1.0) 0.8 (0.6, 1.0) 0.8 (0.6, 1.0) 0.7 (0.5, 1.0) 
rs692890 T 0.7 (0.6, 0.9) 0.7 (0.5, 0.9) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 
rs755004 T 1.3 (1.0, 1.7) 1.5 (1.1, 2.1) 0.6 (0.3, 1.2) 0.6 (0.2, 1.7) 
rs16830949 T 4.1 (1.3, 13.2) 0.0 (0.0, 0.0) 0.8 (0.5, 1.2) 0.9 (0.6, 1.5) 
rs2243115 G 1.2 (0.9, 1.7) 1.3 (0.8, 1.9) 1.1 (0.8, 1.6) 0.8 (0.5, 1.5) 
rs583911 G 1.0 (0.8, 1.3) 1.0 (0.7, 1.4) 0.9 (0.7, 1.2) 1.2 (0.8, 1.8) 
rs2243151 T 1.2 (1.0, 1.5) 1.2 (0.9, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.5) 
rs2243154 A 0.9 (0.6, 1.3) 0.7 (0.4, 1.2) 1.3 (0.6, 2.8) 1.8 (0.7, 4.7) 
rs4608735 C 1.3 (0.9, 1.7) 1.3 (0.8, 1.9) 1.2 (0.9, 1.7) 1.0 (0.6, 1.7) 
rs17826053 G 0.7 (0.5, 1.0) 0.7 (0.5, 1.1) 1.0 (0.7, 1.4) 0.7 (0.4, 1.2) 
rs485497 A 1.1 (0.9, 1.3) 1.0 (0.8, 1.4) 1.0 (0.7, 1.3) 1.2 (0.8, 1.9) 
rs4680536 G 1.1 (0.9, 1.4) 1.3 (1.0, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs12492730 G 0.8 (0.2, 3.0) 0.8 (0.1, 5.5) 1.1 (0.8, 1.5) 0.7 (0.4, 1.2) 
rs9852519 T 0.9 (0.7, 1.1) 0.8 (0.6, 1.2) 1.0 (0.7, 1.3) 1.2 (0.8, 1.7) 
rs598638 T 1.0 (0.8, 1.4) 0.8 (0.5, 1.2) 1.1 (0.5, 2.4) 1.3 (0.5, 3.8) 
IFNGR2      
rs6517167 T 1.3 (1.0, 1.7) 1.1 (0.7, 1.6) 1.1 (0.8, 1.4) 0.9 (0.6, 1.3) 
rs11702844 G 0.8 (0.6, 1.1) 0.7 (0.5, 1.2) 1.2 (0.6, 2.4) 0.6 (0.2, 2.5) 
rs16990664 T 0.7 (0.4, 1.3) 0.6 (0.3, 1.4) 1.1 (0.8, 1.4) 0.9 (0.6, 1.3) 
rs9976971 A 1.0 (0.8, 1.2) 1.0 (0.8, 1.3) 1.0 (0.6, 1.7) 1.0 (0.5, 2.1) 
rs9980428 T 1.2 (0.9, 1.6) 1.3 (1.0, 1.9) 0.8 (0.6, 1.2) 0.8 (0.5, 1.3) 
rs9978223 A 0.7 (0.5, 0.9) 0.6 (0.4, 1.0) 1.1 (0.8, 1.4) 1.1 (0.7, 1.5) 
rs2268241 A 0.6 (0.5, 0.9) 0.6 (0.3, 0.9) 1.2 (0.9, 1.6) 1.3 (0.9, 1.8) 
rs9808685 G 1.3 (1.1, 1.7) 1.3 (1.0, 1.8) 1.0 (0.8, 1.3) 0.9 (0.6, 1.3) 
rs2834210 A 1.3 (1.0, 1.6) 1.3 (0.9, 1.7) 1.0 (0.8, 1.4) 0.9 (0.6, 1.3) 
rs9808753 G 0.7 (0.5, 1.0) 0.6 (0.4, 1.0) 1.2 (0.9, 1.6) 1.1 (0.7, 1.8) 
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  European Americana African Americana 
Gene/SNPb 
Variant 
Allelec 
Preterm Spont. Preterm Preterm Spont. Preterm 
rs2834212 C 0.9 (0.7, 1.3) 1.1 (0.7, 1.8) 1.0 (0.4, 2.6) 1.7 (0.6, 4.8) 
rs2834213 G 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.2 (0.7, 2.1) 1.8 (0.9, 3.5) 
rs2012075 C 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 1.0 (0.7, 1.4) 1.1 (0.7, 1.8) 
rs8131980 A 1.2 (1.0, 1.6) 1.3 (0.9, 1.7) 1.0 (0.7, 1.5) 0.9 (0.5, 1.6) 
KIR3DL2      
rs10407958 A 0.8 (0.5, 1.1) 0.7 (0.4, 1.1) 1.2 (0.8, 1.6) 1.4 (0.9, 2.2) 
rs1654644 G 1.2 (1.0, 1.5) 1.2 (0.9, 1.6) 0.9 (0.7, 1.2) 1.1 (0.7, 1.5) 
rs4806457 C 1.7 (1.1, 2.7) 1.5 (0.7, 3.1) 1.0 (0.5, 1.8) 0.7 (0.3, 1.7) 
rs3745900 T 1.2 (0.9, 1.5) 1.2 (0.9, 1.7) 0.8 (0.6, 1.1) 0.8 (0.6, 1.2) 
rs11672983 A 1.3 (1.0, 1.5) 1.3 (1.0, 1.7) 0.8 (0.6, 1.0) 0.9 (0.6, 1.4) 
rs3816051 C 1.4 (1.2, 1.7) 1.4 (1.1, 1.9) 0.9 (0.6, 1.1) 0.9 (0.6, 1.3) 
IL3      
rs31400 T 1.1 (0.9, 1.3) 1.2 (0.9, 1.6) 1.0 (0.8, 1.3) 1.1 (0.8, 1.6) 
rs3091335 G 2.5 (1.1, 5.9) 2.2 (0.5, 8.6) 0.9 (0.7, 1.2) 0.9 (0.6, 1.4) 
rs31481 A 1.4 (1.1, 1.8) 1.0 (0.7, 1.5) 1.3 (0.9, 1.8) 1.2 (0.7, 2.0) 
rs2069801 G   0.8 (0.5, 1.3) 0.7 (0.4, 1.3) 
rs246844 A 1.2 (0.9, 1.5) 0.9 (0.6, 1.3) 1.1 (0.8, 1.6) 1.2 (0.7, 1.9) 
rs11575022 C 1.6 (1.1, 2.3) 1.5 (0.9, 2.6) 1.1 (0.7, 1.5) 1.0 (0.6, 1.7) 
rs246841 T 1.0 (0.7, 1.5) 0.8 (0.5, 1.4) 1.1 (0.5, 2.3) 1.7 (0.7, 4.0) 
rs168681 A 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 1.1 (0.8, 1.6) 1.3 (0.9, 2.0) 
rs721121 G 0.8 (0.7, 1.0) 0.9 (0.7, 1.2) 0.7 (0.5, 1.0) 0.6 (0.4, 0.9) 
CSF2      
rs4705916 A 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 0.6 (0.4, 0.9) 
rs743677 G 1.8 (0.4, 7.6) 2.1 (0.3, 14.8) 1.1 (0.7, 1.6) 0.8 (0.4, 1.5) 
rs2069626 G 1.2 (0.5, 3.0) 1.5 (0.5, 4.6) 1.1 (0.7, 1.8) 1.3 (0.7, 2.5) 
rs743564 G 0.8 (0.6, 1.0) 0.9 (0.6, 1.2) 0.7 (0.5, 1.0) 0.8 (0.5, 1.2) 
rs25881 T 1.4 (1.0, 1.8) 1.2 (0.8, 1.7) 1.0 (0.8, 1.4) 0.9 (0.6, 1.4) 
rs25882 C 1.3 (1.0, 1.7) 1.1 (0.7, 1.6) 1.1 (0.8, 1.5) 1.0 (0.7, 1.6) 
rs27438 A 1.3 (1.0, 1.7) 1.1 (0.8, 1.6) 0.9 (0.7, 1.1) 0.8 (0.6, 1.2) 
rs25887 C 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.1 (0.9, 1.5) 1.2 (0.8, 1.7) 
rs6898270 T 0.8 (0.6, 1.0) 0.9 (0.6, 1.2) 0.8 (0.6, 1.2) 0.8 (0.5, 1.3) 
IL13      
rs7737470 A 1.4 (1.1, 1.8) 1.9 (1.4, 2.5) 1.1 (0.8, 1.4) 1.0 (0.6, 1.5) 
rs4621555 C   1.1 (0.8, 1.6) 1.2 (0.7, 1.9) 
rs3091307 G 1.4 (1.1, 1.8) 1.9 (1.4, 2.6) 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 
rs1881457 C 1.5 (1.1, 1.9) 1.8 (1.3, 2.5) 1.0 (0.7, 1.3) 1.1 (0.7, 1.8) 
rs2069744 T 0.7 (0.2, 3.2) 0.8 (0.1, 5.8) 1.0 (0.7, 1.3) 1.0 (0.7, 1.5) 
rs1295686 G 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 1.1 (0.9, 1.5) 1.2 (0.8, 1.7) 
rs20541 T 1.2 (0.9, 1.6) 1.5 (1.1, 2.1) 0.9 (0.6, 1.2) 0.8 (0.5, 1.3) 
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rs848 T 1.2 (0.9, 1.6) 1.5 (1.0, 2.0) 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 
rs1295683 T 1.3 (0.9, 1.7) 1.5 (1.0, 2.2) 0.8 (0.5, 1.3) 0.7 (0.4, 1.4) 
rs2243204 T 1.2 (0.9, 1.8) 1.5 (0.9, 2.3) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs2243210 A 1.0 (0.7, 1.6) 1.3 (0.8, 2.2) 0.8 (0.6, 1.1) 0.8 (0.5, 1.3) 
rs2243218 A 1.2 (0.8, 1.7) 1.5 (1.0, 2.3) 1.0 (0.7, 1.3) 1.0 (0.7, 1.5) 
rs2243219 G 1.2 (0.9, 1.8) 1.5 (1.0, 2.3) 1.0 (0.8, 1.3) 0.9 (0.7, 1.3) 
IL4      
rs2243240 T 3.6 (0.7, 18.7)  1.1 (0.7, 1.9) 0.9 (0.4, 2.1) 
rs2243246 C 3.5 (0.7, 18.6)  0.8 (0.6, 1.2) 0.8 (0.4, 1.3) 
rs2243248 G 1.0 (0.6, 1.5) 1.2 (0.7, 2.0) 1.2 (0.9, 1.7) 1.3 (0.9, 2.0) 
rs2243250 C 0.7 (0.5, 0.9) 0.6 (0.4, 0.9) 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 
rs2243253 T 6.1 (3.6, 10.4) 9.5 (2.9, 31.8) 1.2 (0.8, 1.7) 1.3 (0.8, 2.1) 
rs2243261 T 3.5 (0.7, 18.6)  0.9 (0.6, 1.3) 0.8 (0.4, 1.4) 
rs2243263 C 1.2 (0.9, 1.7) 1.6 (1.1, 2.3) 1.1 (0.8, 1.5) 1.2 (0.8, 1.9) 
rs2243267 C 1.5 (1.1, 2.0) 1.8 (1.2, 2.6) 1.1 (0.8, 1.5) 1.2 (0.8, 1.9) 
rs2243270 G 1.4 (1.1, 1.9) 1.7 (1.1, 2.5) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs2243283 G 1.5 (0.6, 4.0) 1.9 (0.5, 7.8) 1.1 (0.7, 1.5) 1.1 (0.6, 1.8) 
rs2243292 C 1.2 (0.3, 5.3) 0.0 (0.0, 0.0) 0.9 (0.5, 1.5) 0.6 (0.3, 1.5) 
rs11242122 G 0.7 (0.6, 0.9) 0.5 (0.4, 0.7) 1.0 (0.8, 1.3) 0.8 (0.5, 1.2) 
rs11242123 T 1.4 (1.0, 1.9) 1.7 (1.2, 2.6) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
Single SNPs      
IL1A      
rs17561 T 1.2 (0.9, 1.5) 1.2 (0.9, 1.6) 0.8 (0.6, 1.2) 0.7 (0.5, 1.2) 
rs1800587 T 1.2 (0.9, 1.5) 1.2 (0.9, 1.7) 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 
IL1B      
rs1143634 T 1.2 (0.9, 1.5) 1.2 (0.8, 1.6) 0.8 (0.5, 1.1) 0.7 (0.4, 1.2) 
rs1143627 T 1.1 (0.8, 1.3) 0.9 (0.7, 1.3) 0.9 (0.7, 1.1) 0.8 (0.6, 1.3) 
TGFB3      
rs4252345 G   1.0 (0.5, 2.0) 1.0 (0.4, 2.6) 
rs11466414 T 1.2 (0.8, 1.8) 1.3 (0.7, 2.2) 1.1 (0.4, 2.9) 0.4 (0.1, 3.4) 
TGFB1      
rs1800471 C 0.7 (0.4, 1.1) 0.4 (0.2, 0.9) 0.8 (0.5, 1.5) 0.6 (0.2, 1.5) 
TNFRSF1B      
rs496888 G 1.1 (0.9, 1.3) 1.1 (0.8, 1.5) 0.9 (0.6, 1.1) 0.8 (0.5, 1.2) 
rs3766730 T 0.8 (0.6, 1.1) 0.7 (0.5, 1.1) 0.4 (0.1, 0.9) 0.1 (0.0, 1.0) 
rs816050 T 1.1 (0.9, 1.5) 1.1 (0.8, 1.6) 0.8 (0.6, 1.1) 0.7 (0.4, 1.1) 
rs1201157 T 1.0 (0.8, 1.2) 0.9 (0.7, 1.2) 1.0 (0.7, 1.3) 0.8 (0.5, 1.1) 
rs1061622 G 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 0.9 (0.6, 1.2) 0.7 (0.5, 1.2) 
rs5746051 G 0.9 (0.7, 1.2) 0.8 (0.5, 1.2) 0.7 (0.4, 1.3) 0.4 (0.1, 1.2) 
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rs5746053 A 0.9 (0.7, 1.2) 0.7 (0.5, 1.1) 0.9 (0.6, 1.3) 0.7 (0.4, 1.2) 
rs1061624 G 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 1.0 (0.8, 1.3) 0.9 (0.6, 1.4) 
rs1061628 T 1.3 (1.0, 1.6) 1.4 (1.1, 1.8) 0.8 (0.6, 1.1) 0.8 (0.6, 1.3) 
IL6R      
rs11265607 G 1.0 (0.8, 1.3) 1.2 (0.9, 1.6) 0.9 (0.7, 1.2) 1.2 (0.8, 1.7) 
rs6427627 C 1.0 (0.8, 1.3) 1.2 (0.9, 1.6) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 
rs11265608 A 1.0 (0.7, 1.4) 1.0 (0.6, 1.6) 0.9 (0.6, 1.4) 0.9 (0.5, 1.6) 
rs17654071 G 0.9 (0.7, 1.2) 0.8 (0.6, 1.0) 1.1 (0.8, 1.5) 0.9 (0.6, 1.5) 
rs2054855 T 1.1 (0.8, 1.5) 1.4 (0.9, 2.1) 1.1 (0.9, 1.5) 1.1 (0.7, 1.7) 
rs4845615 A 0.9 (0.1, 7.0) 2.4 (0.3, 18.5) 0.7 (0.4, 1.2) 0.9 (0.5, 1.6) 
rs1552481 G 0.7 (0.1, 5.2) 1.7 (0.2, 12.3) 1.0 (0.7, 1.4) 1.0 (0.6, 1.5) 
rs4845617 A 1.0 (0.8, 1.3) 1.2 (0.9, 1.6) 0.8 (0.6, 1.1) 0.9 (0.6, 1.3) 
rs6427641 G 1.1 (0.9, 1.3) 1.2 (0.9, 1.6) 0.8 (0.6, 1.0) 0.8 (0.6, 1.2) 
rs11265610 C 1.2 (0.3, 5.2) 1.8 (0.3, 13.6) 1.1 (0.8, 1.4) 1.2 (0.8, 1.8) 
rs12083537 G 1.0 (0.8, 1.3) 1.1 (0.8, 1.6) 0.9 (0.6, 1.2) 1.0 (0.7, 1.5) 
rs1386821 C 1.0 (0.8, 1.3) 1.1 (0.8, 1.6) 0.9 (0.6, 1.4) 0.9 (0.5, 1.7) 
rs12090237 A 1.1 (0.5, 2.6) 0.9 (0.3, 3.5) 0.9 (0.6, 1.4) 0.9 (0.5, 1.5) 
rs6684439 T 1.0 (0.8, 1.2) 1.1 (0.8, 1.5) 1.0 (0.7, 1.3) 1.0 (0.6, 1.4) 
rs12096944 T   1.0 (0.6, 1.6) 0.9 (0.5, 1.9) 
rs12060250 G   1.0 (0.6, 1.6) 1.0 (0.5, 1.9) 
rs4845618 G 1.1 (0.8, 1.3) 1.0 (0.7, 1.3) 1.0 (0.7, 1.2) 0.9 (0.7, 1.4) 
rs7549250 C 1.1 (0.9, 1.4) 1.0 (0.7, 1.3) 0.9 (0.7, 1.2) 0.9 (0.6, 1.4) 
rs7518199 C 0.9 (0.7, 1.2) 1.0 (0.8, 1.4) 0.9 (0.7, 1.3) 0.9 (0.6, 1.3) 
rs4553185 C 1.1 (0.9, 1.3) 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) 1.0 (0.6, 1.4) 
rs4845623 G 0.9 (0.7, 1.2) 1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 1.1 (0.7, 1.7) 
rs4537545 T 1.0 (0.8, 1.2) 1.1 (0.8, 1.5) 0.9 (0.7, 1.3) 1.0 (0.7, 1.6) 
rs4845626 T 1.0 (0.8, 1.4) 1.1 (0.7, 1.5) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 
rs4845374 A 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 1.2 (0.9, 1.7) 1.4 (0.9, 2.1) 
rs11265618 T 1.0 (0.8, 1.4) 1.1 (0.7, 1.5) 0.9 (0.7, 1.2) 1.1 (0.8, 1.6) 
rs4329505 C 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 1.2 (0.9, 1.5) 1.3 (0.9, 1.9) 
rs4341355 C 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 1.0 (0.7, 1.2) 1.0 (0.7, 1.4) 
rs2229238 T 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 1.1 (0.8, 1.5) 0.9 (0.6, 1.4) 
rs4072391 T 1.0 (0.8, 1.3) 1.1 (0.7, 1.5) 1.1 (0.8, 1.4) 0.9 (0.6, 1.3) 
rs11265621 G 1.0 (0.8, 1.3) 1.0 (0.7, 1.4) 1.1 (0.9, 1.5) 1.1 (0.7, 1.6) 
rs7526293 T 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 1.0 (0.8, 1.3) 0.9 (0.7, 1.3) 
IL10      
rs7539748 A 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 1.5 (0.9, 2.7) 2.0 (0.9, 4.2) 
rs11119451 C 1.2 (0.9, 1.5) 1.1 (0.8, 1.5) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
rs6658896 T 0.6 (0.2, 1.4)  0.9 (0.6, 1.4) 0.7 (0.3, 1.3) 
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rs6692511 T 0.9 (0.7, 1.2) 1.0 (0.8, 1.4) 1.1 (0.8, 1.5) 1.0 (0.6, 1.6) 
rs6699203 A 0.9 (0.8, 1.2) 1.0 (0.8, 1.4) 1.1 (0.8, 1.5) 1.1 (0.7, 1.7) 
rs4390174 G 1.0 (0.8, 1.2) 0.8 (0.6, 1.0) 1.1 (0.9, 1.5) 1.1 (0.8, 1.7) 
rs6673928 T 1.1 (0.9, 1.4) 1.1 (0.9, 1.5) 1.1 (0.8, 1.6) 1.5 (0.9, 2.4) 
rs3024496 C 1.1 (0.9, 1.4) 1.2 (0.9, 1.6) 1.1 (0.9, 1.4) 1.2 (0.8, 1.7) 
rs1878672 G 1.1 (0.9, 1.4) 1.2 (0.9, 1.5) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
rs3024493 T 1.1 (0.9, 1.5) 1.1 (0.7, 1.6) 0.9 (0.4, 2.0) 0.5 (0.1, 2.2) 
rs3024491 T 1.1 (0.9, 1.4) 1.2 (0.9, 1.5) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
rs3024490 T 0.9 (0.7, 1.1) 0.8 (0.6, 1.2) 0.8 (0.6, 1.1) 0.8 (0.5, 1.1) 
rs1800871 T 0.9 (0.7, 1.1) 0.8 (0.6, 1.2) 0.8 (0.6, 1.1) 0.7 (0.5, 1.1) 
rs1800890 A 1.2 (0.9, 1.4) 1.1 (0.9, 1.5) 1.1 (0.8, 1.4) 1.2 (0.8, 1.8) 
rs17015767 C 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.2 (0.8, 1.7) 1.6 (1.0, 2.6) 
rs10494879 G 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.1 (0.9, 1.5) 1.4 (1.0, 1.9) 
rs6686931 T 0.8 (0.6, 1.1) 0.8 (0.5, 1.1) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 
IL8RB      
rs4674258 C 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 1.1 (0.8, 1.3) 1.1 (0.8, 1.5) 
rs4674259 G 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 1.0 (0.7, 1.3) 1.0 (0.7, 1.5) 
rs6761387 T 1.0 (0.6, 1.6) 0.9 (0.4, 1.9) 0.9 (0.6, 1.3) 0.9 (0.6, 1.5) 
rs4674261 C 1.0 (0.8, 1.2) 0.9 (0.7, 1.3) 0.9 (0.7, 1.2) 0.8 (0.6, 1.2) 
rs11677534 T 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 1.1 (0.9, 1.5) 1.2 (0.8, 1.6) 
rs11676348 C 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 0.9 (0.7, 1.2) 1.0 (0.7, 1.4) 
IL8      
rs7654490 T 2.2 (0.3, 17.9)  0.9 (0.6, 1.3) 1.1 (0.7, 1.7) 
rs16849893 A   0.7 (0.5, 1.0) 0.6 (0.4, 1.1) 
rs16849896 T   0.8 (0.5, 1.1) 1.0 (0.6, 1.5) 
rs4694634 C   0.9 (0.7, 1.2) 0.9 (0.6, 1.4) 
rs16849907 T   0.8 (0.5, 1.3) 1.1 (0.6, 1.8) 
rs12506479 C 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 0.8 (0.6, 1.1) 0.8 (0.5, 1.2) 
rs10805066 G 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.0 (0.8, 1.3) 1.3 (0.9, 2.0) 
rs7693566 C   0.9 (0.6, 1.3) 1.1 (0.7, 1.8) 
rs4694635 T 1.6 (0.6, 4.1) 1.1 (0.3, 5.3) 1.2 (0.8, 1.7) 1.2 (0.8, 2.0) 
rs16849928 A 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 1.1 (0.9, 1.4) 1.3 (1.0, 1.9) 
rs11730667 A 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 1.1 (0.8, 1.4) 1.2 (0.9, 1.8) 
rs13142454 G 1.1 (0.2, 8.1)  1.1 (0.8, 1.6) 1.2 (0.7, 2.0) 
rs11729759 A 1.1 (0.2, 8.1)  1.0 (0.7, 1.4) 1.2 (0.8, 1.9) 
rs1951240 G 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 1.0 (0.8, 1.3) 0.8 (0.5, 1.2) 
rs16849958 C 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 1.2 (0.9, 1.7) 0.8 (0.5, 1.3) 
rs1951242 T 0.9 (0.7, 1.1) 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 1.1 (0.8, 1.7) 
rs7658422 C 1.1 (0.2, 8.1)  1.1 (0.8, 1.5) 1.4 (0.9, 2.1) 
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CXCL10      
rs3733236 T 1.0 (0.6, 1.5) 1.0 (0.5, 1.8) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs10031051 C 1.0 (0.4, 2.5) 1.2 (0.4, 3.3) 0.9 (0.6, 1.5) 0.8 (0.4, 1.6) 
rs7670156 A 0.9 (0.6, 1.4) 1.0 (0.6, 1.8) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs12651276 G 1.0 (0.7, 1.2) 0.9 (0.6, 1.2) 1.1 (0.6, 1.9) 1.7 (0.9, 3.3) 
rs10518143 C 0.9 (0.7, 1.2) 1.1 (0.8, 1.5) 0.9 (0.6, 1.3) 0.8 (0.4, 1.5) 
rs867562 A 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 1.1 (0.6, 2.2) 1.5 (0.7, 3.5) 
rs4508917 G 0.9 (0.7, 1.2) 1.1 (0.8, 1.5) 1.0 (0.7, 1.4) 1.1 (0.7, 1.7) 
rs12504339 C 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 
rs4302486 A 1.1 (0.9, 1.4) 1.0 (0.8, 1.4) 1.2 (0.9, 1.6) 1.0 (0.6, 1.5) 
NFKB1      
rs980455 G 0.9 (0.8, 1.2) 1.0 (0.8, 1.3) 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 
rs3774933 C 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs17032705 A 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 0.8 (0.6, 1.1) 0.8 (0.5, 1.2) 
rs1599961 A 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs17032740 G 0.7 (0.1, 4.9)  0.8 (0.5, 1.3) 0.9 (0.5, 1.7) 
rs230533 T 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 1.0 (0.7, 1.3) 0.9 (0.6, 1.4) 
rs230530 C 1.0 (0.8, 1.3) 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 0.9 (0.6, 1.5) 
rs230529 A 0.9 (0.8, 1.2) 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 1.1 (0.7, 1.5) 
rs17032779 C 0.9 (0.3, 2.7) 1.5 (0.5, 4.7) 1.2 (0.8, 1.8) 1.1 (0.6, 2.0) 
rs230515 C 0.9 (0.7, 1.2) 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 0.9 (0.5, 1.4) 
rs230493 A 1.0 (0.8, 1.2) 1.1 (0.8, 1.4) 1.1 (0.8, 1.5) 1.1 (0.7, 1.7) 
rs17032815 A 0.9 (0.3, 2.6) 1.5 (0.5, 4.6) 1.0 (0.7, 1.6) 0.8 (0.4, 1.6) 
rs909332 T 0.8 (0.5, 1.4) 0.7 (0.3, 1.6) 0.9 (0.6, 1.5) 1.2 (0.6, 2.3) 
rs1801 C 0.9 (0.8, 1.2) 1.1 (0.8, 1.4) 1.2 (0.9, 1.6) 1.2 (0.8, 1.7) 
rs4648058 C 0.9 (0.7, 1.2) 1.1 (0.8, 1.4) 1.3 (1.0, 1.6) 1.3 (0.9, 1.8) 
rs3755867 G 0.9 (0.7, 1.2) 1.1 (0.8, 1.4) 1.2 (0.9, 1.5) 1.2 (0.8, 1.7) 
rs4648090 A 1.1 (0.9, 1.5) 1.1 (0.8, 1.7) 1.1 (0.7, 1.6) 1.1 (0.6, 1.9) 
rs4648110 A 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 
rs3817685 G 0.9 (0.8, 1.2) 1.1 (0.8, 1.4) 1.0 (0.8, 1.4) 1.1 (0.7, 1.7) 
rs4648127 T 0.8 (0.5, 1.3) 0.8 (0.5, 1.5) 1.5 (0.4, 5.6) 1.6 (0.2, 10.7) 
rs230547 T 1.2 (0.8, 1.7) 1.4 (0.8, 2.3) 1.1 (0.8, 1.6) 1.1 (0.7, 1.9) 
rs4648135 G 1.0 (0.6, 1.6) 1.0 (0.5, 1.9) 1.1 (0.7, 1.5) 1.3 (0.8, 2.1) 
rs4648141 A 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 1.1 (0.9, 1.5) 1.0 (0.7, 1.5) 
rs7674640 C 1.1 (0.8, 1.3) 1.0 (0.7, 1.3) 1.0 (0.8, 1.4) 1.2 (0.8, 1.7) 
rs10489113 G 1.1 (0.9, 1.4) 1.1 (0.8, 1.6) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs11733293 T 0.9 (0.7, 1.1) 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 1.0 (0.7, 1.6) 
rs17033015 A 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 0.9 (0.7, 1.4) 0.9 (0.5, 1.5) 
rs12648696 C 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 
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IL2      
rs17454584 G 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 0.5 (0.2, 1.1) 0.5 (0.1, 1.6) 
rs35914000 A 1.1 (0.8, 1.3) 1.0 (0.7, 1.4) 0.5 (0.3, 1.1) 0.3 (0.1, 1.1) 
rs10034410 T 2.0 (0.3, 11.6) 4.2 (0.8, 21.7) 0.8 (0.5, 1.2) 0.5 (0.3, 1.1) 
rs10027390 C 0.9 (0.8, 1.2) 0.9 (0.7, 1.3)   
rs11932411 C 1.5 (0.4, 5.4) 1.4 (0.2, 9.6) 1.1 (0.8, 1.4) 0.9 (0.6, 1.4) 
rs2069776 C 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 1.1 (0.8, 1.5) 1.1 (0.7, 1.7) 
rs2069778 T 0.9 (0.7, 1.3) 0.8 (0.5, 1.2) 0.8 (0.3, 2.0) 0.4 (0.1, 2.7) 
rs2069762 G 1.1 (0.9, 1.4) 1.2 (0.9, 1.6) 1.2 (0.8, 1.9) 1.1 (0.6, 2.2) 
rs4833248 A 1.1 (0.9, 1.4) 1.2 (0.9, 1.6) 1.2 (0.7, 1.9) 1.0 (0.5, 2.0) 
IL15      
rs6837991 T 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 1.1 (0.8, 1.5) 1.2 (0.8, 1.9) 
rs12508866 C 1.0 (0.8, 1.3) 0.9 (0.7, 1.3) 1.1 (0.7, 1.9) 0.5 (0.2, 1.5) 
rs17007476 C   1.3 (0.9, 1.9) 1.3 (0.8, 2.0) 
rs17007480 A   1.4 (0.9, 2.3) 1.6 (0.9, 3.1) 
rs1519551 G 0.9 (0.7, 1.1) 0.9 (0.6, 1.2) 1.2 (0.9, 1.6) 1.0 (0.7, 1.5) 
rs17461269 A 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 0.8 (0.4, 1.6) 0.9 (0.3, 2.2) 
rs17007503 C   1.2 (0.8, 1.8) 1.4 (0.8, 2.5) 
rs1519552 A 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 1.2 (0.9, 1.6) 1.3 (0.9, 1.9) 
rs17007508 G   1.0 (0.7, 1.5) 1.3 (0.8, 2.2) 
rs7698675 T 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 1.2 (0.9, 1.7) 1.2 (0.8, 1.9) 
rs13117878 C 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 1.2 (0.9, 1.5) 1.0 (0.7, 1.5) 
rs17364630 G 1.0 (0.7, 1.3) 1.1 (0.8, 1.6) 1.0 (0.6, 1.5) 0.7 (0.3, 1.3) 
rs12498901 C 1.0 (0.7, 1.3) 1.1 (0.8, 1.6) 0.9 (0.6, 1.4) 0.7 (0.3, 1.3) 
rs7671458 G 0.9 (0.7, 1.2) 1.1 (0.7, 1.5) 0.9 (0.7, 1.3) 0.7 (0.4, 1.2) 
rs10519610 C 0.9 (0.7, 1.2) 1.0 (0.7, 1.4) 0.9 (0.7, 1.2) 0.7 (0.5, 1.1) 
rs6850492 A 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 1.0 (0.8, 1.4) 0.8 (0.5, 1.3) 
rs2087849 T 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 1.2 (0.9, 1.5) 1.2 (0.8, 1.8) 
rs2857261 G 1.2 (0.9, 1.4) 1.2 (0.9, 1.6) 1.0 (0.8, 1.3) 1.2 (0.9, 1.8) 
rs1907949 T 1.0 (0.7, 1.4) 1.0 (0.6, 1.5) 1.0 (0.7, 1.5) 0.7 (0.4, 1.3) 
rs3775597 C 1.0 (0.7, 1.4) 0.9 (0.6, 1.5) 1.0 (0.7, 1.5) 0.8 (0.4, 1.6) 
rs12508955 T 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 1.2 (0.9, 1.7) 1.2 (0.7, 1.9) 
rs17007610 T 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 1.0 (0.8, 1.3) 0.8 (0.6, 1.2) 
IL12B      
rs7730126 T 0.9 (0.7, 1.2) 1.0 (0.7, 1.4) 0.9 (0.7, 1.3) 0.9 (0.6, 1.5) 
rs2099327 C 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 1.1 (0.7, 1.8) 1.1 (0.6, 2.0) 
rs1549922 G 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 1.0 (0.7, 1.6) 
rs4921466 C 0.9 (0.6, 1.2) 1.1 (0.7, 1.6) 0.9 (0.6, 1.3) 0.8 (0.5, 1.5) 
rs10072923 C 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 1.2 (0.9, 1.5) 1.0 (0.7, 1.5) 
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rs1368439 G 1.3 (1.0, 1.8) 1.3 (0.9, 1.8) 0.9 (0.5, 1.5) 1.0 (0.5, 2.1) 
rs3212227 C 1.1 (0.8, 1.4) 1.1 (0.7, 1.6) 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 
rs11574790 T 0.9 (0.6, 1.2) 1.0 (0.7, 1.5) 1.0 (0.8, 1.4) 1.1 (0.8, 1.6) 
rs2195940 T 0.8 (0.6, 1.2) 1.0 (0.6, 1.5) 0.9 (0.6, 1.2) 0.9 (0.6, 1.5) 
rs919766 C 0.9 (0.6, 1.2) 1.0 (0.7, 1.5) 1.0 (0.7, 1.3) 1.1 (0.7, 1.6) 
rs2853694 C 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 0.8 (0.6, 1.2) 0.7 (0.4, 1.2) 
rs2569253 C 0.9 (0.7, 1.1) 0.9 (0.6, 1.1) 1.0 (0.7, 1.3) 0.9 (0.6, 1.5) 
rs3212220 T 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 1.1 (0.8, 1.4) 1.0 (0.6, 1.5) 
rs1433048 G 1.2 (0.9, 1.6) 1.1 (0.7, 1.6) 0.9 (0.5, 1.7) 1.3 (0.6, 2.7) 
rs2546893 A 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 1.2 (0.9, 1.6) 1.2 (0.8, 1.8) 
rs2546890 A 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs10052709 G 0.9 (0.6, 1.2) 0.8 (0.5, 1.3) 1.0 (0.7, 1.5) 0.8 (0.5, 1.4) 
rs7709212 C 1.2 (0.9, 1.5) 1.2 (0.9, 1.7) 1.1 (0.8, 1.4) 1.1 (0.7, 1.7) 
rs6868898 C 0.9 (0.7, 1.1) 0.9 (0.6, 1.2) 0.9 (0.6, 1.2) 0.9 (0.6, 1.5) 
LTA&TNF (NFKBIL1)     
rs2857605 G 0.9 (0.7, 1.2) 0.8 (0.5, 1.1) 0.8 (0.5, 1.5) 1.4 (0.8, 2.6) 
rs2239707 G 1.0 (0.8, 1.3) 0.8 (0.6, 1.1) 0.9 (0.6, 1.3) 1.1 (0.7, 1.9) 
rs2230365 T 1.1 (0.8, 1.5) 0.8 (0.5, 1.3) 0.9 (0.6, 1.6) 0.8 (0.4, 1.9) 
rs3130062 C 1.1 (0.8, 1.7) 0.9 (0.5, 1.5) 0.6 (0.1, 2.6) 1.2 (0.3, 5.2) 
rs4947324 T 0.9 (0.6, 1.3) 1.0 (0.6, 1.5) 1.0 (0.7, 1.6) 1.0 (0.5, 1.8) 
rs2857709 T 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 0.6 (0.3, 1.4) 1.0 (0.4, 2.4) 
LTA&TNF (LTA)     
rs915654 T 1.0 (0.8, 1.3) 0.9 (0.7, 1.2) 1.1 (0.8, 1.4) 0.8 (0.6, 1.2) 
rs909253 C 1.1 (0.9, 1.4) 1.2 (0.9, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs2229094 C 1.0 (0.8, 1.2) 0.9 (0.6, 1.2) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs1041981 A 1.1 (0.9, 1.4) 1.2 (0.9, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 
LTA&TNF (intergenic)     
rs1799964 C 0.9 (0.7, 1.2) 0.8 (0.5, 1.1) 0.9 (0.6, 1.2) 0.8 (0.5, 1.3) 
rs1800630 A 1.0 (0.8, 1.4) 0.9 (0.6, 1.3) 1.0 (0.7, 1.5) 0.9 (0.5, 1.6) 
LTA&TNF (TNF)     
rs1800629 A 1.0 (0.7, 1.4) 1.2 (0.8, 1.8) 1.0 (0.7, 1.5) 1.0 (0.6, 1.7) 
LTA&TNF (LST1)     
rs7769073 A 1.1 (0.7, 1.9) 1.3 (0.6, 2.4) 1.0 (0.7, 1.5) 0.9 (0.5, 1.6) 
IL6      
rs6949149 T 1.7 (1.2, 2.4) 1.8 (1.1, 2.9) 0.7 (0.4, 1.0) 0.8 (0.5, 1.3) 
rs6954897 G 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 0.9 (0.7, 1.2) 0.9 (0.6, 1.4) 
rs6954681 T 1.4 (1.1, 1.8) 1.2 (0.8, 1.8) 1.0 (0.7, 1.2) 0.9 (0.7, 1.3) 
rs6969927 A 0.8 (0.6, 1.1) 1.0 (0.7, 1.4) 1.2 (0.9, 1.7) 1.5 (1.0, 2.3) 
rs10156056 C 1.2 (0.9, 1.6) 0.9 (0.5, 1.5) 1.0 (0.8, 1.4) 0.9 (0.6, 1.3) 
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rs7776857 G 1.0 (0.8, 1.3) 1.1 (0.8, 1.6) 1.1 (0.6, 2.0) 1.3 (0.6, 2.6) 
rs4719711 C 1.2 (1.0, 1.5) 1.2 (0.9, 1.7) 1.1 (0.8, 1.4) 1.2 (0.8, 1.8) 
rs6963444 G 1.0 (0.5, 2.0) 0.7 (0.2, 2.2) 0.9 (0.6, 1.3) 0.7 (0.4, 1.2) 
rs1546762 C 1.2 (0.9, 1.5) 1.2 (0.9, 1.7) 1.1 (0.8, 1.5) 1.2 (0.8, 1.8) 
rs7805828 A 0.8 (0.7, 1.0) 0.9 (0.7, 1.2) 1.1 (0.9, 1.5) 1.3 (0.9, 1.8) 
rs1880241 G 1.0 (0.8, 1.2) 1.1 (0.8, 1.4) 1.2 (0.9, 1.5) 1.4 (1.0, 2.0) 
rs2056576 T 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 0.9 (0.7, 1.1) 0.9 (0.6, 1.3) 
rs7784987 A 0.9 (0.4, 1.9) 0.5 (0.1, 1.9) 0.9 (0.6, 1.3) 0.9 (0.5, 1.5) 
rs3087221 T 0.9 (0.4, 2.4) 1.0 (0.3, 3.5) 0.8 (0.6, 1.2) 0.7 (0.4, 1.2) 
rs2069824 C 1.0 (0.7, 1.6) 0.7 (0.4, 1.5) 1.0 (0.7, 1.4) 1.1 (0.7, 1.7) 
rs1800797 A 1.0 (0.8, 1.2) 1.1 (0.8, 1.4) 1.2 (0.7, 2.0) 1.3 (0.7, 2.6) 
rs1800795 C 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 1.2 (0.7, 1.9) 1.3 (0.7, 2.6) 
rs2069835 C 1.0 (0.6, 1.6) 0.8 (0.3, 1.7) 0.8 (0.5, 1.2) 0.6 (0.3, 1.2) 
rs1474347 G 1.0 (0.8, 1.2) 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 0.7 (0.4, 1.3) 
rs2069840 G 0.8 (0.7, 1.0) 0.9 (0.6, 1.2) 1.4 (1.1, 1.9) 1.6 (1.1, 2.5) 
rs2069842 A 4.1 (1.6, 10.7)  1.2 (0.8, 1.8) 1.3 (0.7, 2.3) 
rs1548216 C 1.4 (0.8, 2.4) 1.3 (0.5, 3.2) 0.9 (0.6, 1.3) 0.8 (0.4, 1.3) 
rs2069843 A 1.4 (0.8, 2.4) 1.3 (0.5, 3.2) 1.0 (0.6, 1.5) 0.9 (0.5, 1.6) 
rs2069845 G 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 0.8 (0.6, 1.1) 0.7 (0.5, 1.1) 
rs2069849 T 1.4 (0.8, 2.4) 1.3 (0.5, 3.2) 0.9 (0.6, 1.4) 0.8 (0.5, 1.4) 
rs10242595 G 1.0 (0.8, 1.2) 1.0 (0.7, 1.4) 1.0 (0.7, 1.3) 0.9 (0.6, 1.4) 
GATA3      
rs406571 C 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 0.8 (0.6, 1.1) 0.7 (0.5, 1.1) 
rs1877739 C 0.9 (0.7, 1.1) 0.8 (0.6, 1.2) 1.0 (0.7, 1.3) 1.2 (0.8, 1.7) 
rs532854 C 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 0.8 (0.7, 1.1) 0.9 (0.6, 1.3) 
rs10795588 G 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 1.0 (0.6, 1.5) 
rs263425 T   0.9 (0.6, 1.3) 1.1 (0.7, 1.9) 
rs263423 A 1.0 (0.8, 1.3) 0.8 (0.5, 1.1) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs1244186 T 0.9 (0.7, 1.1) 0.7 (0.5, 1.0) 1.0 (0.7, 1.4) 0.7 (0.4, 1.2) 
rs2275806 A 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.0 (0.7, 1.4) 0.9 (0.6, 1.4) 
rs1269486 A 0.9 (0.7, 1.1) 0.7 (0.5, 1.0) 0.9 (0.6, 1.3) 0.6 (0.3, 1.0) 
rs1399180 T 0.9 (0.7, 1.2) 0.8 (0.6, 1.2) 1.0 (0.7, 1.3) 1.0 (0.7, 1.5) 
rs369421 C 0.9 (0.7, 1.2) 0.8 (0.5, 1.2) 0.9 (0.6, 1.5) 0.6 (0.3, 1.3) 
rs3781094 G 1.1 (0.9, 1.4) 1.0 (0.7, 1.3) 1.1 (0.8, 1.5) 1.0 (0.7, 1.5) 
rs3781093 G 1.0 (0.7, 1.3) 1.3 (0.9, 1.8) 0.8 (0.6, 1.1) 0.9 (0.6, 1.4) 
rs376397 A 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 1.0 (0.8, 1.4) 0.9 (0.6, 1.4) 
rs570613 G 0.9 (0.7, 1.1) 1.0 (0.8, 1.4) 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 
rs10752126 G 0.9 (0.7, 1.1) 1.0 (0.8, 1.4) 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 
rs569421 C 1.0 (0.8, 1.3) 1.2 (0.9, 1.7) 0.8 (0.6, 1.1) 1.0 (0.7, 1.4) 
 212 
  European Americana African Americana 
Gene/SNPb 
Variant 
Allelec 
Preterm Spont. Preterm Preterm Spont. Preterm 
rs444929 C 0.8 (0.6, 1.1) 0.8 (0.6, 1.2) 1.2 (0.9, 1.6) 0.9 (0.6, 1.4) 
rs2280015 A 1.1 (0.8, 1.4) 1.3 (0.9, 1.8) 0.8 (0.6, 1.2) 1.1 (0.7, 1.7) 
rs422628 C 0.8 (0.6, 1.1) 0.8 (0.6, 1.2) 1.1 (0.8, 1.5) 0.8 (0.5, 1.2) 
rs406103 T 1.0 (0.8, 1.3) 1.3 (0.9, 1.7) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 
rs528778 T 0.9 (0.7, 1.1) 0.9 (0.6, 1.3) 1.3 (0.9, 1.7) 0.9 (0.5, 1.4) 
rs11567934 A   1.0 (0.7, 1.4) 1.0 (0.6, 1.7) 
rs388957 T 0.7 (0.3, 1.4) 0.9 (0.4, 2.3) 1.0 (0.7, 1.4) 1.0 (0.7, 1.6) 
rs10905284 A 1.1 (0.9, 1.3) 0.9 (0.7, 1.2) 1.2 (0.9, 1.7) 1.2 (0.8, 1.9) 
rs1058240 G 0.8 (0.6, 1.1) 0.8 (0.6, 1.2) 1.1 (0.8, 1.4) 0.7 (0.4, 1.0) 
rs263419 T 1.0 (0.8, 1.3) 1.3 (0.9, 1.8) 0.9 (0.7, 1.2) 1.2 (0.8, 1.7) 
rs12262237 A   1.1 (0.7, 1.8) 1.3 (0.7, 2.5) 
rs7100967 A   0.8 (0.5, 1.3) 1.2 (0.7, 2.1) 
rs477461 G 1.0 (0.8, 1.4) 1.3 (0.9, 1.9) 0.8 (0.6, 1.1) 1.1 (0.8, 1.7) 
rs434645 A 0.8 (0.6, 1.1) 0.9 (0.6, 1.3) 1.0 (0.8, 1.4) 0.7 (0.5, 1.2) 
rs379568 T 1.1 (0.8, 1.6) 1.2 (0.8, 1.9) 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) 
rs1778058 A 0.9 (0.7, 1.1) 1.0 (0.8, 1.3) 1.1 (0.9, 1.5) 1.2 (0.8, 1.8) 
rs12412241 A 0.8 (0.6, 1.1) 0.9 (0.6, 1.2) 1.0 (0.8, 1.4) 0.9 (0.6, 1.3) 
IL18      
rs4937075 G 1.2 (1.0, 1.5) 1.2 (0.9, 1.6) 1.0 (0.8, 1.4) 1.0 (0.6, 1.4) 
rs578784 T 1.2 (1.0, 1.6) 1.1 (0.8, 1.5) 1.0 (0.8, 1.4) 1.0 (0.6, 1.6) 
rs11214098 A   1.0 (0.6, 1.5) 0.8 (0.4, 1.6) 
rs543810 G 0.9 (0.6, 1.3) 0.9 (0.6, 1.5) 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs5744280 T 0.8 (0.7, 1.1) 0.7 (0.5, 1.0) 1.1 (0.8, 1.4) 1.1 (0.7, 1.5) 
rs5744238 A 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 1.2 (0.7, 2.3) 1.1 (0.5, 2.6) 
rs2043055 G 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 1.1 (0.8, 1.4) 1.0 (0.7, 1.5) 
rs360714 G   0.8 (0.6, 1.3) 1.1 (0.7, 1.9) 
rs1946518 T 1.0 (0.8, 1.3) 0.9 (0.7, 1.2) 0.8 (0.6, 1.1) 0.9 (0.6, 1.4) 
rs5744223 G 2.7 (0.7, 10.3) 0.0 (0.0, 0.0) 1.0 (0.7, 1.5) 1.0 (0.5, 1.8) 
rs5744222 A 1.1 (0.9, 1.4) 1.4 (1.0, 1.8) 0.8 (0.4, 1.5) 0.9 (0.4, 2.2) 
rs11214105 A 1.1 (0.9, 1.4) 1.0 (0.7, 1.3) 0.9 (0.6, 1.2) 0.9 (0.6, 1.4) 
KLDR1      
rs3759270 C 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 1.1 (0.8, 1.4) 1.1 (0.8, 1.7) 
rs3809214 T 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 0.9 (0.6, 1.1) 0.8 (0.6, 1.3) 
rs2302489 A 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 1.2 (0.9, 1.5) 1.2 (0.8, 1.7) 
rs7301562 C 2.2 (0.8, 6.3)  0.9 (0.6, 1.3) 1.0 (0.6, 1.7) 
rs10772256 T 2.2 (0.8, 6.3)  0.9 (0.6, 1.3) 1.1 (0.6, 1.8) 
rs2270238 T 1.0 (0.8, 1.2)  0.9 (0.5, 1.7)  
rs11611333 G 1.0 (0.8, 1.2) 0.9 (0.7, 1.2) 1.2 (0.9, 1.5) 1.1 (0.8, 1.6) 
rs12829155 G 1.0 (0.8, 1.2) 1.1 (0.8, 1.4) 0.7 (0.5, 1.0) 0.8 (0.5, 1.3) 
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  European Americana African Americana 
Gene/SNPb 
Variant 
Allelec 
Preterm Spont. Preterm Preterm Spont. Preterm 
IFNG      
rs10878760 T 1.2 (0.9, 1.6) 1.0 (0.7, 1.5) 1.2 (0.7, 2.2) 1.4 (0.7, 2.9) 
rs17104856 T   1.3 (0.8, 1.9) 1.4 (0.8, 2.6) 
rs2193047 T 1.1 (0.9, 1.4) 1.0 (0.7, 1.3) 1.3 (1.0, 1.7) 1.4 (1.0, 2.0) 
rs2041864 T 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 
rs11177074 C 1.0 (0.7, 1.5) 1.1 (0.7, 1.9) 1.3 (0.9, 1.8) 1.3 (0.8, 2.0) 
rs6581794 T 1.1 (0.9, 1.4) 0.9 (0.7, 1.3) 1.0 (0.7, 1.5) 1.1 (0.7, 1.8) 
rs3181035 A 1.0 (0.7, 1.5) 1.1 (0.7, 1.9) 1.4 (1.0, 1.8) 1.4 (1.0, 2.1) 
rs2069727 G 1.0 (0.8, 1.2) 1.1 (0.8, 1.4) 0.8 (0.6, 1.2) 0.6 (0.3, 1.1) 
rs1861494 C 1.1 (0.9, 1.4) 0.9 (0.7, 1.3) 1.1 (0.8, 1.6) 1.2 (0.7, 2.0) 
rs3181032 G 1.2 (0.6, 2.6) 1.1 (0.3, 4.0) 1.1 (0.7, 1.5) 1.0 (0.6, 1.6) 
rs7302488 G 1.1 (0.9, 1.4) 0.9 (0.7, 1.3) 1.2 (0.8, 1.6) 1.2 (0.7, 1.9) 
rs12306852 C 0.8 (0.6, 1.1) 0.9 (0.6, 1.4) 1.0 (0.8, 1.3) 1.2 (0.8, 1.7) 
TBX21      
rs2013383 A 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 0.9 (0.7, 1.2) 1.1 (0.7, 1.6) 
rs1808192 T 0.9 (0.7, 1.2) 1.1 (0.8, 1.5) 1.0 (0.7, 1.4) 1.3 (0.9, 2.1) 
rs4461115 C 1.0 (0.8, 1.3) 1.0 (0.7, 1.4) 1.1 (0.6, 2.1) 1.5 (0.7, 3.4) 
rs16946264 A 0.9 (0.6, 1.3) 1.1 (0.6, 1.7) 1.3 (1.0, 1.8) 1.2 (0.8, 1.8) 
rs11079788 T 0.9 (0.7, 1.2) 1.0 (0.7, 1.4) 1.1 (0.8, 1.5) 1.2 (0.8, 1.7) 
rs16946878 C 1.2 (0.8, 1.9) 1.4 (0.8, 2.4) 1.5 (1.0, 2.2) 1.3 (0.8, 2.2) 
rs16947078 G 0.9 (0.7, 1.2) 0.9 (0.7, 1.4) 1.2 (0.9, 1.6) 1.1 (0.7, 1.7) 
KIR3DL3      
rs4441391 A 1.0 (0.8, 1.2) 1.1 (0.8, 1.4) 0.8 (0.6, 1.2) 1.0 (0.6, 1.7) 
rs1325155 T 1.1 (0.9, 1.4) 1.1 (0.8, 1.4) 1.0 (0.8, 1.3) 0.8 (0.5, 1.2) 
rs1325156 A 0.8 (0.6, 1.1) 0.8 (0.6, 1.2) 1.1 (0.8, 1.4) 1.2 (0.9, 1.8) 
rs12151161 G 1.0 (0.7, 1.3) 0.8 (0.5, 1.3) 1.1 (0.8, 1.4) 1.4 (0.9, 2.0) 
rs7249048 G   1.1 (0.8, 1.6) 1.4 (0.9, 2.2) 
rs270775 G 1.0 (0.8, 1.2) 0.9 (0.7, 1.2) 1.1 (0.8, 1.5) 0.8 (0.5, 1.2) 
rs2296370 A 1.1 (0.9, 1.4) 1.1 (0.9, 1.5) 0.9 (0.7, 1.2) 0.8 (0.6, 1.3) 
rs2296371 A 1.0 (0.8, 1.2) 1.1 (0.8, 1.4) 1.2 (0.9, 1.6) 1.4 (1.0, 2.1) 
rs12982559 A 1.1 (0.9, 1.3) 1.1 (0.8, 1.4) 1.2 (0.9, 1.6) 1.2 (0.8, 1.9) 
rs11883241 T 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 1.0 (0.8, 1.3) 1.2 (0.9, 1.7) 
rs6509899 A 0.8 (0.6, 1.1) 0.9 (0.6, 1.4) 1.1 (0.8, 1.4) 1.3 (0.9, 1.9) 
rs1325158 T 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 1.2 (0.9, 1.6) 1.6 (1.1, 2.3) 
rs11671355 C 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 0.7 (0.4, 1.3) 0.5 (0.2, 1.3) 
rs16985907 C 1.0 (0.6, 1.7) 0.8 (0.4, 1.8) 1.0 (0.7, 1.6) 1.0 (0.6, 1.8) 
KIR2DL4      
rs35950908 A 1.2 (0.9, 1.6) 1.2 (0.8, 1.7) 0.6 (0.3, 1.1) 1.0 (0.5, 1.8) 
rs17771961 G 1.4 (1.1, 1.7) 1.7 (1.2, 2.3) 0.9 (0.6, 1.3) 0.8 (0.5, 1.4) 
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a Based on genetic ancestry 
b SNPs arranged by base pair position within each gene. Following the Stage 2 genes, genes are 
arranged from Chromosome 1- 19 according to position on the chromosome with SNPs arranged 
by base pair position within gene. 
c Variant allele chosen as the minor allele if the minor allele was the same in both ancestry 
groups. Otherwise variant is the Global Minor Allele from dbSNP. 
Empty cells are non-polymorphic for that ancestry group, were out of HWE, or had no cases. 
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Table S17: Paper#2 Demographics for entire PIN cohort, eligible cohort and genotyped cohort 
 All N=5169 Eligible N=3065 Genotyped N=1646 
Self-Reported Race: White 3035 (58.7) 1918 (62.6) 1031 (62.6) 
African American 1746 (33.8) 1147 (37.4) 615 (37.4) 
Other 387 (7.5) 0 0 
Missing race 1 0 0 
Age (years): Mean (SD) 26.8 (6.2) 26.2 (6.3) 26.1 (6.3) 
Smokera 935 (20.8) 657 (23.6) 383 (25.6) 
Missing smoking 670 0 152 
BMIb (m2/kg): Mean (IQR) 26.0 (21-29) 25.8 (21-29) 26.5 (21-30) 
Missing BMI 364 188 82 
Poverty: Mean (median, IQR) 305 (223, 109-476) 284.0 (198, 96-473) 273.0 (179, 95-464) 
Missing poverty 741 375 199 
Married 2959 (57.4) 1646 (53.7) 868 (52.8) 
Single 1843 (35.8) 1199 (39.1) 658 (40.0) 
Other 352 (6.8) 218 (7.1) 119 (7.2) 
Missing marital 15 2 1 
Education: 13+ years 3013 (58.5) 1663 (54.3) 854 (51.9) 
Missing Education 19 4 0 
First birth 2347 (45.6) 1400 (45.8) 769 (46.8) 
Multiparous 2803 (54.4) 1659 (54.2) 873 (53.1) 
Missing parity 19 5 4 
Prexisting Hypertension 263 (5.6) 139 (4.9) 112 (7.0) 
Gestational Hypertension 673 (14.2) 418 (14.8) 398 
Preeclampsia 294 (6.2) 185 (6.5) 170 
Missing  440 233 57 
Small for gestational age 371 (8.2) 239 (8.3) 216 
Missing SGA 658 167 105 
Preterm 686 (13.5) 377 (12.3) 347 
Missing PTB 80 0 0 
a Self-reported smoking during months 1-6 of pregnancy. 
b Pre-pregnancy BMI calculated from self-reported pre-pregnancy weight and measured height. 
Abbreviations: SD standard deviation, IQR interquartile range, BMI Body Mass index (kg/m2) 
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Table S18: Paper #2 Risk ratio and 95% confidence interval for all genotyped SNPs for SGA and 
Term SGA stratified by genetic ancestry 
Gene/SNP 
Variant 
Allele 
European American African American 
SGA Term SGA SGA Term SGA 
IL6 
 
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
rs6949149 T 0.7 (0.3, 1.5) 0.6 (0.2, 1.6) 1.0 (0.6, 1.8) 1.3 (0.7, 2.4) 
rs6954897 G 1.4 (0.8, 2.5) 1.4 (0.7, 2.6) 1.4 (0.9, 2.1) 1.4 (0.8, 2.4) 
rs6954681 T 1.0 (0.7, 1.5) 1.0 (0.6, 1.6) 0.8 (0.5, 1.3) 0.7 (0.4, 1.2) 
rs6969927 A 1.0 (0.7, 1.5) 1.0 (0.7, 1.6) 0.9 (0.5, 1.4) 1.0 (0.5, 1.7) 
rs10156056 C 1.1 (0.7, 1.8) 1.1 (0.7, 1.9) 0.9 (0.6, 1.5) 0.7 (0.4, 1.1) 
rs7776857 G 0.8 (0.5, 1.1) 0.8 (0.5, 1.2) 1.2 (0.6, 2.5) 0.7 (0.2, 2.0) 
rs4719711 C 0.6 (0.4, 0.9) 0.7 (0.4, 1.0) 1.0 (0.7, 1.6) 0.9 (0.5, 1.5) 
rs6963444 G 1.9 (1.0, 3.7) 2.1 (1.0, 4.2) 1.8 (1.2, 2.8) 2.5 (1.5, 4.2) 
rs1546762 C 0.6 (0.4, 0.9) 0.6 (0.4, 1.0) 1.1 (0.7, 1.7) 0.8 (0.5, 1.5) 
rs7805828* A 1.2 (0.9, 1.5) 1.1 (0.8, 1.4) 0.9 (0.6, 1.2) 0.9 (0.6, 1.3) 
rs1880241* G 1.0 (0.8, 1.4) 0.9 (0.7, 1.3) 0.8 (0.6, 1.1) 0.8 (0.5, 1.2) 
rs2056576 T 1.1 (0.7, 1.5) 0.9 (0.6, 1.4) 1.1 (0.7, 1.7) 1.0 (0.6, 1.7) 
rs7784987 A 2.0 (1.0, 3.8) 2.1 (1.1, 4.4) 1.5 (1.0, 2.4) 2.1 (1.2, 3.6) 
rs3087221 T 2.3 (1.0, 5.4) 2.0 (0.8, 5.4) 1.4 (0.9, 2.3) 1.8 (1.1, 3.1) 
rs2069824 C 1.2 (0.7, 2.0) 1.1 (0.6, 2.1) 1.1 (0.7, 1.8) 0.8 (0.4, 1.5) 
rs1800797 A 1.0 (0.6, 1.4) 1.1 (0.7, 1.7) 1.2 (0.6, 2.3) 0.7 (0.3, 1.8) 
rs1800795 C 0.9 (0.6, 1.3) 1.0 (0.7, 1.6) 1.1 (0.6, 2.2) 0.7 (0.3, 1.8) 
rs2069835 C 1.0 (0.5, 1.9) 0.8 (0.4, 1.7) 0.8 (0.4, 1.3) 0.7 (0.3, 1.4) 
rs1474347 G 0.9 (0.6, 1.3) 1.0 (0.6, 1.5) 0.9 (0.6, 1.5) 0.7 (0.4, 1.3) 
rs2069840 G 1.0 (0.7, 1.4) 1.0 (0.6, 1.5) 0.9 (0.6, 1.5) 1.1 (0.6, 2.0) 
rs2069842 A   1.1 (0.6, 1.9) 1.4 (0.7, 2.6) 
rs1548216 C 2.3 (1.2, 4.2) 2.4 (1.2, 4.7) 1.6 (1.0, 2.5) 2.1 (1.2, 3.5) 
rs2069843 A 2.2 (1.2, 4.1) 2.4 (1.2, 4.6) 1.5 (1.0, 2.5) 2.0 (1.2, 3.5) 
rs2069845* G 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 1.3 (0.9, 1.8) 1.4 (0.9, 2.1) 
rs2069849 T 2.2 (1.2, 4.1) 2.4 (1.2, 4.6) 1.4 (0.9, 2.3) 1.9 (1.1, 3.2) 
rs10242595* G 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 1.2 (0.8, 1.6) 1.3 (0.9, 2.0) 
KLRD1 
 
    rs3759270 C 1.3 (0.9, 2.0) 1.3 (0.8, 2.0) 0.6 (0.4, 1.0) 0.4 (0.3, 0.8) 
rs3809214* T 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 1.3 (0.9, 1.8) 1.6 (1.1, 2.4) 
rs2302489* T 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 1.3 (0.9, 1.8) 1.6 (1.1, 2.4) 
rs7301562 C 1.1 (0.2, 7.9) 1.6 (0.2, 11.8) 0.6 (0.4, 1.0) 0.5 (0.3, 0.9) 
rs10772256 T 1.1 (0.2, 7.9) 1.6 (0.2, 11.8) 0.6 (0.4, 1.0) 0.5 (0.3, 0.9) 
rs2270238 T 1.5 (1.0, 2.2) 1.5 (1.0, 2.4) 0.8 (0.4, 1.8) 0.8 (0.3, 2.1) 
rs11611333* G 1.3 (1.0, 1.6) 1.2 (0.9, 1.7) 1.1 (0.8, 1.5) 1.0 (0.7, 1.5) 
rs12829155* G 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 1.3 (0.9, 1.9) 1.5 (0.9, 2.4) 
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Gene/SNP 
Variant 
Allele 
European American African American 
SGA Term SGA SGA Term SGA 
TNFRSF1B 
 
    rs496888* G 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 1.0 (0.7, 1.4) 1.0 (0.6, 1.4) 
rs3766730 T 0.8 (0.5, 1.3) 0.7 (0.4, 1.2) 0.6 (0.3, 1.5) 0.5 (0.2, 1.6) 
rs816050 T 1.2 (0.8, 1.8) 1.1 (0.7, 1.8) 1.1 (0.7, 1.7) 1.1 (0.6, 1.9) 
rs1201157* T 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 0.9 (0.6, 1.4) 
rs1061622 G 0.8 (0.5, 1.1) 0.7 (0.4, 1.1) 0.9 (0.5, 1.4) 0.8 (0.4, 1.4) 
rs5746051 G 0.7 (0.5, 1.1) 0.6 (0.4, 1.0) 0.6 (0.3, 1.4) 0.5 (0.2, 1.3) 
rs5746053 A 0.7 (0.4, 1.0) 0.6 (0.4, 1.0) 0.6 (0.4, 1.1) 0.6 (0.3, 1.2) 
rs1061624* G 1.0 (0.8, 1.3) 0.9 (0.7, 1.3) 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 
rs1061628* T 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 0.8 (0.6, 1.2) 0.9 (0.6, 1.3) 
IL6R 
 
    rs11265607 G 0.8 (0.6, 1.2) 0.9 (0.6, 1.4) 0.6 (0.4, 1.0) 0.5 (0.3, 0.8) 
rs6427627* C 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 0.6 (0.4, 0.9) 
rs11265608 A 0.9 (0.6, 1.5) 0.7 (0.4, 1.3) 0.8 (0.5, 1.5) 0.8 (0.4, 1.6) 
rs17654071 G 1.5 (1.0, 2.4) 0.0 (0.0, 0.0) 1.1 (0.7, 1.6) 1.2 (0.7, 2.0) 
rs2054855 T 0.8 (0.5, 1.3) 0.8 (0.4, 1.3) 1.1 (0.7, 1.8) 1.3 (0.8, 2.2) 
rs4845615 A 2.6 (0.5, 12.2) 3.0 (0.6, 15.3) 1.0 (0.6, 1.8) 1.0 (0.5, 2.0) 
rs1552481 G 3.0 (0.9, 10.5) 3.4 (0.9, 12.6) 1.1 (0.7, 1.7) 1.0 (0.6, 1.8) 
rs4845617 A 0.8 (0.5, 1.2) 0.8 (0.5, 1.2) 1.1 (0.7, 1.8) 1.3 (0.7, 2.3) 
rs6427641* G 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 0.8 (0.6, 1.2) 0.8 (0.6, 1.1) 
rs11265610 C 2.0 (0.4, 8.7) 2.5 (0.5, 11.4) 0.9 (0.6, 1.3) 0.7 (0.4, 1.2) 
rs12083537 G 1.1 (0.7, 1.6) 1.1 (0.7, 1.7) 0.9 (0.6, 1.3) 0.7 (0.4, 1.1) 
rs1386821 C 1.0 (0.7, 1.5) 1.0 (0.6, 1.6) 0.7 (0.4, 1.3) 0.5 (0.2, 1.1) 
rs12090237 A 1.5 (0.6, 3.9) 1.9 (0.7, 4.9) 1.3 (0.8, 2.1) 1.0 (0.5, 1.8) 
rs6684439 T 1.5 (1.0, 2.3) 1.9 (1.2, 3.1) 1.3 (0.8, 2.1) 1.4 (0.8, 2.5) 
rs12096944 T   0.9 (0.5, 1.7) 1.2 (0.6, 2.4) 
rs12060250 G   1.0 (0.5, 1.8) 1.2 (0.6, 2.4) 
rs4845618* G 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 
rs7549250* C 1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 0.9 (0.6, 1.4) 
rs7518199 C 1.3 (0.9, 2.0) 1.5 (0.9, 2.5) 1.0 (0.7, 1.6) 1.0 (0.6, 1.7) 
rs4553185* C 1.1 (0.8, 1.4) 1.0 (0.8, 1.4) 0.9 (0.7, 1.3) 0.9 (0.6, 1.3) 
rs4845623* G 1.1 (0.8, 1.4) 1.2 (0.9, 1.5) 1.2 (0.9, 1.6) 1.3 (0.9, 2.0) 
rs4537545* T 1.2 (0.9, 1.5) 1.3 (1.0, 1.8) 1.0 (0.7, 1.4) 1.1 (0.8, 1.7) 
rs4845626 T 0.9 (0.6, 1.3) 0.8 (0.5, 1.2) 0.7 (0.5, 1.1) 0.9 (0.5, 1.6) 
rs4845374 A 0.8 (0.5, 1.3) 0.8 (0.5, 1.2) 1.0 (0.6, 1.5) 0.8 (0.4, 1.3) 
rs11265618 T 0.9 (0.6, 1.3) 0.8 (0.5, 1.2) 0.8 (0.5, 1.2) 1.0 (0.6, 1.6) 
rs4329505 C 0.8 (0.5, 1.3) 0.8 (0.5, 1.2) 1.4 (0.9, 2.3) 1.4 (0.8, 2.4) 
rs4341355* C 1.2 (0.8, 1.6) 1.2 (0.8, 1.7) 0.9 (0.6, 1.2) 0.9 (0.6, 1.3) 
rs2229238 T 0.9 (0.6, 1.3) 0.9 (0.6, 1.5) 1.1 (0.7, 1.7) 1.0 (0.6, 1.8) 
rs4072391 T 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 1.3 (0.8, 2.0) 1.3 (0.8, 2.2) 
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Gene/SNP 
Variant 
Allele 
European American African American 
SGA Term SGA SGA Term SGA 
rs11265621* G 0.9 (0.6, 1.2) 0.8 (0.6, 1.1) 0.9 (0.7, 1.3) 1.0 (0.7, 1.4) 
rs7526293 T 1.0 (0.7, 1.5) 1.0 (0.6, 1.5) 1.0 (0.6, 1.6) 1.0 (0.6, 1.7) 
IL10 
 
    rs7539748 A 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 1.7 (0.9, 3.3) 1.9 (0.9, 4.2) 
rs11119451* C 1.2 (0.9, 1.7) 1.1 (0.8, 1.6) 1.0 (0.7, 1.5) 1.0 (0.7, 1.5) 
rs6658896 T 1.4 (0.6, 2.9) 1.3 (0.6, 3.1) 0.7 (0.4, 1.2) 0.6 (0.3, 1.3) 
rs6692511* T 0.9 (0.7, 1.2) 1.0 (0.7, 1.4) 1.0 (0.7, 1.6) 1.0 (0.6, 1.7) 
rs6699203* A 0.8 (0.6, 1.1) 1.0 (0.7, 1.3) 1.0 (0.7, 1.6) 1.0 (0.6, 1.7) 
rs4390174* G 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 1.2 (0.9, 1.7) 1.3 (0.9, 1.9) 
rs6673928 T 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 1.3 (0.8, 2.1) 1.8 (1.0, 3.1) 
rs3024496* C 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 1.1 (0.8, 1.4) 1.0 (0.7, 1.5) 
rs1878672 G 0.9 (0.6, 1.4) 0.9 (0.6, 1.4) 1.3 (0.8, 2.0) 1.2 (0.7, 2.1) 
rs3024493 T 0.9 (0.6, 1.4) 0.8 (0.5, 1.3) 1.2 (0.5, 2.8) 1.0 (0.3, 2.8) 
rs3024491 T 0.9 (0.6, 1.3) 0.8 (0.5, 1.3) 1.2 (0.8, 1.9) 1.1 (0.7, 1.8) 
rs3024490* T 0.8 (0.6, 1.1) 0.9 (0.6, 1.4) 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 
rs1800871* T 0.8 (0.6, 1.1) 0.9 (0.6, 1.4) 1.0 (0.7, 1.4) 1.0 (0.7, 1.4) 
rs1800890 A 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 1.3 (0.9, 2.1) 1.4 (0.9, 2.4) 
rs17015767 C 1.0 (0.7, 1.5) 1.0 (0.7, 1.6) 1.2 (0.7, 2.0) 1.6 (0.9, 2.9) 
rs10494879* G 1.1 (0.9, 1.5) 1.1 (0.8, 1.5) 1.2 (0.8, 1.6) 1.2 (0.8, 1.8) 
rs6686931* T 0.9 (0.7, 1.3) 1.0 (0.7, 1.4) 0.9 (0.7, 1.3) 0.9 (0.7, 1.4) 
IL1A 
 
    rs17561 T 1.0 (0.6, 1.4) 1.0 (0.6, 1.5) 1.1 (0.7, 1.8) 1.0 (0.6, 1.7) 
rs1800587 T 1.0 (0.7, 1.4) 1.0 (0.6, 1.5) 1.0 (0.6, 1.5) 0.9 (0.5, 1.6) 
IL1B 
 
    rs1143634 T 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 0.7 (0.4, 1.3) 0.6 (0.3, 1.2) 
rs1143627* T 1.1 (0.8, 1.6) 1.0 (0.7, 1.4) 0.9 (0.7, 1.3) 0.8 (0.5, 1.2) 
IL8RB 
 
    rs4674258* C 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 1.0 (0.7, 1.3) 0.9 (0.6, 1.2) 
rs4674259 G 0.8 (0.5, 1.2) 0.9 (0.5, 1.4) 0.7 (0.5, 1.2) 0.7 (0.4, 1.2) 
rs6761387 T 1.4 (0.7, 2.5) 1.3 (0.6, 2.5) 1.0 (0.6, 1.6) 0.8 (0.5, 1.5) 
rs4674261* C 1.3 (1.0, 1.7) 1.2 (0.9, 1.7) 1.1 (0.8, 1.5) 1.2 (0.8, 1.7) 
rs11677534 T 0.8 (0.5, 1.2) 0.9 (0.5, 1.4) 1.0 (0.6, 1.5) 1.0 (0.6, 1.6) 
rs11676348* C 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.7 (0.5, 1.0) 
IL12A 
 
    rs503582* T 0.9 (0.7, 1.1) 0.9 (0.6, 1.2) 0.9 (0.7, 1.2) 0.8 (0.6, 1.2) 
rs532953 C 0.8 (0.5, 1.2) 0.7 (0.4, 1.2) 1.4 (0.8, 2.2) 1.3 (0.7, 2.5) 
rs7653097 C 0.8 (0.5, 1.5) 0.8 (0.4, 1.6) 1.2 (0.7, 1.8) 1.1 (0.6, 1.9) 
rs1014486* G 1.1 (0.9, 1.5) 1.2 (0.9, 1.6) 1.2 (0.9, 1.6) 1.1 (0.8, 1.6) 
rs13064168 A 0.8 (0.5, 1.3) 1.0 (0.6, 1.5) 1.4 (0.8, 2.5) 1.3 (0.6, 2.7) 
rs609907 C 0.7 (0.5, 1.1) 0.7 (0.5, 1.1) 1.2 (0.7, 1.9) 1.1 (0.6, 2.0) 
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rs2647929 A 1.1 (0.7, 1.6) 1.0 (0.6, 1.5) 0.7 (0.4, 1.1) 0.7 (0.4, 1.3) 
rs2886666 T 1.8 (1.2, 2.6) 1.7 (1.1, 2.7) 0.6 (0.2, 1.6) 0.7 (0.2, 2.0) 
rs9811792 C 1.3 (0.8, 2.0) 1.2 (0.8, 2.0) 0.9 (0.6, 1.3) 0.9 (0.5, 1.5) 
rs16830946 G   0.8 (0.5, 1.4) 0.8 (0.4, 1.6) 
rs7372767 G 1.1 (0.7, 1.6) 1.0 (0.6, 1.6) 0.7 (0.4, 1.1) 0.7 (0.4, 1.3) 
rs6441282* T 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 0.9 (0.6, 1.3) 
rs692890* T 0.8 (0.6, 1.1) 0.9 (0.6, 1.2) 1.0 (0.7, 1.4) 0.9 (0.6, 1.4) 
rs755004 T 1.1 (0.8, 1.7) 1.2 (0.8, 2.0) 1.2 (0.6, 2.4) 1.5 (0.7, 3.2) 
rs16830949 T   1.1 (0.7, 1.7) 1.1 (0.6, 1.9) 
rs2243115 G 1.0 (0.6, 1.7) 0.9 (0.5, 1.6) 1.3 (0.8, 2.2) 1.4 (0.7, 2.6) 
rs583911 G 1.5 (0.9, 2.3) 1.5 (0.9, 2.4) 0.9 (0.6, 1.4) 1.2 (0.7, 2.0) 
rs2243151* T 0.9 (0.7, 1.2) 0.8 (0.6, 1.1) 1.0 (0.8, 1.4) 0.9 (0.6, 1.4) 
rs2243154 A 1.0 (0.6, 1.7) 1.2 (0.7, 2.0) 0.7 (0.2, 2.7) 1.0 (0.3, 4.0) 
rs4608735 C 1.0 (0.6, 1.6) 0.9 (0.5, 1.6) 1.4 (0.9, 2.2) 1.3 (0.7, 2.3) 
rs17826053 G 0.8 (0.5, 1.2) 0.8 (0.5, 1.3) 0.9 (0.5, 1.4) 0.7 (0.4, 1.3) 
rs485497 A 1.4 (0.9, 2.3) 1.5 (0.9, 2.4) 0.9 (0.6, 1.4) 1.1 (0.6, 1.8) 
rs4680536* G 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 1.1 (0.8, 1.6) 1.0 (0.7, 1.5) 
rs12492730 G   1.4 (0.9, 2.3) 1.4 (0.8, 2.5) 
rs9852519 T 1.3 (0.9, 2.0) 1.3 (0.9, 2.1) 0.8 (0.5, 1.2) 1.0 (0.5, 1.7) 
rs598638 T 1.0 (0.7, 1.5) 0.9 (0.6, 1.5) 1.3 (0.5, 3.1) 1.5 (0.5, 4.2) 
IL8 
 
    rs7654490 T 4.0 (0.5, 30.7)  0.8 (0.5, 1.3) 0.8 (0.5, 1.5) 
rs16849893 A   1.0 (0.6, 1.6) 0.9 (0.5, 1.6) 
rs16849896 T   0.7 (0.4, 1.1) 0.7 (0.4, 1.3) 
rs4694634 C   1.1 (0.7, 1.7) 0.8 (0.5, 1.4) 
rs16849907 T   1.0 (0.6, 1.8) 1.1 (0.6, 2.1) 
rs12506479 C 0.9 (0.6, 1.3) 0.8 (0.5, 1.2) 0.9 (0.6, 1.4) 0.9 (0.5, 1.5) 
rs10805066* G 1.4 (1.0, 1.8) 1.6 (1.2, 2.1) 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs7693566 C   0.7 (0.4, 1.1) 0.6 (0.3, 1.0) 
rs4694635 T 1.8 (0.6, 5.6) 1.2 (0.3, 5.4) 1.3 (0.8, 2.0) 1.4 (0.8, 2.5) 
rs16849928* A 1.1 (0.8, 1.4) 1.2 (0.9, 1.6) 1.3 (0.9, 1.7) 1.4 (1.0, 2.0) 
rs11730667 A 1.3 (0.8, 2.1) 1.7 (1.0, 3.1) 1.4 (0.9, 2.2) 1.5 (0.9, 2.5) 
rs13142454 G   1.3 (0.8, 2.1) 1.6 (0.9, 2.7) 
rs11729759 A   1.4 (0.9, 2.2) 1.9 (1.1, 3.2) 
rs1951240* G 0.9 (0.7, 1.2) 0.8 (0.6, 1.1) 1.0 (0.7, 1.4) 1.1 (0.7, 1.6) 
rs16849958 C 1.0 (0.6, 1.5) 0.9 (0.6, 1.4) 0.8 (0.5, 1.3) 0.7 (0.4, 1.3) 
rs1951242 T 1.4 (0.8, 2.3) 1.8 (1.0, 3.2) 1.1 (0.7, 1.8) 1.2 (0.7, 2.0) 
rs7658422 C   1.3 (0.9, 2.1) 1.8 (1.1, 3.0) 
CXCL10 
 
    rs3733236 T 1.5 (0.9, 2.4) 1.5 (0.9, 2.6) 1.2 (0.8, 1.8) 1.4 (0.9, 2.4) 
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rs10031051 C 0.8 (0.3, 2.5) 0.7 (0.2, 2.7) 1.1 (0.6, 1.9) 1.1 (0.5, 2.1) 
rs7670156 A 1.3 (0.8, 2.0) 1.3 (0.8, 2.2) 1.2 (0.7, 2.0) 1.5 (0.8, 2.8) 
rs12651276 G 1.0 (0.7, 1.5) 1.0 (0.6, 1.5) 0.5 (0.2, 1.3) 0.3 (0.1, 1.2) 
rs10518143 C 0.7 (0.5, 1.1) 0.7 (0.4, 1.0) 0.6 (0.3, 1.1) 0.5 (0.2, 1.1) 
rs867562 A 1.0 (0.7, 1.5) 0.9 (0.6, 1.4) 0.9 (0.4, 2.1) 0.6 (0.2, 2.1) 
rs4508917 G 0.7 (0.5, 1.0) 0.7 (0.4, 1.0) 0.8 (0.5, 1.2) 0.8 (0.5, 1.4) 
rs12504339* C 1.1 (0.8, 1.5) 1.1 (0.8, 1.5) 1.0 (0.8, 1.4) 1.2 (0.8, 1.7) 
rs4302486 A 1.1 (0.7, 1.6) 1.1 (0.7, 1.8) 1.0 (0.7, 1.6) 0.9 (0.5, 1.6) 
NFKB1 
 
    rs980455* G 0.8 (0.6, 1.1) 0.9 (0.6, 1.2) 0.9 (0.6, 1.2) 1.0 (0.7, 1.5) 
rs3774933* C 0.9 (0.6, 1.1) 0.9 (0.6, 1.2) 1.0 (0.7, 1.5) 1.2 (0.8, 1.9) 
rs17032705* A 0.8 (0.6, 1.1) 0.9 (0.6, 1.2) 1.2 (0.8, 1.7) 1.4 (0.9, 2.2) 
rs1599961* A 0.9 (0.6, 1.1) 0.9 (0.6, 1.2) 1.1 (0.8, 1.6) 1.3 (0.8, 2.0) 
rs17032740 G 1.1 (0.2, 8.4) 1.3 (0.2, 9.9) 0.9 (0.5, 1.5) 1.2 (0.7, 2.2) 
rs230533 T 0.9 (0.6, 1.3) 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 1.0 (0.6, 1.7) 
rs230530 C 1.1 (0.7, 1.7) 1.1 (0.7, 1.7) 1.2 (0.7, 1.8) 1.1 (0.6, 1.9) 
rs230529 A 0.8 (0.5, 1.1) 0.8 (0.5, 1.2) 0.9 (0.6, 1.4) 0.9 (0.5, 1.6) 
rs17032779 C 1.4 (0.4, 4.2) 1.6 (0.5, 5.1) 1.1 (0.6, 1.8) 1.1 (0.6, 2.1) 
rs230515 C 0.9 (0.6, 1.3) 0.9 (0.6, 1.3) 0.8 (0.5, 1.4) 0.8 (0.5, 1.5) 
rs230493 A 0.8 (0.6, 1.2) 0.8 (0.6, 1.3) 1.0 (0.6, 1.5) 0.9 (0.5, 1.5) 
rs17032815 A 1.8 (0.7, 4.7) 2.1 (0.8, 5.7) 0.9 (0.5, 1.6) 1.0 (0.5, 1.9) 
rs909332 T 1.0 (0.5, 2.1) 1.2 (0.6, 2.6) 1.2 (0.7, 2.1) 1.0 (0.5, 2.0) 
rs1801* C 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 1.1 (0.8, 1.5) 1.1 (0.7, 1.7) 
rs4648058* C 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 1.1 (0.7, 1.5) 1.1 (0.7, 1.7) 
rs3755867* G 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 1.0 (0.7, 1.5) 1.1 (0.7, 1.7) 
rs4648090 A 1.0 (0.6, 1.5) 0.9 (0.5, 1.5) 0.8 (0.5, 1.3) 0.7 (0.4, 1.3) 
rs4648110* A 1.2 (0.9, 1.6) 1.1 (0.8, 1.6) 0.8 (0.6, 1.1) 0.7 (0.5, 1.1) 
rs3817685 G 0.8 (0.5, 1.1) 0.8 (0.5, 1.2) 1.1 (0.7, 1.7) 1.2 (0.7, 2.0) 
rs4648127 T 1.5 (0.9, 2.5) 1.6 (1.0, 2.7) 1.2 (0.2, 8.1) 1.9 (0.3, 11.9) 
rs230547 T 0.8 (0.4, 1.4) 0.7 (0.4, 1.5) 1.2 (0.7, 1.9) 1.2 (0.6, 2.2) 
rs4648135 G 0.9 (0.4, 1.8) 1.1 (0.5, 2.3) 1.1 (0.7, 1.7) 0.9 (0.5, 1.5) 
rs4648141* A 1.2 (0.9, 1.7) 1.3 (0.9, 1.8) 0.8 (0.6, 1.1) 0.7 (0.5, 1.1) 
rs7674640* C 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.1 (0.8, 1.6) 1.0 (0.7, 1.6) 
rs10489113* G 1.4 (1.0, 1.9) 1.4 (1.0, 2.0) 0.8 (0.6, 1.1) 0.8 (0.5, 1.2) 
rs11733293* T 0.7 (0.6, 1.0) 0.7 (0.5, 1.0) 1.1 (0.8, 1.6) 1.2 (0.8, 1.8) 
rs17033015 A 1.0 (0.7, 1.5) 1.0 (0.6, 1.5) 1.0 (0.6, 1.6) 0.9 (0.5, 1.6) 
rs12648696* C 0.8 (0.6, 1.0) 0.8 (0.5, 1.0) 1.2 (0.8, 1.6) 1.3 (0.9, 2.0) 
IL2 
 
    rs17454584 G 0.9 (0.6, 1.3) 0.9 (0.6, 1.3) 0.9 (0.4, 2.0) 1.0 (0.4, 2.5) 
rs35914000 A 0.8 (0.6, 1.2) 0.8 (0.5, 1.2) 1.1 (0.5, 2.1) 1.0 (0.5, 2.3) 
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rs10034410 T 7.1 (2.5, 19.8) 9.7 (3.9, 24.4) 0.8 (0.4, 1.4) 0.5 (0.2, 1.0) 
rs10027390 C 1.0 (0.7, 1.5) 1.1 (0.7, 1.7)   
rs11932411 C 2.4 (0.7, 9.1) 3.2 (0.9, 11.9) 0.8 (0.5, 1.3) 0.6 (0.4, 1.0) 
rs2069776 C 1.0 (0.7, 1.5) 1.1 (0.7, 1.6) 1.2 (0.7, 1.8) 1.3 (0.8, 2.3) 
rs2069778 T 0.7 (0.4, 1.0) 0.7 (0.4, 1.1) 1.4 (0.6, 3.2) 1.6 (0.6, 4.3) 
rs2069762 G 1.3 (0.9, 2.0) 1.4 (0.9, 2.1) 1.5 (0.9, 2.6) 1.2 (0.6, 2.5) 
rs4833248 A 1.3 (0.9, 2.0) 1.4 (0.9, 2.1) 1.5 (0.9, 2.6) 1.2 (0.6, 2.5) 
IL15 
 
    rs6837991 T 0.8 (0.5, 1.1) 0.7 (0.5, 1.1) 1.0 (0.7, 1.6) 1.2 (0.7, 2.1) 
rs12508866 C 1.0 (0.7, 1.5) 1.0 (0.7, 1.6) 1.2 (0.7, 2.3) 0.9 (0.4, 2.2) 
rs17007476 C 5.0 (1.0, 24.3) 5.4 (1.1, 26.4) 1.1 (0.6, 1.7) 0.7 (0.4, 1.4) 
rs17007480 A 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.7 (0.4, 1.5) 0.8 (0.3, 1.9) 
rs1519551* G 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 0.7 (0.5, 1.0) 
rs17461269 A 0.9 (0.6, 1.3) 0.9 (0.6, 1.4) 1.2 (0.6, 2.3) 1.2 (0.5, 2.8) 
rs17007503 C   0.7 (0.4, 1.4) 0.7 (0.3, 1.6) 
rs1519552 A 0.8 (0.5, 1.2) 0.8 (0.5, 1.2) 1.2 (0.8, 2.0) 1.2 (0.7, 2.0) 
rs17007508 G 2.2 (0.4, 14.1) 2.4 (0.4, 14.9) 0.9 (0.6, 1.5) 1.0 (0.6, 1.8) 
rs7698675 T 0.8 (0.5, 1.1) 0.8 (0.5, 1.2) 1.2 (0.8, 1.9) 1.2 (0.7, 2.0) 
rs13117878* C 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 1.1 (0.8, 1.4) 0.8 (0.6, 1.2) 
rs17364630 G 1.0 (0.7, 1.6) 1.2 (0.8, 1.9) 0.9 (0.5, 1.6) 0.7 (0.3, 1.3) 
rs12498901 C 1.0 (0.7, 1.6) 1.2 (0.8, 1.9) 1.0 (0.6, 1.7) 0.8 (0.4, 1.6) 
rs7671458 G 1.0 (0.7, 1.5) 1.2 (0.8, 1.9) 0.9 (0.6, 1.5) 0.8 (0.4, 1.4) 
rs10519610 C 1.0 (0.7, 1.5) 1.2 (0.8, 1.8) 0.9 (0.6, 1.3) 0.7 (0.4, 1.2) 
rs6850492 A 0.8 (0.6, 1.2) 0.9 (0.6, 1.4) 1.1 (0.7, 1.7) 0.8 (0.5, 1.4) 
rs2087849 T 0.8 (0.6, 1.2) 0.8 (0.5, 1.3) 1.4 (0.9, 2.2) 1.5 (0.9, 2.6) 
rs2857261* G 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.0 (0.7, 1.3) 1.2 (0.9, 1.8) 
rs1907949 T 1.2 (0.8, 1.9) 1.0 (0.6, 1.7) 0.6 (0.3, 1.0) 0.4 (0.2, 0.9) 
rs3775597 C 1.1 (0.7, 1.8) 0.9 (0.5, 1.6) 1.0 (0.6, 1.8) 0.9 (0.5, 1.8) 
rs12508955 T 0.9 (0.6, 1.2) 0.8 (0.5, 1.3) 1.5 (0.9, 2.3) 1.2 (0.7, 2.2) 
rs17007610* T 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 0.7 (0.5, 1.1) 
CSF2 
 
    rs31400* T 1.0 (0.8, 1.4) 1.0 (0.7, 1.3) 0.9 (0.7, 1.2) 0.9 (0.6, 1.3) 
rs3091335 G 3.3 (1.2, 8.8) 2.5 (0.6, 10.2) 1.2 (0.7, 1.8) 1.0 (0.6, 1.6) 
rs31481 A 1.3 (0.9, 1.9) 1.2 (0.7, 1.8) 1.4 (0.9, 2.2) 1.5 (0.8, 2.5) 
rs2069801 G 3.9 (0.5, 28.4) 4.0 (0.6, 29.1) 0.6 (0.3, 1.1) 0.5 (0.2, 1.1) 
rs246844 A 1.1 (0.7, 1.7) 0.9 (0.6, 1.5) 0.9 (0.6, 1.4) 1.0 (0.6, 1.6) 
rs11575022 C 1.3 (0.7, 2.3) 1.0 (0.4, 2.1) 0.9 (0.6, 1.4) 1.0 (0.6, 1.8) 
rs246841 T 1.2 (0.7, 1.9) 1.1 (0.6, 1.8) 1.9 (0.9, 3.9) 1.8 (0.7, 4.5) 
rs168681 A 1.2 (0.8, 1.9) 1.2 (0.8, 2.0) 1.0 (0.6, 1.5) 1.0 (0.6, 1.7) 
rs721121* G 0.9 (0.7, 1.1) 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 1.0 (0.6, 1.4) 
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rs4705916 A 0.9 (0.6, 1.4) 1.0 (0.6, 1.6) 0.6 (0.4, 1.0) 0.6 (0.3, 1.0) 
rs743677 G 1.4 (0.2, 10.7) 
 
1.8 (1.2, 2.9) 1.5 (0.9, 2.6) 
rs2069626 G 0.8 (0.2, 3.3) 0.5 (0.1, 3.9) 1.5 (0.9, 2.5) 1.5 (0.8, 2.9) 
rs743564* G 0.8 (0.6, 1.1) 0.9 (0.6, 1.2) 0.6 (0.4, 1.0) 0.6 (0.3, 1.0) 
rs25881 T 1.1 (0.8, 1.7) 1.0 (0.6, 1.6) 1.0 (0.6, 1.5) 1.0 (0.6, 1.7) 
rs25882 C 1.1 (0.8, 1.7) 1.0 (0.6, 1.6) 1.4 (0.9, 2.3) 1.4 (0.8, 2.3) 
rs27438 A 1.2 (0.8, 1.8) 1.1 (0.7, 1.7) 1.2 (0.6, 2.2) 1.0 (0.5, 2.2) 
rs25887* C 1.1 (0.8, 1.4) 1.2 (0.9, 1.6) 1.3 (1.0, 1.9) 1.4 (0.9, 2.1) 
rs6898270 T 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 0.6 (0.4, 0.9) 0.5 (0.3, 0.9) 
IL13 
 
    rs7737470 A 1.1 (0.7, 1.6) 1.1 (0.7, 1.8) 1.1 (0.7, 1.7) 1.1 (0.6, 1.8) 
rs4621555 C   1.1 (0.7, 1.8) 1.0 (0.6, 1.9) 
rs3091307 G 1.1 (0.7, 1.6) 1.1 (0.7, 1.8) 1.2 (0.6, 2.4) 1.4 (0.6, 3.5) 
rs1881457 C 1.1 (0.8, 1.7) 1.2 (0.7, 1.8) 1.1 (0.7, 1.7) 1.0 (0.6, 1.8) 
rs2069744 T 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 1.0 (0.6, 1.5) 1.2 (0.7, 2.0) 
rs1295686 G 0.7 (0.3, 1.7) 0.7 (0.2, 1.8) 1.1 (0.7, 1.6) 1.2 (0.7, 2.0) 
rs20541 T 0.9 (0.6, 1.4) 0.9 (0.5, 1.4) 0.9 (0.6, 1.4) 0.9 (0.5, 1.5) 
rs848 T 1.0 (0.6, 1.4) 0.8 (0.5, 1.4) 0.9 (0.5, 1.4) 0.8 (0.5, 1.5) 
rs1295683 T 1.1 (0.7, 1.8) 1.0 (0.6, 1.7) 0.6 (0.3, 1.1) 0.8 (0.4, 1.6) 
rs2243204 T 0.7 (0.4, 1.3) 0.6 (0.3, 1.3) 1.5 (0.8, 2.8) 1.4 (0.6, 2.9) 
rs2243210 A 0.9 (0.5, 1.7) 1.0 (0.5, 1.8) 1.0 (0.7, 1.6) 1.0 (0.6, 1.7) 
rs2243218 A 0.9 (0.5, 1.7) 1.0 (0.6, 1.9) 1.3 (0.8, 2.0) 1.1 (0.6, 1.9) 
rs2243219 G 1.1 (0.6, 1.8) 1.1 (0.6, 2.0) 1.2 (0.7, 2.2) 1.0 (0.5, 2.0) 
IL4 
 
    rs2243240 T   1.4 (0.8, 2.6) 1.3 (0.6, 2.8) 
rs2243246 C   0.9 (0.5, 1.4) 0.8 (0.4, 1.4) 
rs2243248 G 0.9 (0.5, 1.6) 0.8 (0.4, 1.6) 1.2 (0.8, 1.9) 1.1 (0.6, 1.9) 
rs2243250 C 0.3 (0.1, 0.8) 0.3 (0.1, 0.7) 1.2 (0.8, 1.9) 1.3 (0.7, 2.1) 
rs2243253 T   1.7 (1.1, 2.7) 1.7 (1.0, 3.0) 
rs2243261 T   0.9 (0.5, 1.5) 0.8 (0.4, 1.4) 
rs2243263 C 1.1 (0.7, 1.7) 1.1 (0.7, 1.9) 1.1 (0.7, 1.7) 1.1 (0.6, 1.9) 
rs2243267 C 1.0 (0.6, 1.6) 1.0 (0.6, 1.7) 1.1 (0.7, 1.7) 1.1 (0.7, 1.9) 
rs2243270 G 1.1 (0.7, 1.7) 1.1 (0.7, 1.9) 1.1 (0.5, 2.1) 1.0 (0.5, 2.4) 
rs2243283 G 1.3 (0.3, 5.2) 0.8 (0.1, 5.6) 0.8 (0.5, 1.2) 0.7 (0.4, 1.3) 
rs2243292 C 3.1 (0.9, 10.6) 2.6 (0.6, 11.9) 1.0 (0.5, 1.8) 1.3 (0.6, 2.6) 
rs11242122* G 0.9 (0.7, 1.3) 0.9 (0.6, 1.3) 1.1 (0.8, 1.5) 1.2 (0.8, 1.7) 
rs11242123 T 1.0 (0.6, 1.6) 1.1 (0.6, 1.8) 0.7 (0.4, 1.0) 0.5 (0.3, 0.9) 
IL12B 
 
    rs7730126 T 1.1 (0.8, 1.6) 1.0 (0.7, 1.5) 0.9 (0.5, 1.3) 0.7 (0.4, 1.3) 
rs2099327 C 1.4 (0.9, 2.1) 1.4 (0.9, 2.1) 0.8 (0.4, 1.6) 0.7 (0.3, 1.7) 
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rs1549922* G 0.8 (0.6, 1.1) 0.9 (0.7, 1.2) 0.8 (0.6, 1.2) 1.0 (0.6, 1.5) 
rs4921466 C 0.7 (0.4, 1.1) 0.6 (0.3, 1.1) 1.0 (0.6, 1.7) 0.8 (0.4, 1.5) 
rs10072923 C 1.3 (0.8, 1.9) 1.3 (0.8, 2.0) 1.3 (0.8, 2.1) 1.2 (0.7, 2.1) 
rs1368439 G 0.8 (0.5, 1.3) 0.9 (0.6, 1.5) 0.8 (0.4, 1.6) 0.9 (0.4, 2.0) 
rs3212227 C 1.2 (0.8, 1.8) 1.3 (0.8, 2.0) 1.1 (0.7, 1.7) 1.1 (0.6, 1.8) 
rs11574790 T 0.7 (0.4, 1.1) 0.7 (0.4, 1.2) 1.0 (0.6, 1.5) 0.8 (0.5, 1.4) 
rs2195940 T 0.7 (0.4, 1.1) 0.7 (0.4, 1.2) 1.0 (0.6, 1.5) 0.9 (0.5, 1.6) 
rs919766 C 0.7 (0.4, 1.1) 0.7 (0.4, 1.2) 1.0 (0.7, 1.6) 1.0 (0.6, 1.7) 
rs2853694 C 0.8 (0.5, 1.2) 0.9 (0.6, 1.5) 0.6 (0.4, 1.0) 0.7 (0.4, 1.2) 
rs2569253 C 1.1 (0.7, 1.7) 1.0 (0.6, 1.6) 0.8 (0.5, 1.3) 0.9 (0.5, 1.5) 
rs3212220 T 1.3 (0.9, 1.9) 1.3 (0.9, 2.0) 1.1 (0.7, 1.8) 1.1 (0.7, 1.9) 
rs1433048 G 0.8 (0.5, 1.3) 0.9 (0.5, 1.4) 0.3 (0.1, 0.9) 0.4 (0.1, 1.3) 
rs2546893 A 1.4 (0.9, 2.3) 1.3 (0.8, 2.2) 0.9 (0.6, 1.4) 1.0 (0.6, 1.7) 
rs2546890* A 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 1.0 (0.7, 1.4) 1.2 (0.8, 1.8) 
rs10052709 G 0.8 (0.5, 1.3) 0.7 (0.4, 1.2) 1.0 (0.6, 1.7) 0.9 (0.5, 1.7) 
rs7709212* C 1.1 (0.9, 1.5) 1.2 (0.9, 1.6) 1.0 (0.7, 1.5) 1.0 (0.7, 1.6) 
rs6868898 C 1.1 (0.7, 1.6) 1.1 (0.7, 1.6) 1.0 (0.6, 1.6) 1.2 (0.7, 2.1) 
LTA & TNF 
 
    rs2857605 G 0.8 (0.6, 1.2) 0.9 (0.6, 1.4) 0.8 (0.4, 1.5) 1.0 (0.5, 2.2) 
rs2239707 G 1.1 (0.8, 1.7) 1.2 (0.8, 1.9) 0.9 (0.5, 1.5) 1.1 (0.6, 2.1) 
rs2230365 T 1.4 (0.9, 2.1) 1.5 (1.0, 2.4) 1.0 (0.5, 2.0) 1.0 (0.5, 2.3) 
rs3130062 C 0.9 (0.5, 1.6) 0.9 (0.5, 1.7) 1.0 (0.2, 4.4) 1.3 (0.3, 6.1) 
rs4947324 T 0.6 (0.4, 1.1) 0.7 (0.4, 1.2) 1.0 (0.6, 1.7) 1.1 (0.6, 2.0) 
rs2857709 T 0.9 (0.6, 1.3) 0.9 (0.6, 1.5) 0.6 (0.2, 1.6) 0.9 (0.3, 2.3) 
rs915654* T 1.1 (0.8, 1.4) 1.2 (0.9, 1.5) 1.0 (0.8, 1.4) 0.9 (0.6, 1.3) 
rs909253* C 1.1 (0.8, 1.5) 1.2 (0.8, 1.6) 1.1 (0.8, 1.5) 1.1 (0.7, 1.6) 
rs2229094 C 1.0 (0.7, 1.4) 1.1 (0.7, 1.7) 0.9 (0.6, 1.4) 0.9 (0.5, 1.5) 
rs1041981* A 1.1 (0.8, 1.5) 1.2 (0.8, 1.6) 1.1 (0.8, 1.5) 1.1 (0.7, 1.6) 
rs1799964 C 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 1.0 (0.6, 1.5) 0.9 (0.5, 1.6) 
rs1800630 A 1.2 (0.8, 1.8) 1.3 (0.8, 2.0) 1.1 (0.7, 1.8) 1.0 (0.6, 1.9) 
rs1800629 A 1.3 (0.8, 1.9) 1.3 (0.8, 2.1) 1.1 (0.6, 1.8) 1.2 (0.7, 2.2) 
rs7769073 A 0.8 (0.4, 1.7) 0.8 (0.4, 1.8) 0.9 (0.5, 1.7) 0.9 (0.4, 1.8) 
GATA3 
 
    rs406571* C 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 
rs1877739 C 0.8 (0.5, 1.2) 0.8 (0.5, 1.3) 1.0 (0.6, 1.6) 1.0 (0.6, 1.8) 
rs532854* C 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 0.7 (0.5, 1.0) 0.8 (0.6, 1.2) 
rs10795588* G 0.9 (0.7, 1.2) 0.8 (0.6, 1.0) 1.4 (1.0, 1.9) 1.6 (1.1, 2.3) 
rs263425 T   0.5 (0.3, 1.0) 0.7 (0.4, 1.2) 
rs263423* A 1.2 (0.9, 1.7) 1.3 (0.9, 1.9) 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 
rs1244186 T 1.2 (0.8, 1.7) 1.2 (0.8, 1.8) 0.9 (0.5, 1.4) 0.7 (0.4, 1.3) 
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rs2275806 A 1.0 (0.6, 1.6) 0.9 (0.5, 1.5) 1.3 (0.9, 2.1) 1.5 (0.9, 2.5) 
rs1269486 A 1.2 (0.8, 1.7) 1.2 (0.7, 1.8) 0.9 (0.5, 1.4) 0.7 (0.4, 1.3) 
rs1399180 T 1.1 (0.7, 1.7) 1.1 (0.7, 1.8) 0.7 (0.5, 1.1) 0.7 (0.4, 1.1) 
rs369421 C 1.2 (0.8, 1.9) 1.2 (0.8, 1.9) 0.9 (0.5, 1.6) 0.8 (0.4, 1.6) 
rs3781094* G 1.0 (0.8, 1.3) 0.9 (0.7, 1.2) 1.6 (1.2, 2.2) 1.6 (1.1, 2.4) 
rs3781093 G 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 0.9 (0.6, 1.4) 1.1 (0.6, 1.8) 
rs376397 A 1.0 (0.7, 1.5) 1.0 (0.7, 1.6) 0.7 (0.5, 1.1) 0.6 (0.4, 1.1) 
rs570613* G 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 0.8 (0.6, 1.0) 0.8 (0.6, 1.2) 
rs10752126* G 1.1 (0.8, 1.4) 1.1 (0.8, 1.5) 0.7 (0.5, 1.0) 0.6 (0.4, 0.9) 
rs569421 C 1.2 (0.8, 1.7) 1.2 (0.8, 1.9) 0.8 (0.5, 1.3) 0.8 (0.5, 1.4) 
rs444929 C 0.8 (0.6, 1.2) 0.9 (0.5, 1.3) 1.1 (0.7, 1.8) 1.1 (0.7, 1.9) 
rs2280015 A 1.1 (0.8, 1.7) 1.1 (0.7, 1.8) 0.7 (0.4, 1.1) 0.9 (0.5, 1.5) 
rs422628 C 0.9 (0.6, 1.3) 0.9 (0.6, 1.4) 0.9 (0.6, 1.4) 0.8 (0.5, 1.4) 
rs406103 T 1.3 (0.9, 1.9) 1.3 (0.9, 2.0) 0.6 (0.4, 1.0) 0.6 (0.4, 1.0) 
rs528778 T 0.8 (0.6, 1.2) 0.8 (0.5, 1.3) 1.2 (0.8, 1.8) 1.1 (0.7, 1.9) 
rs11567934 A   0.7 (0.4, 1.2) 0.5 (0.2, 1.0) 
rs388957 T 1.3 (0.6, 2.7) 1.3 (0.6, 2.9) 0.7 (0.4, 1.1) 0.5 (0.3, 0.9) 
rs10905284 A 1.1 (0.7, 1.9) 1.0 (0.6, 1.7) 1.7 (1.1, 2.6) 1.5 (0.9, 2.6) 
rs1058240 G 0.9 (0.6, 1.3) 0.9 (0.5, 1.4) 1.2 (0.7, 1.8) 1.1 (0.6, 1.8) 
rs263419 T 1.2 (0.8, 1.8) 1.1 (0.7, 1.8) 0.9 (0.6, 1.4) 0.9 (0.5, 1.5) 
rs12262237 A   0.9 (0.4, 1.9) 0.7 (0.3, 1.9) 
rs7100967 A   1.0 (0.6, 1.8) 1.4 (0.8, 2.6) 
rs477461 G 1.0 (0.7, 1.6) 1.0 (0.6, 1.6) 0.9 (0.6, 1.4) 0.9 (0.6, 1.6) 
rs434645 A 0.8 (0.5, 1.3) 0.9 (0.5, 1.4) 1.0 (0.7, 1.6) 0.9 (0.5, 1.6) 
rs379568 T 1.5 (1.0, 2.3) 1.7 (1.0, 2.7) 0.6 (0.4, 1.0) 0.6 (0.4, 1.1) 
rs1778058* A 1.1 (0.8, 1.4) 1.1 (0.8, 1.5) 1.1 (0.8, 1.5) 1.4 (0.9, 2.0) 
rs12412241* A 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 1.1 (0.8, 1.5) 1.2 (0.8, 1.7) 
IL18 
 
    rs4937075* G 1.1 (0.8, 1.5) 1.2 (0.8, 1.6) 1.2 (0.8, 1.7) 1.3 (0.8, 2.0) 
rs578784* T 1.1 (0.8, 1.5) 1.1 (0.8, 1.6) 1.3 (0.9, 1.9) 1.5 (1.0, 2.4) 
rs11214098 A   1.4 (0.9, 2.2) 1.8 (1.1, 3.2) 
rs543810 G 0.8 (0.5, 1.3) 0.7 (0.4, 1.3) 1.2 (0.8, 1.8) 1.3 (0.8, 2.2) 
rs5744280 T 0.9 (0.6, 1.3) 0.8 (0.5, 1.3) 1.4 (0.9, 2.2) 1.2 (0.7, 2.0) 
rs5744238 A   1.2 (0.6, 2.3) 1.5 (0.7, 3.4) 
rs2043055* G 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 1.2 (0.9, 1.5) 1.0 (0.7, 1.4) 
rs360714 G 0.6 (0.1, 2.4) 0.6 (0.1, 2.5) 0.6 (0.4, 1.1) 0.6 (0.3, 1.2) 
rs1946518* T 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) 0.8 (0.6, 1.1) 0.8 (0.5, 1.1) 
rs5744223 G   1.2 (0.7, 2.1) 1.2 (0.6, 2.2) 
rs5744222 A 1.0 (0.7, 1.5) 1.1 (0.7, 1.7) 0.6 (0.2, 1.4) 0.3 (0.1, 1.3) 
rs11214105 A 1.2 (0.8, 1.8) 1.3 (0.8, 1.9) 0.8 (0.5, 1.3) 0.8 (0.5, 1.4) 
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IFNG 
 
    rs10878760 T 1.3 (0.8, 1.9) 1.4 (0.9, 2.2) 1.1 (0.5, 2.7) 1.4 (0.5, 3.7) 
rs17104856 T   1.1 (0.6, 2.0) 1.3 (0.7, 2.6) 
rs2193047* T 1.1 (0.8, 1.4) 1.1 (0.8, 1.5) 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 
rs2041864* T 0.9 (0.7, 1.2) 0.9 (0.7, 1.3) 0.9 (0.6, 1.2) 0.9 (0.6, 1.3) 
rs11177074 C 1.1 (0.6, 1.8) 1.0 (0.5, 1.8) 0.9 (0.6, 1.5) 0.8 (0.5, 1.5) 
rs6581794 T 1.1 (0.8, 1.6) 1.2 (0.8, 1.9) 1.0 (0.6, 1.6) 1.0 (0.6, 1.7) 
rs3181035 A 1.1 (0.6, 1.8) 1.0 (0.5, 1.8) 0.9 (0.6, 1.3) 0.8 (0.5, 1.4) 
rs2069727 G 0.7 (0.5, 1.1) 0.7 (0.4, 1.1) 0.8 (0.5, 1.3) 0.7 (0.4, 1.2) 
rs1861494 C 1.1 (0.8, 1.6) 1.2 (0.8, 1.9) 1.0 (0.6, 1.6) 0.9 (0.5, 1.6) 
rs3181032 G 2.2 (1.0, 4.8) 1.7 (0.6, 4.6) 0.9 (0.5, 1.5) 0.8 (0.4, 1.5) 
rs7302488 G 1.1 (0.8, 1.7) 1.3 (0.8, 1.9) 1.0 (0.6, 1.6) 0.9 (0.5, 1.6) 
rs12306852 C 1.3 (0.9, 2.0) 1.3 (0.8, 2.0) 1.1 (0.7, 1.8) 1.0 (0.6, 1.8) 
TGFB3 
 
    rs4252345 G   1.0 (0.4, 2.4) 0.7 (0.2, 2.4) 
rs11466414 T 1.0 (0.6, 1.8) 1.1 (0.6, 2.1) 0.8 (0.2, 2.9) 0.0 (0.0, 0.0) 
TBX21 
 
    rs2013383 A 1.1 (0.8, 1.7) 1.2 (0.8, 1.9) 1.0 (0.6, 1.5) 0.9 (0.5, 1.4) 
rs1808192 T 1.1 (0.7, 1.6) 1.1 (0.7, 1.7) 1.0 (0.6, 1.5) 0.8 (0.5, 1.4) 
rs4461115 C 0.9 (0.6, 1.3) 0.8 (0.5, 1.3) 1.5 (0.8, 2.9) 1.8 (0.9, 4.0) 
rs16946264 A 1.0 (0.6, 1.6) 0.9 (0.5, 1.5) 1.2 (0.7, 1.9) 1.2 (0.7, 2.1) 
rs11079788 T 0.9 (0.6, 1.4) 0.9 (0.6, 1.4) 1.3 (0.9, 2.0) 1.5 (0.9, 2.5) 
rs16946878 C 1.2 (0.7, 2.1) 0.9 (0.5, 1.9) 1.2 (0.7, 2.1) 1.5 (0.8, 2.9) 
rs16947078 G 0.9 (0.6, 1.4) 0.9 (0.6, 1.4) 1.3 (0.9, 2.0) 1.6 (1.0, 2.7) 
TGFB1 
 
    rs1800471 C 0.7 (0.4, 1.2) 0.8 (0.4, 1.5) 1.2 (0.7, 2.2) 1.2 (0.6, 2.4) 
KIR3DL3 
 
    rs4441391 A 0.7 (0.5, 1.1) 0.7 (0.4, 1.1) 0.7 (0.4, 1.1) 0.8 (0.4, 1.4) 
rs1325155* T 1.3 (1.0, 1.6) 1.3 (1.0, 1.7) 1.1 (0.8, 1.4) 1.1 (0.8, 1.7) 
rs1325156 A 1.0 (0.7, 1.6) 1.1 (0.7, 1.7) 1.2 (0.8, 1.9) 1.1 (0.6, 1.8) 
rs12151161 G 1.4 (0.9, 2.1) 1.4 (0.9, 2.3) 1.1 (0.7, 1.7) 1.1 (0.7, 1.9) 
rs7249048 G 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 1.3 (0.8, 2.1) 1.3 (0.8, 2.3) 
rs270775* G 1.3 (1.0, 1.6) 1.2 (0.9, 1.6) 1.2 (0.9, 1.7) 1.3 (0.9, 1.9) 
rs2296370* A 1.0 (0.8, 1.3) 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 0.8 (0.6, 1.3) 
rs2296371* A 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 
rs12982559 A 1.0 (0.7, 1.4) 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 0.9 (0.5, 1.6) 
rs11883241 T 0.9 (0.6, 1.3) 0.8 (0.5, 1.2) 1.1 (0.7, 1.7) 1.0 (0.6, 1.7) 
rs6509899 A 0.7 (0.4, 1.3) 0.9 (0.5, 1.6) 1.1 (0.7, 1.7) 1.1 (0.7, 1.9) 
rs1325158* T 0.8 (0.6, 1.0) 0.7 (0.5, 1.0) 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs11671355 C 1.2 (0.8, 1.8) 1.3 (0.8, 2.0) 1.0 (0.5, 1.9) 1.3 (0.6, 2.6) 
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rs16985907 C 1.5 (0.8, 2.7) 1.6 (0.8, 3.0) 1.3 (0.8, 2.1) 1.0 (0.6, 1.9) 
KIR2DL4 
 
    rs35950908 A 1.0 (0.7, 1.5) 1.0 (0.6, 1.6) 0.8 (0.4, 1.5) 0.9 (0.4, 1.8) 
rs17771961 G 0.8 (0.5, 1.2) 0.8 (0.5, 1.2) 1.4 (0.9, 2.4) 1.5 (0.8, 2.8) 
KIR3DL2 
 
    rs10407958 A 1.0 (0.7, 1.7) 1.1 (0.6, 1.8) 1.1 (0.7, 1.8) 1.2 (0.7, 2.1) 
rs1654644* G 1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 
rs4806457 C 1.1 (0.5, 2.3) 1.3 (0.6, 2.9) 0.6 (0.2, 1.3) 0.7 (0.3, 1.7) 
rs3745900 T 0.8 (0.6, 1.2) 0.9 (0.6, 1.4) 0.8 (0.5, 1.3) 0.8 (0.4, 1.4) 
rs11672983 A 1.0 (0.7, 1.5) 1.0 (0.6, 1.5) 0.7 (0.5, 1.1) 0.7 (0.4, 1.2) 
rs3816051* C 1.1 (0.8, 1.4) 1.0 (0.7, 1.3) 0.9 (0.6, 1.2) 0.8 (0.5, 1.2) 
IFNGR2 
 
    rs6517167 T 1.0 (0.6, 1.4) 0.9 (0.6, 1.5) 1.0 (0.6, 1.5) 1.1 (0.7, 1.9) 
rs11702844 G 1.0 (0.7, 1.6) 1.0 (0.6, 1.6) 0.6 (0.2, 2.1) 0.6 (0.1, 2.6) 
rs16990664 T 1.2 (0.6, 2.2) 1.5 (0.8, 2.8) 1.1 (0.7, 1.8) 1.2 (0.7, 2.1) 
rs9976971 A 1.2 (0.8, 1.9) 1.3 (0.8, 2.1) 1.0 (0.5, 1.8) 1.1 (0.6, 2.3) 
rs9980428 T 1.1 (0.7, 1.6) 1.0 (0.6, 1.5) 0.9 (0.6, 1.4) 0.9 (0.5, 1.4) 
rs9978223 A 0.9 (0.6, 1.5) 1.0 (0.6, 1.6) 1.0 (0.6, 1.7) 0.9 (0.5, 1.7) 
rs2268241 A 1.0 (0.6, 1.5) 1.0 (0.6, 1.6) 1.1 (0.7, 1.8) 1.2 (0.7, 2.1) 
rs9808685* G 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.1 (0.8, 1.5) 1.0 (0.7, 1.4) 
rs2834210 A 1.0 (0.6, 1.6) 1.1 (0.7, 1.8) 1.1 (0.7, 1.8) 1.0 (0.6, 1.6) 
rs9808753 G 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 1.2 (0.8, 1.8) 1.5 (0.9, 2.5) 
rs2834212 C 1.4 (0.9, 2.2) 1.4 (0.9, 2.3) 0.9 (0.3, 3.0) 1.3 (0.4, 4.5) 
rs2834213 G 0.9 (0.6, 1.3) 0.9 (0.6, 1.4) 1.3 (0.7, 2.7) 1.6 (0.7, 3.4) 
rs2012075 C 1.2 (0.8, 1.9) 1.2 (0.7, 1.8) 0.9 (0.5, 1.5) 0.7 (0.4, 1.4) 
rs8131980 A 1.1 (0.7, 1.5) 1.1 (0.7, 1.7) 1.0 (0.6, 1.6) 0.8 (0.5, 1.6) 
GADD45A 
 
    rs12405855 T 0.8 (0.6, 1.3) 0.8 (0.5, 1.3) 1.2 (0.5, 2.7) 0.6 (0.1, 2.6) 
rs344934* C 0.9 (0.7, 1.2) 1.1 (0.8, 1.5) 1.2 (0.9, 1.6) 1.2 (0.8, 1.8) 
rs4655749 G 0.6 (0.3, 1.3) 0.7 (0.3, 1.5) 1.2 (0.8, 2.0) 1.3 (0.7, 2.3) 
rs344916 C 0.7 (0.5, 1.1) 0.9 (0.6, 1.4) 1.3 (0.7, 2.3) 1.2 (0.6, 2.4) 
rs10889710 A 1.1 (0.6, 1.9) 0.9 (0.5, 1.7) 0.6 (0.4, 1.0) 0.6 (0.4, 1.1) 
rs646652 C 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 1.1 (0.7, 1.8) 1.2 (0.7, 2.0) 
rs2055904 T 0.6 (0.3, 1.3) 0.6 (0.3, 1.4) 1.3 (0.8, 2.1) 1.4 (0.8, 2.5) 
rs604043 G 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 1.4 (0.9, 2.1) 1.2 (0.7, 2.0) 
rs2815266 A 1.0 (0.6, 1.8) 1.3 (0.7, 2.2) 1.2 (0.7, 1.9) 1.3 (0.7, 2.3) 
rs624790 C 1.0 (0.6, 1.5) 1.2 (0.8, 1.9) 1.0 (0.7, 1.6) 0.9 (0.6, 1.6) 
rs1511686 T   1.1 (0.7, 1.8) 0.8 (0.4, 1.6) 
rs3783468 A 1.1 (0.7, 1.8) 0.9 (0.6, 1.6) 1.0 (0.6, 1.5) 0.9 (0.5, 1.6) 
rs532446* C 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
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rs607375* C 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 1.2 (0.9, 1.6) 1.2 (0.8, 1.8) 
rs685724* G 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 0.8 (0.6, 1.0) 0.8 (0.5, 1.1) 
rs675327 T 0.9 (0.6, 1.4) 0.9 (0.6, 1.5) 1.5 (1.0, 2.3) 1.4 (0.8, 2.5) 
rs11583718* C 1.0 (0.7, 1.3) 1.1 (0.8, 1.5) 1.1 (0.8, 1.5) 1.1 (0.8, 1.7) 
rs7546055 C 0.8 (0.5, 1.1) 0.9 (0.6, 1.3) 0.8 (0.5, 1.2) 0.7 (0.4, 1.3) 
rs598602 T 0.9 (0.6, 1.4) 0.9 (0.5, 1.4) 1.3 (0.8, 2.0) 1.3 (0.8, 2.3) 
rs12408005 T 1.2 (0.7, 2.0) 1.0 (0.6, 1.7) 1.0 (0.6, 1.5) 1.0 (0.6, 1.7) 
RASSF1 
 
    rs35455589 C   0.6 (0.4, 1.1) 0.7 (0.4, 1.2) 
rs709210 T 1.4 (0.9, 2.0) 1.4 (0.9, 2.2) 1.0 (0.6, 1.8) 0.9 (0.5, 1.8) 
rs2073498 A 1.1 (0.7, 1.7) 1.1 (0.7, 1.8) 1.4 (0.5, 3.4) 0.9 (0.2, 3.6) 
rs2236947* A 0.8 (0.6, 1.0) 0.8 (0.6, 1.1) 1.5 (1.1, 2.0) 1.4 (0.9, 2.1) 
rs2073499 G 1.0 (0.6, 1.5) 0.9 (0.6, 1.5) 0.5 (0.3, 0.8) 0.6 (0.3, 1.0) 
rs6446203 T 1.0 (0.4, 2.4) 0.7 (0.2, 2.1) 0.7 (0.4, 1.0) 0.7 (0.4, 1.2) 
rs1989839 C 1.0 (0.6, 1.6) 1.0 (0.6, 1.7) 0.8 (0.5, 1.3) 0.9 (0.5, 1.5) 
CCNA2 
 
    rs6825926 T 0.9 (0.5, 1.6) 1.0 (0.6, 1.9) 0.9 (0.5, 1.4) 0.8 (0.5, 1.4) 
rs1803183 G 0.7 (0.2, 2.2) 0.5 (0.1, 2.3) 0.7 (0.5, 1.1) 0.7 (0.4, 1.2) 
rs6815050* C 1.1 (0.9, 1.5) 1.2 (0.8, 1.6) 0.7 (0.5, 1.0) 0.8 (0.5, 1.2) 
rs3217773 C 1.0 (0.7, 1.5) 1.1 (0.7, 1.6) 1.2 (0.7, 1.9) 1.0 (0.6, 1.8) 
rs3217771 T 1.0 (0.7, 1.5) 1.1 (0.7, 1.6) 1.2 (0.7, 1.9) 1.0 (0.6, 1.8) 
rs3217770 C   0.9 (0.5, 1.5) 1.1 (0.6, 2.0) 
rs2071486* G 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 1.1 (0.8, 1.5) 1.3 (0.9, 1.8) 
rs3217760 A   1.2 (0.5, 2.4) 0.7 (0.2, 2.0) 
rs1507994* A 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) 0.9 (0.7, 1.2) 0.8 (0.6, 1.2) 
CCNH 
 
    rs2266690 C 1.4 (1.0, 2.1) 1.4 (0.9, 2.2) 1.6 (0.9, 2.7) 1.7 (0.9, 3.3) 
NOV 
 
    rs13261466 T 1.0 (0.7, 1.5) 1.0 (0.7, 1.5) 0.7 (0.3, 1.8) 0.6 (0.2, 1.8) 
rs2071526 A 1.0 (0.7, 1.4) 1.0 (0.7, 1.6) 0.7 (0.4, 1.1) 0.7 (0.4, 1.2) 
rs7834596 T 1.0 (0.7, 1.5) 1.1 (0.7, 1.7) 0.9 (0.6, 1.4) 0.9 (0.6, 1.6) 
rs7014927 C 1.0 (0.6, 1.4) 1.0 (0.7, 1.6) 0.7 (0.4, 1.3) 0.7 (0.4, 1.5) 
rs11538929 A 0.8 (0.5, 1.3) 0.7 (0.4, 1.3) 1.7 (0.8, 3.4) 1.6 (0.7, 3.9) 
rs1381337 G 4.2 (0.7, 24.6) 4.5 (0.9, 23.7) 1.7 (1.1, 2.6) 1.6 (0.9, 2.7) 
rs16892531 G 0.9 (0.3, 2.4) 1.1 (0.4, 3.1) 0.8 (0.4, 1.4) 0.8 (0.4, 1.5) 
rs11775043 G 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 0.6 (0.4, 1.1) 0.7 (0.4, 1.3) 
rs10505358 G 0.8 (0.3, 2.1) 1.0 (0.4, 2.6) 1.2 (0.7, 2.1) 1.2 (0.6, 2.3) 
rs1870779 C 0.8 (0.4, 1.7) 1.0 (0.5, 2.1) 1.0 (0.6, 1.5) 0.9 (0.5, 1.5) 
rs1461693 T 0.9 (0.6, 1.4) 1.0 (0.6, 1.5) 0.6 (0.4, 0.9) 0.6 (0.4, 1.1) 
rs16892578 T 1.4 (0.6, 3.4) 1.7 (0.7, 4.2) 1.4 (0.9, 2.1) 1.4 (0.8, 2.3) 
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rs16892586 A 0.6 (0.2, 1.7) 0.7 (0.2, 2.1) 0.8 (0.4, 1.3) 0.7 (0.4, 1.4) 
rs7001184 A 2.5 (0.7, 8.7) 3.7 (1.1, 11.9) 1.3 (0.8, 2.0) 1.2 (0.7, 2.2) 
CDKN2A  
 
    rs2811720 G 1.1 (0.7, 1.7) 1.1 (0.7, 1.7) 0.9 (0.6, 1.4) 0.9 (0.5, 1.6) 
rs2518722* T 1.2 (0.9, 1.6) 1.3 (1.0, 1.8) 0.9 (0.6, 1.2) 0.8 (0.5, 1.2) 
rs10757261* A 1.2 (0.9, 1.5) 1.2 (0.9, 1.7) 0.7 (0.5, 1.0) 0.7 (0.5, 1.0) 
rs2027938 A 1.2 (0.8, 1.7) 1.2 (0.8, 1.8) 1.0 (0.6, 1.5) 1.0 (0.6, 1.7) 
rs717326 G 1.2 (0.7, 1.9) 1.2 (0.7, 2.0) 0.9 (0.5, 1.5) 0.8 (0.4, 1.6) 
rs3731257 T 1.0 (0.7, 1.5) 0.9 (0.6, 1.4) 1.2 (0.7, 2.0) 1.6 (0.9, 2.9) 
rs3088440 A 1.1 (0.6, 1.8) 1.0 (0.6, 1.8) 0.9 (0.5, 1.4) 0.9 (0.5, 1.6) 
rs2811708 T 1.3 (0.9, 1.9) 1.4 (0.9, 2.2) 1.0 (0.6, 1.5) 1.0 (0.6, 1.8) 
rs3731239 C 0.9 (0.6, 1.4) 0.9 (0.6, 1.4) 1.4 (0.8, 2.4) 1.2 (0.6, 2.5) 
rs4074785 A 1.4 (0.8, 2.2) 1.4 (0.8, 2.4) 0.9 (0.5, 1.5) 0.8 (0.4, 1.5) 
CDKN2B 
 
    rs3731206 A 0.6 (0.1, 2.5) 0.7 (0.2, 3.0) 0.8 (0.5, 1.3) 0.7 (0.4, 1.3) 
rs3731204 G 1.4 (1.0, 2.1) 1.6 (1.0, 2.4) 0.8 (0.4, 1.5) 0.9 (0.4, 1.8) 
rs10757262 T 1.1 (0.7, 1.6) 1.1 (0.7, 1.8) 1.1 (0.7, 1.8) 1.1 (0.7, 2.0) 
rs3731194 C 0.7 (0.2, 2.9) 0.8 (0.2, 3.5) 0.8 (0.4, 1.4) 0.8 (0.4, 1.6) 
rs3731191 T 0.6 (0.1, 2.5) 0.7 (0.2, 3.0) 0.9 (0.6, 1.4) 0.9 (0.5, 1.5) 
rs2811711 C 1.3 (0.9, 2.0) 1.5 (0.9, 2.3) 1.4 (0.9, 2.1) 1.2 (0.7, 2.1) 
rs3218022 G 1.6 (0.4, 6.0) 1.9 (0.5, 7.2) 1.5 (0.9, 2.4) 1.5 (0.8, 2.8) 
rs3218020 T 1.2 (0.8, 1.8) 1.3 (0.8, 2.0) 0.7 (0.4, 1.2) 0.7 (0.4, 1.3) 
rs3218009 C 1.0 (0.6, 1.6) 1.0 (0.6, 1.7) 1.0 (0.4, 2.9) 0.8 (0.2, 2.9) 
rs3218002 T 1.0 (0.6, 1.5) 1.0 (0.6, 1.7) 1.1 (0.7, 1.8) 1.1 (0.7, 1.9) 
rs3217999 C 1.5 (0.4, 5.7) 1.8 (0.5, 6.7) 1.3 (0.8, 2.2) 1.3 (0.7, 2.3) 
rs3217992 A 1.2 (0.8, 1.8) 1.3 (0.8, 2.0) 0.6 (0.4, 1.1) 0.5 (0.3, 1.1) 
rs1063192 C 1.2 (0.8, 1.8) 1.2 (0.7, 1.8) 1.2 (0.7, 2.2) 1.2 (0.6, 2.5) 
rs3217989 G   1.2 (0.8, 1.8) 1.6 (0.9, 2.7) 
CNNM2 
 
    rs11191457 T 0.8 (0.5, 1.2) 0.9 (0.6, 1.4) 0.8 (0.5, 1.4) 1.0 (0.5, 1.9) 
rs7897654 C 0.9 (0.6, 1.3) 1.0 (0.7, 1.6) 1.2 (0.7, 1.8) 1.3 (0.8, 2.2) 
rs2297787 A 1.3 (0.8, 2.2) 1.4 (0.8, 2.4) 1.0 (0.7, 1.6) 1.4 (0.8, 2.3) 
rs17787717 G 1.1 (0.7, 1.8) 1.0 (0.6, 1.8) 2.3 (1.2, 4.2) 2.8 (1.4, 5.6) 
rs7902220 C 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 2.1 (1.1, 3.7) 1.5 (0.6, 3.6) 
rs6584535 T 1.3 (0.9, 2.0) 1.4 (0.9, 2.1) 0.3 (0.1, 1.0) 0.2 (0.0, 1.1) 
rs11191512 G 0.8 (0.5, 1.2) 0.9 (0.6, 1.4) 1.3 (0.8, 2.1) 1.3 (0.8, 2.3) 
rs7914558* A 1.1 (0.8, 1.5) 1.1 (0.8, 1.5) 1.2 (0.9, 1.6) 1.3 (0.9, 1.8) 
rs4917991* C 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 1.2 (0.9, 1.6) 1.2 (0.8, 1.7) 
rs11191527 T 0.8 (0.5, 1.3) 0.9 (0.6, 1.4) 0.7 (0.4, 1.2) 0.8 (0.4, 1.6) 
rs12264034 T 2.1 (0.3, 12.9) 2.3 (0.4, 14.0) 1.0 (0.6, 1.5) 1.1 (0.7, 1.9) 
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rs11191537 G 1.1 (0.7, 1.7) 1.2 (0.8, 1.9) 1.2 (0.8, 2.0) 1.3 (0.7, 2.3) 
rs7087944 T 4.7 (0.9, 24.2) 5.0 (1.0, 26.4) 1.0 (0.6, 1.7) 1.0 (0.6, 1.8) 
rs2296569 C 0.7 (0.4, 1.1) 0.7 (0.4, 1.1) 0.8 (0.3, 2.2) 1.1 (0.4, 2.9) 
rs4917995 A 1.0 (0.7, 1.6) 0.9 (0.6, 1.5) 1.3 (0.8, 2.0) 1.2 (0.7, 2.1) 
rs11191549* T 1.0 (0.8, 1.4) 1.1 (0.8, 1.5) 1.2 (0.9, 1.7) 1.2 (0.8, 1.7) 
CCND1 
 
    rs7106515 G   0.8 (0.5, 1.3) 0.7 (0.4, 1.4) 
rs1982774 T 0.9 (0.6, 1.3) 0.8 (0.5, 1.3) 1.5 (0.9, 2.3) 1.7 (1.0, 2.9) 
rs592483 C 0.8 (0.6, 1.2) 0.8 (0.5, 1.3) 1.5 (1.0, 2.3) 1.6 (0.9, 2.7) 
rs611003* A 1.2 (0.9, 1.6) 1.2 (0.9, 1.6) 1.1 (0.8, 1.5) 1.1 (0.7, 1.6) 
rs11827026 A 0.9 (0.4, 1.8) 0.8 (0.3, 1.9) 0.8 (0.5, 1.2) 0.8 (0.5, 1.4) 
rs655089* G 1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 0.9 (0.7, 1.2) 0.8 (0.6, 1.2) 
rs667515* C 1.1 (0.8, 1.4) 1.1 (0.8, 1.5) 1.0 (0.8, 1.4) 1.3 (0.9, 1.8) 
rs2450254* T 1.0 (0.8, 1.4) 1.0 (0.7, 1.4) 0.9 (0.7, 1.2) 1.2 (0.8, 1.6) 
rs3212860 T 2.7 (0.4, 17.8) 4.7 (0.7, 33.4) 0.9 (0.6, 1.5) 0.9 (0.5, 1.6) 
rs1352075 T 0.9 (0.6, 1.3) 0.8 (0.5, 1.3) 0.9 (0.6, 1.4) 0.9 (0.5, 1.5) 
rs3862792 T 0.9 (0.4, 2.3) 0.7 (0.2, 2.1) 0.7 (0.4, 1.3) 0.7 (0.4, 1.4) 
rs603965 A 1.0 (0.6, 1.5) 0.9 (0.6, 1.5) 0.8 (0.5, 1.2) 0.8 (0.4, 1.3) 
rs3918298 A 1.1 (0.5, 2.6) 0.9 (0.3, 2.4) 0.7 (0.5, 1.1) 0.7 (0.4, 1.2) 
rs649392* G 0.9 (0.7, 1.3) 0.9 (0.7, 1.3) 1.0 (0.7, 1.4) 1.0 (0.7, 1.5) 
rs3212891* C 0.9 (0.7, 1.2) 0.9 (0.6, 1.2) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
rs7121246 T 2.6 (0.2, 27.3) 2.6 (0.2, 28.8) 0.8 (0.5, 1.3) 0.9 (0.5, 1.5) 
rs12281701 C 2.6 (0.2, 27.3) 2.6 (0.2, 28.8) 0.8 (0.5, 1.4) 0.8 (0.4, 1.5) 
rs1192925* C 1.0 (0.7, 1.3) 0.9 (0.7, 1.3) 1.1 (0.8, 1.6) 1.2 (0.8, 1.9) 
MDM2 
 
    rs769412 G 1.3 (0.8, 2.1) 1.2 (0.7, 2.2) 0.8 (0.4, 1.4) 0.7 (0.4, 1.5) 
 
Empty cell reflect non-polymorphic SNPs, zero cell counts or deviation from HWE 
(IL2:rs10027390). 
*Additive model presented 
Minor allele chosen as minor for both ancestry groups or the Global Minor Allele noted in dbSNP 
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NFKBIL1 
 
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
rs2857605 G 1.1 (0.7, 1.6) 0.8 (0.6, 1.1) 1.0 (0.5, 1.9) 1.0 (0.6, 1.6) 
rs2239707 G 1.0 (0.6, 1.5) 0.9 (0.7, 1.2) 1.4 (0.8, 2.4) 1.1 (0.7, 1.7) 
rs2230365 T 0.9 (0.6, 1.5) 1.3 (0.9, 1.7) 1.5 (0.8, 3.0) 1.2 (0.7, 2.0) 
rs3130062 C 1.2 (0.7, 2.1) 0.8 (0.5, 1.2) 1.7 (0.5, 5.4) 1.0 (0.3, 2.8) 
rs4947324 T 0.6 (0.3, 1.1) 0.7 (0.5, 1.1) 0.9 (0.5, 1.7) 1.2 (0.8, 1.9) 
rs2857709 T 1.0 (0.6, 1.6) 0.7 (0.5, 1.0) 0.8 (0.3, 1.9) 0.8 (0.4, 1.6) 
LTA 
     
rs915654* T 0.9 (0.7, 1.2) 1.1 (0.9, 1.4) 1.4 (1.0, 2.0) 1.1 (0.9, 1.4) 
rs909253* C 1.5 (1.1, 2.0) 1.1 (0.9, 1.4) 1.0 (0.7, 1.4) 0.8 (0.6, 1.1) 
rs2229094 C 0.6 (0.4, 1.0) 1.1 (0.8, 1.4) 1.3 (0.8, 2.1) 1.4 (1.0, 2.0) 
rs1041981* A 1.4 (1.0, 2.0) 1.1 (0.9, 1.3) 1.0 (0.7, 1.5) 0.8 (0.7, 1.1) 
TNF 
     
rs1799964 C 0.7 (0.4, 1.1) 1.0 (0.8, 1.4) 1.0 (0.6, 1.8) 1.4 (1.0, 2.0) 
rs1800630 A 0.8 (0.5, 1.2) 1.2 (0.9, 1.7) 1.4 (0.8, 2.4) 1.4 (0.9, 2.1) 
rs1800629 A 1.8 (1.1, 2.7) 1.1 (0.8, 1.4) 0.6 (0.3, 1.2) 1.0 (0.7, 1.6) 
rs7769073 A 0.8 (0.4, 1.8) 0.6 (0.4, 1.1) 0.9 (0.4, 1.7) 1.2 (0.8, 2.0) 
TBKBP1 
     
rs2013383 A 0.6 (0.4, 0.9) 1.1 (0.8, 1.5) 1.1 (0.7, 1.8) 1.0 (0.7, 1.5) 
rs1808192 T 0.6 (0.4, 0.9) 1.1 (0.8, 1.4) 1.0 (0.6, 1.6) 1.1 (0.8, 1.6) 
TBX21 
     
rs4461115 C 1.2 (0.8, 1.9) 1.2 (0.9, 1.5) 0.8 (0.3, 2.0) 1.3 (0.8, 2.2) 
rs16946264 A 1.1 (0.6, 1.8) 0.9 (0.6, 1.3) 1.0 (0.6, 1.6) 1.1 (0.8, 1.7) 
rs11079788 T 0.8 (0.5, 1.3) 0.9 (0.7, 1.2) 1.2 (0.7, 1.9) 1.1 (0.8, 1.6) 
rs16946878 C 1.3 (0.7, 2.4) 0.8 (0.5, 1.4) 1.0 (0.5, 1.9) 1.2 (0.8, 1.9) 
rs16947078 G 0.8 (0.5, 1.3) 0.9 (0.7, 1.2) 0.8 (0.5, 1.3) 1.1 (0.8, 1.6) 
TNFRSF1B 
     
rs496888* G 0.8 (0.6, 1.1) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 0.8 (0.6, 1.1) 
rs3766730 T 1.3 (0.8, 2.0) 0.9 (0.7, 1.3) 0.9 (0.4, 2.0) 0.8 (0.4, 1.5) 
rs816050 T 1.3 (0.8, 2.0) 1.1 (0.8, 1.4) 0.5 (0.3, 0.9) 0.9 (0.6, 1.3) 
rs1201157* T 0.8 (0.6, 1.1) 1.0 (0.8, 1.2) 1.3 (0.9, 1.8) 1.1 (0.8, 1.4) 
rs1061622 G 1.0 (0.6, 1.5) 1.0 (0.7, 1.3) 0.7 (0.4, 1.3) 0.9 (0.6, 1.3) 
rs5746051 G 1.3 (0.8, 1.9) 1.0 (0.7, 1.3) 0.7 (0.3, 1.6) 0.9 (0.5, 1.5) 
rs5746053 A 1.2 (0.8, 1.9) 1.0 (0.7, 1.3) 1.1 (0.6, 1.9) 0.9 (0.6, 1.4) 
rs1061624* G 1.0 (0.7, 1.3) 0.8 (0.7, 1.0) 1.0 (0.7, 1.4) 0.8 (0.6, 1.0) 
rs1061628* T 1.1 (0.8, 1.4) 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 0.9 (0.7, 1.2) 
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IL6R 
     
rs11265607* G 1.2 (0.8, 1.6) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 0.9 (0.7, 1.2) 
rs6427627* C 1.2 (0.9, 1.7) 0.9 (0.8, 1.1) 0.8 (0.6, 1.1) 0.9 (0.7, 1.2) 
rs11265608 A 1.2 (0.7, 2.1) 0.8 (0.6, 1.2) 0.9 (0.5, 1.6) 1.0 (0.7, 1.6) 
rs17654071 G 0.8 (0.5, 1.3) 1.1 (0.8, 1.5) 1.1 (0.7, 1.8) 1.1 (0.8, 1.6) 
rs2054855 T 0.7 (0.4, 1.2) 1.0 (0.7, 1.4) 1.6 (1.0, 2.7) 1.3 (0.9, 1.9) 
rs4845615 A  1.7 (0.4, 7.2) 1.3 (0.7, 2.4) 1.0 (0.6, 1.6) 
rs1552481 G  2.6 (1.0, 6.4) 1.3 (0.8, 2.1) 1.0 (0.7, 1.4) 
rs4845617 A 1.0 (0.6, 1.6) 0.9 (0.7, 1.3) 0.8 (0.5, 1.2) 0.7 (0.5, 1.0) 
rs6427641* G 1.1 (0.8, 1.5) 1.1 (0.9, 1.3) 0.9 (0.6, 1.2) 0.8 (0.6, 1.1) 
rs11265610 C 
 
2.0 (0.6, 6.1) 0.9 (0.6, 1.5) 1.0 (0.7, 1.4) 
rs12083537 G 1.0 (0.6, 1.5) 1.7 (1.3, 2.2) 0.8 (0.5, 1.3) 0.8 (0.6, 1.2) 
rs1386821 C 1.0 (0.6, 1.6) 1.7 (1.3, 2.2) 1.3 (0.7, 2.2) 1.0 (0.7, 1.5) 
rs12090237 A 1.3 (0.4, 3.9) 1.5 (0.8, 2.8) 0.6 (0.3, 1.1) 0.8 (0.6, 1.3) 
rs6684439 T 0.9 (0.6, 1.4) 1.0 (0.8, 1.3) 0.8 (0.5, 1.3) 1.0 (0.7, 1.4) 
rs12096944 T   0.9 (0.5, 1.9) 0.9 (0.5, 1.5) 
rs12060250 G   0.9 (0.5, 1.9) 0.9 (0.6, 1.5) 
rs4845618* G 1.1 (0.8, 1.5) 1.0 (0.8, 1.2) 1.0 (0.7, 1.5) 1.0 (0.8, 1.3) 
rs7549250* C 1.1 (0.8, 1.5) 1.0 (0.8, 1.3) 1.0 (0.6, 1.4) 1.1 (0.8, 1.4) 
rs7518199* C 1.0 (0.7, 1.4) 1.0 (0.8, 1.2) 1.2 (0.8, 1.9) 1.3 (1.0, 1.8) 
rs4553185* C 1.1 (0.8, 1.5) 1.0 (0.8, 1.3) 1.1 (0.8, 1.7) 1.2 (0.9, 1.5) 
rs4845623* G 1.0 (0.7, 1.4) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 1.1 (0.9, 1.5) 
rs4537545* T 1.0 (0.7, 1.4) 1.0 (0.8, 1.2) 0.8 (0.6, 1.2) 1.1 (0.8, 1.4) 
rs4845626 T 0.9 (0.6, 1.5) 1.1 (0.8, 1.5) 0.9 (0.6, 1.5) 0.8 (0.6, 1.2) 
rs4845374 A 0.8 (0.5, 1.4) 1.2 (0.9, 1.6) 0.8 (0.5, 1.3) 0.7 (0.5, 0.9) 
rs11265618 T 0.9 (0.6, 1.5) 1.1 (0.8, 1.5) 0.9 (0.6, 1.5) 0.9 (0.6, 1.2) 
rs4329505 C 0.8 (0.5, 1.3) 1.2 (0.9, 1.5) 0.8 (0.5, 1.3) 0.9 (0.7, 1.4) 
rs4341355 C 1.1 (0.7, 1.6) 0.9 (0.7, 1.2) 1.2 (0.6, 2.2) 0.9 (0.6, 1.4) 
rs2229238 T 1.0 (0.7, 1.6) 0.8 (0.6, 1.1) 1.4 (0.8, 2.2) 1.1 (0.7, 1.5) 
rs4072391 T 1.0 (0.7, 1.6) 0.8 (0.6, 1.1) 1.2 (0.8, 2.0) 1.1 (0.8, 1.6) 
rs11265621* G 1.0 (0.7, 1.4) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 0.8 (0.6, 1.0) 
rs7526293 T 1.2 (0.8, 1.8) 0.9 (0.6, 1.2) 1.3 (0.8, 2.1) 1.1 (0.8, 1.6) 
IL10 
     
rs7539748 A 1.0 (0.6, 1.5) 0.9 (0.7, 1.2) 1.5 (0.7, 3.2) 1.0 (0.6, 1.9) 
rs11119451 C 0.9 (0.6, 1.4) 1.0 (0.8, 1.4) 0.9 (0.6, 1.5) 1.2 (0.9, 1.8) 
rs6658896 T 0.5 (0.1, 1.9) 0.7 (0.4, 1.5) 1.0 (0.6, 1.9) 0.9 (0.6, 1.4) 
rs6692511 T 0.9 (0.6, 1.4) 0.8 (0.6, 1.0) 1.2 (0.7, 1.9) 1.1 (0.8, 1.6) 
rs6699203 A 0.9 (0.6, 1.4) 0.8 (0.6, 1.0) 1.2 (0.7, 1.9) 1.1 (0.8, 1.6) 
rs4390174* G 1.1 (0.8, 1.4) 1.0 (0.8, 1.2) 1.0 (0.7, 1.4) 1.1 (0.9, 1.5) 
rs6673928 T 1.3 (0.9, 2.1) 1.0 (0.8, 1.3) 0.7 (0.4, 1.4) 1.1 (0.7, 1.6) 
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rs3024496* C 0.9 (0.7, 1.3) 1.2 (1.0, 1.4) 1.0 (0.7, 1.4) 1.2 (0.9, 1.5) 
rs1878672* G 0.9 (0.7, 1.3) 1.2 (1.0, 1.4) 0.9 (0.6, 1.4) 1.2 (0.9, 1.5) 
rs3024493 T 0.8 (0.5, 1.3) 1.5 (1.1, 2.0) 1.0 (0.4, 2.5) 1.1 (0.6, 2.0) 
rs3024491* T 1.0 (0.7, 1.3) 1.2 (1.0, 1.4) 0.9 (0.6, 1.4) 1.1 (0.9, 1.5) 
rs3024490 T 1.0 (0.6, 1.5) 0.8 (0.6, 1.1) 0.6 (0.4, 0.9) 1.1 (0.8, 1.6) 
rs1800871 T 0.9 (0.6, 1.5) 0.8 (0.6, 1.1) 0.6 (0.4, 0.9) 1.1 (0.8, 1.7) 
rs1800890 A 1.0 (0.7, 1.6) 1.2 (0.9, 1.5) 0.8 (0.5, 1.2) 1.1 (0.8, 1.6) 
rs17015767 C 1.4 (0.9, 2.1) 1.0 (0.8, 1.4) 0.8 (0.5, 1.5) 1.0 (0.7, 1.5) 
rs10494879* G 1.0 (0.7, 1.3) 1.2 (1.0, 1.4) 0.8 (0.5, 1.2) 1.0 (0.8, 1.4) 
rs6686931 T 1.1 (0.7, 1.7) 0.8 (0.6, 1.1) 0.8 (0.5, 1.2) 1.1 (0.8, 1.6) 
IL1A 
     
rs17561 T 0.9 (0.6, 1.4) 1.1 (0.9, 1.5) 0.8 (0.5, 1.4) 0.8 (0.5, 1.2) 
rs1800587* T 0.9 (0.7, 1.3) 1.2 (1.0, 1.5) 0.7 (0.5, 1.0) 0.8 (0.6, 1.0) 
IL1B 
     
rs1143634 T 1.1 (0.7, 1.7) 1.3 (1.0, 1.7) 0.7 (0.4, 1.3) 0.9 (0.6, 1.3) 
rs1143627* T 0.8 (0.6, 1.2) 0.9 (0.8, 1.2) 1.3 (0.9, 1.8) 0.9 (0.7, 1.2) 
IL8RB 
     
rs4674258* C 0.9 (0.7, 1.2) 1.0 (0.8, 1.2) 1.1 (0.8, 1.5) 0.9 (0.7, 1.1) 
rs4674259 G 0.7 (0.5, 1.2) 1.0 (0.7, 1.4) 1.3 (0.8, 2.1) 0.8 (0.6, 1.2) 
rs6761387 T 0.9 (0.4, 2.1) 1.1 (0.7, 1.7) 0.6 (0.3, 1.0) 1.0 (0.6, 1.4) 
rs4674261* C 1.0 (0.8, 1.4) 1.0 (0.8, 1.3) 1.1 (0.8, 1.6) 1.1 (0.9, 1.4) 
rs11677534* T 0.9 (0.6, 1.2) 1.0 (0.8, 1.2) 1.4 (1.0, 2.0) 0.9 (0.7, 1.2) 
rs11676348* C 0.9 (0.6, 1.2) 1.0 (0.8, 1.2) 0.8 (0.6, 1.1) 0.8 (0.7, 1.1) 
IL12A 
     
rs503582* T 1.3 (0.9, 1.7) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 1.1 (0.9, 1.4) 
rs532953 C 0.5 (0.3, 0.9) 1.1 (0.8, 1.4) 1.0 (0.6, 1.8) 0.9 (0.6, 1.4) 
rs7653097 C 1.3 (0.7, 2.2) 0.9 (0.6, 1.4) 1.3 (0.8, 2.1) 0.8 (0.6, 1.2) 
rs1014486* G 1.0 (0.8, 1.4) 1.0 (0.8, 1.2) 1.2 (0.8, 1.6) 1.1 (0.8, 1.4) 
rs13064168 A 0.9 (0.6, 1.4) 0.9 (0.7, 1.2) 0.7 (0.3, 1.6) 0.9 (0.5, 1.5) 
rs609907 C 0.7 (0.4, 1.0) 0.9 (0.7, 1.1) 0.9 (0.5, 1.6) 0.9 (0.6, 1.3) 
rs2647929 A 1.2 (0.7, 1.8) 1.0 (0.7, 1.3) 1.2 (0.7, 2.0) 1.0 (0.7, 1.5) 
rs2886666 T 1.2 (0.8, 1.8) 1.2 (0.9, 1.6) 0.8 (0.3, 2.0) 1.4 (0.8, 2.5) 
rs9811792* C 1.2 (0.9, 1.6) 1.0 (0.8, 1.3) 1.2 (0.8, 1.8) 1.0 (0.8, 1.3) 
rs16830946 G 
 
1.3 (0.3, 6.1) 1.0 (0.6, 1.8) 0.8 (0.5, 1.2) 
rs7372767 G 1.2 (0.7, 1.9) 1.0 (0.7, 1.3) 1.0 (0.6, 1.6) 1.0 (0.7, 1.4) 
rs6441282* T 0.8 (0.6, 1.1) 1.0 (0.8, 1.2) 1.0 (0.7, 1.5) 0.9 (0.7, 1.1) 
rs692890 T 0.7 (0.5, 1.1) 0.9 (0.7, 1.2) 0.7 (0.4, 1.4) 0.8 (0.5, 1.3) 
rs755004 T 1.3 (0.8, 2.0) 1.1 (0.8, 1.5) 0.7 (0.2, 1.7) 1.2 (0.7, 2.1) 
rs16830949 T   0.9 (0.5, 1.6) 0.7 (0.5, 1.1) 
rs2243115 G 0.8 (0.4, 1.4) 1.0 (0.7, 1.5) 0.6 (0.3, 1.2) 1.2 (0.8, 1.8) 
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rs583911 G 1.2 (0.7, 1.8) 1.1 (0.8, 1.5) 1.3 (0.8, 2.1) 0.9 (0.6, 1.4) 
rs2243151* T 1.2 (0.8, 1.6) 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 1.1 (0.8, 1.4) 
rs2243154 A 1.6 (1.0, 2.6) 0.9 (0.6, 1.3) 1.8 (0.8, 4.5) 1.2 (0.6, 2.5) 
rs4608735 C 0.7 (0.4, 1.3) 1.0 (0.7, 1.5) 0.9 (0.5, 1.7) 1.3 (0.9, 2.0) 
rs17826053 G 0.5 (0.3, 0.9) 0.9 (0.7, 1.3) 0.9 (0.5, 1.6) 0.9 (0.6, 1.3) 
rs485497 A 1.2 (0.7, 1.9) 1.2 (0.9, 1.6) 1.1 (0.7, 1.8) 0.8 (0.6, 1.2) 
rs4680536* G 1.0 (0.8, 1.4) 0.9 (0.7, 1.1) 1.3 (0.9, 1.8) 0.8 (0.6, 1.1) 
rs12492730 G 1.0 (0.1, 7.2) 2.5 (1.2, 5.2) 1.0 (0.5, 1.7) 1.3 (0.9, 2.0) 
rs9852519 T 1.0 (0.6, 1.5) 0.9 (0.7, 1.2) 1.2 (0.7, 2.0) 1.0 (0.7, 1.5) 
rs598638 T 0.7 (0.4, 1.2) 1.2 (0.9, 1.6) 0.8 (0.3, 2.5) 1.0 (0.5, 2.0) 
IL8 
     
rs7654490 T   1.2 (0.7, 2.0) 0.7 (0.5, 1.1) 
rs16849893 A  1.5 (0.3, 8.6) 0.7 (0.4, 1.3) 0.7 (0.5, 1.1) 
rs16849896 T  0.0 (0.0, 0.0) 1.1 (0.6, 1.9) 0.7 (0.4, 1.1) 
rs4694634 C  1.5 (0.3, 8.6) 0.5 (0.3, 0.9) 0.7 (0.5, 1.1) 
rs16849907 T  
 
1.0 (0.5, 1.9) 0.7 (0.4, 1.2) 
rs12506479 C 1.0 (0.6, 1.5) 1.0 (0.8, 1.4) 0.8 (0.5, 1.3) 1.2 (0.9, 1.7) 
rs10805066 G 0.9 (0.6, 1.4) 1.0 (0.8, 1.3) 0.9 (0.5, 1.7) 1.0 (0.6, 1.6) 
rs7693566 C 
 
1.5 (0.3, 8.5) 0.8 (0.5, 1.4) 0.7 (0.5, 1.0) 
rs4694635 T 0.5 (0.1, 4.3) 1.5 (0.6, 4.0) 1.7 (1.0, 2.8) 1.3 (0.9, 2.0) 
rs16849928* A 0.9 (0.7, 1.2) 0.9 (0.7, 1.1) 1.4 (1.0, 2.0) 1.2 (0.9, 1.5) 
rs11730667 A 0.9 (0.6, 1.5) 0.8 (0.6, 1.2) 1.3 (0.8, 2.1) 1.2 (0.8, 1.7) 
rs13142454 G  3.8 (1.5, 9.9) 1.5 (0.9, 2.6) 1.3 (0.9, 1.9) 
rs11729759 A  3.8 (1.5, 9.9) 1.3 (0.8, 2.1) 1.3 (0.9, 1.8) 
rs1951240* G 1.1 (0.8, 1.4) 1.1 (0.9, 1.4) 0.9 (0.7, 1.3) 1.1 (0.9, 1.4) 
rs16849958 C 1.2 (0.8, 2.0) 1.2 (0.9, 1.7) 1.0 (0.6, 1.6) 1.2 (0.8, 1.8) 
rs1951242 T 0.9 (0.6, 1.5) 0.9 (0.6, 1.2) 1.2 (0.8, 2.0) 1.1 (0.8, 1.6) 
rs7658422 C 0.0 (0.0, 0.0) 3.8 (1.5, 9.9) 1.1 (0.7, 1.9) 1.2 (0.8, 1.7) 
CXCL10 
     
rs3733236 T 0.8 (0.4, 1.5) 0.7 (0.5, 1.1) 0.9 (0.5, 1.5) 1.0 (0.7, 1.4) 
rs10031051 C 1.1 (0.4, 3.5) 1.1 (0.5, 2.4) 1.3 (0.7, 2.4) 0.7 (0.4, 1.1) 
rs7670156 A 0.9 (0.5, 1.6) 0.8 (0.5, 1.2) 1.0 (0.6, 1.7) 0.9 (0.6, 1.3) 
rs12651276 G 1.2 (0.8, 1.8) 1.0 (0.7, 1.3) 0.4 (0.1, 1.2) 1.4 (0.8, 2.3) 
rs10518143 C 0.8 (0.5, 1.3) 1.1 (0.8, 1.4) 1.3 (0.7, 2.2) 0.8 (0.5, 1.2) 
rs867562 A 1.3 (0.8, 2.0) 1.0 (0.7, 1.4) 0.3 (0.1, 1.3) 1.1 (0.6, 2.0) 
rs4508917* G 0.8 (0.6, 1.2) 1.1 (0.9, 1.3) 1.1 (0.7, 1.6) 1.1 (0.8, 1.5) 
rs12504339 C 1.1 (0.7, 1.8) 1.0 (0.7, 1.3) 0.9 (0.5, 1.5) 1.0 (0.7, 1.4) 
rs4302486* A 1.1 (0.8, 1.5) 0.9 (0.8, 1.2) 1.2 (0.8, 1.7) 1.0 (0.8, 1.3) 
NFKB1 
     
rs980455* G 0.8 (0.6, 1.1) 1.0 (0.8, 1.2) 1.2 (0.8, 1.7) 0.9 (0.7, 1.1) 
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rs3774933* C 0.8 (0.6, 1.1) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 1.0 (0.8, 1.3) 
rs17032705* A 0.8 (0.6, 1.1) 1.0 (0.8, 1.2) 0.9 (0.6, 1.4) 1.1 (0.8, 1.5) 
rs1599961* A 0.8 (0.6, 1.1) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 1.0 (0.8, 1.3) 
rs230533* T 0.9 (0.6, 1.2) 1.0 (0.2, 4.3) 1.1 (0.6, 2.0) 0.9 (0.6, 1.4) 
rs230530 C 1.2 (0.8, 1.9) 1.0 (0.9, 1.3) 0.8 (0.5, 1.3) 0.9 (0.7, 1.3) 
rs230529* A 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 1.2 (0.7, 1.9) 1.2 (0.9, 1.8) 
rs17032779 C 1.1 (0.3, 4.2) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 0.9 (0.7, 1.2) 
rs230515 C 0.7 (0.5, 1.1) 1.4 (0.7, 3.0) 1.1 (0.6, 2.0) 0.7 (0.4, 1.1) 
rs230493 A 0.8 (0.5, 1.2) 1.1 (0.9, 1.5) 0.8 (0.5, 1.3) 1.0 (0.7, 1.5) 
rs17032815 A 1.0 (0.3, 4.1) 1.1 (0.8, 1.5) 0.8 (0.5, 1.4) 1.1 (0.7, 1.5) 
rs909332 T 0.6 (0.2, 1.8) 1.6 (0.8, 3.2) 1.2 (0.6, 2.1) 0.9 (0.5, 1.4) 
rs1801* C 0.9 (0.6, 1.2) 1.0 (0.6, 1.7) 0.9 (0.5, 1.8) 1.1 (0.7, 1.7) 
rs4648058 C 0.9 (0.6, 1.4) 1.0 (0.8, 1.2) 1.0 (0.7, 1.4) 1.0 (0.8, 1.3) 
rs3755867* G 0.9 (0.7, 1.3) 1.2 (0.9, 1.6) 0.9 (0.5, 1.4) 1.1 (0.8, 1.6) 
rs4648090 A 1.0 (0.6, 1.6) 1.1 (0.9, 1.3) 0.8 (0.5, 1.3) 1.0 (0.8, 1.3) 
rs4648110 A 0.9 (0.6, 1.4) 1.1 (0.8, 1.5) 0.9 (0.5, 1.6) 0.9 (0.6, 1.4) 
rs3817685 G 0.9 (0.6, 1.4) 1.1 (0.8, 1.5) 1.0 (0.6, 1.6) 0.8 (0.6, 1.1) 
rs4648127 T 0.8 (0.4, 1.5) 1.2 (0.9, 1.6) 0.8 (0.5, 1.3) 1.2 (0.8, 1.7) 
rs230547 T 1.1 (0.6, 1.9) 1.2 (0.8, 1.7) 2.3 (0.6, 8.5) 1.6 (0.6, 4.5) 
rs4648135 G 0.9 (0.4, 2.0) 1.0 (0.7, 1.5) 0.9 (0.5, 1.7) 1.1 (0.7, 1.6) 
rs4648141 A 0.9 (0.6, 1.5) 0.9 (0.6, 1.6) 0.8 (0.5, 1.4) 0.9 (0.6, 1.4) 
rs7674640* C 1.2 (0.9, 1.7) 1.3 (1.0, 1.7) 1.3 (0.7, 2.3) 0.9 (0.6, 1.3) 
rs10489113 G 0.9 (0.6, 1.4) 0.8 (0.7, 1.0) 0.9 (0.6, 1.3) 1.2 (0.9, 1.5) 
rs11733293* T 1.0 (0.7, 1.3) 1.3 (1.0, 1.7) 1.0 (0.6, 1.8) 0.8 (0.5, 1.1) 
rs17033015 A 1.1 (0.7, 1.8) 1.0 (0.8, 1.2) 0.9 (0.6, 1.4) 1.0 (0.8, 1.4) 
rs12648696* C 0.9 (0.7, 1.3) 0.8 (0.6, 1.1) 1.0 (0.6, 1.8) 1.2 (0.9, 1.8) 
rs12648696* C 
 
1.0 (0.9, 1.3) 0.8 (0.6, 1.3) 1.0 (0.8, 1.3) 
IL2 
     
rs17454584 G 1.0 (0.7, 1.6) 1.2 (0.9, 1.6) 0.8 (0.3, 2.0) 0.7 (0.4, 1.4) 
rs35914000 A 0.9 (0.6, 1.4) 1.1 (0.8, 1.5) 0.8 (0.4, 1.7) 0.8 (0.5, 1.4) 
rs10034410 T 
 
2.1 (0.3, 13.3) 0.8 (0.4, 1.6) 0.6 (0.4, 1.1) 
rs10027390 C 1.4 (0.9, 2.2) 0.7 (0.6, 1.0)   
rs11932411 C 0.0 (0.0, 0.0) 1.9 (0.7, 5.4) 0.9 (0.6, 1.5) 0.8 (0.6, 1.1) 
rs2069776 C 1.4 (0.9, 2.1) 0.7 (0.6, 1.0) 1.0 (0.6, 1.7) 1.1 (0.8, 1.7) 
rs2069778 T 1.3 (0.8, 2.0) 0.7 (0.5, 0.9) 0.5 (0.1, 2.0) 0.6 (0.3, 1.6) 
rs2069762 G 1.1 (0.7, 1.6) 1.3 (1.0, 1.7) 1.9 (1.1, 3.3) 1.4 (0.9, 2.2) 
rs4833248 A 1.1 (0.7, 1.6) 1.3 (1.0, 1.7) 1.9 (1.1, 3.4) 1.4 (0.9, 2.2) 
      
IL15 
     
rs6837991 T 0.9 (0.6, 1.3) 1.0 (0.8, 1.3) 1.5 (0.9, 2.4) 0.8 (0.6, 1.2) 
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rs12508866 C 0.9 (0.6, 1.4) 0.8 (0.6, 1.1) 1.3 (0.6, 2.6) 0.9 (0.5, 1.6) 
rs17007476 C 
 
4.2 (1.8, 10.0) 0.9 (0.5, 1.7) 1.4 (1.0, 2.0) 
rs17007480 A   1.0 (0.5, 2.1) 1.5 (1.0, 2.4) 
rs1519551* G 0.7 (0.5, 1.0) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 1.0 (0.8, 1.3) 
rs17461269 A 1.6 (1.0, 2.5) 1.0 (0.7, 1.3) 0.6 (0.3, 1.5) 0.6 (0.3, 1.2) 
rs17007503 C   1.1 (0.6, 2.1) 1.3 (0.8, 2.0) 
rs1519552 A 0.9 (0.6, 1.3) 1.0 (0.8, 1.3) 1.4 (0.8, 2.4) 1.1 (0.7, 1.6) 
rs17007508 G 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.8 (0.4, 1.3) 0.9 (0.6, 1.3) 
rs7698675 T 0.9 (0.6, 1.4) 1.0 (0.8, 1.3) 1.3 (0.8, 2.2) 1.0 (0.7, 1.5) 
rs13117878* C 0.7 (0.6, 1.0) 0.9 (0.8, 1.2) 1.1 (0.8, 1.5) 1.0 (0.8, 1.3) 
rs17364630 G 0.7 (0.4, 1.2) 0.9 (0.7, 1.3) 0.8 (0.4, 1.5) 0.6 (0.4, 1.1) 
rs12498901 C 0.7 (0.4, 1.2) 0.9 (0.7, 1.3) 0.8 (0.4, 1.5) 0.6 (0.4, 1.1) 
rs7671458 G 0.7 (0.4, 1.2) 0.9 (0.7, 1.3) 0.9 (0.5, 1.5) 0.8 (0.6, 1.2) 
rs10519610 C 0.7 (0.4, 1.1) 0.9 (0.7, 1.2) 1.1 (0.7, 1.8) 0.9 (0.6, 1.3) 
rs6850492* A 0.7 (0.5, 1.0) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 0.9 (0.7, 1.2) 
rs2087849 T 0.9 (0.6, 1.4) 1.1 (0.8, 1.4) 1.4 (0.9, 2.3) 1.2 (0.8, 1.7) 
rs2857261* G 1.3 (1.0, 1.7) 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 1.1 (0.8, 1.4) 
rs1907949 T 1.1 (0.6, 1.8) 0.9 (0.7, 1.4) 0.8 (0.5, 1.5) 1.0 (0.7, 1.5) 
rs3775597 C 1.1 (0.6, 1.8) 1.0 (0.7, 1.4) 1.0 (0.6, 1.9) 1.2 (0.8, 1.8) 
rs12508955 T 0.9 (0.6, 1.4) 1.1 (0.8, 1.4) 1.2 (0.7, 2.0) 1.1 (0.8, 1.6) 
rs17007610* T 0.8 (0.6, 1.0) 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 0.9 (0.7, 1.2) 
CSF2 
     
rs31400* T 1.1 (0.9, 1.5) 1.0 (0.8, 1.2) 0.8 (0.6, 1.2) 0.8 (0.6, 1.0) 
rs3091335 G 0.0 (0.0, 0.0) 0.9 (0.2, 3.6) 1.0 (0.6, 1.6) 0.9 (0.7, 1.3) 
rs31481 A 1.4 (0.9, 2.2) 1.2 (0.9, 1.6) 0.8 (0.5, 1.5) 1.1 (0.7, 1.6) 
rs2069801 G 0.0 (0.0, 0.0) 2.4 (0.3, 18.3) 1.1 (0.6, 2.0) 1.0 (0.6, 1.5) 
rs246844 A 1.4 (0.9, 2.1) 1.3 (1.0, 1.8) 0.8 (0.5, 1.3) 1.2 (0.8, 1.6) 
rs11575022 C 1.2 (0.6, 2.4) 1.7 (1.2, 2.5) 1.0 (0.6, 1.6) 1.1 (0.7, 1.6) 
rs246841 T 1.4 (0.8, 2.2) 0.9 (0.7, 1.3) 0.4 (0.1, 1.6) 0.7 (0.3, 1.6) 
rs168681 A 1.0 (0.6, 1.5) 0.9 (0.7, 1.2) 0.7 (0.4, 1.2) 0.9 (0.6, 1.3) 
rs721121* G 0.9 (0.7, 1.3) 0.9 (0.8, 1.2) 1.2 (0.8, 1.7) 1.1 (0.9, 1.5) 
rs4705916 A 0.8 (0.5, 1.3) 0.8 (0.6, 1.1) 1.1 (0.7, 1.8) 1.0 (0.7, 1.4) 
rs743677 G 0.0 (0.0, 0.0) 0.7 (0.1, 5.0) 1.2 (0.7, 2.0) 0.9 (0.6, 1.3) 
rs2069626 G 1.1 (0.3, 4.5) 0.8 (0.3, 2.1) 1.2 (0.7, 2.3) 0.8 (0.5, 1.3) 
rs743564* G 0.9 (0.6, 1.2) 0.9 (0.8, 1.1) 1.0 (0.7, 1.4) 0.8 (0.6, 1.1) 
rs25881 T 1.3 (0.8, 2.0) 1.1 (0.8, 1.5) 0.9 (0.6, 1.6) 1.2 (0.8, 1.7) 
rs25882 C 1.0 (0.6, 1.6) 1.1 (0.8, 1.4) 1.3 (0.8, 2.2) 1.0 (0.7, 1.5) 
rs27438* A 1.2 (0.8, 1.9) 1.1 (0.8, 1.4) 1.0 (0.7, 1.6) 1.2 (0.9, 1.6) 
rs25887* C 0.9 (0.7, 1.2) 1.0 (0.8, 1.2) 0.9 (0.7, 1.3) 1.0 (0.7, 1.2) 
rs6898270 T 0.7 (0.5, 1.2) 0.8 (0.6, 1.1) 1.0 (0.6, 1.7) 0.9 (0.6, 1.3) 
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IL13 
     
rs7737470 A 1.1 (0.7, 1.7) 1.4 (1.1, 1.9) 1.5 (1.0, 2.5) 0.8 (0.6, 1.1) 
rs4621555 C  0.0 (0.0, 0.0) 1.1 (0.6, 1.9) 1.2 (0.8, 1.7) 
rs3091307 G 1.0 (0.7, 1.6) 1.4 (1.1, 1.9) 1.5 (0.7, 3.3) 1.1 (0.6, 1.8) 
rs1881457 C 1.0 (0.6, 1.6) 1.4 (1.1, 1.9) 1.1 (0.7, 1.9) 0.7 (0.5, 1.1) 
rs2069744 T 
 
0.6 (0.1, 2.3) 1.3 (0.8, 2.1) 1.1 (0.8, 1.5) 
rs1295686 G 1.1 (0.3, 3.4) 0.9 (0.5, 1.8) 0.7 (0.4, 1.1) 1.1 (0.8, 1.6) 
rs20541 T 0.8 (0.5, 1.3) 1.1 (0.8, 1.5) 1.2 (0.7, 1.9) 1.2 (0.8, 1.7) 
rs848 T 0.8 (0.5, 1.3) 1.1 (0.8, 1.5) 1.5 (0.8, 2.8) 1.4 (0.9, 2.2) 
rs1295683 T 0.7 (0.4, 1.3) 1.1 (0.8, 1.5) 1.1 (0.6, 1.9) 0.9 (0.6, 1.4) 
rs2243204 T 0.7 (0.4, 1.5) 1.0 (0.7, 1.5) 1.0 (0.5, 1.9) 1.0 (0.6, 1.5) 
rs2243210 A 0.8 (0.4, 1.6) 0.9 (0.5, 1.3) 1.3 (0.8, 2.1) 1.1 (0.7, 1.5) 
rs2243218 A 0.8 (0.4, 1.6) 0.9 (0.6, 1.3) 1.3 (0.8, 2.2) 1.0 (0.7, 1.4) 
rs2243219 G 0.8 (0.4, 1.6) 0.9 (0.6, 1.3) 1.0 (0.5, 1.7) 1.0 (0.6, 1.5) 
IL4 
     
rs2243240 T   0.9 (0.4, 2.1) 1.1 (0.7, 1.9) 
rs2243246 C   0.9 (0.6, 1.6) 0.8 (0.5, 1.1) 
rs2243248 G 0.7 (0.4, 1.5) 0.9 (0.6, 1.3) 1.0 (0.6, 1.7) 1.1 (0.7, 1.6) 
rs2243250* C 0.7 (0.5, 1.0) 0.9 (0.7, 1.2) 0.8 (0.5, 1.1) 1.1 (0.9, 1.5) 
rs2243253 T  2.5 (0.5, 12.9) 1.0 (0.6, 1.8) 1.3 (0.9, 1.9) 
rs2243261 T   0.6 (0.3, 1.0) 0.8 (0.5, 1.2) 
rs2243263 C 0.8 (0.5, 1.4) 1.2 (0.8, 1.6) 0.8 (0.5, 1.4) 1.1 (0.8, 1.7) 
rs2243267 C 1.4 (0.9, 2.3) 1.1 (0.8, 1.5) 1.4 (0.8, 2.3) 0.8 (0.6, 1.2) 
rs2243270 G 1.4 (0.9, 2.2) 1.1 (0.8, 1.5) 1.7 (0.7, 4.0) 0.8 (0.5, 1.3) 
rs2243283 G 1.0 (0.1, 7.7) 1.5 (0.6, 4.0) 1.1 (0.7, 1.8) 0.9 (0.6, 1.4) 
rs2243292 C 2.7 (0.6, 12.3) 0.5 (0.1, 3.8) 1.4 (0.7, 2.6) 1.0 (0.6, 1.6) 
rs11242122* G 0.9 (0.6, 1.3) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 1.2 (1.0, 1.6) 
rs11242123 T 1.3 (0.8, 2.1) 1.2 (0.9, 1.6) 0.9 (0.6, 1.6) 0.6 (0.4, 0.9) 
IL12B 
     
rs7730126* T 0.9 (0.7, 1.3) 1.2 (1.0, 1.5) 1.1 (0.7, 1.6) 0.9 (0.7, 1.2) 
rs2099327 C 0.9 (0.6, 1.5) 1.3 (1.0, 1.8) 1.7 (0.9, 3.1) 0.6 (0.4, 1.1) 
rs1549922* G 1.1 (0.8, 1.4) 0.8 (0.6, 0.9) 0.9 (0.6, 1.3) 1.0 (0.8, 1.3) 
rs4921466 C 0.9 (0.5, 1.5) 0.9 (0.6, 1.3) 0.8 (0.5, 1.5) 1.1 (0.7, 1.7) 
rs10072923 C 1.0 (0.7, 1.6) 1.2 (0.9, 1.5) 1.1 (0.7, 1.8) 1.1 (0.8, 1.5) 
rs1368439 G 1.1 (0.7, 1.8) 0.7 (0.5, 1.0) 0.9 (0.4, 1.9) 1.0 (0.6, 1.8) 
rs3212227 C 1.1 (0.7, 1.7) 1.1 (0.9, 1.5) 0.9 (0.6, 1.5) 0.9 (0.6, 1.2) 
rs11574790 T 0.8 (0.5, 1.4) 0.9 (0.7, 1.3) 0.9 (0.5, 1.5) 1.2 (0.8, 1.7) 
rs2195940 T 0.8 (0.5, 1.4) 0.9 (0.6, 1.3) 0.7 (0.4, 1.2) 1.2 (0.8, 1.8) 
rs919766 C 0.8 (0.5, 1.4) 0.9 (0.7, 1.3) 0.9 (0.5, 1.4) 1.2 (0.9, 1.7) 
rs2853694* C 1.0 (0.8, 1.4) 0.8 (0.6, 1.0) 1.0 (0.6, 1.5) 1.0 (0.7, 1.3) 
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rs2569253 C 1.2 (0.7, 2.0) 1.0 (0.7, 1.4) 1.2 (0.8, 2.0) 0.8 (0.6, 1.1) 
rs3212220 T 1.1 (0.7, 1.7) 1.1 (0.9, 1.5) 0.9 (0.6, 1.5) 1.0 (0.7, 1.4) 
rs1433048 G 1.2 (0.8, 1.9) 0.9 (0.7, 1.2) 0.6 (0.2, 1.6) 1.1 (0.6, 1.9) 
rs2546893 A 1.2 (0.7, 2.1) 1.0 (0.8, 1.4) 1.3 (0.8, 2.1) 0.8 (0.6, 1.2) 
rs2546890* A 1.0 (0.7, 1.4) 0.8 (0.7, 1.0) 1.0 (0.7, 1.4) 0.9 (0.7, 1.2) 
rs10052709 G 0.8 (0.5, 1.4) 0.8 (0.6, 1.1) 1.1 (0.6, 2.0) 1.0 (0.7, 1.6) 
rs7709212* C 1.0 (0.8, 1.4) 1.3 (1.0, 1.6) 1.2 (0.8, 1.7) 1.0 (0.7, 1.3) 
rs6868898 C 0.9 (0.6, 1.4) 0.8 (0.6, 1.1) 1.0 (0.6, 1.7) 1.3 (0.9, 1.8) 
IL6 
     
rs6949149 T 
    
rs6954897 G 1.6 (0.9, 2.9) 1.5 (1.0, 2.2) 1.2 (0.7, 2.1) 1.0 (0.7, 1.6) 
rs6954681 T 0.8 (0.5, 1.4) 1.0 (0.7, 1.5) 0.8 (0.5, 1.4) 0.9 (0.6, 1.3) 
rs6969927 A 1.3 (0.9, 2.1) 1.6 (1.2, 2.1) 1.0 (0.6, 1.7) 1.0 (0.6, 1.5) 
rs10156056 C 0.9 (0.6, 1.4) 0.8 (0.6, 1.1) 1.2 (0.7, 2.0) 1.5 (1.0, 2.1) 
rs7776857 G 1.0 (0.6, 1.7) 1.5 (1.1, 2.0) 0.9 (0.5, 1.4) 0.9 (0.6, 1.3) 
rs4719711 C 1.0 (0.7, 1.6) 0.9 (0.7, 1.2) 1.2 (0.6, 2.5) 0.8 (0.4, 1.4) 
rs6963444 G 0.9 (0.6, 1.5) 0.9 (0.7, 1.2) 1.4 (0.9, 2.3) 0.7 (0.5, 1.1) 
rs1546762 C 1.8 (0.8, 3.9) 1.5 (0.9, 2.5) 0.7 (0.4, 1.3) 0.9 (0.6, 1.4) 
rs7805828* A 1.0 (0.6, 1.5) 0.9 (0.7, 1.2) 1.2 (0.7, 1.9) 0.7 (0.5, 1.1) 
rs1880241* G 0.8 (0.6, 1.2) 0.9 (0.7, 1.0) 1.1 (0.8, 1.5) 1.3 (1.0, 1.6) 
rs2056576* T 0.9 (0.7, 1.3) 0.9 (0.8, 1.1) 1.1 (0.8, 1.5) 1.2 (0.9, 1.5) 
rs7784987 A 0.8 (0.6, 1.1) 1.0 (0.8, 1.3) 1.0 (0.7, 1.4) 1.1 (0.8, 1.3) 
rs3087221 T 1.9 (0.9, 4.0) 1.4 (0.9, 2.4) 1.0 (0.5, 1.7) 1.0 (0.6, 1.5) 
rs2069824 C 1.5 (0.5, 4.5) 1.0 (0.4, 2.5) 0.6 (0.4, 1.2) 1.0 (0.7, 1.5) 
rs1800797 A 1.1 (0.6, 2.0) 1.5 (1.1, 2.2) 1.1 (0.6, 1.9) 1.2 (0.8, 1.8) 
rs1800795 C 0.8 (0.5, 1.2) 0.8 (0.6, 1.1) 0.9 (0.5, 1.9) 0.6 (0.3, 1.1) 
rs2069835 C 0.8 (0.5, 1.3) 0.8 (0.6, 1.0) 0.9 (0.5, 1.9) 0.6 (0.3, 1.1) 
rs1474347 G 1.4 (0.7, 2.6) 1.4 (0.9, 2.1) 1.1 (0.6, 2.0) 0.8 (0.5, 1.2) 
rs2069840 G 0.8 (0.5, 1.3) 0.8 (0.6, 1.1) 0.7 (0.4, 1.3) 0.8 (0.5, 1.2) 
rs2069842 A 0.7 (0.4, 1.0) 0.9 (0.7, 1.2) 1.6 (1.0, 2.7) 1.2 (0.8, 1.7) 
rs1548216 C   1.5 (0.9, 2.7) 1.4 (0.9, 2.2) 
rs2069843 A 1.7 (0.8, 3.7) 1.6 (1.0, 2.6) 0.9 (0.5, 1.5) 1.0 (0.6, 1.4) 
rs2069845* G 1.7 (0.8, 3.7) 1.6 (1.0, 2.6) 0.8 (0.4, 1.5) 0.8 (0.5, 1.3) 
rs2069849 T 0.9 (0.7, 1.3) 0.9 (0.7, 1.1) 0.7 (0.5, 1.1) 0.9 (0.6, 1.2) 
rs10242595* G 1.7 (0.8, 3.7) 1.6 (1.0, 2.6) 0.9 (0.5, 1.6) 0.9 (0.6, 1.4) 
GATA3 
 
1.0 (0.7, 1.4) 0.8 (0.7, 1.0) 1.0 (0.7, 1.4) 0.9 (0.7, 1.2) 
rs406571* C 
    
rs1877739 C 1.0 (0.7, 1.4) 1.1 (0.9, 1.4) 0.9 (0.6, 1.2) 1.3 (1.0, 1.7) 
rs532854* C 1.0 (0.7, 1.6) 0.9 (0.7, 1.2) 0.8 (0.5, 1.3) 0.9 (0.6, 1.3) 
rs10795588 G 1.2 (0.9, 1.6) 1.0 (0.8, 1.2) 0.9 (0.6, 1.3) 1.0 (0.8, 1.2) 
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rs263425 T 1.2 (0.8, 2.0) 0.8 (0.6, 1.1) 1.3 (0.8, 2.1) 0.9 (0.7, 1.3) 
rs263423 A   0.4 (0.2, 0.8) 1.1 (0.8, 1.7) 
rs1244186 T 1.4 (0.9, 2.2) 1.3 (1.0, 1.7) 1.0 (0.6, 1.7) 0.8 (0.6, 1.2) 
rs2275806 A 1.2 (0.8, 1.9) 1.1 (0.8, 1.5) 1.0 (0.6, 1.7) 1.4 (1.0, 2.0) 
rs1269486 A 1.0 (0.6, 1.8) 1.0 (0.7, 1.3) 0.7 (0.4, 1.2) 1.0 (0.7, 1.5) 
rs1399180 T 1.2 (0.8, 1.9) 1.2 (0.9, 1.5) 1.2 (0.7, 1.9) 1.4 (0.9, 1.9) 
rs369421 C 1.7 (1.1, 2.5) 1.3 (0.9, 1.7) 0.6 (0.4, 1.0) 1.1 (0.8, 1.7) 
rs3781094* G 1.5 (1.0, 2.3) 1.3 (1.0, 1.7) 0.9 (0.5, 1.7) 1.3 (0.8, 1.9) 
rs3781093 G 0.9 (0.7, 1.1) 0.9 (0.8, 1.1) 1.1 (0.8, 1.6) 1.1 (0.8, 1.5) 
rs376397* A 0.9 (0.6, 1.5) 0.9 (0.7, 1.2) 1.4 (0.9, 2.3) 0.8 (0.5, 1.1) 
rs570613* G 1.0 (0.8, 1.4) 1.0 (0.9, 1.3) 0.9 (0.6, 1.4) 1.0 (0.8, 1.3) 
rs10752126* G 1.0 (0.8, 1.4) 1.0 (0.9, 1.3) 1.1 (0.8, 1.5) 0.9 (0.7, 1.1) 
rs569421 C 1.1 (0.8, 1.4) 1.0 (0.9, 1.2) 1.0 (0.7, 1.5) 0.8 (0.6, 1.1) 
rs444929 C 1.0 (0.7, 1.6) 0.9 (0.7, 1.3) 1.0 (0.6, 1.7) 0.7 (0.5, 1.1) 
rs2280015 A 1.4 (0.9, 2.1) 1.0 (0.8, 1.3) 1.2 (0.7, 2.0) 1.2 (0.9, 1.8) 
rs422628 C 1.2 (0.8, 1.9) 1.0 (0.8, 1.4) 1.2 (0.8, 2.0) 0.7 (0.5, 1.0) 
rs406103 T 1.2 (0.8, 1.9) 1.0 (0.7, 1.3) 1.3 (0.8, 2.0) 1.2 (0.8, 1.7) 
rs528778 T 1.2 (0.8, 1.9) 1.0 (0.8, 1.4) 1.0 (0.6, 1.6) 0.5 (0.4, 0.8) 
rs11567934 A 1.2 (0.8, 1.9) 1.0 (0.7, 1.3) 1.2 (0.7, 1.9) 1.3 (0.9, 1.8) 
rs388957 T 4.3 (0.7, 26.7) 
 
1.1 (0.6, 1.9) 0.7 (0.4, 1.1) 
rs10905284 A 1.0 (0.4, 2.6) 0.8 (0.4, 1.5) 0.8 (0.5, 1.4) 0.7 (0.5, 1.0) 
rs1058240 G 1.5 (0.8, 2.8) 1.3 (0.9, 1.8) 1.4 (0.9, 2.3) 1.4 (1.0, 2.0) 
rs263419 T 1.1 (0.7, 1.7) 0.9 (0.7, 1.2) 1.0 (0.6, 1.7) 1.4 (1.0, 2.0) 
rs12262237 A 1.2 (0.7, 1.8) 1.1 (0.8, 1.4) 1.0 (0.6, 1.7) 0.8 (0.6, 1.2) 
rs7100967 A   1.7 (0.9, 3.2) 1.1 (0.7, 1.9) 
rs477461 G  0.8 (0.1, 10.3) 1.1 (0.6, 2.1) 0.8 (0.5, 1.3) 
rs434645 A 1.2 (0.7, 1.9) 1.1 (0.8, 1.5) 0.9 (0.5, 1.4) 0.7 (0.5, 1.1) 
rs379568 T 1.0 (0.6, 1.6) 0.9 (0.7, 1.3) 0.9 (0.5, 1.5) 1.1 (0.7, 1.5) 
rs1778058* A 1.2 (0.7, 1.9) 1.2 (0.9, 1.7) 0.9 (0.5, 1.4) 1.1 (0.7, 1.5) 
rs12412241* A 1.0 (0.8, 1.4) 1.1 (0.9, 1.4) 0.9 (0.6, 1.2) 1.1 (0.9, 1.4) 
IL18 
 
0.9 (0.6, 1.3) 1.1 (0.9, 1.4) 1.0 (0.7, 1.5) 1.3 (1.0, 1.7) 
rs4937075* G 
    
rs578784 T 1.2 (0.8, 1.6) 1.0 (0.8, 1.2) 1.2 (0.8, 1.8) 0.8 (0.6, 1.0) 
rs11214098 A 1.2 (0.8, 1.8) 0.9 (0.7, 1.2) 1.3 (0.8, 2.2) 0.9 (0.6, 1.3) 
rs543810 G   0.8 (0.4, 1.5) 0.8 (0.5, 1.3) 
rs5744280* T 1.1 (0.7, 1.8) 1.3 (0.9, 1.7) 0.9 (0.6, 1.5) 0.9 (0.6, 1.3) 
rs5744238 A 1.0 (0.7, 1.3) 1.0 (0.8, 1.2) 1.0 (0.7, 1.4) 1.1 (0.9, 1.5) 
rs2043055* G   1.0 (0.5, 2.3) 1.2 (0.6, 2.1) 
rs360714 G 1.0 (0.8, 1.4) 1.0 (0.8, 1.2) 1.0 (0.7, 1.5) 1.1 (0.8, 1.4) 
rs1946518* T 1.1 (0.3, 3.6) 1.2 (0.6, 2.5) 0.7 (0.4, 1.4) 1.0 (0.7, 1.5) 
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rs5744223 G 1.3 (1.0, 1.8) 1.0 (0.8, 1.3) 0.8 (0.6, 1.2) 0.8 (0.6, 1.1) 
rs5744222 A 
 
2.5 (0.5, 11.6) 1.0 (0.5, 1.8) 0.7 (0.4, 1.1) 
rs11214105 A 0.7 (0.5, 1.1) 1.0 (0.8, 1.4) 1.1 (0.5, 2.4) 1.1 (0.6, 2.0) 
KLRD1 
 
1.3 (0.8, 2.0) 0.9 (0.7, 1.3) 0.8 (0.5, 1.4) 0.8 (0.6, 1.2) 
rs3759270 C 
    
rs3809214* T 1.0 (0.6, 1.5) 1.0 (0.8, 1.3) 0.9 (0.5, 1.4) 0.9 (0.6, 1.3) 
rs2302489* T 0.9 (0.7, 1.3) 1.0 (0.8, 1.2) 0.9 (0.6, 1.4) 1.1 (0.8, 1.4) 
rs7301562 C 1.0 (0.7, 1.3) 1.0 (0.8, 1.2) 0.9 (0.6, 1.4) 1.1 (0.8, 1.4) 
rs10772256 T 1.7 (0.2, 11.7) 1.3 (0.3, 5.2) 0.9 (0.6, 1.6) 1.1 (0.8, 1.6) 
rs2270238 T 1.7 (0.2, 11.7) 1.3 (0.3, 5.2) 0.9 (0.6, 1.6) 1.1 (0.8, 1.6) 
rs11611333* G 1.0 (0.7, 1.6) 1.1 (0.8, 1.4) 1.0 (0.4, 2.2) 0.8 (0.4, 1.5) 
rs12829155 G 1.0 (0.8, 1.4) 1.0 (0.8, 1.2) 1.0 (0.7, 1.5) 1.1 (0.8, 1.4) 
IFNG 
 
0.9 (0.5, 1.5) 1.0 (0.7, 1.5) 1.3 (0.8, 2.2) 0.9 (0.6, 1.3) 
rs10878760 T 1.1 (0.7, 1.7) 1.0 (0.7, 1.3) 0.4 (0.1, 1.9) 1.1 (0.6, 2.2) 
rs17104856 T   1.0 (0.5, 1.9) 1.0 (0.6, 1.7) 
rs2193047* T 1.1 (0.8, 1.5) 0.9 (0.7, 1.1) 0.9 (0.6, 1.3) 0.9 (0.7, 1.2) 
rs2041864* T 1.0 (0.7, 1.3) 1.0 (0.9, 1.3) 1.1 (0.8, 1.5) 1.0 (0.7, 1.2) 
rs11177074 C 0.9 (0.5, 1.6) 0.8 (0.6, 1.3) 1.0 (0.6, 1.6) 0.9 (0.6, 1.4) 
rs6581794 T 1.0 (0.7, 1.6) 1.0 (0.7, 1.3) 0.7 (0.4, 1.2) 0.9 (0.6, 1.3) 
rs3181035 A 0.9 (0.5, 1.6) 0.8 (0.6, 1.3) 1.0 (0.6, 1.6) 0.9 (0.6, 1.3) 
rs2069727 G 0.9 (0.6, 1.4) 1.2 (0.9, 1.7) 1.1 (0.6, 1.7) 1.0 (0.7, 1.4) 
rs1861494 C 1.0 (0.7, 1.6) 1.0 (0.7, 1.3) 0.6 (0.3, 1.1) 0.9 (0.6, 1.4) 
rs3181032 G 2.3 (1.0, 5.6) 1.0 (0.5, 2.3) 1.2 (0.7, 2.0) 0.9 (0.6, 1.4) 
rs7302488 G 1.0 (0.7, 1.6) 1.0 (0.7, 1.3) 0.5 (0.3, 1.0) 1.0 (0.6, 1.4) 
rs12306852 C 1.2 (0.7, 1.9) 0.9 (0.7, 1.3) 1.7 (0.9, 3.0) 1.1 (0.8, 1.7) 
TGFB3 
     
rs4252345 G   2.5 (1.3, 5.0) 0.9 (0.4, 1.8) 
rs11466414 T 1.7 (1.0, 3.0) 1.0 (0.7, 1.5) 0.9 (0.2, 3.1) 0.4 (0.1, 1.4) 
TGFB1 
     
rs1800471 C 0.8 (0.4, 1.5) 0.8 (0.5, 1.2) 0.9 (0.4, 1.9) 1.0 (0.6, 1.7) 
KIR3DL3 
     
rs4441391 A 1.0 (0.6, 1.5) 0.8 (0.6, 1.0) 1.0 (0.6, 1.7) 0.7 (0.5, 1.1) 
rs1325155* T 1.1 (0.9, 1.5) 1.2 (1.0, 1.4) 1.2 (0.9, 1.6) 0.8 (0.6, 1.1) 
rs1325156 A 0.9 (0.6, 1.5) 1.3 (0.9, 1.7) 0.9 (0.6, 1.5) 1.2 (0.9, 1.8) 
rs12151161 G 1.0 (0.6, 1.7) 1.4 (1.0, 1.9) 0.9 (0.6, 1.5) 1.4 (1.0, 2.0) 
rs7249048 G 4.6 (0.6, 37.3) 0.0 (0.0, 0.0) 0.6 (0.4, 1.2) 1.6 (1.1, 2.3) 
rs270775* G 0.9 (0.7, 1.3) 1.0 (0.8, 1.2) 1.1 (0.8, 1.6) 1.1 (0.8, 1.4) 
rs2296370* A 1.0 (0.8, 1.4) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 0.8 (0.6, 1.0) 
rs2296371* A 1.1 (0.8, 1.5) 0.8 (0.7, 1.0) 1.0 (0.6, 1.4) 1.1 (0.8, 1.4) 
rs12982559 A 1.3 (0.8, 2.0) 0.8 (0.6, 1.1) 1.4 (0.8, 2.2) 1.1 (0.8, 1.6) 
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rs11883241* T 0.9 (0.7, 1.3) 0.8 (0.7, 1.0) 1.3 (0.9, 1.7) 1.1 (0.9, 1.5) 
rs6509899 A 1.0 (0.6, 1.7) 1.1 (0.8, 1.5) 0.6 (0.3, 1.0) 1.2 (0.8, 1.7) 
rs1325158* T 1.0 (0.7, 1.3) 0.8 (0.7, 1.0) 1.1 (0.8, 1.5) 1.3 (1.0, 1.6) 
rs11671355 C 1.2 (0.8, 1.9) 0.9 (0.7, 1.2) 1.3 (0.7, 2.5) 0.9 (0.5, 1.5) 
rs16985907 C 1.3 (0.7, 2.6) 1.0 (0.7, 1.7) 0.4 (0.2, 0.9) 0.7 (0.5, 1.2) 
KIR2DL4 
     
rs35950908 A 1.2 (0.7, 1.8) 1.2 (0.9, 1.6) 0.6 (0.3, 1.2) 0.7 (0.4, 1.2) 
rs17771961 G 0.9 (0.5, 1.4) 0.8 (0.6, 1.1) 1.1 (0.6, 2.1) 1.3 (0.9, 1.9) 
KIR3DL2 
     
rs10407958 A 0.7 (0.4, 1.2) 1.2 (0.9, 1.6) 1.0 (0.6, 1.7) 1.1 (0.8, 1.6) 
rs1654644* G 1.1 (0.8, 1.4) 1.0 (0.8, 1.3) 0.9 (0.6, 1.3) 0.8 (0.6, 1.0) 
rs4806457 C 1.9 (0.9, 3.7) 1.0 (0.6, 1.8) 0.6 (0.2, 1.5) 1.0 (0.6, 1.7) 
rs3745900 T 1.3 (0.8, 1.9) 1.0 (0.7, 1.3) 0.8 (0.5, 1.4) 1.4 (1.0, 2.0) 
rs11672983 A 1.4 (0.9, 2.2) 1.2 (0.9, 1.6) 0.8 (0.5, 1.3) 0.7 (0.5, 1.0) 
rs3816051* C 1.3 (0.9, 1.7) 1.1 (0.9, 1.3) 0.8 (0.5, 1.1) 0.7 (0.5, 0.9) 
IFNGR2 
     
rs6517167 T 1.3 (0.9, 2.1) 0.8 (0.6, 1.1) 0.7 (0.4, 1.2) 1.2 (0.8, 1.7) 
rs11702844 G 1.4 (0.9, 2.2) 1.1 (0.8, 1.5) 1.7 (0.8, 3.9) 1.1 (0.6, 2.2) 
rs16990664 T 0.5 (0.2, 1.4) 0.7 (0.4, 1.2) 0.8 (0.5, 1.4) 1.0 (0.7, 1.4) 
rs9976971 A 0.8 (0.5, 1.2) 1.1 (0.8, 1.5) 1.5 (0.8, 2.7) 1.4 (0.9, 2.1) 
rs9980428 T 1.5 (1.0, 2.3) 0.9 (0.7, 1.2) 0.8 (0.5, 1.2) 0.8 (0.6, 1.2) 
rs9978223 A 1.1 (0.7, 1.8) 0.9 (0.7, 1.3) 1.0 (0.6, 1.8) 0.6 (0.4, 0.9) 
rs2268241 A 1.1 (0.7, 1.8) 0.9 (0.7, 1.3) 1.3 (0.8, 2.2) 0.9 (0.6, 1.3) 
rs9808685* G 1.3 (1.0, 1.8) 1.1 (0.9, 1.3) 0.7 (0.5, 1.0) 1.1 (0.8, 1.4) 
rs2834210 A 1.5 (0.8, 2.5) 0.9 (0.7, 1.2) 0.8 (0.5, 1.2) 1.2 (0.9, 1.8) 
rs9808753 G 1.0 (0.7, 1.7) 0.9 (0.7, 1.3) 1.3 (0.8, 2.1) 0.9 (0.6, 1.3) 
rs2834212 C 0.7 (0.4, 1.3) 1.1 (0.8, 1.5) 2.0 (0.8, 4.9) 0.9 (0.3, 2.1) 
rs2834213 G 1.3 (0.8, 1.9) 1.0 (0.8, 1.4) 1.5 (0.7, 3.0) 1.4 (0.8, 2.4) 
rs2012075 C 0.9 (0.6, 1.5) 0.7 (0.5, 1.0) 1.0 (0.6, 1.7) 0.9 (0.6, 1.3) 
rs8131980 A 1.2 (0.8, 1.8) 1.0 (0.7, 1.3) 0.7 (0.4, 1.2) 1.0 (0.7, 1.5) 
GADD45A 
     
rs12405855 T 0.9 (0.5, 1.4) 1.1 (0.8, 1.4) 1.1 (0.5, 2.8) 1.1 (0.5, 2.2) 
rs344934* C 1.0 (0.7, 1.4) 1.1 (0.9, 1.3) 0.9 (0.7, 1.3) 0.9 (0.7, 1.2) 
rs4655749 G 1.0 (0.5, 2.0) 0.9 (0.6, 1.4) 0.7 (0.4, 1.3) 1.1 (0.7, 1.6) 
rs344916 C 0.9 (0.5, 1.3) 1.1 (0.9, 1.5) 0.7 (0.4, 1.2) 0.7 (0.5, 1.1) 
rs10889710 A 1.1 (0.6, 2.2) 1.3 (0.8, 2.0) 1.1 (0.7, 1.8) 0.9 (0.6, 1.2) 
rs646652 C 0.9 (0.5, 1.4) 0.8 (0.6, 1.1) 1.0 (0.6, 1.7) 1.1 (0.8, 1.6) 
rs2055904 T 1.1 (0.6, 2.1) 0.9 (0.6, 1.4) 0.7 (0.4, 1.3) 1.0 (0.7, 1.6) 
rs604043 G 0.8 (0.5, 1.3) 0.8 (0.6, 1.1) 1.4 (0.9, 2.3) 1.1 (0.7, 1.5) 
rs2815266 A 1.1 (0.6, 1.9) 1.1 (0.8, 1.6) 1.3 (0.7, 2.1) 0.9 (0.6, 1.4) 
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rs624790 C 0.9 (0.6, 1.5) 1.3 (0.9, 1.7) 1.0 (0.6, 1.6) 0.8 (0.6, 1.1) 
rs1511686 T   1.3 (0.7, 2.2) 1.4 (0.9, 2.0) 
rs3783468 A 1.1 (0.6, 1.9) 1.1 (0.8, 1.7) 1.1 (0.7, 1.8) 1.0 (0.7, 1.5) 
rs532446* C 1.0 (0.7, 1.4) 0.9 (0.7, 1.1) 0.8 (0.6, 1.2) 1.0 (0.8, 1.3) 
rs607375* C 1.0 (0.7, 1.3) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 1.0 (0.8, 1.2) 
rs685724* G 1.0 (0.7, 1.4) 1.1 (0.9, 1.4) 1.0 (0.7, 1.4) 1.1 (0.8, 1.3) 
rs675327 T 0.8 (0.5, 1.3) 0.9 (0.6, 1.2) 1.2 (0.7, 2.0) 1.3 (0.9, 1.9) 
rs11583718* C 1.0 (0.7, 1.3) 0.9 (0.8, 1.1) 1.0 (0.7, 1.4) 1.0 (0.7, 1.2) 
rs7546055 C 1.0 (0.7, 1.6) 1.0 (0.7, 1.3) 0.6 (0.4, 1.0) 0.9 (0.6, 1.3) 
rs598602 T 0.8 (0.5, 1.4) 0.9 (0.6, 1.2) 1.6 (1.0, 2.6) 1.2 (0.8, 1.8) 
rs12408005 T 1.4 (0.8, 2.5) 1.0 (0.7, 1.4) 1.1 (0.7, 1.8) 0.9 (0.6, 1.2) 
RASSF1 
     
rs35455589 C 2.8 (0.4, 19.2) 1.3 (0.3, 5.6) 0.8 (0.5, 1.4) 1.1 (0.8, 1.6) 
rs709210 T 1.5 (0.9, 2.3) 0.9 (0.6, 1.1) 1.6 (0.9, 2.8) 0.7 (0.4, 1.1) 
rs2073498 A 0.8 (0.5, 1.4) 0.7 (0.5, 1.0) 0.9 (0.3, 2.9) 0.9 (0.4, 2.0) 
rs2236947 A 0.7 (0.4, 1.0) 1.4 (1.0, 2.0) 0.8 (0.5, 1.3) 1.1 (0.7, 1.5) 
rs2073499 G 1.0 (0.6, 1.6) 0.8 (0.6, 1.1) 1.1 (0.5, 2.1) 0.9 (0.6, 1.4) 
rs6446203 T 1.8 (0.8, 4.0) 1.2 (0.6, 2.2) 1.3 (0.8, 2.1) 0.7 (0.5, 1.1) 
rs1989839 C 0.9 (0.5, 1.4) 0.7 (0.5, 1.1) 1.1 (0.7, 1.9) 1.2 (0.8, 1.7) 
CCNA2 
     
rs6825926 T 1.1 (0.6, 2.0) 1.0 (0.7, 1.5) 1.1 (0.6, 1.9) 0.8 (0.6, 1.2) 
rs1803183 G 0.8 (0.2, 2.8) 1.0 (0.4, 2.1) 1.3 (0.8, 2.1) 0.8 (0.6, 1.1) 
rs6815050* C 0.9 (0.6, 1.2) 1.0 (0.8, 1.2) 1.0 (0.7, 1.5) 0.8 (0.6, 1.1) 
rs3217773 C 1.0 (0.6, 1.5) 1.1 (0.8, 1.4) 1.2 (0.7, 2.0) 1.2 (0.8, 1.8) 
rs3217771 T 1.0 (0.6, 1.5) 1.1 (0.8, 1.4) 1.2 (0.7, 2.0) 1.2 (0.8, 1.8) 
rs3217770 C 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.7 (0.4, 1.3) 1.2 (0.8, 1.8) 
rs2071486* G 1.0 (0.7, 1.3) 1.0 (0.8, 1.2) 0.9 (0.7, 1.3) 1.1 (0.9, 1.4) 
rs3217760 A   1.0 (0.4, 2.4) 0.9 (0.5, 1.8) 
rs1507994* A 1.0 (0.7, 1.4) 1.0 (0.8, 1.2) 1.1 (0.8, 1.6) 0.9 (0.7, 1.1) 
CCNH 
     
rs2266690 C 1.4 (0.9, 2.2) 1.1 (0.9, 1.5) 0.8 (0.4, 1.6) 1.2 (0.7, 1.9) 
      
NOV 
     
rs13261466 T 0.8 (0.5, 1.2) 1.3 (1.0, 1.7) 0.1 (0.0, 1.0) 1.0 (0.5, 1.8) 
rs2071526 A 1.2 (0.8, 1.8) 0.8 (0.6, 1.0) 0.7 (0.5, 1.2) 0.9 (0.6, 1.3) 
rs7834596 T 1.1 (0.7, 1.7) 0.8 (0.6, 1.1) 1.0 (0.6, 1.7) 1.1 (0.8, 1.6) 
rs7014927 C 1.2 (0.8, 1.8) 0.8 (0.6, 1.0) 1.0 (0.5, 1.9) 1.0 (0.6, 1.7) 
rs11538929 A 0.8 (0.5, 1.4) 1.1 (0.8, 1.5) 2.2 (1.1, 4.7) 0.5 (0.2, 1.3) 
rs1381337 G   1.2 (0.7, 2.0) 1.0 (0.7, 1.4) 
rs16892531 G 1.1 (0.4, 3.3) 1.0 (0.5, 2.1) 0.6 (0.3, 1.3) 0.9 (0.6, 1.4) 
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rs11775043 G 1.1 (0.7, 1.8) 0.8 (0.6, 1.1) 1.1 (0.7, 1.9) 1.3 (0.9, 1.9) 
rs10505358 G 0.9 (0.3, 2.5) 0.6 (0.3, 1.3) 0.9 (0.5, 1.7) 0.8 (0.5, 1.3) 
rs1870779 C 1.0 (0.5, 2.1) 0.7 (0.4, 1.3) 0.7 (0.4, 1.2) 0.9 (0.6, 1.2) 
rs1461693 T 1.1 (0.7, 1.8) 0.8 (0.6, 1.1) 0.9 (0.5, 1.4) 1.1 (0.7, 1.5) 
rs16892578 T 1.2 (0.4, 3.5) 0.9 (0.4, 2.1) 1.1 (0.7, 1.8) 0.8 (0.6, 1.2) 
rs16892586 A 0.8 (0.3, 2.3) 0.6 (0.3, 1.3) 0.6 (0.3, 1.2) 1.0 (0.6, 1.5) 
rs7001184 A 5.2 (1.8, 14.7) 
 
1.2 (0.7, 2.1) 0.8 (0.6, 1.3) 
CDKN2A 
     
rs2811720 G 0.9 (0.5, 1.4) 0.9 (0.6, 1.2) 0.9 (0.6, 1.5) 1.0 (0.7, 1.4) 
rs2518722* T 1.0 (0.7, 1.4) 0.9 (0.7, 1.1) 1.2 (0.9, 1.7) 1.0 (0.8, 1.2) 
rs10757261* A 0.8 (0.6, 1.1) 0.9 (0.7, 1.1) 1.0 (0.7, 1.5) 0.9 (0.7, 1.2) 
rs2027938* A 1.0 (0.7, 1.4) 0.9 (0.7, 1.1) 1.3 (0.9, 1.9) 1.1 (0.8, 1.4) 
rs717326 G 0.5 (0.2, 1.0) 0.8 (0.6, 1.2) 0.8 (0.4, 1.4) 0.8 (0.5, 1.3) 
rs3731257 T 1.6 (1.1, 2.5) 1.0 (0.7, 1.3) 0.7 (0.3, 1.4) 1.3 (0.8, 2.0) 
rs3088440 A 0.5 (0.2, 1.0) 0.9 (0.6, 1.4) 1.0 (0.6, 1.7) 0.9 (0.6, 1.3) 
rs2811708* T 1.0 (0.7, 1.3) 0.9 (0.7, 1.1) 1.2 (0.8, 1.9) 1.1 (0.8, 1.5) 
rs3731239 C 0.8 (0.5, 1.3) 1.2 (0.9, 1.6) 1.2 (0.6, 2.2) 1.1 (0.7, 1.8) 
rs4074785 A 0.5 (0.2, 1.1) 0.9 (0.6, 1.4) 0.7 (0.4, 1.3) 0.8 (0.5, 1.2) 
CDKN2B 
     
rs3731206 A 1.2 (0.3, 3.9) 1.2 (0.5, 2.7) 1.0 (0.6, 1.7) 1.0 (0.7, 1.5) 
rs3731204 G 1.2 (0.8, 1.9) 0.9 (0.7, 1.3) 1.4 (0.8, 2.5) 0.8 (0.5, 1.4) 
rs10757262 T 0.8 (0.5, 1.3) 0.8 (0.6, 1.1) 1.1 (0.6, 1.9) 1.4 (1.0, 2.0) 
rs3731194 C 1.3 (0.4, 4.6) 1.1 (0.5, 2.7) 1.3 (0.7, 2.3) 1.1 (0.7, 1.8) 
rs3731191 T 1.3 (0.4, 4.4) 1.6 (0.8, 3.5) 1.0 (0.6, 1.6) 0.8 (0.6, 1.2) 
rs2811711 C 1.1 (0.7, 1.8) 0.9 (0.7, 1.2) 1.5 (0.9, 2.5) 1.3 (0.9, 1.8) 
rs3218022 G 2.4 (0.6, 9.1) 2.5 (1.2, 5.1) 1.5 (0.8, 2.7) 1.0 (0.6, 1.5) 
rs3218020 T 1.8 (1.1, 2.8) 1.1 (0.8, 1.4) 0.8 (0.5, 1.3) 1.3 (0.9, 1.9) 
rs3218009 C 0.9 (0.5, 1.6) 1.4 (1.0, 1.9) 1.0 (0.4, 3.1) 1.2 (0.6, 2.6) 
rs3218002 T 0.7 (0.4, 1.2) 1.0 (0.7, 1.3) 1.2 (0.7, 2.0) 1.1 (0.8, 1.6) 
rs3217999 C 2.2 (0.6, 8.5) 2.8 (1.5, 5.3) 1.3 (0.8, 2.3) 0.9 (0.6, 1.4) 
rs3217992 A 2.0 (1.3, 3.2) 1.0 (0.8, 1.3) 0.9 (0.5, 1.6) 1.3 (0.9, 1.9) 
rs1063192 C 1.1 (0.7, 1.8) 1.0 (0.7, 1.3) 1.3 (0.7, 2.5) 1.3 (0.8, 2.0) 
rs3217989 G  1.5 (0.2, 9.2) 0.8 (0.5, 1.3) 1.0 (0.7, 1.4) 
CNNM2 
     
rs11191457 T 0.8 (0.5, 1.3) 1.0 (0.8, 1.3) 1.2 (0.7, 2.1) 0.9 (0.6, 1.4) 
rs7897654 C 0.7 (0.5, 1.1) 1.0 (0.8, 1.3) 1.2 (0.7, 1.9) 0.9 (0.6, 1.3) 
rs2297787 A 0.9 (0.5, 1.7) 0.9 (0.6, 1.4) 1.0 (0.6, 1.6) 1.0 (0.7, 1.4) 
rs17787717 G 0.5 (0.3, 1.0) 1.3 (0.9, 1.8) 1.2 (0.5, 2.9) 1.7 (1.0, 2.8) 
rs7902220 C   1.0 (0.4, 2.4) 1.3 (0.8, 2.3) 
rs6584535 T 1.4 (0.9, 2.1) 1.0 (0.8, 1.4) 0.8 (0.4, 2.0) 1.5 (0.9, 2.5) 
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rs11191512 G 0.8 (0.5, 1.3) 1.0 (0.8, 1.3) 1.2 (0.7, 2.0) 0.9 (0.6, 1.3) 
rs7914558* A 0.7 (0.5, 1.0) 1.1 (0.9, 1.4) 0.9 (0.6, 1.2) 1.1 (0.8, 1.4) 
rs4917991* C 0.7 (0.5, 1.0) 1.1 (0.9, 1.4) 0.8 (0.6, 1.2) 1.0 (0.8, 1.3) 
rs11191527 T 0.7 (0.4, 1.2) 1.2 (0.9, 1.5) 1.1 (0.6, 2.0) 0.7 (0.4, 1.2) 
rs12264034 T 5.4 (1.6, 17.8) 3.2 (1.4, 7.3) 0.9 (0.6, 1.4) 1.0 (0.7, 1.5) 
rs11191537 G 1.0 (0.6, 1.6) 0.8 (0.6, 1.1) 1.7 (1.0, 2.9) 1.0 (0.6, 1.5) 
rs7087944 T 0.0 (0.0, 0.0) 4.1 (1.7, 9.9) 1.1 (0.7, 2.0) 1.3 (0.9, 1.9) 
rs2296569 C 0.9 (0.6, 1.4) 1.1 (0.8, 1.4) 1.1 (0.5, 2.7) 0.4 (0.2, 1.0) 
rs4917995 A 0.7 (0.4, 1.1) 1.1 (0.8, 1.5) 0.6 (0.3, 1.1) 1.3 (0.9, 1.9) 
rs11191549* T 0.7 (0.5, 1.0) 1.1 (0.9, 1.4) 0.8 (0.5, 1.1) 1.0 (0.8, 1.3) 
CCND1 
     
rs7106515 G   0.9 (0.5, 1.6) 0.7 (0.5, 1.2) 
rs1982774* T 0.9 (0.7, 1.3) 1.1 (0.9, 1.3) 1.0 (0.7, 1.5) 1.0 (0.7, 1.3) 
rs592483* C 0.9 (0.6, 1.2) 1.1 (0.9, 1.3) 1.1 (0.7, 1.6) 1.1 (0.8, 1.5) 
rs611003* A 1.2 (0.9, 1.7) 0.9 (0.8, 1.1) 0.8 (0.6, 1.3) 1.1 (0.9, 1.5) 
rs11827026 A 0.8 (0.3, 1.8) 1.2 (0.7, 1.9) 1.3 (0.8, 2.1) 1.1 (0.7, 1.5) 
rs655089* G 1.3 (0.9, 1.7) 0.9 (0.8, 1.1) 0.8 (0.6, 1.2) 0.9 (0.7, 1.1) 
rs667515* C 1.3 (0.9, 1.7) 0.9 (0.8, 1.2) 1.1 (0.8, 1.5) 0.9 (0.7, 1.2) 
rs2450254* T 1.2 (0.9, 1.6) 1.0 (0.8, 1.2) 1.2 (0.8, 1.6) 1.0 (0.8, 1.2) 
rs3212860 T   0.7 (0.4, 1.3) 0.8 (0.5, 1.2) 
rs1352075 T 1.0 (0.6, 1.7) 0.8 (0.6, 1.1) 1.5 (0.9, 2.5) 1.4 (1.0, 2.0) 
rs3862792 T 0.6 (0.2, 2.1) 1.0 (0.5, 1.9) 1.3 (0.8, 2.2) 0.9 (0.6, 1.4) 
rs603965 A 1.1 (0.7, 1.8) 0.9 (0.7, 1.2) 1.2 (0.8, 2.0) 1.3 (0.9, 1.8) 
rs3918298 A 0.6 (0.2, 2.1) 1.0 (0.5, 1.9) 0.8 (0.5, 1.3) 1.0 (0.7, 1.4) 
rs649392* G 1.0 (0.7, 1.4) 1.0 (0.8, 1.2) 0.9 (0.7, 1.4) 0.9 (0.7, 1.2) 
rs3212891* C 1.0 (0.7, 1.3) 1.0 (0.8, 1.2) 1.0 (0.7, 1.4) 1.1 (0.8, 1.4) 
rs7121246 T 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 1.1 (0.7, 1.8) 0.9 (0.6, 1.3) 
rs12281701 C 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 1.0 (0.6, 1.7) 1.1 (0.7, 1.6) 
rs1192925* C 1.3 (1.0, 1.8) 1.0 (0.8, 1.2) 1.0 (0.6, 1.4) 0.9 (0.7, 1.2) 
MDM2 
     
rs769412 G 0.8 (0.4, 1.5) 1.0 (0.7, 1.6) 0.7 (0.4, 1.3) 1.3 (0.9, 2.0) 
Empty cells reflect non-polymorphic SNP, null cell counts or out of HWE (IL2:rs10027390). 
*Additive model displayed 
Minor allele is the common minor allele for both ancestry groups or the Global Minor Allele as 
noted in dbSNP 
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Table S20 Single SNP results [RR (95 %Confidence Interval)] for cell cycle genes and preterm  
 European American† African American† 
Gene/SNP Preterm Spontaneous Preterm Preterm Spontaneous Preterm 
GADD45A     
rs12405855 1.1 (0.8, 1.4) 1.1 (0.8, 1.6) 1.6 (0.9, 2.8) 0.7 (0.2, 2.8) 
rs344934 1.0 (0.8, 1.2) 0.8 (0.6, 1.1) 1.2 (0.9, 1.6) 1.4 (1.0, 2.0) 
rs4655749 1.0 (0.7, 1.6) 0.7 (0.3, 1.4) 1.1 (0.8, 1.6) 1.1 (0.7, 1.8) 
rs344916 1.0 (0.8, 1.4) 0.9 (0.6, 1.3) 1.0 (0.8, 1.3) 1.2 (0.8, 1.8) 
rs10889710 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 0.9 (0.6, 1.2) 0.7 (0.4, 1.1) 
rs646652 0.9 (0.7, 1.3) 1.0 (0.7, 1.5) 1.0 (0.7, 1.3) 1.0 (0.7, 1.4) 
rs2055904 1.0 (0.6, 1.6) 0.7 (0.3, 1.4) 1.1 (0.7, 1.5) 0.9 (0.6, 1.6) 
rs604043 0.9 (0.7, 1.2) 1.0 (0.6, 1.5) 0.9 (0.7, 1.3) 0.8 (0.5, 1.3) 
rs2815266 1.2 (0.8, 1.7) 1.2 (0.7, 1.9) 1.1 (0.8, 1.5) 1.3 (0.8, 2.0) 
rs624790 1.1 (0.8, 1.5) 1.0 (0.7, 1.5) 1.0 (0.8, 1.3) 1.1 (0.8, 1.6) 
rs1511686 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.9 (0.6, 1.4) 0.6 (0.3, 1.2) 
rs3783468 1.1 (0.9, 1.4) 1.2 (0.9, 1.6) 1.2 (0.9, 1.7) 1.0 (0.6, 1.6) 
rs532446 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.9 (0.6, 1.3) 
rs607375 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 0.8 (0.5, 1.1) 
rs685724 1.2 (0.9, 1.5) 1.2 (0.9, 1.7) 1.2 (0.9, 1.5) 1.3 (0.9, 1.9) 
rs675327 0.9 (0.6, 1.2) 1.0 (0.6, 1.5) 1.2 (0.8, 1.7) 1.2 (0.7, 2.0) 
rs11583718 0.9 (0.7, 1.1) 0.9 (0.6, 1.2) 0.9 (0.7, 1.3) 1.0 (0.7, 1.6) 
rs7546055 0.9 (0.7, 1.1) 0.7 (0.4, 1.0) 0.8 (0.6, 1.1) 1.0 (0.7, 1.4) 
rs598602 0.9 (0.7, 1.2) 1.0 (0.7, 1.5) 0.8 (0.5, 1.2) 0.7 (0.4, 1.3) 
rs12408005 1.1 (0.9, 1.4) 1.2 (0.9, 1.6) 1.1 (0.8, 1.5) 0.9 (0.6, 1.4) 
RASSF1     
rs35455589 0.9 (0.2, 3.5) 1.0 (0.1, 11.4) 0.9 (0.6, 1.3) 0.8 (0.5, 1.5) 
rs709210 0.9 (0.7, 1.1) 0.9 (0.6, 1.2) 1.0 (0.7, 1.5) 1.1 (0.6, 1.8) 
rs2073498 1.0 (0.7, 1.4) 1.1 (0.7, 1.7) 1.6 (0.8, 3.2) 1.5 (0.5, 4.3) 
rs2236947 1.2 (0.9, 1.5) 1.2 (0.9, 1.7) 1.1 (0.8, 1.5) 1.3 (0.9, 2.0) 
rs2073499 0.9 (0.6, 1.2) 0.9 (0.6, 1.5) 0.9 (0.7, 1.2) 0.8 (0.5, 1.1) 
rs6446203 0.6 (0.2, 1.4) 0.2 (0.0, 1.7) 0.9 (0.7, 1.2) 0.7 (0.5, 1.1) 
rs1989839 1.0 (0.7, 1.4) 1.1 (0.7, 1.7) 1.1 (0.8, 1.4) 1.0 (0.7, 1.6) 
CCNA2     
rs6825926 0.8 (0.5, 1.2) 0.6 (0.3, 1.2) 1.0 (0.7, 1.3) 0.8 (0.6, 1.2) 
rs1803183 0.9 (0.4, 2.0) 0.5 (0.1, 2.2) 0.8 (0.6, 1.1) 0.7 (0.4, 1.0) 
rs6815050 1.1 (0.8, 1.3) 0.9 (0.7, 1.3) 1.0 (0.8, 1.4) 1.2 (0.8, 1.9) 
rs3217773 1.0 (0.8, 1.3) 1.3 (0.9, 1.7) 1.1 (0.7, 1.5) 0.8 (0.5, 1.4) 
rs3217771 1.0 (0.8, 1.3) 1.2 (0.9, 1.7) 1.0 (0.7, 1.5) 0.8 (0.5, 1.4) 
rs3217770 3.9 (0.9, 18.0) 8.1 (2.2, 30.4) 1.3 (0.9, 1.8) 1.8 (1.1, 2.7) 
rs2071486 1.0 (0.8, 1.3) 0.8 (0.6, 1.1) 1.0 (0.8, 1.3) 1.4 (1.0, 2.0) 
rs3217760 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.8 (0.4, 1.7) 0.7 (0.2, 2.0) 
rs1507994 1.0 (0.8, 1.3) 1.2 (0.9, 1.6) 1.0 (0.8, 1.3) 0.7 (0.5, 1.0) 
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 European American† African American† 
Gene/SNP Preterm Spontaneous Preterm Preterm Spontaneous Preterm 
CCNH     
rs2266690 1.0 (0.7, 1.2) 0.9 (0.6, 1.2) 1.0 (0.6, 1.6) 1.0 (0.5, 1.9) 
NOV     
rs13261466 1.0 (0.8, 1.3) 0.7 (0.5, 1.1) 0.4 (0.2, 1.0) 0.5 (0.1, 1.5) 
rs2071526 0.8 (0.6, 1.0) 0.9 (0.6, 1.3) 0.9 (0.7, 1.2) 0.8 (0.5, 1.2) 
rs7834596 0.8 (0.6, 1.0) 0.9 (0.6, 1.4) 1.0 (0.8, 1.4) 1.0 (0.6, 1.5) 
rs7014927 0.8 (0.6, 1.0) 0.9 (0.6, 1.3) 0.9 (0.7, 1.1) 0.9 (0.6, 1.3) 
rs11538929 1.2 (0.9, 1.6) 1.0 (0.7, 1.5) 1.0 (0.5, 2.1) 0.5 (0.1, 2.0) 
rs1381337   0.9 (0.6, 1.3) 0.9 (0.5, 1.6) 
rs16892531 1.0 (0.5, 2.2) 0.7 (0.2, 2.3) 0.8 (0.5, 1.3) 0.9 (0.5, 1.6) 
rs11775043 0.7 (0.5, 1.0) 0.9 (0.6, 1.3) 0.9 (0.6, 1.3) 1.0 (0.6, 1.6) 
rs10505358 0.9 (0.5, 1.9) 1.0 (0.4, 2.6) 1.2 (0.9, 1.8) 1.0 (0.6, 1.7) 
rs1870779 1.0 (0.6, 1.6) 0.9 (0.4, 1.8) 1.0 (0.8, 1.4) 0.9 (0.6, 1.4) 
rs1461693 0.8 (0.6, 1.0) 0.9 (0.6, 1.3) 0.9 (0.6, 1.2) 1.0 (0.7, 1.6) 
rs16892578 0.9 (0.4, 2.1) 0.7 (0.2, 2.4) 1.0 (0.7, 1.3) 0.8 (0.5, 1.3) 
rs16892586 1.0 (0.5, 1.8) 1.0 (0.4, 2.4) 1.0 (0.6, 1.5) 1.1 (0.6, 2.0) 
rs7001184 2.1 (0.7, 5.9) 4.3 (1.5, 12.6) 1.2 (0.9, 1.6) 0.9 (0.6, 1.6) 
CDKN2A/2B     
rs2811720 0.9 (0.7, 1.2) 0.8 (0.5, 1.2) 1.0 (0.8, 1.4) 1.2 (0.8, 1.8) 
rs2518722 1.0 (0.8, 1.2) 0.9 (0.6, 1.2) 1.1 (0.8, 1.4) 1.1 (0.8, 1.7) 
rs10757261 0.9 (0.7, 1.1) 0.8 (0.6, 1.0) 1.1 (0.9, 1.5) 1.2 (0.8, 1.8) 
rs2027938 0.9 (0.7, 1.2) 0.8 (0.6, 1.2) 1.1 (0.8, 1.5) 1.0 (0.7, 1.6) 
rs717326 0.9 (0.6, 1.3) 0.7 (0.4, 1.3) 1.1 (0.7, 1.6) 1.1 (0.6, 1.9) 
rs3731257 1.1 (0.8, 1.3) 1.1 (0.8, 1.5) 1.1 (0.7, 1.7) 1.2 (0.7, 2.2) 
rs3088440 0.9 (0.6, 1.3) 0.8 (0.5, 1.4) 1.0 (0.7, 1.4) 0.9 (0.6, 1.5) 
rs2811708 1.0 (0.8, 1.2) 0.9 (0.7, 1.3) 1.1 (0.8, 1.4) 1.0 (0.6, 1.5) 
rs3731239 1.0 (0.8, 1.3) 1.2 (0.9, 1.5) 0.6 (0.4, 1.0) 0.6 (0.3, 1.3) 
rs4074785 0.9 (0.6, 1.3) 0.9 (0.5, 1.5) 1.1 (0.7, 1.6) 1.0 (0.6, 1.8) 
rs3731206 0.7 (0.3, 1.9) 1.0 (0.3, 3.1) 1.1 (0.8, 1.5) 1.2 (0.8, 1.9) 
rs3731204 1.0 (0.7, 1.3) 0.9 (0.6, 1.3) 1.2 (0.8, 1.8) 0.9 (0.5, 1.8) 
rs10757262 0.9 (0.7, 1.2) 0.8 (0.5, 1.3) 1.0 (0.7, 1.4) 0.9 (0.6, 1.5) 
rs3731194 0.8 (0.3, 2.3) 1.2 (0.4, 4.1) 1.2 (0.8, 1.8) 1.5 (0.9, 2.4) 
rs3731191 0.9 (0.4, 2.3) 1.2 (0.3, 3.9) 0.8 (0.6, 1.1) 0.7 (0.4, 1.1) 
rs2811711 0.9 (0.7, 1.3) 0.9 (0.6, 1.3) 1.4 (1.0, 1.9) 1.3 (0.8, 2.1) 
rs3218022 0.9 (0.2, 3.6) 1.1 (0.2, 7.3) 0.8 (0.5, 1.3) 0.5 (0.2, 1.3) 
rs3218020 1.0 (0.8, 1.2) 1.0 (0.7, 1.3) 1.2 (0.9, 1.7) 1.3 (0.8, 2.0) 
rs3218009 1.5 (1.1, 2.0) 1.5 (1.0, 2.3) 0.7 (0.3, 2.0) 0.3 (0.0, 2.1) 
rs3218002 0.9 (0.6, 1.2) 0.8 (0.5, 1.2) 0.9 (0.6, 1.2) 1.0 (0.6, 1.5) 
rs3217999 0.9 (0.2, 3.4) 1.0 (0.1, 6.8) 1.0 (0.6, 1.4) 1.0 (0.6, 1.7) 
rs3217992 1.0 (0.8, 1.3) 1.0 (0.8, 1.4) 1.2 (0.8, 1.8) 1.3 (0.8, 2.3) 
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 European American† African American† 
Gene/SNP Preterm Spontaneous Preterm Preterm Spontaneous Preterm 
rs1063192 1.1 (0.9, 1.3) 1.1 (0.9, 1.4) 1.0 (0.6, 1.6) 1.1 (0.6, 2.0) 
rs3217989 0.9 (0.3, 3.4)  0.9 (0.7, 1.2) 0.7 (0.5, 1.1) 
CNNM2     
rs11191457 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 1.0 (0.7, 1.4) 1.0 (0.6, 1.6) 
rs7897654 1.1 (0.9, 1.4) 1.1 (0.8, 1.6) 1.2 (0.9, 1.6) 1.4 (0.9, 2.0) 
rs2297787 1.2 (0.8, 1.7) 1.3 (0.8, 2.3) 1.0 (0.7, 1.3) 1.0 (0.7, 1.6) 
rs17787717 1.1 (0.7, 1.5) 0.9 (0.6, 1.5) 1.1 (0.6, 2.2) 1.1 (0.4, 2.9) 
rs7902220   2.0 (1.3, 3.0) 2.8 (1.7, 4.5) 
rs6584535 1.0 (0.8, 1.4) 1.0 (0.7, 1.5) 0.8 (0.5, 1.5) 0.6 (0.2, 1.5) 
rs11191512 1.1 (0.8, 1.4) 1.1 (0.7, 1.5) 1.2 (0.9, 1.6) 1.3 (0.9, 1.9) 
rs7914558 1.1 (0.9, 1.4) 1.1 (0.8, 1.5) 1.2 (0.9, 1.5) 1.4 (1.0, 2.0) 
rs4917991 1.1 (0.8, 1.3) 1.0 (0.7, 1.4) 1.1 (0.8, 1.4) 1.3 (0.9, 1.8) 
rs11191527 1.1 (0.8, 1.5) 1.0 (0.7, 1.5) 0.9 (0.6, 1.4) 0.9 (0.5, 1.6) 
rs12264034   0.9 (0.7, 1.2) 0.9 (0.6, 1.4) 
rs11191537 0.8 (0.6, 1.1) 0.7 (0.5, 1.1) 1.0 (0.6, 1.5) 0.7 (0.3, 1.3) 
rs7087944 0.0 (0.0, 0.0) 0.0 (0.0, 0.0) 0.9 (0.6, 1.3) 0.8 (0.5, 1.5) 
rs2296569 1.1 (0.8, 1.4) 1.2 (0.8, 1.7) 0.2 (0.0, 0.9) 0.4 (0.1, 1.7) 
rs4917995 1.0 (0.7, 1.4) 0.9 (0.6, 1.4) 1.0 (0.7, 1.4) 1.1 (0.7, 1.8) 
rs11191549 1.1 (0.8, 1.3) 1.0 (0.7, 1.4) 1.1 (0.9, 1.5) 1.3 (0.9, 1.9) 
CCND1     
rs7106515   1.0 (0.7, 1.5) 1.2 (0.7, 2.1) 
rs1982774 1.0 (0.8, 1.3) 1.1 (0.8, 1.4) 0.9 (0.7, 1.3) 1.0 (0.6, 1.5) 
rs592483 1.0 (0.8, 1.2) 1.0 (0.8, 1.4) 1.0 (0.8, 1.4) 1.1 (0.7, 1.6) 
rs611003 1.1 (0.8, 1.3) 1.1 (0.8, 1.4) 1.1 (0.8, 1.4) 1.0 (0.7, 1.4) 
rs11827026 0.9 (0.5, 1.6) 0.7 (0.3, 1.5) 1.1 (0.8, 1.4) 0.9 (0.6, 1.4) 
rs655089 0.9 (0.7, 1.2) 0.9 (0.7, 1.2) 0.9 (0.7, 1.1) 1.0 (0.7, 1.4) 
rs667515 1.0 (0.8, 1.2) 0.9 (0.7, 1.3) 0.8 (0.6, 1.1) 1.0 (0.7, 1.5) 
rs2450254 0.9 (0.7, 1.1) 0.8 (0.6, 1.1) 1.0 (0.8, 1.3) 1.2 (0.8, 1.7) 
rs3212860 3.4 (0.9, 11.9) 3.3 (0.5, 22.6) 1.0 (0.7, 1.4) 0.9 (0.5, 1.6) 
rs1352075 0.9 (0.7, 1.1) 0.9 (0.7, 1.2) 1.2 (0.9, 1.6) 1.0 (0.7, 1.6) 
rs3862792 0.7 (0.3, 1.5) 0.4 (0.1, 1.6) 1.1 (0.8, 1.6) 1.0 (0.6, 1.7) 
rs603965 0.9 (0.8, 1.2) 1.0 (0.7, 1.3) 1.1 (0.8, 1.6) 1.2 (0.7, 1.9) 
rs3918298 0.6 (0.3, 1.5) 0.4 (0.1, 1.5) 1.0 (0.7, 1.4) 0.8 (0.5, 1.4) 
rs649392 1.2 (1.0, 1.5) 1.3 (1.0, 1.8) 0.9 (0.7, 1.2) 1.1 (0.8, 1.7) 
rs3212891 1.2 (1.0, 1.5) 1.3 (0.9, 1.7) 1.0 (0.8, 1.3) 1.0 (0.7, 1.5) 
rs7121246   0.9 (0.6, 1.2) 0.8 (0.5, 1.3) 
rs12281701   0.8 (0.5, 1.3) 0.8 (0.5, 1.5) 
rs1192925 1.0 (0.8, 1.3) 1.1 (0.8, 1.5) 1.0 (0.8, 1.4) 1.1 (0.7, 1.7) 
MDM2     
rs769412 1.1 (0.7, 1.6) 0.9 (0.5, 1.6) 1.0 (0.6, 1.5) 0.9 (0.5, 1.6) 
†Stratified by genetic ancestry 
 
  
 247 
REFERENCES 
1. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory 
response to pregnancy. Am J Obstet Gynecol. 1999;180:499-506.  
2. Crider KS, Whitehead N, Buus RM. Genetic variation associated with preterm birth: a HuGE 
review. Genet Med. 2005;7:593-604.  
3. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the 
pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69:1-7.  
4. Engel SA, Olshan AF, Savitz DA, Thorp J, Erichsen HC, Chanock SJ. Risk of small-for-gestational 
age is associated with common anti-inflammatory cytokine polymorphisms. Epidemiology. 
2005;16:478-486.  
5. Furuya M, Ishida J, Aoki I, Fukamizu A. Pathophysiology of placentation abnormalities in 
pregnancy-induced hypertension. Vasc Health Risk Manag. 2008;4:1301-1313.  
6. Engel SA, Erichsen HC, Savitz DA, Thorp J, Chanock SJ, Olshan AF. Risk of spontaneous preterm 
birth is associated with common proinflammatory cytokine polymorphisms. Epidemiology. 
2005;16:469-477.  
7. Bartha JL, Romero-Carmona R, Comino-Delgado R. Inflammatory cytokines in intrauterine 
growth retardation. Acta Obstet Gynecol Scand. 2003;82:1099-1102.  
8. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the 
pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep. 2007;9:480-485.  
9. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth 
restriction and preeclampsia. Am J Obstet Gynecol. 2006;195:40-49.  
10. Kingdom JC, Kaufmann P. Oxygen and placental vascular development. Adv Exp Med Biol. 
1999;474:259-275.  
11. Skjaerven R, Vatten LJ, Wilcox AJ, Ronning T, Irgens LM, Lie RT. Recurrence of pre-eclampsia 
across generations: exploring fetal and maternal genetic components in a population based 
cohort. BMJ. 2005;331:877.  
 248 
12. Wilcox AJ, Skjaerven R, Lie RT. Familial patterns of preterm delivery: maternal and fetal 
contributions. Am J Epidemiol. 2008;167:474-479.  
13. Boyd HA, Poulsen G, Wohlfahrt J, Murray JC, Feenstra B, Melbye M. Maternal contributions 
to preterm delivery. Am J Epidemiol. 2009;170:1358-1364.  
14. Svensson AC, Sandin S, Cnattingius S, et al. Maternal effects for preterm birth: a genetic 
epidemiologic study of 630,000 families. Am J Epidemiol. 2009;170:1365-1372.  
15. Svensson AC, Pawitan Y, Cnattingius S, Reilly M, Lichtenstein P. Familial aggregation of small-
for-gestational-age births: the importance of fetal genetic effects. Am J Obstet Gynecol. 
2006;194:475-479.  
16. Fang Y, Kong B, Yang Q, Ma D, Qu X. MDM2 309 polymorphism is associated with missed 
abortion. Hum Reprod. 2009;24:1346-1349.  
17. Lauenborg J, Grarup N, Damm P, et al. Common type 2 diabetes risk gene variants associate 
with gestational diabetes. J Clin Endocrinol Metab. 2009;94:145-150.  
18. Wahlstrand B, Orho-Melander M, Delling L, et al. The myocardial infarction associated 
CDKN2A/CDKN2B locus on chromosome 9p21 is associated with stroke independently of 
coronary events in patients with hypertension. J Hypertens. 2009;27:769-773.  
19. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 
diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341-1345.  
20. De Falco M, Fedele V, Cobellis L, et al. Pattern of expression of cyclin D1/CDK4 complex in 
human placenta during gestation. Cell Tissue Res. 2004;317:187-194.  
21. Handwerger S, Aronow B. Dynamic changes in gene expression during human trophoblast 
differentiation. Recent Prog Horm Res. 2003;58:263-281.  
22. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799.  
23. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. 
Lancet. 2008;371:75-84.  
 249 
24. Hediger ML, Scholl TO, Schall JI, Miller LW, Fischer RL. Fetal growth and the etiology of 
preterm delivery. Obstet Gynecol. 1995;85:175-182.  
25. Behrman RE, Butler AS, Institute of Medicine. Preterm Birth: Causes, Consequences, and 
Prevention. Washington, D.C.: National Academies Press; 2007.  
26. McElrath TF, Hecht JL, Dammann O, et al. Pregnancy disorders that lead to delivery before 
the 28th week of gestation: an epidemiologic approach to classification. Am J Epidemiol. 
2008;168:980-989.  
27. Savitz DA. Invited commentary: disaggregating preterm birth to determine etiology. Am J 
Epidemiol. 2008;168:990-2; discussion 993-4.  
28. Ananth CV, Vintzileos AM. Epidemiology of preterm birth and its clinical subtypes. J Matern 
Fetal Neonatal Med. 2006;19:773-782.  
29. NCHS. Advance Report of Final Natality Statistics, 1980. Monthly Vital Statistics Reports. 
1982;31.  
30. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2006. Natl Vital Stat Rep. 
2009;57:1-102.  
31. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Matthews MS, Osterman MHS. Births: final 
data for 2008. Natl Vital Stat Rep. 2010;59:1-105.  
32. Martin JA, Osterman MJ, Sutton PD. Are preterm births on the decline in the United States? 
Recent data from the National Vital Statistics System. NCHS Data Brief. 2010;(39):1-8.  
33. Wilcox AJ. Fertility and Pregnancy: An Epidemiologic Perspective. New York: Oxford 
Univeristy Press; 2010.  
34. Mathews TJ, MacDorman MF. Infant mortality statistics from the 2006 period linked 
birth/infant death data set. Natl Vital Stat Rep. 2010;58:1-31.  
35. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to 
adulthood. Lancet. 2008;371:261-269.  
 250 
36. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. 
N Engl J Med. 2008;359:262-273.  
37. McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births 
compared with births at term. Obstet Gynecol. 2008;111:35-41.  
38. Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm 
(near-term) infants: a summary of the workshop sponsored by the National Institute of Child 
Health and Human Development. Pediatrics. 2006;118:1207-1214.  
39. Ananth CV, Vintzileos AM. Medically indicated preterm birth: recognizing the importance of 
the problem. Clin Perinatol. 2008;35:53-67, viii.  
40. Catov JM, Newman AB, Roberts JM, et al. Preterm Delivery and Later Maternal 
Cardiovascular Disease Risk. Epidemiology. 2007.  
41. Wigle DT, Arbuckle TE, Turner MC, et al. Epidemiologic evidence of relationships between 
reproductive and child health outcomes and environmental chemical contaminants. J Toxicol 
Environ Health B Crit Rev. 2008;11:373-517.  
42. Savitz DA, Murnane P. Behavioral influences on preterm birth: a review. Epidemiology. 
2010;21:291-299.  
43. Miller RS, Thompson ML, Williams MA. Trimester-specific blood pressure levels in relation to 
maternal pre-pregnancy body mass index. Paediatr Perinat Epidemiol. 2007;21:487-494.  
44. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Chronic hypertension in 
pregnancy. ACOG Committee on Practice Bulletins. Obstet Gynecol. 2001;98:suppl 177-85.  
45. ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and 
management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 
2002;99:159-167.  
46. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United 
States, 1991--1999. MMWR Surveill Summ. 2003;52:1-8.  
47. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United 
States, 1998 to 2005. Obstet Gynecol. 2010;116:1302-1309.  
 251 
48. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG. 2004;111:298-302.  
49. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, 
eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens. 
2008;21:521-526.  
50. Basso O, Rasmussen S, Weinberg CR, Wilcox AJ, Irgens LM, Skjaerven R. Trends in fetal and 
infant survival following preeclampsia. JAMA. 2006;296:1357-1362.  
51. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular 
disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335:974.  
52. Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy 
and subsequently measured cardiovascular risk factors. Obstet Gynecol. 2009;114:961-970.  
53. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic 
review of controlled studies. BMJ. 2005;330:565.  
54. England L, Zhang J. Smoking and risk of preeclampsia: a systematic review. Front Biosci. 
2007;12:2471-2483.  
55. Conde-Agudelo A, Althabe F, Belizan JM, Kafury-Goeta AC. Cigarette smoking during 
pregnancy and risk of preeclampsia: a systematic review. Am J Obstet Gynecol. 1999;181:1026-
1035.  
56. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A 
Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention; 2004.  
57. Ness RB, Zhang J, Bass D, Klebanoff MA. Interactions between smoking and weight in 
pregnancies complicated by preeclampsia and small-for-gestational-age birth. Am J Epidemiol. 
2008;168:427-433.  
58. Wilcox AJ. On the importance--and the unimportance--of birthweight. Int J Epidemiol. 
2001;30:1233-1241.  
59. Fry AG, Bernstein IM, Badger GJ. Comparison of fetal growth estimates based on birth 
weight and ultrasound references. J Matern Fetal Neonatal Med. 2002;12:247-252.  
 252 
60. Hutcheon JA, Platt RW. The missing data problem in birth weight percentiles and thresholds 
for "small-for-gestational-age". Am J Epidemiol. 2008;167:786-792.  
61. Kramer MS, Olivier M, McLean FH, Dougherty GE, Willis DM, Usher RH. Determinants of fetal 
growth and body proportionality. Pediatrics. 1990;86:18-26.  
62. Goldenberg RL, Cliver SP. Small for gestational age and intrauterine growth restriction: 
definitions and standards. Clin Obstet Gynecol. 1997;40:704-714.  
63. Rosenberg M. Birth weights in three Norwegian cities, 1860-1984. Secular trends and 
influencing factors. Ann Hum Biol. 1988;15:275-288.  
64. Basso O, Wilcox AJ, Weinberg CR. Birth weight and mortality: causality or confounding? Am J 
Epidemiol. 2006;164:303-311.  
65. Lawlor DA. The developmental origins of health and disease: where do we go from here? 
Epidemiology. 2008;19:206-208.  
66. Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995;311:171-174.  
67. Barker DJ, Clark PM. Fetal undernutrition and disease in later life. Rev Reprod. 1997;2:105-
112.  
68. Barker DJ. In utero programming of chronic disease. Clin Sci (Lond). 1998;95:115-128.  
69. Baker JL, Olsen LW, Sorensen TI. Weight at birth and all-cause mortality in adulthood. 
Epidemiology. 2008;19:197-203.  
70. Davey Smith G, Hypponen E, Power C, Lawlor DA. Offspring birth weight and parental 
mortality: prospective observational study and meta-analysis. Am J Epidemiol. 2007;166:160-
169.  
71. Bukowski R, Davis KE, Wilson PW. Delivery of a small for gestational age infant and greater 
maternal risk of ischemic heart disease. PLoS One. 2012;7:e33047.  
72. Kraus TA, Engel SM, Sperling RS, et al. Characterizing the Pregnancy Immune Phenotype: 
Results of the Viral Immunity and Pregnancy (VIP) Study. J Clin Immunol. 2011.  
 253 
73. Kraus TA, Sperling RS, Engel SM, et al. Peripheral blood cytokine profiling during pregnancy 
and post-partum periods. Am J Reprod Immunol. 2010;64:411-426.  
74. Bowen JM, Chamley L, Keelan JA, Mitchell MD. Cytokines of the placenta and extra-placental 
membranes: roles and regulation during human pregnancy and parturition. Placenta. 
2002;23:257-273.  
75. Christiaens I, Zaragoza DB, Guilbert L, Robertson SA, Mitchell BF, Olson DM. Inflammatory 
processes in preterm and term parturition. J Reprod Immunol. 2008;79:50-57.  
76. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to 
placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age 
infants. Br J Obstet Gynaecol. 1986;93:1049-1059.  
77. Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine 
growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006;194:921-931.  
78. Baschat AA, Hecher K. Fetal growth restriction due to placental disease. Semin Perinatol. 
2004;28:67-80.  
79. Freeman DJ, McManus F, Brown EA, et al. Short- and long-term changes in plasma 
inflammatory markers associated with preeclampsia. Hypertension. 2004;44:708-714.  
80. Bowen JM, Chamley L, Mitchell MD, Keelan JA. Cytokines of the placenta and extra-placental 
membranes: biosynthesis, secretion and roles in establishment of pregnancy in women. 
Placenta. 2002;23:239-256.  
81. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol. 2003;59:161-173.  
82. Saito S. The role of the immune system in preeclampsia. Mol Aspects Med. 2007;28:192-209.  
83. Zabriskie JB. Basic components of the immune system. In: Essential Clinical Immunology. 
Cambridge University Press; 2009.  
84. Goddard KA, Tromp G, Romero R, et al. Candidate-gene association study of mothers with 
pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered. 2007;63:1-16.  
 254 
85. Haggerty CL, Ferrell RE, Hubel CA, Markovic N, Harger G, Ness RB. Association between 
allelic variants in cytokine genes and preeclampsia. Am J Obstet Gynecol. 2005;193:209-215.  
86. Sata F, Toya S, Yamada H, et al. Proinflammatory cytokine polymorphisms and the risk of 
preterm birth and low birthweight in a Japanese population. Mol Hum Reprod. 2009;15:121-130.  
87. Bombell S, McGuire W. Cytokine polymorphisms in women with recurrent pregnancy loss: 
meta-analysis. Aust N Z J Obstet Gynaecol. 2008;48:147-154.  
88. Hollegaard MV, Grove J, Thorsen P, et al. Polymorphisms in the tumor necrosis factor alpha 
and interleukin 1-beta promoters with possible gene regulatory functions increase the risk of 
preterm birth. Acta Obstet Gynecol Scand. 2008;87:1285-1290.  
89. Genc MR, Gerber S, Nesin M, Witkin SS. Polymorphism in the interleukin-1 gene complex 
and spontaneous preterm delivery. Am J Obstet Gynecol. 2002;187:157-163.  
90. Molvarec A, Jermendy A, Nagy B, et al. Association between tumor necrosis factor (TNF)-
alpha G-308A gene polymorphism and preeclampsia complicated by severe fetal growth 
restriction. Clin Chim Acta. 2008;392:52-57.  
91. Crider KS, Whitehead N, Buus RM. Genetic variation associated with preterm birth: a HuGE 
review. Genet Med. 2005;7:593-604.  
92. Giger JN, Strickland OL, Weaver M, Taylor H, Acton RT. Genetic predictors of coronary heart 
disease risk factors in premenopausal African-American women. Ethn Dis. 2005;15:221-232.  
93. Willer CJ, Bonnycastle LL, Conneely KN, et al. Screening of 134 single nucleotide 
polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 
SNPs in nine genes. Diabetes. 2007;56:256-264.  
94. Fortunato SJ, Menon R, Velez DR, Thorsen P, Williams SM. Racial disparity in maternal-fetal 
genetic epistasis in spontaneous preterm birth. Am J Obstet Gynecol. 2008;198:666.e1-9; 
discussion 666.e9-10.  
95. Simhan HN, Krohn MA, Roberts JM, Zeevi A, Caritis SN. Interleukin-6 promoter -174 
polymorphism and spontaneous preterm birth. Am J Obstet Gynecol. 2003;189:915-918.  
 255 
96. Ortlepp JR, Krantz C, Kimmel M, et al. Additive effects of the chemokine receptor 2, vitamin 
D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of 
myocardial infarction in patients below 65 years. Int J Cardiol. 2005;105:90-95.  
97. Menon R, Pearce B, Velez DR, et al. Racial disparity in pathophysiologic pathways of preterm 
birth based on genetic variants. Reprod Biol Endocrinol. 2009;7:62.  
98. Velez DR, Fortunato S, Thorsen P, Lombardi SJ, Williams SM, Menon R. Spontaneous preterm 
birth in African Americans is associated with infection and inflammatory response gene variants. 
Am J Obstet Gynecol. 2009;200:209.e1-209.27.  
99. Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including 
LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome 
Health Study. Am J Hum Genet. 2008;82:1185-1192.  
100. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels 
and risk of coronary heart disease. JAMA. 2009;302:37-48.  
101. Hamid YH, Urhammer SA, Jensen DP, et al. Variation in the interleukin-6 receptor gene 
associates with type 2 diabetes in Danish whites. Diabetes. 2004;53:3342-3345.  
102. Zammiti W, Mtiraoui N, Finan RR, Almawi WY, Mahjoub T. Tumor necrosis factor alpha and 
lymphotoxin alpha haplotypes in idiopathic recurrent pregnancy loss. Fertil Steril. 2009;91:1903-
1908.  
103. Iwanaga Y, Ono K, Takagi S, et al. Association analysis between polymorphisms of the 
lymphotoxin-alpha gene and myocardial infarction in a Japanese population. Atherosclerosis. 
2004;172:197-198.  
104. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are 
associated with susceptibility to myocardial infarction. Nat Genet. 2002;32:650-654.  
105. Annells MF, Hart PH, Mullighan CG, et al. Interleukins-1, -4, -6, -10, tumor necrosis factor, 
transforming growth factor-beta, FAS, and mannose-binding protein C gene polymorphisms in 
Australian women: Risk of preterm birth. Am J Obstet Gynecol. 2004;191:2056-2067.  
106. Mirahmadian M, Kalantar F, Heidari G, Safdarian L, Mansouri R, Amirzargar AA. Association 
of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Iranian patients with 
pre-eclampsia. Am J Reprod Immunol. 2008;60:179-185.  
 256 
107. Daher S, Sass N, Oliveira LG, Mattar R. Cytokine genotyping in preeclampsia. Am J Reprod 
Immunol. 2006;55:130-135.  
108. de Groot CJ, Jansen MW, Bertina RM, Schonkeren JJ, Helmerhorst FM, Huizinga TW. 
Interleukin 10-2849AA genotype protects against pre-eclampsia. Genes Immun. 2004;5:313-314.  
109. Lin MT, Storer B, Martin PJ, et al. Genetic variation in the IL-10 pathway modulates severity 
of acute graft-versus-host disease following hematopoietic cell transplantation: synergism 
between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood. 
2005;106:3995-4001.  
110. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in 
pregnancy. Am J Reprod Immunol. 2010;63:601-610.  
111. Speer EM, Gentile DA, Zeevi A, Pillage G, Huo D, Skoner DP. Role of single nucleotide 
polymorphisms of cytokine genes in spontaneous preterm delivery. Hum Immunol. 2006;67:915-
923.  
112. Rama S, Petrusz P, Rao AJ. Hormonal regulation of human trophoblast differentiation: a 
possible role for 17beta-estradiol and GnRH. Mol Cell Endocrinol. 2004;218:79-94.  
113. Menon R, Velez DR, Morgan N, Lombardi SJ, Fortunato SJ, Williams SM. Genetic regulation 
of amniotic fluid TNF-alpha and soluble TNF receptor concentrations affected by race and 
preterm birth. Hum Genet. 2008;124:243-253.  
114. Menon R, Velez DR, Simhan H, et al. Multilocus interactions at maternal tumor necrosis 
factor-alpha, tumor necrosis factor receptors, interleukin-6 and interleukin-6 receptor genes 
predict spontaneous preterm labor in European-American women. Am J Obstet Gynecol. 
2006;194:1616-1624.  
115. Eguchi T, Maruyama T, Ohno Y, et al. Possible association of tumor necrosis factor receptor 
2 gene polymorphism with severe hypertension using the extreme discordant phenotype design. 
Hypertens Res. 2009;32:775-779.  
116. Barrett JC, Clayton DG, Concannon P, et al. Genome-wide association study and meta-
analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009;41:703-707.  
117. Altinova AE, Engin D, Akbay E, et al. Association of polymorphisms in the IL-18 and IL-12 
genes with susceptibility to Type 1 diabetes in Turkish patients. J Endocrinol Invest. 2010;33:451-
454.  
 257 
118. Windsor L, Morahan G, Huang D, et al. Alleles of the IL12B 3'UTR associate with late onset 
of type 1 diabetes. Hum Immunol. 2004;65:1432-1436.  
119. Thompson SR, Sanders J, Stephens JW, Miller GJ, Humphries SE. A common interleukin 18 
haplotype is associated with higher body mass index in subjects with diabetes and coronary 
heart disease. Metabolism. 2007;56:662-669.  
120. Tiret L, Godefroy T, Lubos E, et al. Genetic analysis of the interleukin-18 system highlights 
the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005;112:643-650.  
121. Fraser R, Walker JJ, Ekbote UV, Martin KL, McShane P, Orsi NM. Interleukin-4 -590 (C>T), 
toll-like receptor-2 +2258 (G>A) and matrix metalloproteinase-9 -1562 (C>T) polymorphisms in 
pre-eclampsia. BJOG. 2008;115:1052-6; discussion 1056.  
122. Paffen E, Medina P, de Visser MC, et al. The -589C>T polymorphism in the interleukin-4 
gene (IL-4) is associated with a reduced risk of myocardial infarction in young individuals. J 
Thromb Haemost. 2008;6:1633-1638.  
123. Pykalainen M, Kinos R, Valkonen S, et al. Association analysis of common variants of STAT6, 
GATA3, and STAT4 to asthma and high serum IgE phenotypes. J Allergy Clin Immunol. 
2005;115:80-87.  
124. Myatt L, Webster RP. Vascular biology of preeclampsia. J Thromb Haemost. 2009;7:375-
384.  
125. Hegazy DM, O'Reilly DA, Yang BM, Hodgkinson AD, Millward BA, Demaine AG. NFkappaB 
polymorphisms and susceptibility to type 1 diabetes. Genes Immun. 2001;2:304-308.  
126. Vargas RG, Bompeixe EP, Franca PP, Marques de Moraes M, da Graca Bicalho M. Activating 
killer cell immunoglobulin-like receptor genes' association with recurrent miscarriage. Am J 
Reprod Immunol. 2009;62:34-43.  
127. Carrington M, Norman P. The KIR Gene Cluster [Internet]. Available at: 
http://www.ncbi.nlm.nih.gov/books/NBK10134/#A399. Accessed Feb/05, 2010.  
128. Hiby SE, Regan L, Lo W, Farrell L, Carrington M, Moffett A. Association of maternal killer-cell 
immunoglobulin-like receptors and parental HLA-C genotypes with recurrent miscarriage. Hum 
Reprod. 2008;23:972-976.  
 258 
129. Hiby SE, Walker JJ, O'shaughnessy KM, et al. Combinations of maternal KIR and fetal HLA-C 
genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200:957-
965.  
130. Thompson JM, Irgens LM, Skjaerven R, Rasmussen S. Placenta weight percentile curves for 
singleton deliveries. BJOG. 2007;114:715-720.  
131. Eskild A, Romundstad PR, Vatten LJ. Placental weight and birthweight: does the association 
differ between pregnancies with and without preeclampsia? Am J Obstet Gynecol. 
2009;201:595.e1-595.e5.  
132. Eskild A, Vatten LJ. Do pregnancies with pre-eclampsia have smaller placentas? A 
population study of 317 688 pregnancies with and without growth restriction in the offspring. 
BJOG. 2010;117:1521-1526.  
133. Dahlstrom B, Romundstad P, Oian P, Vatten LJ, Eskild A. Placenta weight in pre-eclampsia. 
Acta Obstet Gynecol Scand. 2008;87:608-611.  
134. Tsui DW, Chan KC, Chim SS, et al. Quantitative aberrations of hypermethylated RASSF1A 
gene sequences in maternal plasma in pre-eclampsia. Prenat Diagn. 2007;27:1212-1218.  
135. Xiong Y, Liebermann DA, Tront JS, et al. Gadd45a stress signaling regulates sFlt-1 expression 
in preeclampsia. J Cell Physiol. 2009;220:632-639.  
136. Yung HW, Calabrese S, Hynx D, et al. Evidence of placental translation inhibition and 
endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am J 
Pathol. 2008;173:451-462.  
137. Gellhaus A, Schmidt M, Dunk C, Lye SJ, Kimmig R, Winterhager E. Decreased expression of 
the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with 
pre-eclampsia. Mol Hum Reprod. 2006;12:389-399.  
138. Gellhaus A, Schmidt M, Dunk C, Lye SJ, Winterhager E. The circulating proangiogenic factors 
CYR61 (CCN1) and NOV (CCN3) are significantly decreased in placentae and sera of preeclamptic 
patients. Reprod Sci. 2007;14:46-52.  
139. Wolf N, Yang W, Dunk CE, et al. Regulation of the matricellular proteins CYR61 (CCN1) and 
NOV (CCN3) by hypoxia-inducible factor-1{alpha} and transforming-growth factor-{beta}3 in the 
human trophoblast. Endocrinology. 2010;151:2835-2845.  
 259 
140. Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 
diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341-1345.  
141. Gheorghe CP, Mohan S, Oberg KC, Longo LD. Gene expression patterns in the hypoxic 
murine placenta: a role in epigenesis? Reprod Sci. 2007;14:223-233.  
142. Gheorghe CP, Goyal R, Mittal A, Longo LD. Gene expression in the placenta: maternal stress 
and epigenetic responses. Int J Dev Biol. 2010;54:507-523.  
143. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight 
loci associated with blood pressure. Nat Genet. 2009;41:666-676.  
144. Kang HJ, Feng Z, Sun Y, et al. Single-nucleotide polymorphisms in the p53 pathway regulate 
fertility in humans. Proc Natl Acad Sci U S A. 2009;106:9761-9766.  
145. Israni A, Leduc R, Holmes J, et al. Single-nucleotide polymorphisms, acute rejection, and 
severity of tubulitis in kidney transplantation, accounting for center-to-center variation. 
Transplantation. 2010;90:1401-1408.  
146. Weinberg CR, Shi M. The genetics of preterm birth: using what we know to design better 
association studies. Am J Epidemiol. 2009;170:1373-1381.  
147. Lie RT. Intergenerational exchange and perinatal risks: a note on interpretation of 
generational recurrence risks. Paediatr Perinat Epidemiol. 2007;21 Suppl 1:13-18.  
148. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and 
environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG. 
2004;111:200-206.  
149. Velez DR, Fortunato SJ, Thorsen P, Lombardi SJ, Williams SM, Menon R. Preterm birth in 
Caucasians is associated with coagulation and inflammation pathway gene variants. PLoS One. 
2008;3:e3283.  
150. Romero R, Friel LA, Velez Edwards DR, et al. A genetic association study of maternal and 
fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Am J 
Obstet Gynecol. 2010;203:361.e1-361.e30.  
 260 
151. Romero R, Velez Edwards DR, Kusanovic JP, et al. Identification of fetal and maternal single 
nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor 
with intact membranes. Am J Obstet Gynecol. 2010;202:431.e1-431.34.  
152. Myking S, Myhre R, Gjessing HK, et al. Candidate gene analysis of spontaneous preterm 
delivery: New insights from re-analysis of a case-control study using case-parent triads and 
control-mother dyads. BMC Med Genet. 2011;12:174.  
153. Dizon-Townson DS, Major H, Varner M, Ward K. A promoter mutation that increases 
transcription of the tumor necrosis factor-alpha gene is not associated with preterm delivery. 
Am J Obstet Gynecol. 1997;177:810-813.  
154. Hartel C, Finas D, Ahrens P, et al. Polymorphisms of genes involved in innate immunity: 
association with preterm delivery. Mol Hum Reprod. 2004;10:911-915.  
155. Hao K, Wang X, Niu T, et al. A candidate gene association study on preterm delivery: 
application of high-throughput genotyping technology and advanced statistical methods. Hum 
Mol Genet. 2004;13:683-691.  
156. Velez DR, Menon R, Thorsen P, et al. Ethnic differences in interleukin 6 (IL-6) and IL6 
receptor genes in spontaneous preterm birth and effects on amniotic fluid protein levels. Ann 
Hum Genet. 2007;71:586-600.  
157. Stonek F, Metzenbauer M, Hafner E, Philipp K, Tempfer C. Interleukin-10 -1082 G/A 
promoter polymorphism and pregnancy complications: results of a prospective cohort study in 
1,616 pregnant women. Acta Obstet Gynecol Scand. 2008;87:430-433.  
158. Stonek F, Metzenbauer M, Hafner E, Philipp K, Tempfer C. Interleukin 6-174 G/C promoter 
polymorphism and pregnancy complications: results of a prospective cohort study in 1626 
pregnant women. Am J Reprod Immunol. 2008;59:347-351.  
159. Moura E, Mattar R, de Souza E, Torloni MR, Goncalves-Primo A, Daher S. Inflammatory 
cytokine gene polymorphisms and spontaneous preterm birth. J Reprod Immunol. 2009;80:115-
121.  
160. Gebhardt S, Bruiners N, Hillermann R. A novel exonic variant (221delT) in the LGALS13 gene 
encoding placental protein 13 (PP13) is associated with preterm labour in a low risk population. 
J Reprod Immunol. 2009;82:166-173.  
 261 
161. Kalinka J, Bitner A. Selected cytokine gene polymorphisms and the risk of preterm delivery 
in the population of Polish women. Ginekol Pol. 2009;80:111-117.  
162. Gomez LM, Sammel MD, Appleby DH, et al. Evidence of a gene-environment interaction 
that predisposes to spontaneous preterm birth: a role for asymptomatic bacterial vaginosis and 
DNA variants in genes that control the inflammatory response. Am J Obstet Gynecol. 
2010;202:386.e1-386.e6.  
163. Liang M, Wang X, Li J, et al. Association of combined maternal-fetal TNF-alpha gene G308A 
genotypes with preterm delivery: a gene-gene interaction study. J Biomed Biotechnol. 
2010;2010:396184.  
164. Ryckman KK, Morken NH, White MJ, et al. Maternal and fetal genetic associations of 
PTGER3 and PON1 with preterm birth. PLoS One. 2010;5:e9040.  
165. Jones NM, Holzman C, Tian Y, et al. Innate immune system gene polymorphisms in 
maternal and child genotype and risk of preterm delivery. J Matern Fetal Neonatal Med. 2011.  
166. Nuk M, Orendi K, Rosenberger S, et al. Genetic variations in fetal and maternal tumor 
necrosis factor-alpha and interleukin 10: is there an association with preterm birth or 
periventricular leucomalacia? J Perinatol. 2012;32:27-32.  
167. Chappell S, Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci 
(Lond). 2006;110:443-458.  
168. Morrison AC, Srinivas SK, Elovitz MA, Puschett JB. Genetic variation in solute carrier genes 
is associated with preeclampsia. Am J Obstet Gynecol. 2010;203:491.e1-491.e13.  
169. Srinivas SK, Morrison AC, Andrela CM, Elovitz MA. Allelic variations in angiogenic pathway 
genes are associated with preeclampsia. Am J Obstet Gynecol. 2010;202:445.e1-445.11.  
170. Dizon-Townson DS, Major H, Ward K. A promoter mutation in the tumor necrosis factor 
alpha gene is not associated with preeclampsia. J Reprod Immunol. 1998;38:55-61.  
171. Livingston JC, Park V, Barton JR, et al. Lack of association of severe preeclampsia with 
maternal and fetal mutant alleles for tumor necrosis factor alpha and lymphotoxin alpha genes 
and plasma tumor necrosis factor alpha levels. Am J Obstet Gynecol. 2001;184:1273-1277.  
 262 
172. Lachmeijer AM, Nosti-Escanilla MP, Bastiaans EB, et al. Linkage and association studies of 
IL1B and IL1RN gene polymorphisms in preeclampsia. Hypertens Pregnancy. 2002;21:23-38.  
173. Lachmeijer AM, Crusius JB, Pals G, Dekker GA, Arngrimsson R, ten Kate LP. Polymorphisms 
in the tumor necrosis factor and lymphotoxin-alpha gene region and preeclampsia. Obstet 
Gynecol. 2001;98:612-619.  
174. Witt CS, Whiteway JM, Warren HS, et al. Alleles of the KIR2DL4 receptor and their lack of 
association with pre-eclampsia. Eur J Immunol. 2002;32:18-29.  
175. Kamali-Sarvestani E, Kiany S, Gharesi-Fard B, Robati M. Association study of IL-10 and IFN-
gamma gene polymorphisms in Iranian women with preeclampsia. J Reprod Immunol. 
2006;72:118-126.  
176. Saarela T, Hiltunen M, Helisalmi S, Heinonen S, Laakso M. Polymorphisms of interleukin-6, 
hepatic lipase and calpain-10 genes, and preeclampsia. Eur J Obstet Gynecol Reprod Biol. 
2006;128:175-179.  
177. de Lima TH, Sass N, Mattar R, et al. Cytokine gene polymorphisms in preeclampsia and 
eclampsia. Hypertens Res. 2009;32:565-569.  
178. Tan CY, Chong YS, Loganath A, et al. Possible gene-gene interaction of KIR2DL4 with its 
cognate ligand HLA-G in modulating risk for preeclampsia. Reprod Sci. 2009;16:1135-1143.  
179. Johnson MP, Roten LT, Dyer TD, et al. The ERAP2 gene is associated with preeclampsia in 
Australian and Norwegian populations. Hum Genet. 2009;126:655-666.  
180. Fenstad MH, Johnson MP, Roten LT, et al. Genetic and molecular functional 
characterization of variants within TNFSF13B, a positional candidate preeclampsia susceptibility 
gene on 13q. PLoS One. 2010;5:e12993.  
181. Hill LD, Hilliard DD, York TP, et al. Fetal ERAP2 variation is associated with preeclampsia in 
African Americans in a case-control study. BMC Med Genet. 2011;12:64.  
182. Edwards DR, Romero R, Kusanovic JP, et al. Polymorphisms in maternal and fetal genes 
encoding for proteins involved in extracellular matrix metabolism alter the risk for small-for-
gestational-age. J Matern Fetal Neonatal Med. 2011;24:362-380.  
 263 
183. Johnston LB, Ester W, Caliebe J, et al. Network of European studies of genes in growth 
(NESTEGG). Horm Res. 2009;71 Suppl 2:48-54.  
184. Savitz DA, Dole N, Williams J, et al. Determinants of participation in an epidemiological 
study of preterm delivery. Paediatr Perinat Epidemiol. 1999;13:114-125.  
185. Savitz DA, Dole N, Terry JW,Jr, Zhou H, Thorp JM,Jr. Smoking and pregnancy outcome 
among African-American and white women in central North Carolina. Epidemiology. 
2001;12:636-642.  
186. Zhang J, Bowes WA,Jr. Birth-weight-for-gestational-age patterns by race, sex, and parity in 
the United States population. Obstet Gynecol. 1995;86:200-208.  
187. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally 
informative set of single-nucleotide polymorphisms for association analyses using linkage 
disequilibrium. Am J Hum Genet. 2004;74:106-120.  
188. Van Dyke AL, Cote ML, Wenzlaff AS, Land S, Schwartz AG. Cytokine SNPs: Comparison of 
allele frequencies by race and implications for future studies. Cytokine. 2009;46:236-244.  
189. Barnholtz-Sloan JS, Shetty PB, Guan X, et al. FGFR2 and other loci identified in genome-
wide association studies are associated with breast cancer in African-American and younger 
women. Carcinogenesis. 2010;31:1417-1423.  
190. Chen GK, Millikan RC, John EM, et al. The potential for enhancing the power of genetic 
association studies in African Americans through the reuse of existing genotype data. PLoS 
Genet. 2010;6:e1001096.  
191. IOM (Institute of Medicine) and NRC (National Research Council). Weight Gain during 
Pregnancy: Reexamining the Guidelines. Washington, DC: The National Academies Press; 2009.  
192. De la Cruz O, Wen X, Ke B, Song M, Nicolae DL. Gene, region and pathway level analyses in 
whole-genome studies. Genet Epidemiol. 2010;34:222-231.  
193. Kwee LC, Liu D, Lin X, Ghosh D, Epstein MP. A powerful and flexible multilocus association 
test for quantitative traits. Am J Hum Genet. 2008;82:386-397.  
194. Wu MC, Kraft P, Epstein MP, et al. Powerful SNP-set analysis for case-control genome-wide 
association studies. Am J Hum Genet. 2010;86:929-942.  
 264 
195. Schaid DJ. Genomic Similarity and Kernel Methods I: Advancements by Building on 
Mathematical and Statistical Foundations. Hum Hered. 2010;70:109-131.  
196. Schaid DJ. Genomic Similarity and Kernel Methods II: Methods for Genomic Information. 
Hum Hered. 2010;70:132-140.  
197. Zhang D, Lin X. Hypothesis testing in semiparametric additive mixed models. Biostatistics. 
2003;4:57-74.  
198. Rice TK, Schork NJ, Rao DC. Methods for handling multiple testing. Adv Genet. 2008;60:293-
308.  
199. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful 
Approach to Multiple Testing. Journal of the Royal Statistical Society.Series B (Methodological). 
1995;57:pp. 289-300.  
200. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. 
Epidemiology. 2003;14:680-686.  
201. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and 
haplotype maps. Bioinformatics. 2005;21:263-265.  
202. Johnson A, Handsaker R, Pulit S, Nizzari M, O'Donnell C, de Bakker P. SNAP: A web-based 
tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 
2008;24:2938-2939.  
203. Weng HY, Hsueh YH, Messam LL, Hertz-Picciotto I. Methods of covariate selection: directed 
acyclic graphs and the change-in-estimate procedure. Am J Epidemiol. 2009;169:1182-1190.  
204. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a 
prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J 
Epidemiol. 2002;155:176-184.  
205. Coussons-Read ME, Okun ML, Nettles CD. Psychosocial stress increases inflammatory 
markers and alters cytokine production across pregnancy. Brain Behav Immun. 2007;21:343-
350.  
206. Harville EW, Savitz DA, Dole N, Thorp JM,Jr, Herring AH. Psychological and biological 
markers of stress and bacterial vaginosis in pregnant women. BJOG. 2007;114:216-223.  
 265 
207. Dole N, Savitz DA, Hertz-Picciotto I, Siega-Riz AM, McMahon MJ, Buekens P. Maternal stress 
and preterm birth. Am J Epidemiol. 2003;157:14-24.  
208. Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: 
systematic review and metaanalysis. Am J Obstet Gynecol. 2008;198:7-22.  
209. National High Blood Pressure Education Program Working Group on High Blood Pressure in 
Pregnancy*. Report of the National High Blood Pressure Education Program Working Group on 
High Blood Pressure in Pregnancy. Obstet Gynecol. 2000;183:S1-S22.  
210. MacGillivray I, Rose GA, Rowe B. Blood pressure survey in pregnancy. Clin Sci. 1969;37:395-
407.  
211. Barnholtz-Sloan JS, McEvoy B, Shriver MD, Rebbeck TR. Ancestry estimation and correction 
for population stratification in molecular epidemiologic association studies. Cancer Epidemiol 
Biomarkers Prev. 2008;17:471-477.  
212. Burnett MS, Strain KJ, Lesnick TG, de Andrade M, Rocca WA, Maraganore DM. Reliability of 
self-reported ancestry among siblings: implications for genetic association studies. Am J 
Epidemiol. 2006;163:486-492.  
213. Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG. Examining population 
stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol 
Biomarkers Prev. 2005;14:1545-1551.  
214. Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug 
response. Nat Genet. 2001;29:265-269.  
215. Parra EJ, Marcini A, Akey J, et al. Estimating African American admixture proportions by use 
of population-specific alleles. Am J Hum Genet. 1998;63:1839-1851.  
216. Parra EJ, Kittles RA, Argyropoulos G, et al. Ancestral proportions and admixture dynamics in 
geographically defined African Americans living in South Carolina. Am J Phys Anthropol. 
2001;114:18-29.  
217. Pfaff CL, Barnholtz-Sloan J, Wagner JK, Long JC. Information on ancestry from genetic 
markers. Genet Epidemiol. 2004;26:305-315.  
 266 
218. Tiwari HK, Barnholtz-Sloan J, Wineinger N, Padilla MA, Vaughan LK, Allison DB. Review and 
evaluation of methods correcting for population stratification with a focus on underlying 
statistical principles. Hum Hered. 2008;66:67-86.  
219. Tang H, Peng J, Wang P, Risch NJ. Estimation of individual admixture: analytical and study 
design considerations. Genet Epidemiol. 2005;28:289-301.  
220. Price AL. Principal components analysis corrects for stratification in genome-wide 
association studies. Nat Genet. 2006;38:904-9.  
221. Wang H, Haiman CA, Kolonel LN, et al. Self-reported ethnicity, genetic structure and the 
impact of population stratification in a multiethnic study. Hum Genet. 2010;128:165-177.  
222. Eberle MA, Ng PC, Kuhn K, et al. Power to detect risk alleles using genome-wide tag SNP 
panels. PLoS Genet. 2007;3:1827-1837.  
223. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and 
population-based linkage analyses. Am J Hum Genet. 2007;81:559-575.  
224. SAS Institute Inc. SAS/GeneticsTM 9.3 User's Guide. Cary, NC: SAS Institute Inc.; 2011.  
225. Patterson N. Population structure and eigenanalysis. PLoS genetics. 2006;2:e190.  
226. Lockwood CJ, Kuczynski E. Risk stratification and pathological mechanisms in preterm 
delivery. Paediatr Perinat Epidemiol. 2001;15 Suppl 2:78-89.  
227. Dahlstrom B, Esbensen Y, Vollan H, Oian P, Bukholm G. Genome profiles in maternal blood 
during early onset preeclampsia and towards term. J Perinat Med. 2010;38:601-608.  
228. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus 
genotype data. Genetics. 2000;155:945-959.  
229. Shaffer JP. Multiple Hypothesis Testing. Annu Rev Psychol. 1995;46:561-584.  
230. Osborne CS, Vadas MA, Cockerill PN. Transcriptional regulation of mouse granulocyte-
macrophage colony-stimulating factor/IL-3 locus. J Immunol. 1995;155:226-235.  
 267 
231. Lee GR, Fields PE, Griffin TJ, Flavell RA. Regulation of the Th2 cytokine locus by a locus 
control region. Immunity. 2003;19:145-153.  
232. Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med. 2010;362:529-
535.  
233. Abrams ET, Meshnick SR. Malaria during pregnancy in endemic areas: a lens for examining 
maternal-fetal conflict. Am J Hum Biol. 2009;21:643-650.  
234. Muehlenbachs A, Fried M, Lachowitzer J, Mutabingwa TK, Duffy PE. Natural selection of 
FLT1 alleles and their association with malaria resistance in utero. Proc Natl Acad Sci U S A. 
2008;105:14488-14491.  
235. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions 
of hypertension in pregnancy. Obstet Gynecol. 2001;97:261-267.  
236. Howards PP, Schisterman EF, Heagerty PJ. Potential confounding by exposure history and 
prior outcomes: an example from perinatal epidemiology. Epidemiology. 2007;18:544-551.  
237. R Development Core Team. R: A Language and Environment for Statistical Computing. 
Vienna, Austria: R Foundation for Statistical Computing; 2008.  
238. Markert UR, Morales-Prieto DM, Fitzgerald JS. Understanding the link between the IL-6 
cytokine family and pregnancy: implications for future therapeutics. Expert Rev Clin Immunol. 
2011;7:603-609.  
239. Tilburgs T, van der Mast BJ, Nagtzaam NM, Roelen DL, Scherjon SA, Claas FH. Expression of 
NK cell receptors on decidual T cells in human pregnancy. J Reprod Immunol. 2009;80:22-32.  
240. Antoun A, Jobson S, Cook M, Moss P, Briggs D. Ethnic variability in human leukocyte 
antigen-E haplotypes. Tissue Antigens. 2009;73:39-45.  
241. Williams PJ, Pipkin FB. The genetics of pre-eclampsia and other hypertensive disorders of 
pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25:405-417.  
242. Lazarevic V, Glimcher LH. T-bet in disease. Nat Immunol. 2011;12:597-606.  
 268 
243. Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human 
TNF-alpha/NF-kappa B signal transduction pathway. Nat Cell Biol. 2004;6:97-105.  
244. Goncalves A, Burckstummer T, Dixit E, et al. Functional dissection of the TBK1 molecular 
network. PLoS One. 2011;6:e23971.  
245. Harismendy O, Notani D, Song X, et al. 9p21 DNA variants associated with coronary artery 
disease impair interferon-gamma signalling response. Nature. 2011;470:264-268.  
246. Muehlenbachs A, Mutabingwa TK, Edmonds S, Fried M, Duffy PE. Hypertension and 
maternal-fetal conflict during placental malaria. PLoS Med. 2006;3:e446.  
 
